<!DOCTYPE html>
<!-- the doctype declaration should be included at the start of the HTML document -->
<html lang="en">
    
<head>
        <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/3.4.1/css/bootstrap.min.css">
        <link rel="stylesheet" type="text/css" href="style.css">
        <script src="http://ajax.googleapis.com/ajax/libs/jquery/1.7.1/jquery.min.js"></script>
        <script src="https://cdnjs.cloudflare.com/ajax/libs/PapaParse/4.1.2/papaparse.js"></script>
        <meta charset="utf-8">
        <style>.textWrap {float: right; margin:10px;} </style>
        <title>Web Design Challenge</title>
    </head>
    <body>
        <nav class="navbar navbar-custom navbarbar-expand-md navbar-light bg-light sticky-top">
            <div class="container-fluid navbar-custom">
            <div class="row">
              <div class="navbar-header">
                <a class="navbar-brand" href="index.html">Covid Trial Analysis Home</a>
              </div>
    
              <ul class="nav navbar-nav navbar-right">
                <li class="dropdown"><a class="dropdown-toggle" data-toggle="dropdown" href="#">Plots <span class="caret"></span></a>
                <ul class="dropdown-menu">
                    <li><a class="dropdown-item" href="Visualization1.html">Visualization 1</a></li>
                    <li><a class="dropdown-item" href="Visualization2.html">Visualization 2</a></li>
                    <li><a class="dropdown-item" href="Visualization3.html">Visualization 3</a></li>
                    <li><a class="dropdown-item" href="Visualization4.html">Visualization 4</a></li>
                </ul>
                <li class="active"><a href="Comparison.html">Comparison</a></li>
                <li class="active"><a href="Data.html">Data</a></li>
            </div>
            </aside>
            </div>
          </nav>


          <div class="container-fluid">
            <aside id="background-boxes">
              <h1> Data</h1>
              <p>Below are 500 trials that were included in the overall dataset of over 27,000 clinical trials. The rest of trialsa are available on ClinicalTrials.gov</p>
              <div class="table-responsive">
                <table class="table">
                 <table border="1" class="dataframe">  <thead>    <tr style="text-align: right;">      <th></th>      <th>Rank</th>      <th>Title</th>      <th>Status</th>      <th>Study Results</th>      <th>Conditions</th>      <th>Interventions</th>      <th>Sponsor/Collaborators</th>      <th>Phases</th>      <th>Enrollment</th>      <th>Funded Bys</th>      <th>Study Type</th>      <th>Study Designs</th>      <th>First Posted</th>      <th>Locations</th>      <th>URL</th>    </tr>  </thead>  <tbody>    <tr>      <th>0</th>      <td>1</td>      <td>A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Solid Tumor</td>      <td>Biological: PRL3-zumab</td>      <td>Intra-IMMUSG Pte Ltd|Parexel</td>      <td>Phase 2</td>      <td>33.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>1-Jul-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04452955</td>    </tr>    <tr>      <th>1</th>      <td>2</td>      <td>A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Healthy</td>      <td>Drug: OPL-002</td>      <td>Oppilan Pharma Ltd|Celerion</td>      <td>Phase 1</td>      <td>12.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>30-Jun-20</td>      <td>Celerion, Belfast, Northern Ireland, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04451811</td>    </tr>    <tr>      <th>2</th>      <td>3</td>      <td>A Randomised, Double-blinded, Parallel Group, Placebo-Controlled Study to Evaluate the Effects of a Bioactive Peptide on Symptoms of Digestive Discomfort in the Elderly</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Abdominal Pain</td>      <td>Dietary Supplement: Bioactive hydrolysate</td>      <td>Nuritas Ltd|Atlantia Food Clinical Trials</td>      <td>Not Applicable</td>      <td>40.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention</td>      <td>30-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04450979</td>    </tr>    <tr>      <th>3</th>      <td>4</td>      <td>Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Advanced Solid Tumors</td>      <td>Drug: YBL-006</td>      <td>Y Biologics Inc.|Novotech (Australia) Pty Limited</td>      <td>Phase 1</td>      <td>80.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>30-Jun-20</td>      <td>Macquarie University, Macquarie, New South Wales, Australia|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of</td>      <td>https://ClinicalTrials.gov/show/NCT04450901</td>    </tr>    <tr>      <th>4</th>      <td>5</td>      <td>Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>HER2-positive Breast Cancer|HER2-positive Gastric Cancer|Advanced Solid Tumor</td>      <td>Drug: GQ1001</td>      <td>GeneQuantum Healthcare (Suzhou) Co., Ltd.|CRC Oncology</td>      <td>Phase 1</td>      <td>27.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>29-Jun-20</td>      <td>M.D. Anderson Cancer Center, Houston, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04450732</td>    </tr>    <tr>      <th>5</th>      <td>6</td>      <td>Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Asthma|Asthma in Children</td>      <td>Diagnostic Test: Vivatmo pro FeNO Test</td>      <td>Bosch Healthcare Solutions gmbH|Global BioClinical</td>      <td>Not Applicable</td>      <td>120.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic</td>      <td>29-Jun-20</td>      <td>Clinical Research Center of Alabama, Birmingham, Alabama, United States|Kern Research, Inc., Bakersfield, California, United States|Chesapeake Clinical Research, Inc., White Marsh, Maryland, United States|The Clinical Research Center, LLC, Saint Louis, Missouri, United States|North Carolina Clinical Research, Raleigh, North Carolina, United States|Allergy Asthma Research Institute, Waco, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04450108</td>    </tr>    <tr>      <th>6</th>      <td>7</td>      <td>Efficacy of Vinh Wellness Collagen on Skin Health</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Skin Manifestations|Skin Abnormalities</td>      <td>Dietary Supplement: Vinh Wellness Collagen|Dietary Supplement: Placebo</td>      <td>Vinh Hoan Corporation|KGK Science Inc.</td>      <td>Not Applicable</td>      <td>50.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>26-Jun-20</td>      <td>KGK Science Inc, London, Ontario, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04449159</td>    </tr>    <tr>      <th>7</th>      <td>8</td>      <td>A Study of JNJ-70033093 in Healthy Participants</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Healthy</td>      <td>Drug: JNJ-70033093</td>      <td>Janssen Research &amp; Development, LLC|Bristol-Myers Squibb</td>      <td>Phase 1</td>      <td>24.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>26-Jun-20</td>      <td>Clinical Pharmacology Unit, Merksem, Belgium</td>      <td>https://ClinicalTrials.gov/show/NCT04448964</td>    </tr>    <tr>      <th>8</th>      <td>9</td>      <td>M5049 Study in Participants With Coronavirus Disease 2019 (COVID-19) Pneumonia</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Coronavirus Disease 2019</td>      <td>Drug: M5049|Drug: Placebo</td>      <td>EMD Serono Research &amp; Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono</td>      <td>Phase 2</td>      <td>150.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>26-Jun-20</td>      <td>University of Alabama-Birmingham Hospital, Birmingham, Alabama, United States|Sharp Medical Center/Healthcare, San Diego, California, United States|Henry Ford Medical Center, Detroit, Michigan, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04448756</td>    </tr>    <tr>      <th>9</th>      <td>10</td>      <td>Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Locally Advanced or Metastatic Non-Small Cell Lung Cancer</td>      <td>Drug: JMT101</td>      <td>Shanghai JMT-Bio Inc.|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</td>      <td>Phase 1</td>      <td>48.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>25-Jun-20</td>      <td>Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China</td>      <td>https://ClinicalTrials.gov/show/NCT04448379</td>    </tr>    <tr>      <th>10</th>      <td>11</td>      <td>A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Relapsed or Refractory Solid Tumors</td>      <td>Drug: Lenvatinib</td>      <td>Merck Sharp &amp; Dohme Corp.|Eisai Inc.</td>      <td>Phase 2</td>      <td>150.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>25-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04447755</td>    </tr>    <tr>      <th>11</th>      <td>12</td>      <td>Dupilumab Skin Barrier Function Study in Atopic Dermatitis</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Atopic Dermatitis</td>      <td>Drug: Dupilumab SAR231893</td>      <td>Sanofi|Regeneron Pharmaceuticals</td>      <td>Phase 4</td>      <td>40.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>25-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04447417</td>    </tr>    <tr>      <th>12</th>      <td>13</td>      <td>Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Neoplasms</td>      <td>Drug: GSK6097608|Drug: Dostarlimab</td>      <td>GlaxoSmithKline|23andMe, Inc.</td>      <td>Phase 1</td>      <td>100.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>24-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04446351</td>    </tr>    <tr>      <th>13</th>      <td>14</td>      <td>A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Advanced Solid Tumors</td>      <td>Drug: SHR-A1811</td>      <td>Jiangsu HengRui Medicine Co., Ltd.|Atridia Pty Ltd.</td>      <td>Phase 1</td>      <td>226.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>24-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04446260</td>    </tr>    <tr>      <th>14</th>      <td>15</td>      <td>A Study to Evaluate the Efficacy and Safety of Dupilumab in Participants With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Allergic Bronchopulmonary Aspergillosis</td>      <td>Drug: dupilumab|Drug: Placebo</td>      <td>Regeneron Pharmaceuticals|Sanofi</td>      <td>Phase 3</td>      <td>170.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>22-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04442269</td>    </tr>    <tr>      <th>15</th>      <td>16</td>      <td>RandOmised Controlled Trial of STAR Mapping™ Guided Ablation for AF.</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Atrial Fibrillation</td>      <td>Procedure: Pulmonary vein isolation plus ablation guided by novel STAR mapping™|Procedure: Pulmonary vein isolation</td>      <td>Rhythm AI Ltd|Biosense Webster, Inc.</td>      <td>Not Applicable</td>      <td>177.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>22-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04442113</td>    </tr>    <tr>      <th>16</th>      <td>17</td>      <td>Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>covid19</td>      <td>Drug: Nitazoxanide|Drug: Placebo</td>      <td>Azidus Brasil|Farmoquimica S.A.</td>      <td>Phase 2|Phase 3</td>      <td>300.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>22-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04441398</td>    </tr>    <tr>      <th>17</th>      <td>18</td>      <td>Immunometabolic Effects of Non-drug Strategies in the Clinical Management of Obesity: Translational Study</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Obesity|Obesity, Abdominal|Obesity, Visceral|Female</td>      <td>Dietary Supplement: Alpha lipoic acid (plus full hospitalization)|Dietary Supplement: Placebo (full hospitalization: dietary monitoring with an adapted physical activity program)</td>      <td>Fauqué|Institut Polyclinique de Cannes (IPOCA)</td>      <td>Not Applicable</td>      <td>40.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention</td>      <td>18-Jun-20</td>      <td>Policlinic of Oxford (IPOCA), Cannes, France</td>      <td>https://ClinicalTrials.gov/show/NCT04436419</td>    </tr>    <tr>      <th>18</th>      <td>19</td>      <td>Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Infection, Respiratory Tract</td>      <td>Biological: VPM1002|Biological: Placebo</td>      <td>Vakzine Projekt Management GmbH|FGK Clinical Research GmbH</td>      <td>Phase 3</td>      <td>2038.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention</td>      <td>17-Jun-20</td>      <td>Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|SocraTec R&amp;D GmbH, Erfurt, Thüringen, Germany|emovis GmbH, Berlin, Germany|Klinische Forschung Berlin GbR, Berlin, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04435379</td>    </tr>    <tr>      <th>19</th>      <td>20</td>      <td>Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>covid19</td>      <td>Drug: Nitazoxanide|Drug: Placebo</td>      <td>Azidus Brasil|Farmoquimica S.A.</td>      <td>Phase 2</td>      <td>200.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention</td>      <td>17-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04435314</td>    </tr>    <tr>      <th>20</th>      <td>21</td>      <td>An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>COVID-19</td>      <td>Drug: Favipiravir|Drug: Standard of Care</td>      <td>Chromis LLC|Chemical Diversity Research Institute</td>      <td>Phase 2|Phase 3</td>      <td>330.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>16-Jun-20</td>      <td>Republican Clinical Hospital, Makhachkala, Russian Federation|"K+31" Clinic, Moscow, Russian Federation|"Khaven" Llc, Moscow, Russian Federation|Central Clinical Hospital with Polyclinic, Moscow, Russian Federation|Central Research Institute of Epidemiology, Moscow, Russian Federation|City Clinical Hospital n.a. O.M. Filatov, Moscow, Russian Federation|City Clinical Hospital named after S.S. Yudin, Moscow, Russian Federation|City Clinical Hospital No. 24, Moscow, Russian Federation|City Clinical Hospital No. 51, Moscow, Russian Federation|First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Russian Federation|Moscow State University n.a. M. V. Lomonosov, Moscow, Russian Federation|National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russian Federation|City Hospital № 33 of the Leninsky region of Nizhny Novgorod, Nizhny Novgorod, Russian Federation|Infectious clinical hospital No.2 of Nizhny Novgorod, Nizhny Novgorod, Russian Federation|Ryazan State Medical University named after I.P. Pavlov, Ryazan, Russian Federation|Military Medical Academy named after S.M. Kirova, Saint Petersburg, Russian Federation|Saratov State Medical University named after V.I. Razumovsky, Saratov, Russian Federation|Clinical hospital No.1, Smolensk, Russian Federation|Regional Clinic Hospital, Tver, Russian Federation|Bashkir State Medical University, Ufa, Russian Federation|Yakutsk City Clinical Hospital, Yakutsk, Russian Federation|Yaroslavl Regional Clinical Hospital for War Veterans, Yaroslavl, Russian Federation</td>      <td>https://ClinicalTrials.gov/show/NCT04434248</td>    </tr>    <tr>      <th>21</th>      <td>22</td>      <td>A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Paroxysmal Nocturnal Hemoglobinuria</td>      <td>Drug: Crovalimab|Drug: Eculizumab</td>      <td>Hoffmann-La Roche|Chugai Pharmaceutical</td>      <td>Phase 3</td>      <td>200.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>16-Jun-20</td>      <td>University of California Irvine, Irvine, California, United States|UCLA Department of Medicine, Los Angeles, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Indiana Blood &amp; Marrow Transplantation, LLC, Indianapolis, Indiana, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Cook Childrens Medical Center, Fort Worth, Texas, United States|Hospital Italiano, Buenos Aires, Argentina|Hospital Aleman, Caba, Argentina|Organizacion Medica de Investigacion (OMI), Ciudad Autonoma Buenos Aires, Argentina|Academia Nacional de Medicina, Ciudad Autonoma Buenos Aires, Argentina|Sanatorio Allende, Cordoba, Argentina|Liverpool Hospital, Liverpool, New South Wales, Australia|Westmead Hospital; Pharmacy, Northmead, New South Wales, Australia|Fundacion Santa Fe de Bogota, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Hopital Claude Huriez - CHU Lille, Lille, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Universitaetsklinkm, Essen, Germany|Universitaetsklinikum Ulm, Ulm, Germany|University General Hospital of Alexandroupolis; Haemotology, Alexandroup, Greece|Attikon University General Hospital, Athens, Greece|University General Hospital of Ioannina, Ioannina, Greece|General Hospital of Thessaloniki G. Papanikolaou, Thessaloniki, Greece|Semmelweis Egyetem, Budapest, Hungary|Rambam Health Care Center, Haifa, Israel|Azienda Unita Sanitaria Locale- Ravenna, Ravenna, Emilia-Romagna, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio, Italy|Fondazione IRCCS CA\' Granda Ospedale Maggiore Policlinico, Milano, Molise, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana, Italy|Ospedale Di Vicenza; Nefrologia, Ematologia, Vicenza, Veneto, Italy|Sapporo Medical University Hospital, Hokkaido, Japan|University of Tsukuba Hospital, Ibaraki, Japan|Osaka University Hospital, Osaka, Japan|NTT Medical Center Tokyo, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia|Hospital Pulau Pinang; Jabatan Respiratori, Georgetown, Penang, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Ampang, Ampang, Malaysia|Hospital Tengku Ampuan Afzan, Pahang, Malaysia|Global Trial Research Center S.A. de C.V., Monterrey, Nuevo LEON, Mexico|Amsterdam UMC, Locatie AMC, Amsterdam, Netherlands|Radboudumc, NL -nijmegen, Netherlands|Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Hospital Nacional Guillermo Almenara Irigoyen ESSALUD, Lima, Peru|Szpital Uniwersytecki nr2 im. dr J. Biziela, Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii, Gdansk, Poland|SPZOZ Szpital Uniw W Krakowie, Krakow, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1, Lublin, Poland|Examen sp, Skórzewo, Poland|MTZ Clinical Research Sp. z o.o., Warszawa, Poland|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wroclaw, Poland|Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, Portugal|Centro Hospitalar do Porto - Hospital de Santo António, Porto, Portugal|Spitalul Universitar de Urgenta Bucuresti, Bucharest, Romania|Institutul Oncologic "Prof. Dr. Ion Chiricuţă" Cluj Napoca, Cluj-Napoca, Romania|Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca; Radioterapie I - Oncologie, Cluj-Napoca, Romania|Spitalul Clinic Municipal Filantropia Craiova, Craiova, Romania|Spitalul Clinic Municipal DR Gavril Curneanu Oradea; Centrul Oncologie Medicala, Oradea, Romania|Spitalul Clinic Colentina, Sector 2, Romania|Spitalul Clinic Judetean de Urgenta Targu-Mures; compartiment Hematologie, Targu-mures, Romania|FARMOVS (Pty) Ltd, Bloemfontein, South Africa|Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa|Hospital de Basurto, Bilbao, Albacete, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Sant Joan De Deu, Esplugues De Llobregas, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe; Unidad Hemostasis y Trombosis, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Akademiska Sjukhuset; Gastroenterology, Uppsala, Sweden|National Taiwan Universtiy Hospital; Division of Hematology, Taipei, Taiwan|MacKay Memorial Hospital; Hematology and oncology, Taipei, Taiwan|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Siriraj Hospital, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|Ege University Medical Faculty; Hematology, Izmir, Turkey|Ondokuz Mayis Univ. Med. Fac., Samsun, Turkey</td>      <td>https://ClinicalTrials.gov/show/NCT04434092</td>    </tr>    <tr>      <th>22</th>      <td>23</td>      <td>A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Systemic Lupus Erythematosus</td>      <td>Drug: LY3471851|Drug: Placebo</td>      <td>Eli Lilly and Company|Nektar Therapeutics</td>      <td>Phase 2</td>      <td>280.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>16-Jun-20</td>      <td>Desert Medical Advances, Palm Desert, California, United States|Stanford University Hospital, Palo Alto, California, United States|Inland Rheumatology Clinical Trials, Upland, California, United States|University of Colorado School of Medicine, Aurora, Colorado, United States|Clinical Research Center of CT/NY, Danbury, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|New Horizon Research Center, Miami, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|NECCR PrimaCare Research, LLC, Fall River, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Northwell Health, Great Neck, New York, United States|NYU Langone, New York, New York, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Paramount Medical Research, Middleburg Heights, Ohio, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States|Accurate Clinical Management LLC - BayTown, Baytown, Texas, United States|Metroplex Clinical Research Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Accurate Clinical Research, Houston, Texas, United States|University of Washington Medical Center, Seattle, Washington, United States|DOM- Centro de Reumatologia, Caba, Buenos Aires, Argentina|Aprillus Asistencia e Investigacion - Servicio de neurologia, Caba, Buenos Aires, Argentina|Clinica Adventista de Belgrano, Ciudad Autonoma Buenos Aires, Argentina|Hospital Ramos Mejia, Ciudad Autonoma de Buenos Aire, Argentina|Centro de Medicina Familiar Mindout Research, Ciudad Autonoma de Buenos Aire, Argentina|Hospital Cordoba, Cordoba, Argentina|Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan, San Juan, Argentina|Centro Medico Privado de Reumatologia, Tucuman, Argentina|Interni a revmatologicka ambulance, Inrea s.r.o., Ostrava, Czechia|Revmatologicky ustav, Praha 2, Czechia|Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Nordrhein-Westfalen, Germany|Universtitätsklinikum Essen AöR, Essen, North Rhine-Westphalia, Germany|Rheumaklinik Bad Branstedt GmbH, Bad Bramstedt, Schleswig-Holstein, Germany|Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany|Universitätsklinikum Köln, Köln, Germany|Bekes Megyei Pandy Kalman Korhaz, Gyula, Bekes, Hungary|Debreceni Egyetem Orvos-es Egészsegtudomanyi Centrum, Debrecen, Hungary|Rambam Medical Center, Haifa, Israel|Sheba Medical Center, Ramat Gan, Israel|Kojunkai Daido Clinic, Nagoya, Aichi, Japan|National Chiba-East-Hospital, Chuo-ku, Chiba, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|Okayama University Hospital, Okayama, Japan|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Hanyang University Medical Center, Seoul, Korea, Republic of|Centro Medico del Angel S.C., Mexicali, Baja California, Mexico|Dr. Alberto Esteban Bazzoni Ruiz, Torreon, Coahuila, Mexico|RM Pharma Specialists S.A. de C.V., Mexico City, Distrito Federal, Mexico|Clinica para el Diagnostico y Tratamiento de la Enfermedades, Mexico City, Distrito Federal, Mexico|Centro Integral en Reumatologia SA de CV, Guadalajara, Jalisco, Mexico|Clinica en Investigación en Reumatologia y Obesidad S.C., Guadalajara, Jalisco, Mexico|Medycyna Kliniczna, Warszawa, Mazowieckie, Poland|Szpital Uniwersytecki nr 2 im. dr J. Biziela, Bydgoszcz, Poland|Nzoz Bif-Med, Bytom, Poland|Office: Perez-De Jesus, Amarilis, Caguas, Puerto Rico|Latin Clinical Trial Center, San Juan, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico|Mindful Medical Research, San Juan, Puerto Rico|Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed SRL, Brasov, Romania|SC Centrul Medical Sana SRL, Bucuresti, Romania|Spitalul Clinic Sf Maria Bucuresti, Bucuresti, Romania|Spitalul Clinic Judetean de Urgenta "Sf.Apostol Andrei" Compartimentul Reumatologie, Galati, Romania|Chang Gung Memorial Hospital - Kaohsiung, Kaohsiung City, Taiwan|China Medical University Hospital, Taichung City, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Regional Clinical Hospital Center for Emergency medical care, Kharkiv, Ukraine</td>      <td>https://ClinicalTrials.gov/show/NCT04433585</td>    </tr>    <tr>      <th>23</th>      <td>24</td>      <td>A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors.</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Paroxysmal Nocturnal Hemoglobinuria</td>      <td>Drug: Crovalimab|Drug: Eculizumab</td>      <td>Hoffmann-La Roche|Chugai Pharmaceutical</td>      <td>Phase 3</td>      <td>250.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>16-Jun-20</td>      <td>The Oncology Institute of Hope and Innovation, Anaheim, California, United States|University of California Irvine, Irvine, California, United States|UCLA Department of Medicine, Los Angeles, California, United States|Indiana Blood &amp; Marrow Transplantation, LLC, Indianapolis, Indiana, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Cook Childrens Medical Center, Fort Worth, Texas, United States|Liverpool Hospital, Liverpool, New South Wales, Australia|Westmead Hospital; Pharmacy, Northmead, New South Wales, Australia|Cliniques Universitaires Saint-Luc; Pharmacy, Bruxelles, Belgium|AZ Delta Campus Westlaan, Roeselare, Belgium|CHU UCL Namur / site Godinne, Yvoir, Belgium|Fundacion Santa Fe de Bogota, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|CHU Rennes - Hopital Pontchaillou; Service d\'Hémostase Bioclinique, Rennes cedex 9, France|Universitaetsklinikum, Duesseldorf, Germany|Universitaetsklinikum Ulm, Ulm, Germany|University General Hospital of Alexandroupolis, Alexandroupolis, Greece|Attikon University General Hospital, Athens, Greece|AHEPA General Hospital of Thessaloniki, Thessaloniki, Greece|General Hospital of Thessaloniki G. Papanikolaou, Thessaloniki, Greece|General Hospital of Athens LAIKO, Αθηνα, Greece|Semmelweis Egyetem, Budapest, Hungary|Rambam Health Care Center, Haifa, Israel|Azienda Unita Sanitaria Locale- Ravenna, Ravenna, Emilia-Romagna, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio, Italy|Azienda Ospedaliera Sant\'Andrea, Roma, Lazio, Italy|Fondazione IRCCS CA\' Granda Ospedale Maggiore Policlinico, Milano, Molise, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana, Italy|Ospedale Di Vicenza; Nefrologia, Ematologia, Vicenza, Veneto, Italy|Fujita Health University Hospital, Aichi, Japan|Sapporo Medical University Hospital, Hokkaido, Japan|Okinawa Tokushukai Takasago Seibu Hospital, Hyogo, Japan|University of Tsukuba Hospital, Ibaraki, Japan|Mie University Hospital, Mie, Japan|Japanese Red Cross Society Suwa Hospital, Nagano, Japan|Nagasaki University Hospital, Nagasaki, Japan|National Hospital Organization Okayama Medical Center, Okayama, Japan|Osaka University Hospital, Osaka, Japan|NTT Medical Center Tokyo, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Toyama Prefectual Central Hospital, Toyama, Japan|Severance Hospital; Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Global Trial Research Center S.A. de C.V., Monterrey, Nuevo LEON, Mexico|Amsterdam UMC, Locatie AMC, Amsterdam, Netherlands|Radboudumc, NL -nijmegen, Netherlands|Szpital Uniwersytecki nr2 im. dr J. Biziela, Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii, Gdansk, Poland|SPZOZ Szpital Uniw W Krakowie, Krakow, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1, Lublin, Poland|Examen sp, Skórzewo, Poland|MTZ Clinical Research Sp. z o.o., Warszawa, Poland|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wroclaw, Poland|Centro Hospitalar do Porto - Hospital de Santo António, Porto, Portugal|Hospital de Basurto, Bilbao, Albacete, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Sant Joan De Deu, Esplugues De Llobregas, Barcelona, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitari Vall d Hebron, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Complejo Hospitalario de Toledo, Toledo, Spain|Hospital Universitari i Politecnic La Fe; Unidad Hemostasis y Trombosis, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Changhua Christian Hospital, Chang Hua, Taiwan|National Taiwan Universtiy Hospital; Division of Hematology, Taipei, Taiwan|MacKay Memorial Hospital; Hematology and oncology, Taipei, Taiwan|Ege University Medical Faculty; Hematology, Izmir, Turkey|Ondokuz Mayis Univ. Med. Fac., Samsun, Turkey</td>      <td>https://ClinicalTrials.gov/show/NCT04432584</td>    </tr>    <tr>      <th>24</th>      <td>25</td>      <td>Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Tibial Fracture</td>      <td>Biological: ALLOB|Other: placebo</td>      <td>Bone Therapeutics S.A|ICON plc</td>      <td>Phase 2</td>      <td>178.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment</td>      <td>16-Jun-20</td>      <td>Ziekenhuis Oost-Limburg (ZOL) - Campus Andre Dumont - Multidisciplinair PijnCentrum (MPC), Genk, Belgium|Centre Hospitalier Régional Universitaire de Brest - Hôpital de la Cavale Blanche, Brest, France|Markhot Ferenc Oktatókórház, Eger, Hungary|Hospital Clinic de Barcelona, Barcelona, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04432389</td>    </tr>    <tr>      <th>25</th>      <td>26</td>      <td>CAOCT: Intra CoronAry Optical Computerized Tomography in out-of Hospital Cardiac Arrest Patients</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Out of Hospital Cardiac Arrest</td>      <td>Procedure: Optical Coherence Tomography|Procedure: Coronary Angiography|Procedure: Per cutaneous coronary intervention</td>      <td>Ceric Sàrl|Abbott</td>      <td>NaN</td>      <td>131.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Other|Time Perspective: Prospective</td>      <td>16-Jun-20</td>      <td>UZ Leuven, Leuven, Belgium|CHU Gabriel-Montpied, Clermont-Ferrand, France|CHU Timone Adultes, Marseille, France|Hôpital Lariboisière, Paris, France|Hôpital Cochin, Paris, France|CHU Toulouse Rangueil, Toulouse, France|Clinical Center of Serbia. School of medicine, Belgrade, Serbia</td>      <td>https://ClinicalTrials.gov/show/NCT04431661</td>    </tr>    <tr>      <th>26</th>      <td>27</td>      <td>Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Astrocytoma|Brain Cancer|Brain Metastases|Bladder Cancer|Breast Cancer|Cervical Cancer|Cholangiocarcinoma|Colorectal Cancer|Esophagus Cancer|Gastric Cancer|Head and Neck Cancer|Kidney Cancer|Liver Cancer|Lung Cancer|Melanoma|Ovarian Cancer|Pancreatic Cancer|Pleural Mesothelioma|Prostate Cancer|Sarcoma|Tongue Cancer|Thymic Carcinoma|Urinary Tract Cancer</td>      <td>Drug: QBS10072S</td>      <td>Quadriga Biosciences, Inc.|Novotech (Australia) Pty Limited</td>      <td>Phase 1</td>      <td>50.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>12-Jun-20</td>      <td>St George Private Hospital, Kogarah, New South Wales, Australia|Sydney Southwest Private Hospital, Liverpool, New South Wales, Australia</td>      <td>https://ClinicalTrials.gov/show/NCT04430842</td>    </tr>    <tr>      <th>27</th>      <td>28</td>      <td>A Study to Evaluate Nicotine Uptake and Biomarkers in Smokers Using mybluTM Electronic Cigarettes</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy Volunteers</td>      <td>Other: Myblu flavor A 2.4|Other: Myblu flavor B 3.6|Other: Myblu flavor C 2.5|Other: Myblu flavor D 4.0|Other: Myblu flavor A 3.6|Other: Myblu flavor B 2.4|Other: Myblu flavor C 4.0|Other: Myblu flavor E 3.6</td>      <td>Fontem US LLC|Fontem Ventures BV</td>      <td>Not Applicable</td>      <td>40.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>12-Jun-20</td>      <td>Celerion, Lincoln, Nebraska, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04430634</td>    </tr>    <tr>      <th>28</th>      <td>29</td>      <td>A Study to Evaluate Nicotine Uptake and Biomarkers in Adult Smokers Using mybluTM Electronic Cigarettes</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy Volunteers</td>      <td>Other: Myblu flavor 1_2.4|Other: Myblu flavor 2_2.4|Other: Myblu flavor 3_2.4|Other: Myblu flavor 4_2.4|Other: Myblu flavor 1_1.2|Other: Myblu flavor 2_1.2|Other: Myblu flavor 5_2.4|Other: Myblu flavor 6_2.4</td>      <td>Fontem US LLC|Fontem Ventures BV</td>      <td>Not Applicable</td>      <td>38.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>12-Jun-20</td>      <td>Celerion, Lincoln, Nebraska, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04429932</td>    </tr>    <tr>      <th>29</th>      <td>30</td>      <td>AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Peripheral Post-surgical Neuropathic Pain</td>      <td>Drug: AP-325|Drug: Placebo</td>      <td>Algiax Pharmaceuticals GmbH|FGK Clinical Research GmbH</td>      <td>Phase 2</td>      <td>94.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>12-Jun-20</td>      <td>Neurology and Physiotherapy Outpatient Clinic Skopalíkova, Brno, Czechia|NEUROHK, s.r.o., Choceň, Czechia|NeuropsychiatrieHK, s.r.o., Hradec Králové, Czechia|MP-neuro s.r.o., Poliklinika Modrý pavilon, Slezská Ostrava, Czechia|Vivantes Klinikum Neukölln, Klinik für Thoraxchirurgie, Berlin, Germany|Florence-Nightingale-Krankenhaus der Kaiserswerther Diakonie, Klinik für Thoraxchirurgie, Düsseldorf, Germany|Kliniken der Stadt Köln gGmbH, Krankenhaus Köln-Holweide, Brustzentrum, Köln, Germany|Kliniken der Stadt Köln gGmbH, Krankenhaus Köln-Merheim, Lungenklinik am Zentrum für Thoraxchirurgie, Pneumologie/ Onkologie, Schlaf- und Beatmungsmedizin, Klinikum der Universität Witten/Herdecke, Köln, Germany|Universitätsklinikum Würzburg, Klinik und Poliklinik für Anästhesiologie, Zentrum für Interdisziplinäre Schmerzmedizin, Würzburg, Germany|HOSPITAL DEL MAR.#Cod. CNH: 080057#, Barcelona, Spain|HOSPITAL UNIVERSITARIO PUERTA DEL MAR#Cod. CNH: 110012#, Cadiz, Spain|HOSPITAL UNIVERSITARI DE BELLVITGE#Cod. CNH: 080752#, Hospitalet de Llobregat, Spain|HOSPITAL UNIVERSITARIO LA PAZ#Cod. CNH: 280014#, Madrid, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04429919</td>    </tr>    <tr>      <th>30</th>      <td>31</td>      <td>Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Diabetic Macular Edema|Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus</td>      <td>Drug: aflibercept|Drug: High-dose aflibercept</td>      <td>Regeneron Pharmaceuticals|Bayer</td>      <td>Phase 2|Phase 3</td>      <td>640.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>12-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04429503</td>    </tr>    <tr>      <th>31</th>      <td>32</td>      <td>Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Neoplasms, Head and Neck</td>      <td>Drug: GSK3359609|Drug: Pembrolizumab|Drug: Placebo|Drug: Platinum based chemotherapy|Drug: Fluorouracil (5FU)</td>      <td>GlaxoSmithKline|Merck Sharp &amp; Dohme Corp.</td>      <td>Phase 3</td>      <td>640.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>11-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04428333</td>    </tr>    <tr>      <th>32</th>      <td>33</td>      <td>Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Squamous Cell Carcinoma of Head and Neck</td>      <td>Drug: Pembrolizumab|Drug: Lenvatinib|Drug: Docetaxel|Drug: Capecitabine|Drug: Paclitaxel|Drug: Cetuximab</td>      <td>Merck Sharp &amp; Dohme Corp.|Eisai Inc.</td>      <td>Phase 2</td>      <td>400.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>11-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04428151</td>    </tr>    <tr>      <th>33</th>      <td>34</td>      <td>Moisture Management Liner Effectiveness Study</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Amputation Stumps|Amputees|Amputation|Lower Limb Deformities, Congenital|Prosthesis User|Prosthesis</td>      <td>Device: Moisture Management Liner|Device: ICE Socket Cooling System</td>      <td>Liberating Technologies, Inc.|Vivonics, Inc.</td>      <td>Not Applicable</td>      <td>12.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>11-Jun-20</td>      <td>Liberating Technologies, Inc., Holliston, Massachusetts, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04427007</td>    </tr>    <tr>      <th>34</th>      <td>35</td>      <td>Study to Gather Information on Safety and Use of High Dose Aflibercept Injection Into the Eye in Patients With an Age Related Eye Disorder That Causes Blurred Vision or a Blind Spot Due to Abnormal Blood Vessels That Leak Fluid Into the Light Sensitive Lining Inside the Eye</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Neovascular Age-Related Macular Degeneration</td>      <td>Drug: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)|Drug: Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)</td>      <td>Bayer|Regeneron Pharmaceuticals</td>      <td>Phase 3</td>      <td>960.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>9-Jun-20</td>      <td>Arizona Retina and Vitreous Consultants - Research, Phoenix, Arizona, United States|Retina Consultants of Orange County, Fullerton, California, United States|University of California San Diego, La Jolla, California, United States|Jules Stein Eye Institute, UCLA, Los Angeles, California, United States|Northern California Retina-Vitreous Associates, Mountain View, California, United States|California Eye Specialists, Pasadena, California, United States|Retina Consultants of Southern California, Redlands, California, United States|Southern California Permanente Medical Group, Riverside, California, United States|Retina Consultants San Diego, San Diego, California, United States|New England Retina Associates, New London, Connecticut, United States|Florida Eye Clinic, Altamonte Springs, Florida, United States|Retina Group of Florida, Fort Lauderdale, Florida, United States|Southern Vitreoretinal Associates, Gainesville, Florida, United States|Florida Retina Institute, Jacksonville, Florida, United States|Florida Eye Associates, Melbourne, Florida, United States|Retina Macula Specialists of Miami, Miami, Florida, United States|Florida Retina Institute, Orlando, Florida, United States|Retina Specialists, Pensacola, Florida, United States|Retina Vitreous Associates of Florida - Saint Petersburg, Saint Petersburg, Florida, United States|Southern Vitreoretinal Associates, Tallahassee, Florida, United States|Retina Consultants of Hawaii, \'Aiea, Hawaii, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|University Retina and Macula Associates, Oak Forest, Illinois, United States|Illinois Retina Associates, S.C., Skokie, Illinois, United States|Retina Care Center, Baltimore, Maryland, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Vitreo Retinal Surgery PA, Edina, Minnesota, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Retina Consultants of Nevada, Las Vegas, Nevada, United States|Retina Center of New Jersey, Bloomfield, New Jersey, United States|NJ Retina, Edison, New Jersey, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|Long Island Vitreoretinal Consultants, Great Neck, New York, United States|Long Island Vitreoretinal Consultants, Hauppauge, New York, United States|Ophthalmic Consultants of Long Island, Lynbrook, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Midwest Retina - Main Office, Dublin, Ohio, United States|Retina Northwest, PC, Portland, Oregon, United States|Retina Consultants, LLC, Salem, Oregon, United States|Mid Atlantic Retina, Bethlehem, Pennsylvania, United States|Erie Retinal Surgery, Inc., Erie, Pennsylvania, United States|Eye Care Specialists, Kingston, Pennsylvania, United States|Charleston Neuroscience Center, Charleston, South Carolina, United States|Palmetto Retina Center, LLC - Florence, Florence, South Carolina, United States|Palmetto Retina Center, LLC, West Columbia, South Carolina, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Charles Retina Institute, Memphis, Tennessee, United States|Vanderbilt University Medical School, Nashville, Tennessee, United States|Austin Retina Associates, Austin, Texas, United States|Texas Retina Associates, Fort Worth, Texas, United States|Retina Consultants of Houston, Houston, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Retinal Consultants of San Antonio, San Antonio, Texas, United States|Retina Consultants of Houston, The Woodlands, Texas, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Retina Institute of Virginia, Richmond, Virginia, United States|Spokane Eye Clinical Research, Spokane, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|University of Wisconsin - Madison, Madison, Wisconsin, United States|Centro Oftalmologico Miramar (COMir), Miramar, Buenos Aires, Argentina|Clínia Panamericana - Centro de Ojos Dr. Nano, Olivos, Buenos Aires, Argentina|Hospital Universitario Austral, Pilar, Buenos Aires, Argentina|Organizacion Medica de Investigacion (OMI), Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Fundación Zambrano, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Grupo Laser Vision, Rosario, Santa Fe, Argentina|Fundacion Ver Centro privado de Ojos Romagosa SA, Córdoba, Argentina|Eyeclinic Albury Wodonga, Albury, New South Wales, Australia|Sydney Retina Clinic, Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Hobart Eye Surgeons, Hobart, Tasmania, Australia|Marsden Eye Surgery Center, Parramatta, Australia|Klinikum Klagenfurt am Wörthersee, Klagenfurt, Kärnten, Austria|Kepler Universitätsklinikum Campus III, Linz, Oberösterreich, Austria|Konventhospital Barmherzige Brüder Linz, Linz, Oberösterreich, Austria|Medizinische Universität Graz, Graz, Steiermark, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|Hanusch-Krankenhaus Wien, Wien, Austria|Oogartsenpraktijk Alken, Alken, Limburg, Belgium|SOHAT Pentagram, Sofia, Bulgaria|Spec. Hosp. for Active Treatment for Eye Diseases Zrenie, Sofia, Bulgaria|UMHAT Alexandrovska EAD, Sofia, Bulgaria|University Eye Hospital - Akad. Pashev, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Sveta Sofia, Sofia, Bulgaria|Spec. Hospital For Active Treatment of Eye Diseases Zora, Sofia, Bulgaria|Sveta Petka Eye Hospital, Varna, Bulgaria|Misericordia Health Centre, Winnipeg, Manitoba, Canada|St.Joseph\'s Health Care-London, London, Ontario, Canada|Toronto Retina Institute, Toronto, Ontario, Canada|Institut de l\'Oeil des Laurentides, Boisbriand, Quebec, Canada|Clínica Oftalmológica San Diego, Medellín, Antioquia, Colombia|IPS Centro Médico Imbanaco de Cali S.A., Cali, Valle Del Cauca, Colombia|Fakultni Nemocnice Brno, Brno, Czechia|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Ostrava, Ostrava, Czechia|Fakultni nemocnice Plzen, Plzen, Czechia|Charles University in Prague, Prague, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|Lexum a.s., Evropska ocni klinika, Praha 4, Czechia|AXON Clinical s.r.o., Praha 5, Czechia|Aalborg Universitetshospital, Aalborg, Denmark|Copenhagen University Hospital Roskilde, Roskilde, Denmark|East Viru Central Hospital, Kohtla-Jarve, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Dr. Kai Noor Silmakabinet OU, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Avicenne - Bobigny, Bobigny, France|LTD "Clinic LJ", Kutaisi, Georgia|JSC "Evex Hospitals\', Tbilisi, Georgia|LTD "Innova", Tbilisi, Georgia|LTD Israeli-Georgian Medical Research Clinic "Helsicore", Tbilisi, Georgia|LTD "Chichua Medical Center MZERA", Tbilisi, Georgia|Aversi Clinic, Tbilisi, Georgia|Universitätsklinikum Freiburg, Freiburg, Baden-Württemberg, Germany|Universitätsklinikum Regensburg, Regensburg, Bayern, Germany|Klinikum Darmstadt, Darmstadt, Hessen, Germany|Universitätsklinik Gießen und Marburg GmbH, Marburg, Hessen, Germany|Universitätsmedizin der Georg-August-Universität Göttingen, Göttingen, Niedersachsen, Germany|Medizinische Hochschule Hannover (MHH), Hannover, Niedersachsen, Germany|Universitätsklinikum Aachen, Aachen, Nordrhein-Westfalen, Germany|Medizinische Einrichtungen der Universität Bonn, Bonn, Nordrhein-Westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Augenzentrum am St. Franziskus-Hospital, Münster, Nordrhein-Westfalen, Germany|Universitätsklinikum Leipzig AöR, Leipzig, Sachsen, Germany|Universitätsklinikum Schleswig-Holstein (UKSH), Kiel, Schleswig-Holstein, Germany|Sankt Gertrauden Krankenhaus, Berlin, Germany|Charité Campus Benjamin Franklin (CBF), Berlin, Germany|Queen Mary Hospital, Hong Kong, Hong Kong|Hong Kong Eye Hospital, Kowloon, Hong Kong|Szent-Gyorgyi Albert Orvostudomanyi Egyetem, Szeged, Hungary|HaEmek Medical Center, Afula, Israel|Barzilai Medical Center, Ashkelon, Israel|Soroka University Medical Center, Beer Sheva, Israel|Rambam Health Corporation, Haifa, Israel|Bnai Zion Medical Center, Haifa, Israel|Lady Davis Carmel Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Hebrew University Hospital Ein Kerem, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Clalit Health Services through Rabin Medical Center - Beilinson Campus, Petah Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rehovot, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Assuta Medical Centers - HaShalom, Tel Aviv, Israel|Shamir Medical Center (Assaf Harofeh), Zerifin, Israel|ASL2 Lanciano-Vasto-Chieti, Chieti, Abruzzo, Italy|A.O.U. di Bologna Policlinico S.Orsola Malpighi, Bologna, Emilia-Romagna, Italy|ASU Giuliano Isontina, Trieste, Friuli-Venezia Giulia, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, Lazio, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio, Italy|IRCCS Fondazione G.B. Bietti Studio e Ricerca in Otalmologia, Roma, Lazio, Italy|IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy|ASST Fatebenefratelli Sacco, Milano, Lombardia, Italy|A.O.U. di Cagliari, Cagliari, Sardegna, Italy|A.O.U. Policlinico - Vittorio Emanuele, Catania, Sicilia, Italy|A.O. di Perugia, Perugia, Umbria, Italy|A.O. di Padova, Padova, Veneto, Italy|Daiyukai Daiichi Hospital, Ichinomiya, Aichi, Japan|Aichi Medical University Hospital, Nagakute, Aichi, Japan|Sugita Eye Hospital, Nagoya, Aichi, Japan|Nagoya University Hospital, Nagoya, Aichi, Japan|Nagoya City University Hospital, Nagoya, Aichi, Japan|Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan|Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Southern Tohoku Eye Clinic, Koriyama, Fukushima, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan|Kobe University Hospital, Kobe, Hyogo, Japan|Kozawa Eye Hospital and Diabetes Center, Mito, Ibaraki, Japan|Kanazawa Medical University Hospital, Kahoku-gun, Ishikawa, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kagawa University Hospital, Kita-gun, Kagawa, Japan|Dannoue Eye Clinic, Kawasaki, Kanagawa, Japan|Otakeganka Tsukimino Clinic, Yamato, Kanagawa, Japan|Kochi Medical School Hospital, Nankoku, Kochi, Japan|Mie University Hospital, Tsu, Mie, Japan|Tohoku Medical and Pharmaceutical University Hospital, Sendai, Miyagi, Japan|Shinshu University Hospital, Matsumoto, Nagano, Japan|Nara Medical University Hospital, Kashihara, Nara, Japan|Oita University Hospital, Yufu, Oita, Japan|Kurashiki Medical Center, Kurashiki, Okayama, Japan|University of the Ryukyus Hospital, Nakagami, Okinawa, Japan|Kansai Medical University Hospital, Hirakata, Osaka, Japan|Kansai Medical University Medical Center, Moriguchi, Osaka, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan|Shiga University of Medical Science Hospital, Otsu, Shiga, Japan|Dokkyo Medical University Hospital, Shimotsuga-gun, Tochigi, Japan|The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan|Chofu Eye Clinic, Chofu, Tokyo, Japan|St.Luke\'s International Hospital, Chuoku, Tokyo, Japan|Muranaka Eye Clinic, Itabashi-ku, Tokyo, Japan|National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, Japan|Yamaguchi University Hospital, Ube, Yamaguchi, Japan|University of Yamanashi Hospital, Chuo, Yamanashi, Japan|Yamanashi Prefectural Central Hospital, Kofu, Yamanashi, Japan|Akita University Hospital, Akita, Japan|Aomori Prefectural Central Hospital, Aomori, Japan|Hayashi Eye Hospital, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Hiroshima University Hospital, Hiroshima, Japan|Ideta Heisei Retina Consultants, Kumamoto, Japan|University of Miyazaki Hospital, Miyazaki, Japan|Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan|Okayama University Hospital, Okayama, Japan|Sumitomo Hospital, Osaka, Japan|Osaka City University Hospital, Osaka, Japan|Japanese Red Cross Saitama Hospital, Saitama, Japan|Tokushima University Hospital, Tokushima, Japan|Japanese Red Cross Wakayama Medical center, Wakayama, Japan|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggido, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Retina Center Nune Eye Hospital, Seoul, Korea, Republic of|Signes Ozolinas Doctor Praxis in Ophthalmology, Jelgava, Latvia|Department of Ophthalmology, Riga, Latvia|Riga East Clinical University Hospital "Gailezers", Riga, Latvia|Latvian American Eye Center, Riga, Latvia|Lithuanian university of Health science, Kaunas, Lithuania|PI Klaipedos University Hospital, Klaipeda, Lithuania|Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania|Oogziekenhuis, Rotterdam, Netherlands|Hospital de Vila Franca de Xira, Vila Franca de Xira, Lisboa, Portugal|CHVNGE - Hospital Eduardo Santos Silva, Vila Nova de Gaia, Porto, Portugal|AIBILI, Coimbra, Portugal|CHL - Hospital Santo Andre, Leiria, Portugal|ALM Oftalmolaser - Oftalmologia Medica e Cirurgica, Lisboa, Portugal|CHLC - Hospital dos Capuchos, Lisboa, Portugal|CHUP - Hospital Santo Antonio, Porto, Portugal|ULSAM - Hospital Santa Luzia, Viana do Castelo, Portugal|Irkutsk Branch of FBSI IRTC "Eye Microsurgery", Irkutsk, Russian Federation|Scientific Research Institution of Ophthalmic Diseases, Moscow, Russian Federation|FBSI IRTC Eye Microsurgery n.a. acad. S.N. Fyodorov, Moscow, Russian Federation|Regional Ophthalmological Hospital n. a. T.I. Eroshevsky, Samara, Russian Federation|St. Petersburg Medical University n.a. I.P. Pavlov, St. Petersburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical hospital center Zvezdara, Belgrade, Serbia|Clinical Center Nis, Nis, Serbia|Klinicki centar Vojvodine, Novi Sad, Serbia|National University Hospital, Singapore, Singapore|Singapore National Eye Centre, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|Fakultna nemocnica Nitra, Nitra, Slovakia|Nemocnica s Poliklinikou Trebisov, Svet zdravia a.s., Trebisov, Slovakia|Fakultna nemocnica Trencin, Trencin, Slovakia|Fakultna nemocnica s poliklinikou Zilina, Zilina, Slovakia|Instituto Oftalmológico Francisco Gomez Ulla, Santiago de Compostela, A Coruña, Spain|Vissum Corporacion Alicante, Alicante, Spain|Hospital de l\'Esperança, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain|Hospital del Rio Hortega, Valladolid, Spain|Hospital Miguel Servet, Zaragoza, Spain|Universitätsspital Basel, Basel, Basel-Stadt, Switzerland|RétinElysée, Lausanne, Vaud, Switzerland|Berner Augenklinik am Lindenhofspital, Bern, Switzerland|Centre Ophtalmologique de Rive, Genève, Switzerland|Stadtspital Triemli, Zürich, Switzerland|Changhua Christian Hospital, Changhua, Taiwan|Veterans General Hospital, Kaoshiung, Taiwan|Shing-Kong Wu Ho-Su Memorial Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Kharkiv Ophthalmological Clinic #14 named by Hirshman, Kharkiv, Ukraine|Centralna Polyclinica MVS Ukraiiny, Kyiv, Ukraine|Health Technology Ltd. - Ophthalmic Medical Center, Odesa, Ukraine|Poltava Regional Clinical Hospital n.a. M.V. Skliphosovskyi, Poltava, Ukraine|Ophthalmology Clinic of Professor Sergienko, Vinnitsya, Ukraine|Frimley Park Hospital NHS, Camberley, Surrey, United Kingdom|Sunderland Eye Infirmary, Sunderland, Tyne And Wear, United Kingdom|Hospital of St. Cross, Rugby, Warwickshire, United Kingdom|Bristol Eye Hospital, Bristol, United Kingdom|Moorfields Eye Hospital, London, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04423718</td>    </tr>    <tr>      <th>35</th>      <td>36</td>      <td>ImmuneSense Lyme Study</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Lyme Disease</td>      <td>Diagnostic Test: immunoSEQ Dx</td>      <td>Adaptive Biotechnologies|Iqvia Pty Ltd</td>      <td>NaN</td>      <td>990.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>9-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04422314</td>    </tr>    <tr>      <th>36</th>      <td>37</td>      <td>The Chronic Effects of Carnitine on Recovery</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Muscle Soreness|Muscle Damage|Resistance Training|Oxidative Stress|Muscle Strength</td>      <td>Dietary Supplement: Carnipure|Other: Resistance Training</td>      <td>Applied Science &amp; Performance Institute|Lonza Ltd.</td>      <td>Not Applicable</td>      <td>82.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>9-Jun-20</td>      <td>The Applied Science and Performance Institute, Tampa, Florida, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04420377</td>    </tr>    <tr>      <th>37</th>      <td>38</td>      <td>Hydrolyzed Fish Cartilage Effect on Knee Joint Functionality and Discomfort in Adult Population</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Knee Discomfort</td>      <td>Dietary Supplement: Cartidyss</td>      <td>Abyss Ingredients|Artialis</td>      <td>Not Applicable</td>      <td>30.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care</td>      <td>9-Jun-20</td>      <td>Centre medical Chant d\'Oiseau, Woluwe-Saint-Pierre, Bruxelles, Belgium|CHU-Liege-Coordinating Center Liege, Liège, Liege, Belgium|Hopital Princesse Paola, VIVALIA, Marche-en-Famenne, Belgium</td>      <td>https://ClinicalTrials.gov/show/NCT04420091</td>    </tr>    <tr>      <th>38</th>      <td>39</td>      <td>Safety Study of SAR442720 in Combination With Pembrolizumab in Patients With Advanced Malignancies</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Metastatic Neoplasm</td>      <td>Drug: SAR442720|Drug: Pembrolizumab</td>      <td>Sanofi|Revolution Medicines, Inc.</td>      <td>Phase 1</td>      <td>24.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>5-Jun-20</td>      <td>Investigational Site Number 8400001, Houston, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04418661</td>    </tr>    <tr>      <th>39</th>      <td>40</td>      <td>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Advanced Solid Tumor|B Cell Lymphoma</td>      <td>Drug: CN1</td>      <td>Curon Biopharmaceutical (Australia) Co Pty Ltd|Novotech (Australia) Pty Limited</td>      <td>Phase 1</td>      <td>22.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>5-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04418141</td>    </tr>    <tr>      <th>40</th>      <td>41</td>      <td>A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Moderate to Severe Atopic Hand and Foot Dermatitis</td>      <td>Drug: Dupilumab|Drug: Placebo</td>      <td>Regeneron Pharmaceuticals|Sanofi</td>      <td>Phase 3</td>      <td>130.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>5-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04417894</td>    </tr>    <tr>      <th>41</th>      <td>42</td>      <td>First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Advanced Solid Tumors Cancer</td>      <td>Drug: ABBV-CLS-579|Drug: Programmed Cell Death-1 (PD-1) Inhibitor</td>      <td>Calico Life Sciences LLC|AbbVie</td>      <td>Phase 1</td>      <td>43.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>4-Jun-20</td>      <td>Carolina BioOncology Institute, Huntersville, North Carolina, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04417465</td>    </tr>    <tr>      <th>42</th>      <td>43</td>      <td>Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Chronic Hepatitis B</td>      <td>Drug: VIR-2218|Drug: pegylated interferon-alfa 2a</td>      <td>Vir Biotechnology, Inc.|Alnylam Pharmaceuticals</td>      <td>Phase 2</td>      <td>105.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>2-Jun-20</td>      <td>Investigative Site, Birtinya, Queensland, Australia|Investigative Site, Fitzroy, Victoria, Australia|Investigative site, Hong Kong, Hong Kong|Investigative Site, Busan, Korea, Republic of|Investigative Site, Chuncheon, Korea, Republic of|Investigative Site, Daegu, Korea, Republic of|Investigative Site, Seoul, Korea, Republic of|Investigative Site, Seoul, Korea, Republic of|Investigative Site, Yangsan, Korea, Republic of|Investigative Site, Batu Caves, Malaysia|Investigative Site, Kajang, Malaysia|Investigative Site, Kuala Lumpur, Malaysia|Investigative Site, Kuantan, Malaysia|Investigative Site, Auckland, New Zealand|Investigative Site, Auckland, New Zealand|Investigative Site, Bangkok, Thailand|Investigative Site, Bangkok, Thailand|Investigative Site, Bangkok, Thailand|Investigative Site, Chiang Mai, Thailand|Investigative Site, Hat Yai, Thailand|Investigative Site, Khlong Luang, Thailand|Investigative Site, Khon Kaen, Thailand</td>      <td>https://ClinicalTrials.gov/show/NCT04412863</td>    </tr>    <tr>      <th>43</th>      <td>44</td>      <td>ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Advanced EGFR Positive Solid Tumor</td>      <td>Biological: ZZ06</td>      <td>Changchun Intellicrown Pharmaceutical Co. LTD|Covance</td>      <td>Phase 1</td>      <td>60.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>2-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04412616</td>    </tr>    <tr>      <th>44</th>      <td>45</td>      <td>A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Melanoma|Melanoma Stage III|Melanoma Stage IV|Melanoma (Skin)</td>      <td>Biological: Bempegaldesleukin|Biological: Nivolumab</td>      <td>Nektar Therapeutics|Bristol-Myers Squibb</td>      <td>Phase 3</td>      <td>950.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>1-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04410445</td>    </tr>    <tr>      <th>45</th>      <td>46</td>      <td>Study of Roxadustat Conversion in Subjects Receiving Stable ESA or as Initial Anemia Treatment in Chronic Dialysis Patients</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Anemia Associated With End Stage Renal Disease (ESRD)</td>      <td>Drug: Roxadustat</td>      <td>FibroGen|AstraZeneca</td>      <td>Phase 3</td>      <td>200.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>1-Jun-20</td>      <td>Investigational Site, Meridian, Idaho, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04410198</td>    </tr>    <tr>      <th>46</th>      <td>47</td>      <td>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>COVID-19 Pneumonia</td>      <td>Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo</td>      <td>Hoffmann-La Roche|Gilead Sciences</td>      <td>Phase 3</td>      <td>450.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>1-Jun-20</td>      <td>Valleywise Health Medical Center, Phoenix, Arizona, United States|eStudySite - Chula Vista - PPDS, Chula Vista, California, United States|Hoag Hospital Irvine, Irvine, California, United States|Providence St. John\'s Health Center, Santa Monica, California, United States|Holy Cross Hospital Inc, Fort Lauderdale, Florida, United States|University of Miami Miller School of Medicine; Clinical Reseach Building, Miami, Florida, United States|St Luke\'s Health System; Rheumatology Research, Boise, Idaho, United States|Rush University Medical Center, Chicago, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|St. Michael\'S Medical Center, Newark, New Jersey, United States|Wyckoff Heights Medical Center, Staten Island, New York, United States|Novant Health Clinical Research, Charlotte, North Carolina, United States|Cone Health Medical Group, Greensboro, North Carolina, United States|OhioHealth Research Institute, Columbus, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Allegheny Health Network (Pittsburg PA), Pittsburgh, Pennsylvania, United States|Baylor St. Luke\'s Medical Center, Houston, Texas, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States|The Providence Regional Medical Center Everett, Everett, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, MG, Brazil|Instituto de Pesquisa Clinica Evandro Chagas - IPEC FIOCRUZ, Rio de Janeiro, RJ, Brazil|Faculdade de Medicina do ABC - FMABC, Santo Andre, SP, Brazil|Instituto de Infectologia Emilio Ribas, Sao Paulo, SP, Brazil|Instituto do Coração - HCFMUSP, Sao Paulo, SP, Brazil</td>      <td>https://ClinicalTrials.gov/show/NCT04409262</td>    </tr>    <tr>      <th>47</th>      <td>48</td>      <td>Comparison of Sleep Disordered Breathing Events Detected by the CPAP Device "prismaLine" With Polysomnography</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Sleep Apnea Syndromes</td>      <td>Other: CPAP Treatment</td>      <td>Institut für Pneumologie Hagen Ambrock eV|Heinen und Löwenstein GmbH &amp; Co. KG</td>      <td>Not Applicable</td>      <td>50.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic</td>      <td>29-May-20</td>      <td>Kliniken Essen-Mitte, Evang. Huyssens-Stiftung/Knappschaft gGmbH, Essen, NRW, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04407949</td>    </tr>    <tr>      <th>48</th>      <td>49</td>      <td>A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Cardiovascular Disease</td>      <td>Drug: 14C]AZD4831 Oral Solution</td>      <td>AstraZeneca|Quotient Sciences</td>      <td>Phase 1</td>      <td>6.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>29-May-20</td>      <td>Quotient Sciences Limited, Ruddington, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04407091</td>    </tr>    <tr>      <th>49</th>      <td>50</td>      <td>Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HD</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Huntington Disease</td>      <td>NaN</td>      <td>Triplet Therapeutics, Inc.|Medpace, Inc.</td>      <td>NaN</td>      <td>60.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>28-May-20</td>      <td>Centre for Movement Disorders, Toronto, Ontario, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04406636</td>    </tr>    <tr>      <th>50</th>      <td>51</td>      <td>Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Cervical Cancer|Cervix Cancer</td>      <td>Biological: VB10.16|Biological: Atezolizumab</td>      <td>Vaccibody AS|Roche Pharma AG</td>      <td>Phase 2</td>      <td>50.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>28-May-20</td>      <td>Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Hopital de Libramont, Bruxelles, Belgium|Universitair Ziekenhuis Gent (Uz Gent), Gent, Belgium|Chu Ucl Namur, Namur, Belgium|Multiprofile Hospital for Active Treatment for Women\'s Health - Nadezhda Sofia, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski", Sofia, Bulgaria|Multiprofile Hospital for Active Treatment "Serdika"" EOOD, Sofia, Bulgaria|University Multiprofile Hospital For Active Treatment Sofiamed, Sofia, Bulgaria|Masaryk Memorial Cancer Institute, Brno, Czechia|Nemocnice Pardubickeho Kraje Pardubicka Nemocnice, Pardubice, Czechia|University Hospital Kralovske Vinohrady, Praha, Czechia|Nemocnice Na Bulovce, Praha, Czechia|Oslo University Hospital, Oslo, Norway</td>      <td>https://ClinicalTrials.gov/show/NCT04405349</td>    </tr>    <tr>      <th>51</th>      <td>52</td>      <td>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With Moderate to Severe COVID-19 Pneumonia</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>COVID-19|ARDS</td>      <td>Biological: SOC plus 15mg/kg EB05 IV|Other: SOC plus Placebo IV</td>      <td>Edesa Biotech Inc.|JSS Medical Research Inc.</td>      <td>Phase 2|Phase 3</td>      <td>865.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment</td>      <td>26-May-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04401475</td>    </tr>    <tr>      <th>52</th>      <td>53</td>      <td>The Effect of Dupilumab on Lung Function and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Asthma</td>      <td>Drug: Dupilumab SAR231893|Drug: Placebo</td>      <td>Sanofi|Regeneron Pharmaceuticals</td>      <td>Phase 4</td>      <td>153.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment</td>      <td>22-May-20</td>      <td>Investigational Site Number 8400005, Charlotte, North Carolina, United States|Investigational Site Number 8400013, Greenville, South Carolina, United States|Investigational Site Number 8400004, Spartanburg, South Carolina, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04400318</td>    </tr>    <tr>      <th>53</th>      <td>54</td>      <td>A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>HIV Infections</td>      <td>Drug: CAB OLI|Drug: CAB LA|Drug: RPV OLI|Drug: RPV LA|Other: Continuous Quality Improvement (CQI) calls</td>      <td>ViiV Healthcare|Janssen Pharmaceuticals</td>      <td>Phase 3</td>      <td>450.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>22-May-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04399551</td>    </tr>    <tr>      <th>54</th>      <td>55</td>      <td>Moisturizer Mediated Prevention of Symptoms of Atopic Dermatitis in Early Childhood</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Atopic Dermatitis|Infant, Newborn</td>      <td>Drug: SanaCutan Basiscreme</td>      <td>Infectopharm Arzneimittel GmbH|Gesellschaft für Therapieforschung mbH</td>      <td>Phase 3</td>      <td>360.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention</td>      <td>21-May-20</td>      <td>Charité Universitätsmedizin, Berlin, Germany|Evangelisches Klinikum Bethel, Bielefeld, Germany|St. Marien-Hospital, Bonn, Germany|Barmherzige Brüder Klinik St. Hedwig, Regensburg, Germany|Gemeinschaftspraxis für Kinder- und Jugendmedizin, Tuttlingen, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04398758</td>    </tr>    <tr>      <th>55</th>      <td>56</td>      <td>European Non-interventional Study on Refractory Epilepsy With Developmental Delay.</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Refractory Epilepsy|Development Delay</td>      <td>NaN</td>      <td>Zogenix, Inc.|Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.</td>      <td>NaN</td>      <td>1000.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Case-Only|Time Perspective: Retrospective</td>      <td>21-May-20</td>      <td>Birmingham Children\'s Hospital, Birmingham, United Kingdom|Department of Paediatric Neurology, Bristol Royal Hospital for Children, Bristol, United Kingdom|Paedicatric Neurology Addenbrooke\'s Hospital, Cambridge, United Kingdom|Noah\'s Ark Children\'s Hospital for Wales, Cardiff, United Kingdom|The Alan Richens Welsh Epilepsy Unit, University Hospital of Wales, Cardiff, United Kingdom|Royal Hospital for Children, Glasgow, United Kingdom|Guys &amp; St Thomas\' NHS Foundation Trust, Evelina London Children\'s Hospital, Paediatric Neurology, London, United Kingdom|Royal Victoria Infirmary, Newcastle upon Tyne Hospitals, Newcastle Upon Tyne, United Kingdom|Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom|University Hospital Plymouth NHS Trust, Plymouth, United Kingdom|Ryegate Children\'s Centre, Sheffield Children\'s NHS Foundation Trust, Sheffield, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04398667</td>    </tr>    <tr>      <th>56</th>      <td>57</td>      <td>A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Squamous Cell Carcinoma of the Oropharynx</td>      <td>Drug: ISA101B</td>      <td>ISA Pharmaceuticals|Regeneron Pharmaceuticals</td>      <td>Phase 2</td>      <td>86.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>21-May-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04398524</td>    </tr>    <tr>      <th>57</th>      <td>58</td>      <td>First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Ovarian Cancer|Nonsmall Cell Lung Cancer</td>      <td>Biological: XMT-1592</td>      <td>Mersana Therapeutics|IQVIA Biotech</td>      <td>Phase 1|Phase 2</td>      <td>120.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>20-May-20</td>      <td>Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States|Mary Crowley Cancer Research Center, Dallas, Texas, United States|NEXT Oncology, San Antonio, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04396340</td>    </tr>    <tr>      <th>58</th>      <td>59</td>      <td>Safety and Efficacy of JointAlive™ on the Knee-joint Function in Adults With Knee Arthritis</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Osteo Arthritis Knee</td>      <td>Dietary Supplement: JointAlive™|Dietary Supplement: Placebo</td>      <td>Chenland Nutritionals Inc.|KGK Science Inc.</td>      <td>Not Applicable</td>      <td>72.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>20-May-20</td>      <td>KGK Science Inc, London, Ontario, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04395547</td>    </tr>    <tr>      <th>59</th>      <td>60</td>      <td>Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Eosinophilic Esophagitis (EoE)</td>      <td>Drug: Dupilumab|Drug: Matching Placebo</td>      <td>Regeneron Pharmaceuticals|Sanofi</td>      <td>Phase 3</td>      <td>60.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>19-May-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04394351</td>    </tr>    <tr>      <th>60</th>      <td>61</td>      <td>Observational Registry on the HARPOON Device</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Severe Degenerative Mitral Regurgitation Due to Mid-segment Posterior Leaflet Prolapse</td>      <td>Device: HARPOON Beating Heart Mitral Valve Repair System (MVRS)</td>      <td>Edwards Lifesciences|MedPass International</td>      <td>Not Applicable</td>      <td>150.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>19-May-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04393779</td>    </tr>    <tr>      <th>61</th>      <td>62</td>      <td>Study Evaluating the Safety and Efficacy of Tri-wire Balloon for Treatment of Dysfunctional AV Fistula</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Arteriovenous Fistula</td>      <td>Combination Product: Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter</td>      <td>BrosMed Medical Co., Ltd|CCRF Inc., Beijing, China</td>      <td>Not Applicable</td>      <td>168.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>19-May-20</td>      <td>Peking University First Hospital, Beijing, Beijing, China|Beijing Tongren Hospital, Beijing, Beijing, China|The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China|Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhengjiang, China</td>      <td>https://ClinicalTrials.gov/show/NCT04393688</td>    </tr>    <tr>      <th>62</th>      <td>63</td>      <td>Assessment of DAFILON® Suture Material in Oral Surgery (Mucosal Sutures)</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Oral Surgery|Tooth Extraction|Dental Implants</td>      <td>Device: Mucosal Closure</td>      <td>Aesculap AG|B.Braun Surgical SA</td>      <td>NaN</td>      <td>105.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>15-May-20</td>      <td>Praxisklinik für Mund-, Kiefer- und Gesichtschirurgie, Ästhetische und Plastische Chirurgie, Esslingen am Neckar, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04390620</td>    </tr>    <tr>      <th>63</th>      <td>64</td>      <td>To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Type 2 Diabetes Mellitus|NASH - Nonalcoholic Steatohepatitis</td>      <td>Drug: XW003|Drug: Volume-matching Placebo</td>      <td>Sciwind Biosciences APAC CO Pty. Ltd.|Novotech (Australia) Pty Limited</td>      <td>Phase 1</td>      <td>50.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>15-May-20</td>      <td>Nucleus Network, Melbourne, Victoria, Australia</td>      <td>https://ClinicalTrials.gov/show/NCT04389775</td>    </tr>    <tr>      <th>64</th>      <td>65</td>      <td>Safety and Efficacy Study of Qualia Mind on Cognition in a Healthy Population</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Healthy|Cognitive Function</td>      <td>Dietary Supplement: Qualia Mind|Dietary Supplement: Placebo</td>      <td>Neurohacker Collective|KGK Science Inc.</td>      <td>Not Applicable</td>      <td>60.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other</td>      <td>15-May-20</td>      <td>Great Lakes Clinical Trials, Chicago, Illinois, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04389723</td>    </tr>    <tr>      <th>65</th>      <td>66</td>      <td>Follow-up Study of Growth, Safety, and Efficacy of an Infant Formula for Healthy Term Infants</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Healthy|Term Infants</td>      <td>Other: Study Formula (SF)|Other: Comparator Formula (CF)</td>      <td>ByHeart|Paidion Research, Inc.</td>      <td>Not Applicable</td>      <td>300.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other</td>      <td>15-May-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04389606</td>    </tr>    <tr>      <th>66</th>      <td>67</td>      <td>Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Advanced Hematologic Malignancy or Solid Tumor</td>      <td>NaN</td>      <td>iOMEDICO AG|Bristol-Myers Squibb</td>      <td>NaN</td>      <td>500.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Other</td>      <td>15-May-20</td>      <td>MVZ am Klinikum Aschaffenburg, Aschaffenburg, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04389541</td>    </tr>    <tr>      <th>67</th>      <td>68</td>      <td>Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>HIV-1-infection</td>      <td>Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)</td>      <td>The Crofoot Research Center, Inc.|Janssen Scientific Affairs, LLC</td>      <td>Phase 4</td>      <td>100.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>14-May-20</td>      <td>The Crofoot Research Center, Inc., Houston, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04388904</td>    </tr>    <tr>      <th>68</th>      <td>69</td>      <td>Study to Assess VPM1002 in Reducing Healthcare Professionals\' Absenteeism in COVID-19 Pandemic</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Infection, Respiratory Tract</td>      <td>Biological: VPM1002|Biological: Placebo</td>      <td>Vakzine Projekt Management GmbH|FGK Clinical Research GmbH</td>      <td>Phase 3</td>      <td>1200.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention</td>      <td>13-May-20</td>      <td>Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|SocraTec R&amp;D GmbH, Erfurt, Thüringen, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04387409</td>    </tr>    <tr>      <th>69</th>      <td>70</td>      <td>A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Bipolar I Depression</td>      <td>Drug: Lurasidone HCl|Drug: Placebo</td>      <td>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.|Sunovion</td>      <td>Phase 3</td>      <td>362.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>12-May-20</td>      <td>Beijing HuiLongGuan Hospital, Beijing, Beijing, China|Peking University 6th Hospital, Beijing, Beijing, China|The 1st Hospital of Hebei Medical University, Beijing, Beijing, China|Chongqing Mental Health Center, Chongqing, Chongqing, China|Guangzhou Huiai Hospital, Guangzhou, Guangdong, China|The 2nd Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China|Wuhan Mental Health Center, Wuhan, Hubei, China|Brain Hospital of Hunan Province, Changsha, Hunan, China|Nanjing Brain Hospital, Nanjing, Jiangsu, China|Wuxi Mental Health Center, Wuxi, Jiangsu, China|Shanghai Mental Health Center, Shanghai, Shanghai, China|Shanghai Tongji Hospital, Shanghai, Shanghai, China|Mental Health Center of Xi\'an City, Xi\'an, Shanxi, China|Tianjin Anding Hospital, Tianjin, Tianjin, China|Urumqi 4th People\'s Hospital, Urumqi, Xinjiang, China|The 1st Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China|The 1st Hospital of Zhengjiang Provence, Hangzhou, Zhejiang, China</td>      <td>https://ClinicalTrials.gov/show/NCT04383691</td>    </tr>    <tr>      <th>70</th>      <td>71</td>      <td>Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Chronic Hepatitis C Virus Infection</td>      <td>Drug: P1101 + Ribavirin|Drug: PEG-Intron + Ribavirin</td>      <td>PharmaEssentia|Clinipace Worldwide</td>      <td>Phase 3</td>      <td>215.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>11-May-20</td>      <td>Beijing Ditan Hospital Capital Medical University, Beijing, China|Gansu Wuwei Tumour Hospital, Gansu, China|The First Hospital of Lanzhou University, Gansu, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China|Henan Provincial People\'s Hospital, Henan, China|Luoyang Central Hospital, Henan, China|The First Hospital of Jilin University, Jilin, China|Peace Hospital Affiliated to Changzhi Medical College, Shanxi, China|The Sixth People\'s Hospital of Shenyang, Shenyang, China|Tangdu Hospital, Fourth Military Medical University, Xi\'an, China|The Second Affiliated Hospital of Xi\'an Jiaotong University, Xi\'an, China|Xijing Hospital, Fourth Military Medical University, Xi\'an, China|Soonchunhyang University Seoul Hospital, Asan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Inha University Medical Center, Incheon, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Seoul, Korea, Republic of|Yonsei University Gangnam Severance Hospital, Seoul, Korea, Republic of|Saint Vincent Catholic Hospital, Suwon, Korea, Republic of|Changhua Christian Hospital, Changhua City, Taiwan|Chang Gung Memorial Hospital, Chiayi Branch, Chiayi City, Taiwan|Chia-Yi Christian Hospital, Chiayi City, Taiwan|Dalin Tzu Chi Hospital, Chiayi City, Taiwan|St. Martin De Porres Hospital, Chiayi City, Taiwan|Hualien Tzu Chi Hospital, Hualien City, Taiwan|Chang Gung Memorial Hospital, Kaohsiung Branch, Kaohsiung City, Taiwan|E-Da Hospital, Kaohsiung City, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan|Chang Gung Memorial Hospital, Keelung Branch, Keelung, Taiwan|Chang Gung Memorial Hospital, Linkou, New Taipei City, Taiwan|Taichung Veterans General Hospital, Taichung City, Taiwan|China Medical University Hospital, Taichung, Taiwan|Chi Mei Hospital, Liouying, Tainan City, Taiwan|Chi Mei Medical Center, Tainan City, Taiwan|National Cheng Kung University Hospital, Tainan City, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Taitung MacKay Memorial Hospital, Taitung, Taiwan|National Taiwan University Hospital Yun-Lin Branch, Yuanlin, Taiwan</td>      <td>https://ClinicalTrials.gov/show/NCT04382937</td>    </tr>    <tr>      <th>71</th>      <td>72</td>      <td>Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>COVID-19</td>      <td>Drug: Plitidepsin 1.5 mg/day|Drug: Plitidepsin 2.0 mg/day|Drug: Plitidepsin 2.5 mg/day</td>      <td>PharmaMar|Apices Soluciones S.L.</td>      <td>Phase 1</td>      <td>27.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>11-May-20</td>      <td>Hospital Universitario Hm Montepríncipe, Boadilla Del Monte, Madrid, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Ciudad Real, Ciudad Real, Spain|Hospital La Princesa, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04382066</td>    </tr>    <tr>      <th>72</th>      <td>73</td>      <td>A Study in Patients With a Descending TAA or PAU Treated With the E-nya Thoracic Stent Graft System</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Vascular Aneurysm</td>      <td>Device: endovascular repair</td>      <td>JOTEC GmbH|MedPass International</td>      <td>NaN</td>      <td>160.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>11-May-20</td>      <td>Universitätsklinikum Münster, Münster, NRW, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04381507</td>    </tr>    <tr>      <th>73</th>      <td>74</td>      <td>A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Recurrent Cervical Cancer|Metastatic Cervical Cancer</td>      <td>Biological: AK104</td>      <td>Akeso|Akesobio Australia Pty Ltd</td>      <td>Phase 2</td>      <td>40.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>8-May-20</td>      <td>South Florida Oncology &amp; Hematology Consultants, Plantation, Florida, United States|The Blavatnik Family - Chelsea Medical Center at Mount Sinai, New York, New York, United States|Northwell Health LLC, New York, New York, United States|First Health of Carolinas, Pinehurst, North Carolina, United States|University of Texas Southwestern, Dallas, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Pacific Gynecology Specialists, P. C., Seattle, Washington, United States|Monash Health, Clayton, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Adelaide Cancer Centre, Adelaide, Australia|Blacktown Hospital, Blacktown, Australia|ICON Cancer Centre, Brisbane, Australia</td>      <td>https://ClinicalTrials.gov/show/NCT04380805</td>    </tr>    <tr>      <th>74</th>      <td>75</td>      <td>Tableted COVID-19 Therapeutic Vaccine</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Covid19</td>      <td>Biological: V-SARS</td>      <td>Immunitor LLC|Immunitor Inc.</td>      <td>Phase 1|Phase 2</td>      <td>20.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>8-May-20</td>      <td>Immunitor Inc, Vancouver, BC - British Columbia, Canada|Aldar Bourinbayar, Ulaanbaatar, BZD, 3-khoroo, Mongolia</td>      <td>https://ClinicalTrials.gov/show/NCT04380532</td>    </tr>    <tr>      <th>75</th>      <td>76</td>      <td>A Study of NKTR-358 (LY3471851) in Healthy Participants</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy</td>      <td>Drug: LY3471851|Drug: Placebo</td>      <td>Eli Lilly and Company|Nektar Therapeutics</td>      <td>Phase 1</td>      <td>100.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science</td>      <td>8-May-20</td>      <td>PRA Health Sciences, Lenexa, Kansas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04380324</td>    </tr>    <tr>      <th>76</th>      <td>77</td>      <td>A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator\'s Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>COVID-19</td>      <td>Drug: IMU-838|Other: Placebo</td>      <td>Immunic AG|FGK Clinical Research GmbH</td>      <td>Phase 2|Phase 3</td>      <td>230.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>7-May-20</td>      <td>Military Medical Academy, Clinic of Infectious Diseases, Sofia, Bulgaria|UMHATEM N.I.Pirogov, Clinic of internal diseases, Sofia, Bulgaria|University Hospital Frankfurt, Infectious Diseases, Frankfurt, Germany|Clinic of the Hannover Medical School, Pneumology Clinic, Hannover, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04379271</td>    </tr>    <tr>      <th>77</th>      <td>78</td>      <td>A Study in Patients With Complicated Type B Aortic Dissection Treated With the E-nya Thoracic Stent Graft</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Vascular Diseases</td>      <td>Device: endovascular repair</td>      <td>JOTEC GmbH|MedPass International</td>      <td>NaN</td>      <td>160.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>7-May-20</td>      <td>Universitätsklinikum Münster, Münster, NRW, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04378361</td>    </tr>    <tr>      <th>78</th>      <td>79</td>      <td>Effect of Tebipenem on Normal Human Intestinal Microbiota</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Healthy Volunteers</td>      <td>Drug: TBPM-PI-HBr|Drug: amoxicillin-clavulanate</td>      <td>Spero Therapeutics|Iqvia Pty Ltd</td>      <td>Phase 1</td>      <td>30.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>6-May-20</td>      <td>Karolinska University Hospital, Huddinge, Stockholm, Sweden</td>      <td>https://ClinicalTrials.gov/show/NCT04376554</td>    </tr>    <tr>      <th>79</th>      <td>80</td>      <td>The Effect of Probiotic Added to Maternal Diet on Infantile Colic and Intestinal Microbiota Content</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Infantile Colic|Microbial Colonization|Crying</td>      <td>Dietary Supplement: Nobel Probiotics Drop|Dietary Supplement: Placebo</td>      <td>Halic University|Nobel Pharmaceuticals</td>      <td>Not Applicable</td>      <td>120.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention</td>      <td>5-May-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04374955</td>    </tr>    <tr>      <th>80</th>      <td>81</td>      <td>Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Hodgkin Lymphoma</td>      <td>Drug: Cemiplimab|Radiation: Involved-site radiotherapy (IS-RT)</td>      <td>Regeneron Pharmaceuticals|Sanofi</td>      <td>Phase 2</td>      <td>100.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>4-May-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04373083</td>    </tr>    <tr>      <th>81</th>      <td>82</td>      <td>Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>SARS-CoV-2 Infection|COVID-19</td>      <td>Biological: BNT162a1|Biological: BNT162b1|Biological: BNT162b2|Biological: BNT162c2|Other: Placebo</td>      <td>Biontech SE|Pfizer</td>      <td>Phase 1|Phase 2</td>      <td>7600.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention</td>      <td>30-Apr-20</td>      <td>Diablo Clinical Research, Inc., Walnut Creek, California, United States|Research Centers of America, Hollywood, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Meridian Clinical Research, LLC, Savannah, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Kentucky Pediatric/ Adult Research, Bardstown, Kentucky, United States|University of Maryland, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Investigational Pharmacy Service, Boston, Massachusetts, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Meridian Clinical Research, LLC, Norfolk, Nebraska, United States|Quality Clinical Research, Inc., Omaha, Nebraska, United States|NYU Langone Health, New York, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Rochester Regional Health/Rochester General Hospital, Rochester, New York, United States|M3 Wake Research, Inc., Raleigh, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Cincinnati Children\'s Hospital Medical Center, Cincinnati, Ohio, United States|Cincinnati Children\'s Hospital Medical Center, Cincinnati, Ohio, United States|Aventiv Research Inc., Columbus, Ohio, United States|Benchmark Research, Austin, Texas, United States|Ventavia Research Group, LLC, Fort Worth, Texas, United States|Texas Center For Drug Development, Inc., Houston, Texas, United States|J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City, Utah, United States|J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City, Utah, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04368728</td>    </tr>    <tr>      <th>82</th>      <td>83</td>      <td>Evaluating AVM0703 for Treatment of COVID-19</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>COVID-19</td>      <td>Drug: AVM0703|Drug: Placebo|Drug: hydrocortisone</td>      <td>AVM Biotechnology LLC|Medpace, Inc.</td>      <td>Phase 1|Phase 2</td>      <td>126.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>28-Apr-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04366115</td>    </tr>    <tr>      <th>83</th>      <td>84</td>      <td>A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Chronic Kidney Disease</td>      <td>Drug: MEDI8367|Drug: Placebo</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 1</td>      <td>70.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>28-Apr-20</td>      <td>Research Site, Glendale, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04365218</td>    </tr>    <tr>      <th>84</th>      <td>85</td>      <td>Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Beta-Thalassemia</td>      <td>Drug: VIT-2763 once a day (QD)|Drug: VIT-2763 twice a day (BID)|Drug: Placebo</td>      <td>Vifor (International) Inc.|Covance</td>      <td>Phase 2</td>      <td>36.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>28-Apr-20</td>      <td>Clinical Site #101, Beirut, Lebanon</td>      <td>https://ClinicalTrials.gov/show/NCT04364269</td>    </tr>    <tr>      <th>85</th>      <td>86</td>      <td>Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>HIV/AIDS</td>      <td>Biological: ChAdOx1.HTI|Biological: MVA.HTI|Drug: GS-9620|Biological: Placebo|Drug: Placebo Oral Tablet</td>      <td>Aelix Therapeutics|Gilead Sciences</td>      <td>Phase 2</td>      <td>57.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science</td>      <td>27-Apr-20</td>      <td>IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Vall d\'Hebrón, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04364035</td>    </tr>    <tr>      <th>86</th>      <td>87</td>      <td>Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Healthy Subjects</td>      <td>Biological: Experimental: Tezepelumab|Other: Placebo</td>      <td>AstraZeneca|Amgen</td>      <td>Phase 1</td>      <td>45.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment</td>      <td>24-Apr-20</td>      <td>Research Site, Nanchang, China</td>      <td>https://ClinicalTrials.gov/show/NCT04362410</td>    </tr>    <tr>      <th>87</th>      <td>88</td>      <td>Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Cytokine Storm (Covid-19)</td>      <td>Drug: Ruxolitinib|Drug: Placebo</td>      <td>Novartis Pharmaceuticals|Incyte Corporation|Novartis</td>      <td>Phase 3</td>      <td>402.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>24-Apr-20</td>      <td>Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Lubeck, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Blackpool, United Kingdom|Novartis Investigative Site, Harrow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04362137</td>    </tr>    <tr>      <th>88</th>      <td>89</td>      <td>Retrospective Study of Surgical Complications in Patients With Defunctioning Stoma After Low Anterior Resection (LAR)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Rectal Cancer</td>      <td>NaN</td>      <td>Safeheal|Clinical Research Consultants, Inc.</td>      <td>NaN</td>      <td>500.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Case-Only|Time Perspective: Retrospective</td>      <td>24-Apr-20</td>      <td>University of California, Irvine, Irvine, California, United States|Keck School of Medicine of USC, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of South Florida, Tampa, Florida, United States|UMASS Memorial, Worcester, Massachusetts, United States|Northwell Health, Inc., New Hyde Park, New York, United States|Icahn School of Medicine, New York, New York, United States|Lawson Health Research Institute, London, Ontario, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04359498</td>    </tr>    <tr>      <th>89</th>      <td>90</td>      <td>Plasma Adsorption in Patients With Confirmed COVID-19</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Respiratory Failure|ARDS</td>      <td>Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)</td>      <td>Marker Therapeutics AG|Terumo BCT</td>      <td>Not Applicable</td>      <td>2000.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>22-Apr-20</td>      <td>UNM Health Science Center, Albuquerque, New Mexico, United States|Providence Portland Medical Center, Portland, Oregon, United States|UT Southwestern/Clements Hospital, Dallas, Texas, United States|UTMB, Galveston, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04358003</td>    </tr>    <tr>      <th>90</th>      <td>91</td>      <td>Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Non-valvular Atrial Fibrillation (NVAF)</td>      <td>Drug: Rivaroxaban (Xarelto, BAY59-7939)</td>      <td>Bayer|Janssen Research &amp; Development, LLC</td>      <td>NaN</td>      <td>500.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>22-Apr-20</td>      <td>Many Locations, Multiple Locations, Taiwan</td>      <td>https://ClinicalTrials.gov/show/NCT04356989</td>    </tr>    <tr>      <th>91</th>      <td>92</td>      <td>To Investigate the Effect of Arabinogalactan on the Gut Microbiome in Adults</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Gut Microbiota</td>      <td>Other: arabinogalactan|Other: maltodextrin</td>      <td>Biofortis, Merieux NutriSciences|Lonza Inc.</td>      <td>Not Applicable</td>      <td>30.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science</td>      <td>17-Apr-20</td>      <td>Oliver Chen, Addison, Illinois, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04351841</td>    </tr>    <tr>      <th>92</th>      <td>93</td>      <td>Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Mycobacterium Tuberculosis Infection</td>      <td>Biological: VPM1002|Biological: BCG SII</td>      <td>Serum Institute of India Pvt. Ltd.|Vakzine Projekt Management GmbH</td>      <td>Phase 3</td>      <td>6940.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention</td>      <td>17-Apr-20</td>      <td>Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon|Kenya Medical Research Institute / Center for Respiratory Disease Research, Nairobi, Kenya|Kenya Medical Research Institute - Center for Respiratory Disease Research, Siaya, Kenya|Family Clinical Research Unit, Cape Town, South Africa|MeCRU clinical research Unit, Pretoria North, South Africa|Respiratory and Meningeal Pathogens Research Unit, Soweto, South Africa|University of Cape Town South African Tuberculosis Vaccine Initiative, Worcester, South Africa|Ifakara Health Institute, Dar Es Salaam, Tanzania|Medical Research Council / Uganda Virus Research Institute and London School of Hygiene and Tropical Medicines (MRC/UVRI and LSHTM) Uganda Research Unit, Entebbe, Uganda|Makerere University/CISMAC, Kampala, Uganda</td>      <td>https://ClinicalTrials.gov/show/NCT04351685</td>    </tr>    <tr>      <th>93</th>      <td>94</td>      <td>A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE).</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Lung Injury or Acute Respiratory Distress Syndrome Due to COVID-19</td>      <td>Drug: Gimsilumab|Drug: Placebo</td>      <td>Kinevant Sciences GmbH|Roivant Sciences, Inc.</td>      <td>Phase 2</td>      <td>270.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>17-Apr-20</td>      <td>UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|Piedmont Healthcare, Atlanta, Georgia, United States|Emory University School of Medicine, Atlanta, Georgia, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Beaumont Hospital - Royal Oak, Royal Oak, Michigan, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Mount Sinai Beth Israel, New York, New York, United States|Mount Sinai West, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Baylor University Medical Center, Dallas, Texas, United States|Baylor Scott &amp; White Heart Hospital, Plano, Texas, United States|Baylor Scott &amp; White Medical Center - Temple, Temple, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04351243</td>    </tr>    <tr>      <th>94</th>      <td>95</td>      <td>Phase 1, Dose Escalation and Dose Expansion Study of AK117, a CD47-targeting Antibody</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Neoplasms Malignant</td>      <td>Drug: AK117</td>      <td>Akeso|Akesobio Australia Pty Ltd</td>      <td>Phase 1</td>      <td>159.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>16-Apr-20</td>      <td>Blacktown Hospital, Sydney, New South Wales, Australia|ICON Cancer Foundation, South Brisbane, Queensland, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Austin Health, Heidelberg, Victoria, Australia|Linear Clinical Research/Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia</td>      <td>https://ClinicalTrials.gov/show/NCT04349969</td>    </tr>    <tr>      <th>95</th>      <td>96</td>      <td>Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Enteric Fever Vaccine</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Enteric Fever</td>      <td>Biological: ZH9PA and ZH9|Biological: Placebo|Biological: ZH9PA</td>      <td>Prokarium Ltd|Simbec Research</td>      <td>Phase 1</td>      <td>45.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention</td>      <td>16-Apr-20</td>      <td>Simbec Research, Merthyr Tydfil, Wales, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04349553</td>    </tr>    <tr>      <th>96</th>      <td>97</td>      <td>A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Neoplasms</td>      <td>Drug: Bintrafusp alfa</td>      <td>GlaxoSmithKline|Merck KGaA, Darmstadt, Germany</td>      <td>Phase 1</td>      <td>40.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>16-Apr-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04349280</td>    </tr>    <tr>      <th>97</th>      <td>98</td>      <td>An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite"</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Invasive Ductal Carcinoma|Ductal Carcinoma In Situ</td>      <td>Radiation: Intra-operative Radiation Therapy - IORT</td>      <td>Xoft, Inc.|Icad, Inc.</td>      <td>Not Applicable</td>      <td>2000.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>16-Apr-20</td>      <td>Exeter Hospital, Exeter, New Hampshire, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04349111</td>    </tr>    <tr>      <th>98</th>      <td>99</td>      <td>A Study of MD-120 in Patients With Depression</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Major Depressive Disorder</td>      <td>Drug: Desvenlafaxine 100 mg|Drug: Desvenlafaxine 50 mg|Drug: Placebo</td>      <td>Mochida Pharmaceutical Company, Ltd.|Pfizer</td>      <td>Phase 3</td>      <td>594.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>14-Apr-20</td>      <td>Mochida Investigational sites, Tokyo, Japan</td>      <td>https://ClinicalTrials.gov/show/NCT04345471</td>    </tr>    <tr>      <th>99</th>      <td>100</td>      <td>A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of BRM421 for Dry Eye Syndrome</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Dry Eye Syndrome</td>      <td>Drug: BRM421|Drug: Placebo</td>      <td>BRIM Biotechnology Inc.|ORA, Inc.</td>      <td>Phase 2|Phase 3</td>      <td>200.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>13-Apr-20</td>      <td>Eye Research Foundation, Newport Beach, California, United States|Midwest Cornea Associates, LLC, Indianapolis, Indiana, United States|Andover Eye Associates, Andover, Massachusetts, United States|Total Eye Care, Memphis, Tennessee, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04343287</td>    </tr>    <tr>      <th>100</th>      <td>101</td>      <td>A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Carcinoma, Renal Cell</td>      <td>Drug: Atezolizumab|Drug: Cabozantinib</td>      <td>Hoffmann-La Roche|Exelixis</td>      <td>Phase 3</td>      <td>500.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>8-Apr-20</td>      <td>Arizona Oncology Associates, Flagstaff, Arizona, United States|University of Arizona, Tucson, Arizona, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|UC San Diego Health System, La Jolla, California, United States|UCLA, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of California Davis, Sacramento, California, United States|University of California San Francisco, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Rocky Mountain Cancer Center - Denver, Denver, Colorado, United States|Hartford Healthcare, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Woodlands Medical Specialists, P.A., Pensacola, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|MGH, Boston, Massachusetts, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Memorial Sloan Kettering - Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|New York Oncology Hematology,P.C.-Albany, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Memorial Sloan Kettering Cancer Center - Commack, Commack, New York, United States|MSKCC @ West Harrison, Harrison, New York, United States|New York University, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oncology Associates of Oregon, Springfield, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology - Houston (Gessner), Houston, Texas, United States|Texas Oncology - Willowbrook, Houston, Texas, United States|University Of Utah, Salt Lake City, Utah, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Inst. Alexander Fleming; Oncologia, Buenos Aires, Argentina|Hospital Britanico, Ciudad Autonoma Bs As, Argentina|Centro Medico Austral OMI, Ciudad Autonoma Buenos Aires, Argentina|Orange Hospital, Orange, New South Wales, Australia|Macquarie University Hospital, Sydney, New South Wales, Australia|Icon Cancer Foundation, South Brisbane, Queensland, Australia|Royal Hobart Hospital; Medical Oncology, Hobart, Tasmania, Australia|Bendigo Cancer Centre, Bendigo, Victoria, Australia|Box Hill Hospital; Oncology, Box Hill, Victoria, Australia|CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France|CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre, Bordeaux, France|Centre Francois Baclesse; Oncologie, Caen, France|Centre Oscar Lambret; Chir Cancerologie General, Lille, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Institut de cancerologie du Gard, Nimes, France|Hopital Hautepierre; Hematologie Oncologie, Strasbourg, France|Institut Gustave Roussy; Oncologie Medicale, Villejuif, France|Zeisigwaldkliniken Bethanien, Chemnitz, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet; Urologie und Kinderurologie, Frankfurt, Germany|Universitaetsklinikum Freiburg; Urology, Freiburg, Germany|Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie, Halle (Saale), Germany|Uniklinik-Eppendorf; Klinik U Poliklinik F Urologie, Hamburg, Germany|Med. Hochschule Hannover, Hämatologie, Hämostaseologie, Onkologie u. Stammzelltransplantation, Hannover, Germany|Universitaetsklinikum Muenster; Urology, Muenster, Germany|Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik, München, Germany|Universitätsklinikum Tübingen; Klinik für Urologie, Tübingen, Germany|Universitätsklinikum Ulm; Klinik für Urologie, Ulm, Germany|Alexandras General Hospital of Athens; Oncology Department, Athens, Greece|Attikon University General Hospital, Athens, Greece|Athens Medical Center; Dept. of Oncology, Athens, Greece|University Hospital of Larissa;Department of Medical Oncology, Larissa, Greece|Papageorgiou General Hospital; Medical Oncology, Thessaloniki, Greece|Diavalkaniko Hospital, Thessaloniki, Greece|Istituto Tumori Napoli;Unità Operativa Oncologia Medica Uro-Ginecologica, Napoli, Campania, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); SOC Oncologia Medica A, Aviano (PN), Friuli-Venezia Giulia, Italy|Policlinico Universitario "Agostino Gemelli"; U.O.C. Oncologia Medica, Roma, Lazio, Italy|ASST DEGLI SPEDALI CIVILI DI BRESCIA; Oncologia Medica, Brescia, Lombardia, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy|Fondazione Salvatore Maugeri; Divisione Di Oncologia Medica, Pavia, Lombardia, Italy|Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy|Ospedale Di Macerata; Oncologia, Macerata, Marche, Italy|Fondazione del Piemonte per l\'Oncologia (IRCCS); Day Hospital Oncologico Multidisciplinare, Candiolo (TO), Piemonte, Italy|Azienda Ospedaliera S. Maria - Terni; Oncologia, Terni, Umbria, Italy|Yokohama City University Hospital, Kanagawa, Japan|Okayama University Hospital, Okayama, Japan|Keio University Hospital, Tokyo, Japan|Chungnam National University Hospital, Daejeon, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|CHA Bundang Medical Center, Gyeonggi-do, Korea, Republic of|Pusan National University Yangsan Hospital, Gyeongsangnam-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Medical Center, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny, Brzozów, Poland|Centrum Onkologii im. Prof. Franciszka Łukaszczyka; Ambulatorium Chemioterapii, Bydgoszcz, Poland|SP ZOZ Wojewódzki Szpital Specjalistyczny nr 4; Oddzial Onkologii Klinicznej, Bytom, Poland|Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii, Otwock, Poland|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznan, Poland|Wojewódzki Szpital Zespolony im.L.Rydygiera; Oddzial Chemioterapii Nowotworów, Toruń, Poland|Wojskowy Instytut Medyczny; Klinika Onkologii, Warszawa, Poland|Dolnoslaskie Centrum Onkologii, Wrocław, Poland|MEDSI Clinical Hospital on Pyatnitsky Highway; Department of antitumor drug therapy, Moscow, Moskovskaja Oblast, Russian Federation|SBIH "Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM", Moskva, Moskovskaja Oblast, Russian Federation|TSBHI Altai Territorial oncological dispensary, Barnaul, Russian Federation|FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin", Moscow, Russian Federation|Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation|Medical Center Avicenna; Urology, Novosibirsk, Russian Federation</td>      <td>https://ClinicalTrials.gov/show/NCT04338269</td>    </tr>    <tr>      <th>101</th>      <td>102</td>      <td>Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Relapsing Multiple Sclerosis</td>      <td>Drug: Evobrutinib|Drug: Placebo (match to Teriflunomide)|Drug: Teriflunomide|Drug: Placebo (match to Evobrutinib)</td>      <td>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany|EMD Serono Research &amp; Development Institute, Inc.</td>      <td>Phase 3</td>      <td>930.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>8-Apr-20</td>      <td>Please Contact U.S. Medical Information, Rockland, Massachusetts, United States|Please Contact the Communication Center, Darmstadt, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04338061</td>    </tr>    <tr>      <th>102</th>      <td>103</td>      <td>Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Relapsing Multiple Sclerosis</td>      <td>Drug: Evobrutinib|Drug: Placebo (match to Teriflunomide)|Drug: Teriflunomide|Drug: Placebo (match to Evobrutinib)</td>      <td>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany|EMD Serono Research &amp; Development Institute, Inc.</td>      <td>Phase 3</td>      <td>930.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>8-Apr-20</td>      <td>Please Contact U.S. Medical Information, Rockland, Massachusetts, United States|Please Contact the Communication Center, Darmstadt, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04338022</td>    </tr>    <tr>      <th>103</th>      <td>104</td>      <td>A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Leukemia, Myeloid, Acute</td>      <td>Drug: CC-90009|Drug: Venetoclax|Drug: Azacitidine|Drug: Gilteritinib</td>      <td>Celgene|AbbVie</td>      <td>Phase 1|Phase 2</td>      <td>66.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>7-Apr-20</td>      <td>University of California, San Francisco, San Francisco, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Northwestern University, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|University of Alberta, Edmonton, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Institut Paoli-Calmettes, Marseille, France|Hopital Haut Leveque, Pessac Cedex, France|Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole, Toulouse Cedex 9, France|Gustave Roussy, Villejuif CEDEX, France|John Radcliffe Hospital, Oxford, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04336982</td>    </tr>    <tr>      <th>104</th>      <td>105</td>      <td>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Sars-CoV2</td>      <td>Drug: BLD-2660</td>      <td>Blade Therapeutics|Clinipace Worldwide</td>      <td>Phase 2</td>      <td>120.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>6-Apr-20</td>      <td>Blade Research Site, Montgomery, Alabama, United States|Blade Research Site, Irvine, California, United States|Blade Research Site, Los Angeles, California, United States|Blade Reseach Site, San Jose, California, United States|Blade Research Site, Washington, District of Columbia, United States|Blade Research Site, Brandon, Florida, United States|Blade Research Site, Fort Pierce, Florida, United States|Blade Research Site, Panama City, Florida, United States|Blade Research Site, Tampa, Florida, United States|Blade Research Site, Marietta, Georgia, United States|Blade Research Site, Idaho Falls, Idaho, United States|Blade Research Site, Elmhurst, Illinois, United States|Blade Research Site, Peoria, Illinois, United States|Blade Research Site, Ames, Iowa, United States|Blade Research Site, Baltimore, Maryland, United States|Blade Research Site, Detroit, Michigan, United States|Blade Research Site, Farmington Hills, Michigan, United States|Blade Research Site, Chesterfield, Missouri, United States|Blade Research Site, Saint Louis, Missouri, United States|Blade Research Site, North Las Vegas, Nevada, United States|Blade Research Site, Ridgewood, New Jersey, United States|Blade Research Site, Durham, North Carolina, United States|Blade Research Site, Fayetteville, North Carolina, United States|Blade Research Site, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Blade Research Site, Dallas, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04334460</td>    </tr>    <tr>      <th>105</th>      <td>106</td>      <td>Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomatic Knee Osteoarthritis</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Symptomatic Osteoarthritis of the Knee</td>      <td>Drug: JTA-004|Device: Hylan G-F 20|Other: placebo</td>      <td>Bone Therapeutics S.A|Nordic Bioscience A/S</td>      <td>Phase 3</td>      <td>676.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>3-Apr-20</td>      <td>Cliniques universitaires Saint-Luc (UCL), Brussels, Belgium|UZ Leuven University Hospitals Leuven, Leuven, Belgium|CHU Liège, Liège, Belgium|CHU Ambroise Paré, Mons, Belgium|CCR Brno, s.r.o, Brno, Czechia|CCR Czech, a.s, Pardubice, Czechia|CCR Prague s.r.o, Praha, Czechia|The Parker Institute, Frederiksberg, Denmark|Sanos Clinic, Herlev, Denmark|Sanos Clinic, Vejle, Denmark|Hong Kong Center for Clinical Research, Hong Kong, Hong Kong|"Timofei Mosneaga" Republican Clinical Hospital, Sectia Reumatologie,, Chisinau, Moldova, Republic of|RTL SM SRL / Institutul de Cardiologie, sectia consultativa, Chisinau, Moldova, Republic of</td>      <td>https://ClinicalTrials.gov/show/NCT04333160</td>    </tr>    <tr>      <th>106</th>      <td>107</td>      <td>Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Arthritis, Rheumatoid</td>      <td>Biological: GSK3196165|Drug: csDMARD(s)</td>      <td>GlaxoSmithKline|Iqvia Pty Ltd</td>      <td>Phase 3</td>      <td>2640.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>3-Apr-20</td>      <td>GSK Investigational Site, Miami Lakes, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Lincoln, Nebraska, United States|GSK Investigational Site, Vandalia, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Baytown, Texas, United States|GSK Investigational Site, Colleyville, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Lubbock, Texas, United States|GSK Investigational Site, Tomball, Texas, United States|GSK Investigational Site, Siauliai, Lithuania</td>      <td>https://ClinicalTrials.gov/show/NCT04333147</td>    </tr>    <tr>      <th>107</th>      <td>108</td>      <td>Phase 1/2 Study in Patients With Cancer Having a KRAS G12C Mutation</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Advanced Cancer|Metastatic Cancer|Malignant Neoplastic Disease</td>      <td>Drug: MRTX849|Drug: TNO155</td>      <td>Mirati Therapeutics Inc.|Novartis</td>      <td>Phase 1|Phase 2</td>      <td>148.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>1-Apr-20</td>      <td>NEXT Oncology, San Antonio, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04330664</td>    </tr>    <tr>      <th>108</th>      <td>109</td>      <td>The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Lymphoid Malignancies</td>      <td>Drug: Supra-Pharmacologic Dexamethasone sodium phosphate|Drug: Hydrocortisone|Drug: Proton pump inhibitor</td>      <td>AVM Biotechnology LLC|Medpace, Inc.</td>      <td>Phase 1|Phase 2</td>      <td>144.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>1-Apr-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04329728</td>    </tr>    <tr>      <th>109</th>      <td>110</td>      <td>Staccato® Granisetron Multiple Dose PK</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Healthy</td>      <td>Combination Product: 0.5mg AZ-010|Combination Product: 1mg AZ-010|Combination Product: 3mg AZ-010</td>      <td>Alexza Pharmaceuticals, Inc.|Celerion</td>      <td>Phase 1</td>      <td>30.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>31-Mar-20</td>      <td>Celerion, Tempe, Arizona, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04327765</td>    </tr>    <tr>      <th>110</th>      <td>111</td>      <td>Sarilumab COVID-19</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Corona Virus Infection</td>      <td>Drug: Sarilumab SAR153191|Drug: Placebo</td>      <td>Sanofi|Regeneron Pharmaceuticals</td>      <td>Phase 3</td>      <td>400.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>31-Mar-20</td>      <td>Investigational Site Number 0320001, Caba, Argentina|Investigational Site Number 0320003, Caba, Argentina|Investigational Site Number 0760003, Porto Alegre, Brazil|Investigational Site Number 0760001, Sao Paulo, Brazil|Investigational Site Number 0760002, Sao Paulo, Brazil|Investigational Site Number 0760004, São José Do Rio Preto, Brazil|Investigational Site Number 0760005, São Paulo, Brazil|Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240005, Montreal, Canada|Investigational Site Number 1240004, Toronto, Canada|Investigational Site Number 1240002, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 1520003, Santiago, Chile|Investigational Site Number 1520002, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520001, Talca, Chile|Investigational Site Number 2500001, Bordeaux Cedex, France|Investigational Site Number 2500007, Clamart, France|Investigational Site Number 2500006, La Roche Sur Yon Cedex 9, France|Investigational Site Number 2500002, Nantes, France|Investigational Site Number 2500005, Paris Cedex 18, France|Investigational Site Number 2500003, Strasbourg, France|Investigational Site Number 2500004, Suresnes, France|Investigational Site Number 2760003, Bonn, Germany|Investigational Site Number 2760006, Braunschweig, Germany|Investigational Site Number 2760002, Essen, Germany|Investigational Site Number 2760004, Köln, Germany|Investigational Site Number 2760001, Münster, Germany|Investigational Site Number 3760003, Ashdod, Israel|Investigational Site Number 3760002, Jerusalem, Israel|Investigational Site Number 3760001, Ramat Gan, Israel|Investigational Site Number 3800005, Milano, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800003, Modena, Italy|Investigational Site Number 3800004, Parma, Italy|Investigational Site Number 3800006, Rozzano, Italy|Investigational Site Number 3920002, Fuchu-Shi, Japan|Investigational Site Number 3920003, Iruma-Gun, Japan|Investigational Site Number 3920001, Kamakura-Shi, Japan|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 7240003, Barcelona, Spain|Investigational Site Number 7240004, Barcelona, Spain|Investigational Site Number 7240002, Madrid / Madrid, Spain|Investigational Site Number 7240005, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04327388</td>    </tr>    <tr>      <th>111</th>      <td>112</td>      <td>Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Growth Hormone Deficiency|Endocrine System Diseases|Hormones|Pituitary Diseases|Pituitary Disease, Anterior</td>      <td>Drug: TransCon hGH|Drug: daily hGH</td>      <td>Visen Pharmaceuticals (Shanghai) Co., Ltd.|Ascendis Pharma A/S</td>      <td>Phase 3</td>      <td>150.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>30-Mar-20</td>      <td>Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,, Wuhan, Hubei, China</td>      <td>https://ClinicalTrials.gov/show/NCT04326374</td>    </tr>    <tr>      <th>112</th>      <td>113</td>      <td>The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Cardiogenic Shock</td>      <td>Drug: Istaroxime|Drug: Placebo</td>      <td>Windtree Therapeutics|Momentum Research, Inc.</td>      <td>Phase 2</td>      <td>60.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>27-Mar-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04325035</td>    </tr>    <tr>      <th>113</th>      <td>114</td>      <td>Innovative Tool to Analyse Synovial Fluid of Patients With Knee Ostearthritis After IA Injection of Synvisc-one®</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Knee Osteoarthritis|Intra-Articular Injection</td>      <td>Device: Synvisc-One</td>      <td>Pulsalys|Artialis</td>      <td>Not Applicable</td>      <td>15.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care</td>      <td>25-Mar-20</td>      <td>Centre Medical Chant d\'Oiseau, Woluwe-Saint-Pierre, Bruxelles, Belgium</td>      <td>https://ClinicalTrials.gov/show/NCT04321668</td>    </tr>    <tr>      <th>114</th>      <td>115</td>      <td>Objective Pain Measurement Using a Wearable Biosensor and a Mobile Platform in Patients With Endometriosis</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Endometriosis</td>      <td>NaN</td>      <td>Biofourmis Singapore Pte Ltd.|Chugai Pharmaceutical</td>      <td>NaN</td>      <td>124.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Case-Only|Time Perspective: Retrospective</td>      <td>23-Mar-20</td>      <td>Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic, Rochester, Minnesota, United States|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore</td>      <td>https://ClinicalTrials.gov/show/NCT04318275</td>    </tr>    <tr>      <th>115</th>      <td>116</td>      <td>Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>COVID-19</td>      <td>Drug: Sarilumab|Drug: Placebo</td>      <td>Regeneron Pharmaceuticals|Sanofi</td>      <td>Phase 2|Phase 3</td>      <td>2500.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>19-Mar-20</td>      <td>Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Coral Gables, Florida, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site 2, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04315298</td>    </tr>    <tr>      <th>116</th>      <td>117</td>      <td>The Short Term Effects of Oceanix Supplementation on Recovery</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Oxidative Stress|Muscle Strength|Resistance Training|Muscle Damage</td>      <td>Dietary Supplement: Oceanix|Other: Resistance Training</td>      <td>Applied Science &amp; Performance Institute|Lonza Ltd.</td>      <td>Not Applicable</td>      <td>19.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>19-Mar-20</td>      <td>Applied Science &amp; Performance Institute, Tampa, Florida, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04315077</td>    </tr>    <tr>      <th>117</th>      <td>118</td>      <td>Trial of NanoPac Intratumoral Injection in Lung Cancer</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Lung Cancer, Nonsmall Cell|Lung Cancer|Lung Cancer, Small Cell|Neoplasm of Lung</td>      <td>Drug: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension</td>      <td>NanOlogy, LLC|US Biotest, Inc.</td>      <td>Phase 2</td>      <td>18.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>19-Mar-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04314895</td>    </tr>    <tr>      <th>118</th>      <td>119</td>      <td>Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Relapsed/Refractory Large B-cell Lymphoma</td>      <td>Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Lenzilumab|Biological: Axicabtagene Ciloleucel</td>      <td>Kite, A Gilead Company|Humanigen, Inc.|Gilead Sciences</td>      <td>Phase 1|Phase 2</td>      <td>36.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>19-Mar-20</td>      <td>Mayo Clinic, Rochester, Minnesota, United States|MD Anderson Cancer Center, Houston, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04314843</td>    </tr>    <tr>      <th>119</th>      <td>120</td>      <td>The Effects of Antioxidant Supplementation on Multiple Endurance Race Performance, Physiology, and Recovery.</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Oxidative Stress|Muscle Strength|Resistance Training|Body Composition|Muscle Damage</td>      <td>Other: Cross Training Course|Dietary Supplement: Oceanix</td>      <td>Applied Science &amp; Performance Institute|Lonza Ltd.</td>      <td>Not Applicable</td>      <td>18.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>19-Mar-20</td>      <td>Applied Science &amp; Performance Institute, Tampa, Florida, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04314596</td>    </tr>    <tr>      <th>120</th>      <td>121</td>      <td>Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus</td>      <td>Enrolling by invitation</td>      <td>No Results Available</td>      <td>Chondral or Osteochondral Lesion of Talus</td>      <td>Biological: CARTISTEM®|Procedure: Microfracture</td>      <td>SK bioland co., ltd.|Medipost Co Ltd.</td>      <td>Phase 3</td>      <td>100.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>17-Mar-20</td>      <td>Kyunghee University Medical Center, Seoul, Dongdaemun-gu, Korea, Republic of|Gangnam Severance Hospital, Seoul, Gangnam-gu, Korea, Republic of|Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|Korea University Guro Hospital, Seoul, Guro-gu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of|Inha University Hospital, Incheon, Jung-gu, Korea, Republic of</td>      <td>https://ClinicalTrials.gov/show/NCT04310215</td>    </tr>    <tr>      <th>121</th>      <td>122</td>      <td>Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Healthy Volunteers</td>      <td>Drug: CTP-543|Drug: Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)</td>      <td>Concert Pharmaceuticals|Celerion</td>      <td>Phase 1</td>      <td>21.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>16-Mar-20</td>      <td>Celerion, Inc., Tempe, Arizona, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04309643</td>    </tr>    <tr>      <th>122</th>      <td>123</td>      <td>Study of Multiple Ascending Dose of KBL693 in Healthy Participants</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Moderate to Severe Asthma</td>      <td>Drug: KBL693</td>      <td>KoBioLabs|Novotech (Australia) Pty Limited</td>      <td>Phase 1</td>      <td>18.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>13-Mar-20</td>      <td>Linear Clinical Research, Nedlands, Western Australia, Australia</td>      <td>https://ClinicalTrials.gov/show/NCT04307173</td>    </tr>    <tr>      <th>123</th>      <td>124</td>      <td>TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Solid Tumor, Adult</td>      <td>Combination Product: TTX-030, budigalimab and mFOLFOX6|Combination Product: TTX-030, budigalimab and docetaxel|Combination Product: TTX-030 and mFOLFOX6|Combination Product: TTX-030 and budigalimab</td>      <td>Tizona Therapeutics, Inc|AbbVie</td>      <td>Phase 1</td>      <td>152.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>13-Mar-20</td>      <td>Ocala Oncology Center PL, Ocala, Florida, United States|Nebraska Cancer Center Oncology Hematology West P.C., Omaha, Nebraska, United States|West Cancer Center and Research Institute, Germantown, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|NEXT Oncology, San Antonio, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04306900</td>    </tr>    <tr>      <th>124</th>      <td>125</td>      <td>Evaluation of a New Female Urinary Intermittent Catheter</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Female Intermittent Urethral Catheterization</td>      <td>Device: LoFric Elle</td>      <td>Dentsply International|Wellspect HealthCare</td>      <td>Not Applicable</td>      <td>30.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>11-Mar-20</td>      <td>Urologiska kliniken, mottagning Universitetssjukhuset Örebro, Örebro, Örebro Län, Sweden</td>      <td>https://ClinicalTrials.gov/show/NCT04304599</td>    </tr>    <tr>      <th>125</th>      <td>126</td>      <td>Dietary Supplementation Effects on Bowel Movement Frequency and Intestinal Biological Markers in Seniors Presenting Slowed Intestinal Transit</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Constipation</td>      <td>Dietary Supplement: VES002|Other: Placebo</td>      <td>CEN Biotech|Vesale Pharmaceutica</td>      <td>Not Applicable</td>      <td>27.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>11-Mar-20</td>      <td>CEN Nutriment, Dijon, Bourgogne, France</td>      <td>https://ClinicalTrials.gov/show/NCT04304170</td>    </tr>    <tr>      <th>126</th>      <td>127</td>      <td>Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Solid Tumor|Triple Negative Breast Cancer|Microsatellite Stable Colorectal Cancer</td>      <td>Biological: TBio-6517|Biological: Pembrolizumab</td>      <td>Turnstone Biologics, Corp.|Takeda</td>      <td>Phase 1|Phase 2</td>      <td>84.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>9-Mar-20</td>      <td>Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|Sylvester Comprehensive Cancer Center / UMHC, Miami, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Mayo Clinic, Rochester, Minnesota, United States|The Billings Clinic, Billings, Montana, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04301011</td>    </tr>    <tr>      <th>127</th>      <td>128</td>      <td>Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Non-Valvular Atrial Fibrillation</td>      <td>Drug: Rivaroxaban (Xarelto, BAY-597939)|Drug: VKAs</td>      <td>Bayer|Janssen Research &amp; Development, LLC</td>      <td>NaN</td>      <td>25000.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Retrospective</td>      <td>5-Mar-20</td>      <td>Many locations, Multiple Locations, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04297072</td>    </tr>    <tr>      <th>128</th>      <td>129</td>      <td>A Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Epithelial Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer</td>      <td>Drug: Mirvetuximab Soravtansine</td>      <td>ImmunoGen, Inc.|IQVIA Biotech</td>      <td>Phase 3</td>      <td>110.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>5-Mar-20</td>      <td>Arizona Oncology Associates, Phoenix, Arizona, United States|Dr. Sudarshan K. Sharma, Ltd., Hinsdale, Illinois, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Texas Oncology, P.A. - Fort Worth Cancer Center, Fort Worth, Texas, United States|Texas Oncology, P.A. - McAllen, McAllen, Texas, United States|Texas Oncology, P.A. - Sugar Land, Sugar Land, Texas, United States|Texas Oncology, P.A. - Tyler, Tyler, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04296890</td>    </tr>    <tr>      <th>129</th>      <td>130</td>      <td>A Study to Investigate the Effect of MCE on Glucose and Insulin Responses in Healthy Males</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Dysglycemia</td>      <td>Dietary Supplement: MCE|Dietary Supplement: Glucose</td>      <td>Cambridge Glycoscience|Atlantia Food Clinical Trials</td>      <td>Not Applicable</td>      <td>10.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention</td>      <td>5-Mar-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04296045</td>    </tr>    <tr>      <th>130</th>      <td>131</td>      <td>NR600 System Retinal Prosthesis for Patients With Retinal Degenerative Diseases</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Retinitis Pigmentosa|Retinal Degeneration</td>      <td>Device: Retinal surgery with implantation of epi-retinal device</td>      <td>Nano Retina|MedPass International</td>      <td>Not Applicable</td>      <td>35.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>4-Mar-20</td>      <td>UZ Leuven, Leuven, Belgium|San Raffaele, Milan, Italy|Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy</td>      <td>https://ClinicalTrials.gov/show/NCT04295304</td>    </tr>    <tr>      <th>131</th>      <td>132</td>      <td>Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Malignant Melanoma|Angiosarcoma</td>      <td>Other: CICS-1 (investigational device),SPM-011(investigational drug)</td>      <td>Cancer Intelligence Care Systems, Inc.|Stella Pharma Corporation</td>      <td>Not Applicable</td>      <td>9.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>3-Mar-20</td>      <td>National Cancer Center Hospital, Chuo Ku, Tokyo, Japan</td>      <td>https://ClinicalTrials.gov/show/NCT04293289</td>    </tr>    <tr>      <th>132</th>      <td>133</td>      <td>Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Sickle Cell Disease</td>      <td>Drug: Brilinta|Drug: Placebo</td>      <td>AstraZeneca|Iqvia Pty Ltd</td>      <td>Phase 3</td>      <td>182.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment</td>      <td>3-Mar-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04293172</td>    </tr>    <tr>      <th>133</th>      <td>134</td>      <td>Development and Analysis of a Stool Bank for Cancer Patients</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Carcinoma, Non-Small-Cell Lung|Carcinoma, Colorectal</td>      <td>Drug: Pembrolizumab Injection</td>      <td>Persephone Biosciences|Pharm-Olam International</td>      <td>NaN</td>      <td>100.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Case-Only|Time Perspective: Prospective</td>      <td>2-Mar-20</td>      <td>Compassionate Care Research Group, Inc., Fountain Valley, California, United States|Bond and Steele Clinic, P.A., Winter Haven, Florida, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04291755</td>    </tr>    <tr>      <th>134</th>      <td>135</td>      <td>Study to Validate Novel Seizure-Detection Algorithm</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Seizures, Motor|Seizures|Seizure Disorder|Epilepsy|Epileptic Seizures|Epileptic</td>      <td>Device: Motor Seizure Detection Algorithm (mSDA)</td>      <td>Overwatch Digital Health|Bracane Company</td>      <td>Not Applicable</td>      <td>15.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>2-Mar-20</td>      <td>Covenant Hospital and Covenant Medical Group, Lubbock, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04291716</td>    </tr>    <tr>      <th>135</th>      <td>136</td>      <td>Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Melanoma|Hepatocellular Carcinoma|Non Small Cell Lung Cancer|Endometrial Cancer</td>      <td>Biological: VV1|Biological: Cemiplimab</td>      <td>Vyriad, Inc.|Regeneron Pharmaceuticals</td>      <td>Phase 2</td>      <td>152.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>2-Mar-20</td>      <td>City of Hope Medical Center, Duarte, California, United States|Saint John\'s Health Center - John Wayne Cancer Institute (JWCI), Santa Monica, California, United States|Mayo Clinical, Jacksonville, Florida, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Montana Cancer Consortium, Billings, Montana, United States|Mayo Clinical, Phoenix, New Jersey, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Sanford Cancer Center, Sioux Falls, South Dakota, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04291105</td>    </tr>    <tr>      <th>136</th>      <td>137</td>      <td>Safety and Effectiveness of ENTERPRISE 2 Device in the Endovascular Treatment of Intracranial Aneurysms</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Intracranial Aneurysm</td>      <td>Device: ENTERPRISE 2 device</td>      <td>Codman &amp; Shurtleff|Johnson &amp; Johnson Medical (Shanghai) Ltd.</td>      <td>NaN</td>      <td>164.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>28-Feb-20</td>      <td>Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing, China|Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China|The first affiliated hospital of Zhengzhou university, Zhengzhou, Henan, China|Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology, Wuhan, Hubei, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China|The first affiliated hospital of Nanchang university, Nanchang, Jiangxi, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|Renji Hospital, Medical College of Shanghai Jiao Tong University, Shanghai, Shanghai, China|Xinhua Hospital Affiliated to Medicine School of Shanghai Jiaotong University, Shanghai, Shanghai, China|Zhejiang Hospital, Hangzhou, Zhejiang, China</td>      <td>https://ClinicalTrials.gov/show/NCT04289480</td>    </tr>    <tr>      <th>137</th>      <td>138</td>      <td>A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Receptors, Estrogen|Genes, Erbb-2|Breast Neoplasms</td>      <td>Drug: Palbociclib (75, 100, 125 milligram [mg])|Drug: H3B-6545 (300, 450 mg)</td>      <td>H3 Biomedicine Inc.|Eisai Inc.</td>      <td>Phase 1</td>      <td>36.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>27-Feb-20</td>      <td>Florida Cancer Specialists, Sarasota, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Saint Luke\'s Cancer Institute, Saint Peters, Missouri, United States|Tennessee Oncology, Nashville, Tennessee, United States|Royal Marsden NHS Foundation Trust, London, United Kingdom|Christie NHS Foundation Trust, Manchester, United Kingdom|Velindre Cancer Centre, Whitchurch, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04288089</td>    </tr>    <tr>      <th>138</th>      <td>139</td>      <td>Registry of Asthma Patients Initiating DUPIXENT®</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Asthma</td>      <td>Drug: DUPIXENT®</td>      <td>Regeneron Pharmaceuticals|Sanofi</td>      <td>NaN</td>      <td>1000.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>27-Feb-20</td>      <td>Regeneron Study Site, Gilbert, Arizona, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04287621</td>    </tr>    <tr>      <th>139</th>      <td>140</td>      <td>Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Conjunctivitis|Atopic Dermatitis</td>      <td>Drug: dupilumab</td>      <td>Regeneron Pharmaceuticals|Sanofi</td>      <td>NaN</td>      <td>75.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Case-Control|Time Perspective: Prospective</td>      <td>27-Feb-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04287608</td>    </tr>    <tr>      <th>140</th>      <td>141</td>      <td>Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Gastric Cancer|GastroEsophageal Cancer</td>      <td>Device: NovoTTF-100L(P)|Drug: Oxaliplatin|Drug: Capecitabine|Drug: Trastuzumab</td>      <td>NovoCure GmbH|Zai Lab (Shanghai) Co., Ltd.|NovoCure Ltd.</td>      <td>Not Applicable</td>      <td>28.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>24-Feb-20</td>      <td>Queen Mary Hospital, Hong Kong, Hong Kong</td>      <td>https://ClinicalTrials.gov/show/NCT04281576</td>    </tr>    <tr>      <th>141</th>      <td>142</td>      <td>A Study to Evaluate Safety and Efficacy of APO-2 at Three Different Doses in Patients With Diabetic Foot Ulcer</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Diabetic Foot Ulcer (DFU)</td>      <td>Biological: APO-2|Other: Placebo</td>      <td>Aposcience AG|FGK Clinical Research GmbH</td>      <td>Phase 1|Phase 2</td>      <td>132.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>20-Feb-20</td>      <td>A.ö. Krankenhaus der Elisabethinen Klagenfurt GmbH; Abteilung für Chirurgie, Klagenfurt am Wörthersee, Austria|Kepler Universitätsklinikum Linz; Klinik für Dermatologie und Venerologie, Linz, Austria</td>      <td>https://ClinicalTrials.gov/show/NCT04277598</td>    </tr>    <tr>      <th>142</th>      <td>143</td>      <td>Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Agitation Associated With Bipolar Disorder|Agitation,Psychomotor|Bipolar Disorder</td>      <td>Drug: Sublingual film containing Dexmedetomidine (BXCL501)|Drug: Placebo Film</td>      <td>BioXcel Therapeutics Inc|Cognitive Research Corporation</td>      <td>Phase 3</td>      <td>375.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>19-Feb-20</td>      <td>BioXcel Clinical Research Site, Little Rock, Arkansas, United States|BioXcel Clinical Research Site, Cerritos, California, United States|BioXcel Clinical Research Site, Culver City, California, United States|BioXcel Clinical Research Site, Long Beach, California, United States|BioXcel Clinical Research Site, Orange, California, United States|BioXcel Clinical Research Site, Miami Lakes, Florida, United States|BioXcel Clinical Research Site, Chicago, Illinois, United States|BioXcel Clinical Research Site, Gaithersburg, Maryland, United States|BioXcel Clinical Research Site, Las Vegas, Nevada, United States|BioXcel Clinical Research Site, Berlin, New Jersey, United States|BioXcel Clinical Research Site, Marlton, New Jersey, United States|BioXcel Clinical Research Site, Charleston, South Carolina, United States|BioXcel Clinical Research Site, Austin, Texas, United States|BioXcel Clinical Research Site, DeSoto, Texas, United States|BioXcel Clinical Research Site, Richardson, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04276883</td>    </tr>    <tr>      <th>143</th>      <td>144</td>      <td>A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Atrial Fibrillation</td>      <td>Device: Heart healthy Engagement Program with the Apple Watch Series 4 or later|Device: Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later</td>      <td>Janssen Scientific Affairs, LLC|Apple Inc.</td>      <td>NaN</td>      <td>150000.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>19-Feb-20</td>      <td>Evidation Health, San Mateo, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04276441</td>    </tr>    <tr>      <th>144</th>      <td>145</td>      <td>Intratumoral Microdosing of Motolimod in HNSCC</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>HNSCC</td>      <td>Drug: Motolimod|Biological: Nivolumab|Combination Product: Motolimod + Nivolumab</td>      <td>Presage Biosciences|Celgene</td>      <td>Early Phase 1</td>      <td>12.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science</td>      <td>17-Feb-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04272333</td>    </tr>    <tr>      <th>145</th>      <td>146</td>      <td>A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Neovascular (Wet) Age-related Macular Degeneration (AMD)</td>      <td>Drug: ABP 938|Drug: Aflibercept</td>      <td>Amgen|Parexel</td>      <td>Phase 3</td>      <td>566.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment</td>      <td>17-Feb-20</td>      <td>Research Site, Waterford, Connecticut, United States|Research Site, Miami, Florida, United States|Research Site, Winter Haven, Florida, United States|Research Site, Elmhurst, Illinois, United States|Research Site, Northfield, New Jersey, United States|Research Site, Troy, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Kingston, Pennsylvania, United States|Research Site, Abilene, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Willow Park, Texas, United States|Research Site, Tallinn, Harjumaa, Estonia|Research Site, Pécs, Baranya, Hungary|Research Site, Rga, Latvia</td>      <td>https://ClinicalTrials.gov/show/NCT04270747</td>    </tr>    <tr>      <th>146</th>      <td>147</td>      <td>A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Healthy Volunteers</td>      <td>Drug: AZD2373 subcutaneous injection|Drug: Placebo</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 1</td>      <td>48.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>13-Feb-20</td>      <td>Research Site, Baltimore, Maryland, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04269031</td>    </tr>    <tr>      <th>147</th>      <td>148</td>      <td>A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Rheumatoid Arthritis</td>      <td>Biological: Experimental: Arm A: DRL_RI|Biological: Arm B: Rituxan®/Mabthera®</td>      <td>Dr. Reddy\'s Laboratories Limited|PPD</td>      <td>Phase 3</td>      <td>140.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>13-Feb-20</td>      <td>California Allergy and Asthma Medical Group - CRN - PPDS 41230 11th Street West, Suite A, Palmdale, California, United States|Rheumatology Consultant of Delaware dba Delaware Arthritis, Lewes, Delaware, United States|AppleMed Research Group, LLC, Miami, Florida, United States|Integral Rheumatology and Immunology Specialist, 140 Southwest 84th Avenue, Suite B, Plantation, Florida, United States|Springfield Clinic (Clinic location), Springfield, Illinois, United States|Bluegrass Community Research Inc,330 Waller Avenue, Suite 100,, Lexington, Kentucky, United States|Altoona Center For Clinical Research, 175 Meadowbrook Lane,, Duncansville, Pennsylvania, United States|Articularis Healthcare Group, Inc dba Low Country Rheumatology, Summerville, South Carolina, United States|Accurate Clinical Management, LLC, Baytown, Texas, United States|Trinity Clinical Research LLC, 2008 East Hebron Parkway, Suites 120/114/100,, Carrollton, Texas, United States|Accurate Clinical Management, LLC, Houston, Texas, United States|Accurate Clinical Research-Houston, 11003 Resource Parkway, Suite 102, Houston, Texas, United States|Clinical Associates in Research Therapeutics of America, LLC, San Antonio, Texas, United States|Accurate Clinical Research, Inc., San Antonio, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04268771</td>    </tr>    <tr>      <th>148</th>      <td>149</td>      <td>Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Agitation|Schizophrenia|Schizo Affective Disorder|Schizoaffective Disorder|Schizophreniform Disorders</td>      <td>Drug: Sublingual film containing dexmedetomidine (BXCL501)|Drug: Placebo Film</td>      <td>BioXcel Therapeutics Inc|Cognitive Research Corporation</td>      <td>Phase 3</td>      <td>375.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>13-Feb-20</td>      <td>BioXcel Clinical Research Site, Little Rock, Arkansas, United States|BioXcel Clinical Research Site, Cerritos, California, United States|BioXcel Clinical Research Site, Culver City, California, United States|BioXcel Clinical Research Site, Long Beach, California, United States|BioXcel Clinical Research Site, Orange, California, United States|BioXcel Clinical Research Site, Miami Lakes, Florida, United States|BioXcel Clinical Research Site, Chicago, Illinois, United States|BioXcel Clinical Research Site, Gaithersburg, Maryland, United States|BioXcel Clinical Research Site, Las Vegas, Nevada, United States|BioXcel Clinical Research Site, Berlin, New Jersey, United States|BioXcel Clinical Research Site, Marlton, New Jersey, United States|BioXcel Clinical Research Site, Charleston, South Carolina, United States|BioXcel Clinical Research Site, Austin, Texas, United States|BioXcel Clinical Research Site, DeSoto, Texas, United States|BioXcel Clinical Research Site, Richardson, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04268303</td>    </tr>    <tr>      <th>149</th>      <td>150</td>      <td>Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Dry Eye Disease</td>      <td>Drug: PL9643 Ophthalmic Solution|Drug: Placebo Ophthalmic Solution</td>      <td>ORA, Inc.|Palatin Technologies</td>      <td>Phase 2</td>      <td>150.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>13-Feb-20</td>      <td>Andover Eye Associates, Andover, Massachusetts, United States|Andover Eye Associates, Raynham, Massachusetts, United States|Vita Eye Clinc, Shelby, North Carolina, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04268069</td>    </tr>    <tr>      <th>150</th>      <td>151</td>      <td>Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Lupus Nephritis|Lupus Erythematosus, Systemic</td>      <td>Other: Experimental - Test Results and Education</td>      <td>Qure Healthcare, LLC|DxTerity Diagnostics</td>      <td>Not Applicable</td>      <td>166.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic</td>      <td>12-Feb-20</td>      <td>QURE Healthcare, San Francisco, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04266860</td>    </tr>    <tr>      <th>151</th>      <td>152</td>      <td>A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic</td>      <td>Drug: Azacitidine|Drug: Cusatuzumab</td>      <td>Janssen Research &amp; Development, LLC|argenx BVBA</td>      <td>Phase 2</td>      <td>150.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>11-Feb-20</td>      <td>City of Hope, Duarte, California, United States|VA San Diego Healthcare System - UCSD, San Diego, California, United States|Louisville Oncology Suburban - Norton Cancer Institute, Louisville, Kentucky, United States|Dartmouth Hitchcock, Lebanon, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Weill Cornell Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health &amp; Science University, Portland, Oregon, United States|University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|University of Vermont, Burlington, Vermont, United States|Medical College Of Wisconsin, Milwaukee, Wisconsin, United States|St Vincents Hospital Sydney, Darlinghurst, Australia|St Vincents Hospital Melbourne, Fitzroy, Australia|Gold Coast University Hospital, Gold Coast, Australia|Peter MacCallum Cancer Institute, Melbourne, Australia|Royal Perth Hospital, Perth, Australia|Westmead Hospital, Westmead, Australia|Wollongong Hospital, Wollongong, Australia|Hospital Erasto Gaertner- Liga Paranaense de Combate ao Câncer, Curitiba, Brazil|Cepon - Centro De Pesquisas Oncologicas, Florianopolis, Brazil|Liga Norte Riograndense Contra O Cancer, Natal, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Instituto do cancer -COR -Hospital Mae de Deus, Porto Alegre, Brazil|Oncoclínicas, Rio de Janeiro, Brazil|Hospital de Base de São José do Rio Preto, São José do Rio Preto, Brazil|Hospital Paulistano, São Paulo, Brazil|Instituto D\'Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil|CHU d\'Angers, Angers, France|Hopital Saint Vincent de Paul, Lille, France|CHU de Limoges, Hopital Dupuytren, Limoges, France|Hôpital de La Conception, Marseille, France|CHU de Nice Hopital de l Archet, Nice, France|Hopital Saint-Louis, Paris Cedex 10, France|Hopital Cochin APHP, Paris, 75, France|CHRU Tours Hôpital Bretonneau, Tours, France|CHU de Nancy_ Hôpital Brabois, Vandoeuvre Les Nancy, France|Universitatsklinikum Carl Gustav Carcus Dresden, Dresden, Germany|Universitätsklinik Freiburg, Freiburg im Breisgau, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Klinikum rechts der Isar an der Technischen Universität München, München, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Policlinico Sant\'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliero Universitaria di Ferrara, Cona, Italy|Università del Piemonte Orientale - Ospedale Maggiore della Carità di Novara, Novara, Italy|Aou San Luigi Gonzaga, Orbassano, Italy|Grande Ospedale Metropolitano \'Bianchi-Melacrino-Morelli\' Reggio Calabria, Reggio Calabria, Italy|Fondazione Policlinico Tor Vergata, Roma, Italy|Policlinico Umberto I, Roma, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Emergency Hospital of Dzerzhinsk, Dzerzhinsk, Russian Federation|S.P. Botkin Moscow City Clinical Hospital, Moscow, Russian Federation|City Clinical Hospital # 40, Moscow, Russian Federation|Nizhniy Novgorod Region Clinical Hospital, Nizhny Novgorod, Russian Federation|Ryazan Regional Clinical Hospital, Ryazan, Russian Federation|Saint Petersburg City Hospital #15, Saint-Petersburg, Russian Federation|Clinical Research Institute of Hematology and Transfusiology, St-Petersburg, Russian Federation|St.-Petersburg City Clinical Hospital nr 31, St. Petersburg, Russian Federation|Oncology Dispensary of Komi Republic, Syktyvkar, Russian Federation|Hosp. Univ. Germans Trias I Pujol, Badalona, Spain|Hosp. Univ. Vall D\'Hebron, Barcelona, Spain|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Inst. Cat. Doncologia-H Duran I Reynals, Barcelona, Spain|Hosp. Univ. Infanta Leonor, Madrid, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hosp. Univ. Son Espases, Palma, Spain|Hosp. Clinico Univ. de Salamanca, Salamanca, Spain|Hosp. Virgen Del Rocio, Sevilla, Spain|INSELSPITAL, Universitätsspital Bern, Bern, Switzerland|Hopitaux Universitaires de Geneve, Geneve, Switzerland|UniversitaetsSpital Zuerich, Zürich, Switzerland|Gulhane Egitim ve Arastirma Hastanesi, Ankara, Turkey|Dr.Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey|Ankara Universitesi Tip Fakultesi, Ankara, Turkey|Koc Universitesi Hastanesi, Istanbul, Turkey|Ege Universitesi Tip Fakultesi, Izmir, Turkey|Dokuz Eylul Universitesi Tip Fakultesi, Izmir, Turkey|Ondokuz Mayis Universitesi Tip Fakultesi, Samsun, Turkey|St James Hospital, Leeds, United Kingdom|University College London Hospitals, London, United Kingdom|Kings College Hospital, London, United Kingdom|Royal Victoria Infirmary, Newcastle Upun Tyne, United Kingdom|Churchill Hospital, Oxford, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04264806</td>    </tr>    <tr>      <th>152</th>      <td>153</td>      <td>Prospective Observational Study of the Power PICC Family of Devices and Accessories</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Peripherally Inserted Central Catheter</td>      <td>Device: Peripherally Inserted Central Catheter</td>      <td>Becton, Dickinson and Company|FGK Clinical Research GmbH</td>      <td>NaN</td>      <td>450.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Case-Only|Time Perspective: Prospective</td>      <td>11-Feb-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04263649</td>    </tr>    <tr>      <th>153</th>      <td>154</td>      <td>Reduction of Pathogen Load From the Blood in Septic Patients With Suspected, Life-threatening Bloodstream Infection</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Bloodstream Infection</td>      <td>Device: Seraph 100,The Microbind Affinity Blood Filter</td>      <td>ExThera Medical Europe BV|ExThera Medical Corporation</td>      <td>Not Applicable</td>      <td>232.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>7-Feb-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04260789</td>    </tr>    <tr>      <th>154</th>      <td>155</td>      <td>Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Renal Cell Carcinoma|Kidney Cancer|Adenocarcinoma of Kidney|Adenocarcinoma, Renal|Renal Cell Cancer</td>      <td>Drug: NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension</td>      <td>NanOlogy, LLC|US Biotest, Inc.</td>      <td>Phase 1</td>      <td>15.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>7-Feb-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04260360</td>    </tr>    <tr>      <th>155</th>      <td>156</td>      <td>Evaluation of Geistlich Fibro-Gide® + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Gingival Recession</td>      <td>Device: Geistlich Fibro-Gide|Procedure: Connective Tissue Graft (CTG</td>      <td>Geistlich Pharma AG|Medelis Inc.</td>      <td>Not Applicable</td>      <td>30.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>7-Feb-20</td>      <td>Seven Lakes Periodontitis, Fenton, Michigan, United States|Perio Health Professionals, Houston, Texas, United States|Oral Health Specialists, Tacoma, Washington, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04260152</td>    </tr>    <tr>      <th>156</th>      <td>157</td>      <td>Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Metastatic Head and Neck Cancer|Recurrent Head and Neck Cancer|HPV Positive Oropharyngeal Squamous Cell Carcinoma|HPV-Related Esophageal Squamous Cell Carcinoma|Neoplasms, Head and Neck</td>      <td>Combination Product: Pembrolizumab and PDS0101</td>      <td>PDS Biotechnology Corp.|Merck Sharp &amp; Dohme Corp.</td>      <td>Phase 2</td>      <td>96.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>7-Feb-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04260126</td>    </tr>    <tr>      <th>157</th>      <td>158</td>      <td>A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Angelman Syndrome</td>      <td>Drug: GTX-102</td>      <td>GeneTX Biotherapeutics, LLC|Ultragenyx Pharmaceutical Inc</td>      <td>Phase 1|Phase 2</td>      <td>20.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>6-Feb-20</td>      <td>Children\'s Hospital Colorado, Aurora, Colorado, United States|Rare Disease Research, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Cincinnati Children\'s Hospital Medical Center, Cincinnati, Ohio, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04259281</td>    </tr>    <tr>      <th>158</th>      <td>159</td>      <td>Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148</td>      <td>Enrolling by invitation</td>      <td>No Results Available</td>      <td>Irritability Associated With Autism Spectrum Disorder</td>      <td>Drug: Brexpiprazole</td>      <td>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.|H. Lundbeck A/S</td>      <td>Phase 3</td>      <td>100.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>6-Feb-20</td>      <td>For additional information regarding sites, Princeton, New Jersey, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04258839</td>    </tr>    <tr>      <th>159</th>      <td>160</td>      <td>Exploratory Study of Efficacy on Selected Natural Extracts Reducing Post Prandial Blood Glucose Response</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Blood Glucose</td>      <td>Other: Mulberry fruit|Other: Mulberry leaf|Other: White bean|Other: Apple|Other: Elderberry|Other: Turmeric|Other: Rice porridge</td>      <td>Unilever R&amp;D|Lambda Therapeutic Research Ltd.</td>      <td>Not Applicable</td>      <td>72.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science</td>      <td>6-Feb-20</td>      <td>Lambda Therapeutics Research Ttd, Ahmedabad, Gujarat, India</td>      <td>https://ClinicalTrials.gov/show/NCT04258501</td>    </tr>    <tr>      <th>160</th>      <td>161</td>      <td>A Trial of ZL-1201 in Subjects With Advanced Cancer</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Locally Advanced Solid Tumor</td>      <td>Drug: ZL1201</td>      <td>Zai Lab (Shanghai) Co., Ltd.|PPD</td>      <td>Phase 1</td>      <td>65.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>6-Feb-20</td>      <td>New York Cancer &amp; Blood Specialists, New York, New York, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04257617</td>    </tr>    <tr>      <th>161</th>      <td>162</td>      <td>Dose Response Study of a Natural Extract for Reducing Post Prandial Blood Glucose</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Blood Glucose</td>      <td>Other: Boiled Rice|Other: Boiled Rice+0.37 gr mulberry fruit powdered extract|Other: Boiled Rice+0.75 gr mulberry fruit powdered extract|Other: Boiled Rice+1.12 gr mulberry fruit powdered extract|Other: Boiled Rice+1.50 gr mulberry fruit powdered extract|Other: Rice Porridge|Other: Rice porridge+1.50 gr mulberry fruit powdered extract</td>      <td>Unilever R&amp;D|Lambda Therapeutic Research Ltd.</td>      <td>Not Applicable</td>      <td>84.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science</td>      <td>5-Feb-20</td>      <td>Lambda Therapeutics Research Ttd (LTRL), Ahmedabad, Gujarat, India</td>      <td>https://ClinicalTrials.gov/show/NCT04256746</td>    </tr>    <tr>      <th>162</th>      <td>163</td>      <td>A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Healthy Volunteers (Intended Indication: Chronic Kidney Disease)</td>      <td>Drug: Verinurad|Drug: Placebo|Drug: Allopurinol</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 1</td>      <td>24.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>5-Feb-20</td>      <td>Research Site, Berlin, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04256629</td>    </tr>    <tr>      <th>163</th>      <td>164</td>      <td>A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Gastrointestinal Stromal Tumors</td>      <td>Drug: CS3007 (BLU-285)</td>      <td>CStone Pharmaceuticals|Blueprint Medicines Corporation</td>      <td>Phase 1|Phase 2</td>      <td>87.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>5-Feb-20</td>      <td>Beijing Cancer Hospital, Beijing, Beijing, China</td>      <td>https://ClinicalTrials.gov/show/NCT04254939</td>    </tr>    <tr>      <th>164</th>      <td>165</td>      <td>Effects of 2% IDL Lotion on Skin Hydration and Transepidermal Water Loss in Females With Dry Skin</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Xerosis Cutis</td>      <td>Combination Product: IDL lotion|Combination Product: Control lotion</td>      <td>Shyla Cantor|Sytheon Ltd.</td>      <td>Phase 1|Phase 2</td>      <td>16.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>5-Feb-20</td>      <td>Cantor Research Laboratory, Blauvelt, New York, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04253704</td>    </tr>    <tr>      <th>165</th>      <td>166</td>      <td>A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Neuroblastoma</td>      <td>Other: Data-collection</td>      <td>EusaPharma (UK) Limited|United BioSource, LLC</td>      <td>NaN</td>      <td>125.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>5-Feb-20</td>      <td>St. Anna Kinderkrebsforschung, Wien,, Vienna, Austria|Centre Oscar Lambret, Lille, France|Hôpital de la Timone, Hôpital des Enfants, Marseille, France|Institut Curie, Paris, France|Institut Gustave Roussy, Villejuif, France|Charité Berlin, Berlin, Germany|Universitätsmedizin Greifswald, Greifswald, Germany|Uniklinik Köln, Köln, Germany|IRCCS Istituto Giannina Gaslini, Genova, Italy|Uniwersytecki Szpital Dziecięcy, Kraków, Poland|Hospital Universitario y Politecnico La Fe Avenida Fernando Abril Martorell, Valencia, Spain|Birmingham Children\'s Hospital, Birmingham, United Kingdom|University Hospital Southampton, Southampton, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04253015</td>    </tr>    <tr>      <th>166</th>      <td>167</td>      <td>RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects</td>      <td>Terminated</td>      <td>No Results Available</td>      <td>Healthy Volunteers|Impaired Renal Function</td>      <td>Drug: MD1003</td>      <td>MedDay Pharmaceuticals SA|Eurofins Optimed</td>      <td>Phase 1</td>      <td>24.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other</td>      <td>5-Feb-20</td>      <td>Eurofins Optimed, Gières, France|DRC Drug Research Center Ltd., Balatonfüred, Hungary|Semmelweis University Faculty of Medicine, Budapest, Hungary|University of Debrecen Medical and Health Center, Debrecen, Hungary|Clinical Research Units Hungary Ltd., Miskolc, Hungary</td>      <td>https://ClinicalTrials.gov/show/NCT04252430</td>    </tr>    <tr>      <th>167</th>      <td>168</td>      <td>HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects</td>      <td>Terminated</td>      <td>No Results Available</td>      <td>Healthy Volunteers|Hepatic Impairment of Moderate Child Pugh Category</td>      <td>Drug: MD1003</td>      <td>MedDay Pharmaceuticals SA|Eurofins Optimed</td>      <td>Phase 1</td>      <td>15.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other</td>      <td>5-Feb-20</td>      <td>Eurofins Optimed, Gières, France|DRC Drug Research Center Ltd., Balatonfüred, Hungary|Clinical Research Units Hungary Ltd., Miskolc, Hungary</td>      <td>https://ClinicalTrials.gov/show/NCT04252417</td>    </tr>    <tr>      <th>168</th>      <td>169</td>      <td>Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Agitation,Psychomotor|Dementia</td>      <td>Drug: Sublingual film containing Dexmedetomidine|Drug: Sublingual Placebo Film</td>      <td>BioXcel Therapeutics Inc|Cognitive Research Corporation</td>      <td>Phase 1|Phase 2</td>      <td>30.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>5-Feb-20</td>      <td>BioXcel Clinical Research Site, Miami Lakes, Florida, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04251910</td>    </tr>    <tr>      <th>169</th>      <td>170</td>      <td>Study of GNX102 in Patients With Advanced Solid Tumors</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Solid Tumor|Metastatic Cancer|Advanced Cancer|Unresectable Solid Neoplasm</td>      <td>Drug: GNX102</td>      <td>GlycoNex, Inc.|Accelovance</td>      <td>Phase 1</td>      <td>30.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>31-Jan-20</td>      <td>USC Norris Comprehensive Cancer Center and HOAG, Los Angeles, California, United States|Providence Cancer Institute Earle A. Chiles Research Institute, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04250597</td>    </tr>    <tr>      <th>170</th>      <td>171</td>      <td>Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Atrial Fibrillation</td>      <td>Drug: Rivaroxaban (Xarelto)|Drug: Apixaban|Drug: Dabigatran|Drug: Warfarin</td>      <td>Bayer|Janssen, LP</td>      <td>NaN</td>      <td>70000.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Retrospective</td>      <td>31-Jan-20</td>      <td>Many locations, Multiple Locations, Sweden</td>      <td>https://ClinicalTrials.gov/show/NCT04249401</td>    </tr>    <tr>      <th>171</th>      <td>172</td>      <td>Lumenato Nutritional Supplement on Skin Appearance</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Skin</td>      <td>Dietary Supplement: Lumenato</td>      <td>LycoRed Ltd.|ObvioHealth</td>      <td>Not Applicable</td>      <td>72.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>30-Jan-20</td>      <td>o ObvioHealth, Orlando, Florida, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04248699</td>    </tr>    <tr>      <th>172</th>      <td>173</td>      <td>Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab</td>      <td>Available</td>      <td>No Results Available</td>      <td>Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)</td>      <td>Drug: Narsoplimab</td>      <td>Omeros Corporation|Impatients N.V. trading as myTomorrows</td>      <td>NaN</td>      <td>NaN</td>      <td>Industry</td>      <td>Expanded Access:Individual Patients</td>      <td>NaN</td>      <td>30-Jan-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04247906</td>    </tr>    <tr>      <th>173</th>      <td>174</td>      <td>Study to Determine the Effect of a Newly Formulated Tetracaine Product PET500 on Penile Skin Sensation</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy Volunteers</td>      <td>Drug: Tetracaine|Other: Matching placebo (PET500)|Drug: STUD100</td>      <td>Futura Medical Developments Ltd.|Richmond Pharmacology Limited</td>      <td>Phase 1</td>      <td>20.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science</td>      <td>30-Jan-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04247230</td>    </tr>    <tr>      <th>174</th>      <td>175</td>      <td>Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Uterine Cervical Neoplasms</td>      <td>Drug: Bintrafusp alfa</td>      <td>EMD Serono Research &amp; Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono</td>      <td>Phase 2</td>      <td>135.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>29-Jan-20</td>      <td>Dignity Health Arizona General Hospital, Phoenix, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|University of Arkansas Medical Sciences, Little Rock, Arkansas, United States|Stanford University Hospital and Clinics - Stanford Cancer Center, Stanford, California, United States|The Stamford Hospital, Stamford, Connecticut, United States|University of Kansas Medical Center Research Institute, Inc. - University of Kansas Cancer Center/Bloch Pavilion, Westwood, Kansas, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Farmington Hills, Michigan, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Hackensack University Medical Center PARTNER, Hackensack, New Jersey, United States|Northwell Health, Inc. PRIME, Lake Success, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|UC Health Clinical Trials Office, Cincinnati, Ohio, United States|Oregon Health &amp;amp; Science University, Portland, Oregon, United States|The West Clinic, Germantown, Tennessee, United States|SCRI - Tennessee Oncology, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Instituto de Oncología de Rosario, Rosario, Santa Fe, Argentina|Sanatorio El Parque, Salta, Argentina|Centro Medico San Roque S.R.L., Tucuman, Argentina|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Linear Clinical Research Limited, Nedlands, Western Australia, Australia|Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Australia|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Universitair Ziekenhuis Gent - Pneumology, Gent, Belgium|AZ Groeninge - Campus Kennedylaan - account 2, Kortrijk, Belgium|Centre Hospitalier de l\'Ardenne - Pharmacie, Libramont, Belgium|Centre Hospitalier de l\'Ardenne - Pharmacie, Libramont, Belgium|CHU Sart Tilman, Liège, Belgium|UZ Leuven, Pellenberg, Belgium|GZA Ziekenhuizen - Campus Sint-Augustinus, Wilrijk, Belgium|HGB - Hospital Giovanni Battista - Mãe de Deus Center - Centro de Pesquisa Clínica - Instituto do Câncer, Porto Alegre, Rio Grande Do Sul, Brazil|Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda., São Paulo, Brazil|IBCC - Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil|ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira, São Paulo, Brazil|Chongqing Cancer Hospital, Chongqing, Chongqing, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China|Shanghai Cancer Hospital, Fudan University, Shanghai, Shanghai, China|Sun Yat-sen University, Cancer Center, Guangzhou, China|Centre Antoine Lacassagne, Nice, Alpes Maritimes, France|Institut de Cancérologie de Strasbourg Europe - ICANS - Service d\'oncologie médicale, Strasbourg, Bas Rhin, France|CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie, Plérin, Cotes d\'Armor, France|Centre Oscar lambret, Lille, Nord, France|Institut Bergonié, Bordeaux cedex, France|Centre Léon Bérard, Lyon, France|Institut Jean Godinot - Service d\'hématologie et Oncologie Médicale, Marne, France|Hôpital Cochin - Hematologie et Oncologie Médicale, Paris, France|Centre Hospitalier Lyon Sud - service d\'oncologie medicale, Pierre Benite cedex, France|ICO - Site René Gauducheau, Saint Herblain, France|Orszagos Onkologiai Intezet - Nogyogyaszati Osztaly, Budapest, Hungary|Debreceni Egyetem - Szuleszeti es Nogyogyaszati Klinika, Debrecen, Hungary|Bacs-Kiskun Megyei Korhaz - Onkoradiologia, Kecskemet, Hungary|SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz - Onkoradiologia, Nyiregyhaza, Hungary|NHO Kyushu Cancer Center - Dept of Gynecology, Fukuoka-shi, Fukuoka-Ken, Japan|University Hospital, University of the Ryukyus - Dept of Obstetrics/Gynecology, Nakagami-gun, Okinawa-Ken, Japan|Osaka International Cancer Institute - Dept of Gynecology, Osaka-shi, Osaka-Fu, Japan|Saitama Medical University International Medical Center - Dept of Gynecology/Oncology, Hidaka-shi, Saitama-Ken, Japan|National Cancer Center Hospital - Dept of Mammary Gland/Oncology, Chuo-ku, Tokyo-To, Japan|Cancer Institute Hospital of JFCR - Dept of Gynecology, Koto-ku, Tokyo-To, Japan|Jikei University Hospital - Dept of Gynecology, Minato-ku, Tokyo-To, Japan|Kurume University Hospital - Dept of Gynecology, Kurume-shi, Japan|NHO Hokkaido Cancer Center - Dept of Gynecology, Sapporo-shi, Japan|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|LLC Evimed, Chelyabinsk, Russian Federation|SBIH " Clinical Oncological Dispensary" - Location, Krasnodar, Russian Federation|BHI of Omsk region "Clinical Oncology Dispensary", Omsk, Russian Federation|LLC "ClinicaUZI4D", Pyatigorsk, Russian Federation|Pavlov First Saint Petersburg State Medical University - Research Institute of Pulmunology, Saint Petersburg, Russian Federation|FBI "Scientific Research Institute of Oncology n. a. N. N. Petrov", Saint-Petersburg, Russian Federation|ICO l´Hospitalet - Hospital Duran i Reynals, L´Hospitalet de Llobregat, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona - Servicio de Oncologia, Barcelona, Spain|Hospital Universitari Vall d\'Hebron - Dept of Oncology, Barcelona, Spain|ICO Girona - Hospital Doctor Josep Trueta - Servicio de Oncologia Medica, Girona, Spain|Clinica Universidad de Navarra (MAD) - Oncology Service, Madrid, Spain|Hospital Universitario 12 de Octubre - Servicio de Oncologia, Madrid, Spain|Hospital Universitario Ramon y Cajal - Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario de Malaga, Málaga, Spain|Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica, Valencia, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04246489</td>    </tr>    <tr>      <th>175</th>      <td>176</td>      <td>Terumo Aortic Global Endovascular Registry</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Abdominal Aortic Aneurysm|Thoracic Aortic Aneurysm|Surgery</td>      <td>Device: Thoracic|Device: Abdominal|Device: Custom Device|Device: Illiac Artery</td>      <td>Vascutek Ltd.|Bolton Medical</td>      <td>NaN</td>      <td>1000.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>29-Jan-20</td>      <td>Vumc Amsterdam, Amsterdam, Netherlands|Rijnstate Arnham, Arnhem, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|UMC Gronigen, Groningen, Netherlands|Diakonessenhuis, Utrecht, Netherlands|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04246463</td>    </tr>    <tr>      <th>176</th>      <td>177</td>      <td>Assessment of the INVOcell Intravaginal Culture System</td>      <td>Suspended</td>      <td>No Results Available</td>      <td>Infertility</td>      <td>Device: INVOcell</td>      <td>INVO Bioscience, Inc.|Ferring Pharmaceuticals</td>      <td>Not Applicable</td>      <td>180.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>29-Jan-20</td>      <td>Piedmont Reproductive Endocrinology Group, Greenville, South Carolina, United States|Piedmont Reproductive Endocrinology Group, West Columbia, South Carolina, United States|Fertility Center of San Antonio, San Antonio, Texas, United States|The New Hope Center for Reproductive Medicine, Virginia Beach, Virginia, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04246268</td>    </tr>    <tr>      <th>177</th>      <td>178</td>      <td>Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Carcinoma, Hepatocellular</td>      <td>Drug: Lenvatinib|Biological: Pembrolizumab|Drug: Oral Placebo|Drug: IV Placebo|Procedure: TACE</td>      <td>Merck Sharp &amp; Dohme Corp.|Eisai Inc.</td>      <td>Phase 3</td>      <td>950.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>29-Jan-20</td>      <td>Arizona Oncology Associates PC- HOPE ( Site 0770), Tucson, Arizona, United States|Stephenson Cancer Center ( Site 0745), Oklahoma City, Oklahoma, United States|Houston Methodist Research Institute ( Site 0784), Houston, Texas, United States|St George Hospital ( Site 0005), Kogarah, New South Wales, Australia|Princess Alexandra Hospital ( Site 0006), Brisbane, Queensland, Australia|Sociedad de Investigaciones Medicas Limitadas ( Site 0064), Temuco, Araucania, Chile|Fundacion Cardiovascular de Colombia ( Site 0136), Floridablanca, Santander, Colombia|Fundacion Valle del Lili ( Site 0140), Cali, Valle Del Cauca, Colombia|Odense Universitetshospital ( Site 0160), Odense, Syddanmark, Denmark|Rabin Medical Center ( Site 0304), Petah Tikva, HaMerkaz, Israel|Rambam Medical Center ( Site 0305), Haifa, Heifa, Israel|Hadassah Ein Karem Jerusalem ( Site 0303), Jerusaelm, Yerushalayim, Israel|National Cancer Center Hospital East ( Site 0347), Kashiwa, Chiba, Japan|Kagawa Prefectural Central Hospital ( Site 0364), Takamatsu, Kagawa, Japan|Chonnam National University Hwasun Hospital ( Site 0572), Hwasun, Jeonranamdo, Korea, Republic of|Seoul National University Bundang Hospital ( Site 0570), Seongnam-si, Kyonggi-do, Korea, Republic of|Seoul National University Hospital ( Site 0567), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 0564), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Asan Medical Center ( Site 0565), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Auckland City Hospital ( Site 0459), Auckland, New Zealand|National Cheng Kung University Hospital ( Site 0608), Tainan, Taiwan|National Taiwan University Hospital ( Site 0606), Taipei, Taiwan|Hacettepe University Medical Faculty ( Site 0653), Ankara, Turkey|Inonu Universitesi Medical Fakultesi ( Site 0650), Malatya, Turkey|Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 0673), Kharkiv, Kharkivska Oblast, Ukraine|Communal non profit enterprise Regional Clinical Oncology Center ( Site 0669), Kharkiv, Kharkivska Oblast, Ukraine</td>      <td>https://ClinicalTrials.gov/show/NCT04246177</td>    </tr>    <tr>      <th>178</th>      <td>179</td>      <td>LYT-100 in Healthy Volunteers and BCRL</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Breast Cancer Related Lymphoedema|Lymphoedema</td>      <td>Drug: LYT-100|Other: Matching Placebo</td>      <td>PureTech|Novotech (Australia) Pty Limited</td>      <td>Phase 1</td>      <td>82.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment</td>      <td>28-Jan-20</td>      <td>Nucleus Network VIC, Melbourne, Victoria, Australia</td>      <td>https://ClinicalTrials.gov/show/NCT04243837</td>    </tr>    <tr>      <th>179</th>      <td>180</td>      <td>PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial &amp; 3 Vial Formulation Marqibo® in Hematological Malignant Patients</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Hematologic Diseases</td>      <td>Drug: Vincristine Sulfate Liposome|Combination Product: CHOP|Combination Product: R-CHOP</td>      <td>Acrotech Biopharma LLC|Axis Clinicals Limited</td>      <td>Phase 1</td>      <td>56.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>28-Jan-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04243434</td>    </tr>    <tr>      <th>180</th>      <td>181</td>      <td>A Feasibility Study on Ultrafiltration and Blood Volume Measurements</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Acute Decompensated Heart Failure|Fluid Overload</td>      <td>Device: Aquadex FlexFlow System and BVA-100</td>      <td>CHF Solutions|Daxor Corporation</td>      <td>Not Applicable</td>      <td>15.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic</td>      <td>27-Jan-20</td>      <td>Edward Hospital Center for Advanced Heart Failure, Naperville, Illinois, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04241718</td>    </tr>    <tr>      <th>181</th>      <td>182</td>      <td>A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Leukemia, Myeloid, Acute</td>      <td>Drug: Cusatuzumab|Drug: Azacitidine</td>      <td>Janssen Pharmaceutical K.K.|argenx BVBA</td>      <td>Phase 1</td>      <td>9.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>27-Jan-20</td>      <td>Fukushima Medical University Hospital, Fukushima, Japan|Gunmaken Saiseikai Maebashi Hospital, Maebashi, Japan|Osaka City General Hospital, Osaka, Japan|Hokkaido University Hospital, Sapporo, Japan|NTT Medical Center Tokyo, Tokyo, Japan|University of Fukui Hospital, Yoshida, Japan</td>      <td>https://ClinicalTrials.gov/show/NCT04241549</td>    </tr>    <tr>      <th>182</th>      <td>183</td>      <td>ELUCIDATE: Enabling LUng Cancer IDentification Using folATE Receptor Targeting</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Lung Neoplasms|Lung Cancer</td>      <td>Drug: OTL38 for Injection|Device: Near infrared camera imaging system</td>      <td>On Target Laboratories, LLC|Clinipace Worldwide</td>      <td>Phase 3</td>      <td>130.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic</td>      <td>27-Jan-20</td>      <td>Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04241315</td>    </tr>    <tr>      <th>183</th>      <td>184</td>      <td>The Efficacy and Safety of Sirolimus -Coated Balloon (SeQuent® SCB) in Treatment of Patients With Coronary ISR</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Coronary Artery Disease|In Stent Restenosis</td>      <td>Device: drug-coated balloon Catheter</td>      <td>B. Braun Medical International Trading Company Ltd.|CCRF Inc., Beijing, China</td>      <td>Not Applicable</td>      <td>260.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>27-Jan-20</td>      <td>Anhui Provincal Hospital, Hefei, An Hui, China|Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China|Fuwai Hospital Chinese Academy of Medical Sciences (CAMS), Beijing, Beijing, China|Meizhou People\'s Hospital, Meizhou, Guang Dong, China|The First Affiliated Hospital of Sun Yat-sen University, Zhongshan, Guang Dong, China|Cangzhou Central Hospital, Cangzhou, He Bei, China|The First Affiliated Hospital of Zhengzhou University, ZhengZhou, He Nan, China|Daqing Oilfield General Hospital, Daqing, Hei Long Jiang, China|Wuhan Asia Heart Hospital, Wuhan, Hu Bei, China|The First Bethune Hospital of Jilin University, Changchun, Ji Lin, China|The Second Hospital of Jilin University, Changchun, Ji Lin, China|Nanjing First Hospital, Nanjing, Jiang Su, China|General Hospital of Northern Theater Command, Shenyang, Liao Ning, China|Shandong Provincial Hospital, Jinan, Shan Dong, China|Ruijin Hospital，Shanghai Jiaotong University，School of medicine, Shanghai, Shanghai, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, China|Tianjin Chest Hospital, Tianjin, Tianjin, China|Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, Zhe Jiang, China</td>      <td>https://ClinicalTrials.gov/show/NCT04240444</td>    </tr>    <tr>      <th>184</th>      <td>185</td>      <td>Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Hypertriglyceridemia</td>      <td>Drug: Placebo|Drug: Ethyl Icosapentate</td>      <td>Mochida Pharmaceutical Company, Ltd.|Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</td>      <td>Phase 3</td>      <td>300.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>27-Jan-20</td>      <td>Mochida Investigational sites, Changsha, China</td>      <td>https://ClinicalTrials.gov/show/NCT04239950</td>    </tr>    <tr>      <th>185</th>      <td>186</td>      <td>A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5\'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Ovarian Cancer</td>      <td>Drug: Olaparib|Drug: Ceralasertib|Drug: Placebo to match olaparib</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 2</td>      <td>256.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>23-Jan-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04239014</td>    </tr>    <tr>      <th>186</th>      <td>187</td>      <td>A Study to Evaluate the Safety, Tolerability and Amount of Drug Levels in Blood of EI1071 in Healthy Volunteers</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Healthy Volunteers</td>      <td>Drug: EI1071|Drug: Matching Placebo</td>      <td>Elixiron Immunotherapeutics Inc.|Parexel</td>      <td>Phase 1</td>      <td>50.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>23-Jan-20</td>      <td>Parexel Early Phase Clinical Unit, Baltimore, Maryland, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04238364</td>    </tr>    <tr>      <th>187</th>      <td>188</td>      <td>A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects</td>      <td>Completed</td>      <td>No Results Available</td>      <td>TQT Study</td>      <td>Drug: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo|Drug: Moxifloxacin 400mg|Other: Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)|Drug: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)</td>      <td>Spero Therapeutics|Celerion</td>      <td>Phase 1</td>      <td>24.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science</td>      <td>23-Jan-20</td>      <td>Celerion, Tempe, Arizona, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04238195</td>    </tr>    <tr>      <th>188</th>      <td>189</td>      <td>A Study of 99mTc-3PRGD2 Injection in Lung Cancer Patient</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Lung Cancer Metastatic</td>      <td>Drug: 99mTc-3PRGD2</td>      <td>RDO Pharm.|Beijing Pharbers Genesis Pharmaceutical Technology Co., Ltd.</td>      <td>Phase 3</td>      <td>400.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic</td>      <td>18-Jan-20</td>      <td>Peking Union Medical College Hospital, Beijing, Beijing, China|Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Sino-Japanese Friendship Hospital of Jilin Universit, Changchun, Jilin, China|First Hospital of Shanxi Medical Universit, Taiyuan, Shanxi, China</td>      <td>https://ClinicalTrials.gov/show/NCT04233476</td>    </tr>    <tr>      <th>189</th>      <td>190</td>      <td>A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Heart Failure With Preserved Ejection Fraction (HFpEF)</td>      <td>Drug: AZD4831|Drug: Placebo</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 1</td>      <td>32.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment</td>      <td>18-Jan-20</td>      <td>Research Site, Glendale, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04232345</td>    </tr>    <tr>      <th>190</th>      <td>191</td>      <td>Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy Volunteers</td>      <td>Drug: Fedratinib|Drug: Digoxin|Drug: Rosuvastatin|Drug: Metformin</td>      <td>Celgene|Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation</td>      <td>Phase 1</td>      <td>24.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>18-Jan-20</td>      <td>PPD Phase 1 Clinic, Austin, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04231435</td>    </tr>    <tr>      <th>191</th>      <td>192</td>      <td>Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Familial Adenomatous Polyposis</td>      <td>Drug: Encapsulated Rapamycin (eRapa)</td>      <td>Rapamycin Holdings, Inc. dba Emtora Biosciences|Cancer Insight, LLC|Rapamycin Holdings Inc.</td>      <td>Phase 2</td>      <td>30.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>18-Jan-20</td>      <td>Ohio State University Wexner Medical Center, Columbus, Ohio, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04230499</td>    </tr>    <tr>      <th>192</th>      <td>193</td>      <td>A Clinical Study Assessing Efficacy of an Herbal Blend on Menopausal Symptoms and Quality of Life</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Menopause</td>      <td>Dietary Supplement: phytoestrogen herbal blend|Other: Placebo</td>      <td>i-Health, Inc.|ObvioHealth</td>      <td>Not Applicable</td>      <td>130.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment</td>      <td>14-Jan-20</td>      <td>ObvioHealth, Orlando, Florida, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04228757</td>    </tr>    <tr>      <th>193</th>      <td>194</td>      <td>Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions</td>      <td>Enrolling by invitation</td>      <td>No Results Available</td>      <td>Parkinson Disease|Movement Disorders|Neuro-Degenerative Disease|Nervous System Diseases|Brain Diseases</td>      <td>Device: Renishaw Drug Delivery System</td>      <td>Renishaw|Herantis Pharma Plc.</td>      <td>Phase 1|Phase 2</td>      <td>16.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>14-Jan-20</td>      <td>Helsinki University Hospital, Helsinki, Finland|Skåne University Hospital, Lund,, Sweden|Karolinksa University Hospital, Stockholm, Sweden</td>      <td>https://ClinicalTrials.gov/show/NCT04228653</td>    </tr>    <tr>      <th>194</th>      <td>195</td>      <td>A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Locally Advanced or Metastatic Malignant Solid Tumors</td>      <td>Drug: enfortumab vedotin</td>      <td>Astellas Pharma Global Development, Inc.|Seattle Genetics, Inc.|Astellas Pharma Inc</td>      <td>Phase 2</td>      <td>240.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>13-Jan-20</td>      <td>Piedmont Hospital, Atlanta, Georgia, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States|Site JP81004, Nagoya, Aichi, Japan|Site JP81001, Kashiwa, Chiba, Japan|Site JP81003, Chuo, Tokyo, Japan|Site JP81002, Koto, Tokyo, Japan</td>      <td>https://ClinicalTrials.gov/show/NCT04225117</td>    </tr>    <tr>      <th>195</th>      <td>196</td>      <td>To Evaluate the Efficacy and Safety of Injection With HARA as Compared to Restylane® Lidocaine in Temporary Correction of Nasolabial Folds</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Nasolabial FOLD</td>      <td>Device: HARA Filler(Hyaluronic acid Filler)|Device: Restylane® Lidocaine</td>      <td>Huons Co., Ltd.|Humedix Co., Ltd.</td>      <td>Not Applicable</td>      <td>67.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>13-Jan-20</td>      <td>Huons, Seongnam-si, Korea, Republic of</td>      <td>https://ClinicalTrials.gov/show/NCT04224649</td>    </tr>    <tr>      <th>196</th>      <td>197</td>      <td>A Study to Investigate the Safety and Efficacy of a Probiotic on Gastrointestinal Health in Healthy Adults</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Gastrointestinal Health|Healthy</td>      <td>Dietary Supplement: Lactobacillus plantarum 276|Other: Placebo</td>      <td>Church &amp; Dwight Company, Inc.|KGK Science Inc.</td>      <td>Not Applicable</td>      <td>50.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other</td>      <td>10-Jan-20</td>      <td>KGK Science Inc., London, Ontario, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04223388</td>    </tr>    <tr>      <th>197</th>      <td>198</td>      <td>Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male Subjects</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Healthy Volunteers</td>      <td>Drug: [14C]-MD1003</td>      <td>MedDay Pharmaceuticals SA|Quotient Sciences</td>      <td>Phase 1</td>      <td>6.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research</td>      <td>10-Jan-20</td>      <td>Quotient Sciences, Nottingham, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04223232</td>    </tr>    <tr>      <th>198</th>      <td>199</td>      <td>Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Genital Herpes</td>      <td>Biological: HSV 2 Formulation 1|Biological: HSV 2 Formulation 2|Biological: HSV 2 Formulation 3|Biological: HSV 2 Formulation 4|Biological: HSV 2 Formulation 5|Biological: HSV 2 Formulation 6|Biological: Sodium Chloride 0.9%</td>      <td>Sanofi Pasteur, a Sanofi Company|Immune Design|Sanofi</td>      <td>Phase 1|Phase 2</td>      <td>381.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>10-Jan-20</td>      <td>Investigational Site Number 8400010, Hollywood, Florida, United States|Investigational Site Number 8400003, Boston, Massachusetts, United States|Investigational Site Number 8400006, Raleigh, North Carolina, United States|Investigational Site Number 8400001, Seattle, Washington, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04222985</td>    </tr>    <tr>      <th>199</th>      <td>200</td>      <td>Trial of NanoPac Focal Therapy for Prostate Cancer</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Prostate Cancer|Prostate Adenocarcinoma|Prostate Cancer Adenocarcinoma|Prostatic Neoplasm|Urogenital Neoplasms|Genital Neoplasms, Male|Localized Cancer</td>      <td>Drug: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension</td>      <td>NanOlogy, LLC|US Biotest, Inc.</td>      <td>Phase 2</td>      <td>18.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>9-Jan-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04221828</td>    </tr>    <tr>      <th>200</th>      <td>201</td>      <td>A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Insulin Resistance - Type A|Insulin Resistance - Type B|Lipoatrophic Diabetes Mellitus|Insulin Resistance Syndrome</td>      <td>Drug: Empagliflozin Tablets</td>      <td>Kobe University|Boehringer Ingelheim</td>      <td>Phase 3</td>      <td>8.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>9-Jan-20</td>      <td>Kobe University Hospital, Kobe, Hyogo, Japan|Tohoku University Hospita, Sendai, Miyagi, Japan|Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan|NIhon University Hospital, Chiyoda-ku, Tokyo, Japan|Okayama University Hospital, Okayama, Japan</td>      <td>https://ClinicalTrials.gov/show/NCT04221152</td>    </tr>    <tr>      <th>201</th>      <td>202</td>      <td>Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer</td>      <td>Approved for marketing</td>      <td>No Results Available</td>      <td>HER2-positive Breast Cancer</td>      <td>Drug: Tucatinib|Drug: Capecitabine|Drug: Trastuzumab</td>      <td>Seattle Genetics, Inc.|Parexel</td>      <td>NaN</td>      <td>NaN</td>      <td>Industry</td>      <td>Expanded Access:Treatment IND/Protocol</td>      <td>NaN</td>      <td>7-Jan-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04220203</td>    </tr>    <tr>      <th>202</th>      <td>203</td>      <td>Evaluation of Growth, Safety, and Efficacy of an Infant Formula for Healthy Term Infants</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Infants|Newborn</td>      <td>Other: Study Formula (SF)|Other: Comparator Formula (CF)</td>      <td>ByHeart|Paidion Research, Inc.</td>      <td>Not Applicable</td>      <td>300.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other</td>      <td>6-Jan-20</td>      <td>Alabama Clinical Therapeutics, Birmingham, Alabama, United States|Watching Over Mothers and Babies, Tucson, Arizona, United States|The Children\'s Clinic of Jonesboro, P.A., Jonesboro, Arkansas, United States|San Gabriel Women\'s Health, Arcadia, California, United States|Northern California Research, Sacramento, California, United States|Optum, Colorado Springs, Colorado, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|ZOe Pediatrics, Columbus, Georgia, United States|Clinical Research Institute, Stockbridge, Georgia, United States|Zoe Pediatrics, Thomaston, Georgia, United States|Clinical Research Prime, Idaho Falls, Idaho, United States|Southern Clinical Research, Zachary, Louisiana, United States|Sierra Clinical Research, Las Vegas, Nevada, United States|Haywood Pediatric and Adolescent Medicine Group, Clyde, North Carolina, United States|Pediatric Associates of Mt. Carmel, Inc, Cincinnati, Ohio, United States|Schear Family Practice, Dayton, Ohio, United States|Pediatric Associates of Fairfield, Inc., Fairfield, Ohio, United States|Institute of Clinical Research, Mentor, Ohio, United States|Coastal Pediatric Research, Charleston, South Carolina, United States|Coastal Pediatric Associates, Summerville, South Carolina, United States|HMG Primary Care at Sapling Grove, Bristol, Tennessee, United States|Jackson Clinic North, Jackson, Tennessee, United States|HMG Pediatrics at Kingsport, Kingsport, Tennessee, United States|DCOL Center for Clinical Research, Longview, Texas, United States|ACRC Trials Plano Pediatrics, Plano, Texas, United States|Tanner Clinic, Layton, Utah, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04218929</td>    </tr>    <tr>      <th>203</th>      <td>204</td>      <td>Skin Acceptance and Efficacy Assessment of a Topical Product in Acne Treatment When Compared to a Placebo.</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Acne Vulgaris</td>      <td>Other: ACN cream (YUN)|Other: Placebo cream (YUN)</td>      <td>YUN NV|Allergisa Pesquisa Dermato-Cosmetica LTDA</td>      <td>Not Applicable</td>      <td>80.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>2-Jan-20</td>      <td>Allergisa Pesquisa Dermato-Cosmética Ltda, Campinas, SP, Brazil</td>      <td>https://ClinicalTrials.gov/show/NCT04216160</td>    </tr>    <tr>      <th>204</th>      <td>205</td>      <td>Intermittent Pneumatic Compression in Women With Lipo-lymphedema (Lipedema With Swelling)</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Lipedema|Lipolymphedema</td>      <td>Device: Flexitouch Plus and Conservative Care|Other: Conservative Care</td>      <td>Thomas Wright, MD|Tactile Medical</td>      <td>Not Applicable</td>      <td>36.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care</td>      <td>30-Dec-19</td>      <td>Laser Lipo and Vein Center, O\'Fallon, Missouri, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04213989</td>    </tr>    <tr>      <th>205</th>      <td>206</td>      <td>A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Atrial Fibrillation</td>      <td>Biological: MAA868 Cohort 1|Biological: MAA868 Cohort 2|Biological: MAA868 Cohort 3|Other: Placebo</td>      <td>Anthos Therapeutics, Inc.|Covance</td>      <td>Phase 2</td>      <td>48.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention</td>      <td>30-Dec-19</td>      <td>Anthos Investigative Site, Beverly Hills, California, United States|Anthos Investigative Site, Wichita, Kansas, United States|Anthos Investigative Site, Alexandria, Louisiana, United States|Anthos Investigative Site, Lansing, Michigan, United States|Anthos Investigative Site, Minneapolis, Minnesota, United States|Anthos Investigative Site, Wynnewood, Pennsylvania, United States|Anthos Investigative Site, McKinney, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04213807</td>    </tr>    <tr>      <th>206</th>      <td>207</td>      <td>A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy Volunteers</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Coronary Artery Disease (CAD)</td>      <td>Drug: AZD5718 tablet, Formulation A|Drug: AZD5718 tablet, Formulation B|Drug: AZD5718 tablet, Formulation C|Drug: AZD5718 tablet, Formulation D|Drug: AZD5718 film-coated tablet, Reference treatment</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 1</td>      <td>12.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>24-Dec-19</td>      <td>Research Site, Harrow, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04210388</td>    </tr>    <tr>      <th>207</th>      <td>208</td>      <td>Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Vasomotor Symptoms|Menopausal Symptoms</td>      <td>Drug: Estetrol oral tablet|Drug: Placebo oral tablet|Drug: Progesterone oral tablet</td>      <td>Estetra|ICON Clinical Research</td>      <td>Phase 3</td>      <td>1200.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>24-Dec-19</td>      <td>Saules Family Medicine Centre, Kaunas, Lithuania</td>      <td>https://ClinicalTrials.gov/show/NCT04209543</td>    </tr>    <tr>      <th>208</th>      <td>209</td>      <td>A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer.</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Bladder Cancer|Bladder Tumor|Muscle-Invasive Bladder Cancer</td>      <td>Biological: Nivolumab|Biological: NKTR-214|Procedure: Radical cystectomy (RC)</td>      <td>Bristol-Myers Squibb|Nektar Therapeutics</td>      <td>Phase 3</td>      <td>540.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>23-Dec-19</td>      <td>Local Institution, Birmingham, Alabama, United States|Local Institution, Mobile, Alabama, United States|Local Institution, Gilbert, Arizona, United States|Local Institution, Tucson, Arizona, United States|Local Institution, La Jolla, California, United States|Local Institution, Orange, California, United States|Local Institution, Miami, Florida, United States|Local Institution, Pensacola, Florida, United States|Local Institution, Atlanta, Georgia, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Local Institution, New Orleans, Louisiana, United States|Local Institution, Scarborough, Maine, United States|Local Institution, Saint Louis, Missouri, United States|Local Institution, Belleville, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Local Institution, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Local Institution, Johnson City, New York, United States|Local Institution, Lake Success, New York, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|Duke University, Durham, North Carolina, United States|Local Institution, Eugene, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Local Institution, Hershey, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Local Institution, Spartanburg, South Carolina, United States|Local Institution, Chattanooga, Tennessee, United States|Local Institution, Houston, Texas, United States|Local Institution, San Antonio, Texas, United States|Scott And White Memorial Hosp, Temple, Texas, United States|Local Institution, Seattle, Washington, United States|Local Institution, Spokane Valley, Washington, United States|Local Institution, Tacoma, Washington, United States|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, La Plata, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Gosford, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Murdoch, Australia|Local Institution, Graz, Austria|Local Institution, Wien, Austria|Local Institution, Wien, Austria|Local Institution, Antwerpen, Belgium|Local Institution, Brussel, Belgium|Local Institution, Charleroi, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Jau, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, Surrey, British Columbia, Canada|Lakeridge Health Oshawa-Durham Regional Cancer Centre, Oshawa, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Sherbrooke, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Olomouc, Czechia|Local Institution, Praha 4, Czechia|Local Institution, Praha 5, Czechia|Local Institution, Avignon Cedex 9, France|Local Institution, Bordeaux, France|Local Institution, Brest, France|Local Institution, Caen, France|Local Institution, La Roche-sur-yon Cedex 9, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Montpellier Cedex 5, France|Local Institution, Nice, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Rennes Cedex, France|Local Institution, Strasbourg, France|Local Institution, Suresnes, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Tours Cedex, France|Local Institution, Valenciennes, France|Local Institution, Chemnitz, Germany|Local Institution, Dresden, Germany|Local Institution, Duesseldorf, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Hamburg, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Marien Hospital Herne, Herne, Germany|Universitaetsklinikum Jena, Jena, Germany|Local Institution, Luebeck, Germany|Local Institution, Muenster, Germany|Klinikum Nuernberg Nord, Urologische Klinik, Nuernberg, Germany|Local Institution, Tuebingen, Germany|Local Institution, Athens, Greece|Local Institution, Marousi, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Amsterdam, Netherlands|Local Institution, Auckland, New Zealand|Local Institution, Katowice, Poland|Local Institution, Poznan, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Omsk, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, A Coru?a, Spain|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Cordoba, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|H. U. Marques de Valdecilla, Santander, Spain|Local Institution, Sevilla, Spain|Local Institution, Stevenage, Hertfordshire, United Kingdom|Local Institution, Bebington, United Kingdom|Local Institution, Leicester, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Wolverhampton, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04209114</td>    </tr>    <tr>      <th>209</th>      <td>210</td>      <td>Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Metastatic Cancer|Melanoma|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Colorectal Cancer</td>      <td>Biological: VE800|Drug: Nivolumab|Drug: Vancomycin Oral Capsule</td>      <td>Vedanta Biosciences, Inc.|Bristol-Myers Squibb</td>      <td>Phase 1|Phase 2</td>      <td>111.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>23-Dec-19</td>      <td>The Angeles Clinic and Research Institute - West Los Angeles Office, Santa Monica, California, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Swedish Medical Oncology - First Hill, Seattle, Washington, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04208958</td>    </tr>    <tr>      <th>210</th>      <td>211</td>      <td>Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Type 2 Diabetes</td>      <td>Drug: Placebo|Drug: Cotadutide</td>      <td>AstraZeneca|MedImmune LLC</td>      <td>Phase 1</td>      <td>16.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>23-Dec-19</td>      <td>Research Site, Shinjuku-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Suita-shi, Japan</td>      <td>https://ClinicalTrials.gov/show/NCT04208620</td>    </tr>    <tr>      <th>211</th>      <td>212</td>      <td>A Long-term Follow-up Study in Subjects Who Received CTX001</td>      <td>Enrolling by invitation</td>      <td>No Results Available</td>      <td>Beta-Thalassemia|Thalassemia|Sickle Cell Disease|Hematologic Diseases|Hemoglobinopathies|Genetic Diseases, Inborn|Sickle Cell Anemia</td>      <td>Biological: CTX001</td>      <td>Vertex Pharmaceuticals Incorporated|CRISPR Therapeutics</td>      <td>NaN</td>      <td>90.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>23-Dec-19</td>      <td>Columbia University Medical Center (21+ years), New York, New York, United States|The Children\'s Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers, Nashville, Tennessee, United States|Methodist Healthcare System of San Antonio, Methodist Hospital, Methodist Children\'s Hospital, San Antonio, Texas, United States|Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine, Regensburg, Germany|Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS, Rome, Italy</td>      <td>https://ClinicalTrials.gov/show/NCT04208529</td>    </tr>    <tr>      <th>212</th>      <td>213</td>      <td>A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Healthy</td>      <td>Drug: Olorofim</td>      <td>F2G Ltd.|Covance</td>      <td>Phase 1</td>      <td>12.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>23-Dec-19</td>      <td>Covance Clinical Research Unit, Leeds, West Yorkshire, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04207957</td>    </tr>    <tr>      <th>213</th>      <td>214</td>      <td>CERTAS Programmable Valve Registry</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Hydrocephalus|NPH (Normal Pressure Hydrocephalus)|IIH - Idiopathic Intracranial Hypertension</td>      <td>Device: CODMAN CERTAS Programmable Valves</td>      <td>Integra LifeSciences Corporation|Factory CRO</td>      <td>NaN</td>      <td>200.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>20-Dec-19</td>      <td>Klinikum rechts der Isar Technischen Universitat Munchen, München, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04207229</td>    </tr>    <tr>      <th>214</th>      <td>215</td>      <td>Pharmacokinetic Study of KHK7580 in Healthy Adult Volunteers</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Healthy Volunteer</td>      <td>Drug: 1mg KHK7580|Drug: 3mg KHK7580|Drug: 6mg KHK7580|Drug: 12mg KHK7580|Drug: 6mg KHK7580 for 8days</td>      <td>Kyowa Kirin Co., Ltd.|Kyowa Hakko Kirin China Pharmaceutical Co., LTD.</td>      <td>Phase 1</td>      <td>42.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>20-Dec-19</td>      <td>Beijing hospital, Beijing, Beijing, China</td>      <td>https://ClinicalTrials.gov/show/NCT04206657</td>    </tr>    <tr>      <th>215</th>      <td>216</td>      <td>A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Bullous Pemphigoid</td>      <td>Drug: dupilumab|Drug: Matching Placebo|Drug: Oral corticosteroids (OCS)</td>      <td>Regeneron Pharmaceuticals|Sanofi</td>      <td>Phase 2|Phase 3</td>      <td>80.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>20-Dec-19</td>      <td>Regeneron Investigational Site, Macon, Georgia, United States|Regeneron Investigational Site, Rockville, Maryland, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04206553</td>    </tr>    <tr>      <th>216</th>      <td>217</td>      <td>A Study of JNJ-70033093 and Digoxin in Healthy Participants</td>      <td>Suspended</td>      <td>No Results Available</td>      <td>Healthy</td>      <td>Drug: JNJ-70033093|Drug: Digoxin</td>      <td>Janssen Research &amp; Development, LLC|Bristol-Myers Squibb</td>      <td>Phase 1</td>      <td>20.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>20-Dec-19</td>      <td>Clinical Pharmacology Unit, Merksem, Belgium</td>      <td>https://ClinicalTrials.gov/show/NCT04206488</td>    </tr>    <tr>      <th>217</th>      <td>218</td>      <td>Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Dry Eye Syndrome</td>      <td>Drug: SkQ1 Vehicle Solution|Drug: SkQ1 Ophthalmic Solution</td>      <td>Mitotech, SA|ORA, Inc.</td>      <td>Phase 3</td>      <td>600.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>20-Dec-19</td>      <td>Arizona Eye Institute and Cosmetic Laser, Sun City West, Arizona, United States|Andover Eye Associates, Andover, Massachusetts, United States|Eye Clinics of South Texas, San Antonio, Texas, United States|Piedmont Eye Center, Lynchburg, Virginia, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04206020</td>    </tr>    <tr>      <th>218</th>      <td>219</td>      <td>Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Metastatic Squamous Non-Small Cell Lung Cancer|Metastatic Nonsquamous Non-Small Cell Lung Cancer</td>      <td>Drug: Retifanlimab|Drug: Placebo|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin|Drug: Paclitaxel|Drug: nab-Paclitaxel</td>      <td>Incyte Corporation|Zai Lab (Shanghai) Co., Ltd.</td>      <td>Phase 3</td>      <td>530.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>19-Dec-19</td>      <td>Pacific Cancer Medical Center, Inc., Anaheim, California, United States|Innovative Clinical Research Institute, Whittier, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04205812</td>    </tr>    <tr>      <th>219</th>      <td>220</td>      <td>ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Cancer|Melanoma|Ovary Cancer|Pancreatic Cancer|Solid Tumor</td>      <td>Drug: ENB003|Drug: Pembrolizumab</td>      <td>ENB Therapeutics, Inc|Merck Sharp &amp; Dohme Corp.</td>      <td>Phase 1|Phase 2</td>      <td>130.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>19-Dec-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04205227</td>    </tr>    <tr>      <th>220</th>      <td>221</td>      <td>Measuring Practice Pattern Changes and Clinical Utility of a Novel Test for Preeclampsia</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Pre-Eclampsia</td>      <td>Other: Experimental Arm</td>      <td>Qure Healthcare, LLC|Progenity, Inc.</td>      <td>Not Applicable</td>      <td>108.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic</td>      <td>18-Dec-19</td>      <td>QURE Healthcare, San Francisco, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04204018</td>    </tr>    <tr>      <th>221</th>      <td>222</td>      <td>L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Pancreas Cancer</td>      <td>Biological: L-DOS47|Drug: Doxorubicin</td>      <td>Helix BioPharma Corporation|Theradex</td>      <td>Phase 1|Phase 2</td>      <td>20.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>18-Dec-19</td>      <td>Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04203641</td>    </tr>    <tr>      <th>222</th>      <td>223</td>      <td>Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Neurodermatitis</td>      <td>Drug: Dupilumab SAR231893|Drug: Placebo|Drug: Moisturizers|Drug: Low to medium potent topical corticosteroids|Drug: Topical calcineurin inhibitors</td>      <td>Sanofi|Regeneron Pharmaceuticals</td>      <td>Phase 3</td>      <td>150.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>17-Dec-19</td>      <td>Investigational Site Number 8400054, Fort Smith, Arkansas, United States|Investigational Site Number 8400002, Plainfield, Indiana, United States|Investigational Site Number 8400001, Sugar Land, Texas, United States|Investigational Site Number 1240002, Calgary, Canada|Investigational Site Number 1240006, Surrey, Canada|Investigational Site Number 1240001, Toronto, Canada|Investigational Site Number 1520003, Santiago, Chile|Investigational Site Number 1520001, Santiago, Chile|Investigational Site Number 1520002, Santiago, Chile|Investigational Site Number 2500001, Brest, France|Investigational Site Number 6200002, Lisboa, Portugal|Investigational Site Number 1580001, Taipei, Taiwan</td>      <td>https://ClinicalTrials.gov/show/NCT04202679</td>    </tr>    <tr>      <th>223</th>      <td>224</td>      <td>A Study of CS1001 in Subjects With Advanced or Refractory Solid Tumors</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Advanced Solid Tumor</td>      <td>Drug: CS1001|Drug: Regorafenib</td>      <td>CStone Pharmaceuticals|Bayer</td>      <td>Phase 1|Phase 2</td>      <td>138.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>16-Dec-19</td>      <td>Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia</td>      <td>https://ClinicalTrials.gov/show/NCT04200404</td>    </tr>    <tr>      <th>224</th>      <td>225</td>      <td>Staccato® Granisetron Single Dose PK</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy</td>      <td>Combination Product: 0.5mg AZ-010|Combination Product: 1mg AZ-010|Combination Product: 3mg AZ-010|Combination Product: AZ-010 1mg|Drug: IV Granisetron 1mg</td>      <td>Alexza Pharmaceuticals, Inc.|Celerion</td>      <td>Phase 1</td>      <td>36.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>16-Dec-19</td>      <td>Celerion, Tempe, Arizona, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04200092</td>    </tr>    <tr>      <th>225</th>      <td>226</td>      <td>Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers.</td>      <td>Terminated</td>      <td>No Results Available</td>      <td>Chronic Obstructive Pulmonary Disease</td>      <td>Drug: Abediterol (2.4 μg)|Drug: Abediterol (4.8 μg)|Drug: Abediterol (2.5 μg)</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 1</td>      <td>25.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science</td>      <td>16-Dec-19</td>      <td>Research Site, Berlin, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04199598</td>    </tr>    <tr>      <th>226</th>      <td>227</td>      <td>Investigation to Evaluate PAPILOCARE® Gel Effect on Normalization of Cervix Cytological Alterations Caused by HPV.</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>HPV Infection|Lesion Cervix</td>      <td>Device: papilocare vaginal gel</td>      <td>Procare Health Iberia S.L.|Adknoma Health Research</td>      <td>NaN</td>      <td>300.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Case-Only|Time Perspective: Prospective</td>      <td>13-Dec-19</td>      <td>Hospital General Universitario de Alicante, Alicante, Spain|Women´s Health Institute, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Clínica Diatros, Barcelona, Spain|Gabinete Médico Velázquez, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Instituto Palacios de Salud y Medicina de la Mujer, Madrid, Spain|MD Anderson, Madrid, Spain|Hospital Quirón Málaga, Málaga, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04199260</td>    </tr>    <tr>      <th>227</th>      <td>228</td>      <td>Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Human Papilloma Virus|Human Papilloma Virus Infection|Cervix Lesion</td>      <td>Device: Papilocare vaginal gel</td>      <td>Procare Health Iberia S.L.|Adknoma Health Research</td>      <td>Phase 2</td>      <td>288.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>13-Dec-19</td>      <td>Complejo Hospitalario Torrecárdenas, Almeria, Spain|Hospital del Mar, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Assir Hospitalet de Llobregat, Hospitalet de Llobregat, Spain|Hospital de Manacor, Manacor, Spain|Hospital Virgen de la Macarena, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Hospital Álvaro Cunqueiro, Vigo, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04199078</td>    </tr>    <tr>      <th>228</th>      <td>229</td>      <td>Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Solid Tumor|Non-Small Cell Lung Cancer|Melanoma|Head and Neck Cancer|Gastric Cancer|Renal Cell Carcinoma|Urothelial Carcinoma</td>      <td>Drug: INBRX-106 - Hexavalent OX40 agonist antibody|Drug: Pembrolizumab</td>      <td>Inhibrx, Inc.|Merck Sharp &amp; Dohme Corp.</td>      <td>Phase 1</td>      <td>150.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>13-Dec-19</td>      <td>START Midwest, Grand Rapids, Michigan, United States|Providence Cancer Institute, Portland, Oregon, United States|NEXT Oncoloy, San Antonio, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04198766</td>    </tr>    <tr>      <th>229</th>      <td>230</td>      <td>A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Hypercalcemia of Malignancy</td>      <td>Drug: JMT103</td>      <td>Shanghai JMT-Bio Inc.|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</td>      <td>Phase 1|Phase 2</td>      <td>17.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>13-Dec-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04198480</td>    </tr>    <tr>      <th>230</th>      <td>231</td>      <td>Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Migraine</td>      <td>Biological: ALD1910|Biological: Sumatriptan</td>      <td>H. Lundbeck A/S|Alder Biopharmaceuticals, Inc.</td>      <td>Not Applicable</td>      <td>96.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>13-Dec-19</td>      <td>Nucleus Network Pty Ltd, Melbourne, Australia</td>      <td>https://ClinicalTrials.gov/show/NCT04197349</td>    </tr>    <tr>      <th>231</th>      <td>232</td>      <td>Prospective Observational Study of Pain Evolution in Patients With Primary Knee Osteoarthritis Treated With Pronolis® HD</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Osteo Arthritis Knee</td>      <td>NaN</td>      <td>Procare Health Iberia S.L.|Adknoma Health Research</td>      <td>NaN</td>      <td>188.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Case-Only|Time Perspective: Prospective</td>      <td>12-Dec-19</td>      <td>Hospital del Mar, Barcelona, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04196764</td>    </tr>    <tr>      <th>232</th>      <td>233</td>      <td>BDB001-102 Open Label Dose Escalation Combination w Atezolizumab</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Tumor, Solid</td>      <td>Drug: BDB001|Drug: Atezolizumab</td>      <td>Birdie Biopharmaceuticals HK Limited|Seven and Eight Biopharmaceuticals Inc</td>      <td>Phase 1</td>      <td>50.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>12-Dec-19</td>      <td>Florida Cancer Specialists, Sarasota, Florida, United States|Tennessee Oncology, Nashville, Tennessee, United States|NEXT Oncology, San Antonio, Texas, United States|South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04196530</td>    </tr>    <tr>      <th>233</th>      <td>234</td>      <td>A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Advanced Solid Tumors Cancer</td>      <td>Drug: ABBV-368|Drug: Tilsotolimod|Drug: Nab-paclitaxel|Drug: ABBV-181</td>      <td>AbbVie|Idera Pharmaceuticals, Inc.</td>      <td>Phase 1</td>      <td>69.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>12-Dec-19</td>      <td>UCSD Moores Cancer Center - LaJolla /ID# 216181, La Jolla, California, United States|University of Chicago /ID# 217196, Chicago, Illinois, United States|Norton Cancer Institute /ID# 216179, Louisville, Kentucky, United States|Karmanos Cancer Institute /ID# 214050, Detroit, Michigan, United States|Nebraska Methodist Hospital /ID# 215786, Omaha, Nebraska, United States|Atlantic Health System /ID# 216159, Morristown, New Jersey, United States|Roswell Park Comprehensive Cancer Center /ID# 215882, Buffalo, New York, United States|Vanderbilt University Med Ctr /ID# 214040, Nashville, Tennessee, United States|MD Anderson Cancer Center /ID# 214041, Houston, Texas, United States|Institut Curie /ID# 215653, Paris CEDEX 05, Ile-de-France, France|Gustave Roussy /ID# 215865, Villejuif, Ile-de-France, France|Hopital de la Timone /ID# 215657, Marseille CEDEX 05, Provence-Alpes-Cote-d Azur, France|Hopital Saint Andre /ID# 215702, Bordeaux, France|Centre Antoine Lacassagne /ID# 215706, Nice, France|Universitaetsklinikum Erlangen /ID# 214196, Erlangen, Bayern, Germany|Universitaetsklinikum Leipzig /ID# 214200, Leipzig, Sachsen, Germany|Charite-Univ. Berlin, Benjamin-Franklin /ID# 214197, Berlin, Germany|Rabin Medical Center /ID# 215230, Petakh Tikva, Tel-Aviv, Israel|Rambam Health Care Campus /ID# 215231, Haifa, Israel|Hadassah University Hospital /ID# 215862, Jerusalem, Israel|Sheba Medical Center /ID# 215229, Ramat Gan, Israel|Antoni van Leeuwenhoek /ID# 215291, Amsterdam, Noord-Holland, Netherlands|Hospital Clinic de Barcelona /ID# 214264, Barcelona, Spain|ICO l´Hosp- Hosp Duran Reynals /ID# 221402, Barcelona, Spain|Hospital Univ de Fuenlabrada /ID# 214263, Fuenlabrada, Spain|Hosp Univ 12 de Octubre /ID# 214198, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 214110, Madrid, Spain|Hosp Uni Virgen de la Victoria /ID# 214109, Malaga, Spain|Hosp Clin Univ de Valencia /ID# 221401, València, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04196283</td>    </tr>    <tr>      <th>234</th>      <td>235</td>      <td>A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Respiratory Syncytial Virus</td>      <td>Drug: EDP-938|Drug: Placebo</td>      <td>Enanta Pharmaceuticals|PPD</td>      <td>Phase 2</td>      <td>70.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>12-Dec-19</td>      <td>Central Alabama Research, Birmingham, Alabama, United States|Cahaba Research Inc. - Birmingham, Birmingham, Alabama, United States|Lakeview Clinical Research, Guntersville, Alabama, United States|Saint Joseph\'s Clinical Research, Anaheim, California, United States|Diagnamics Inc., Encinitas, California, United States|Allianz Research Institute Inc, Fountain Valley, California, United States|Torrance Clinical Research Institute, Lomita, California, United States|Dream Team Clinical Research - ClinEdge-PPDS, Pomona, California, United States|Riverside Clinical Research, Edgewater, Florida, United States|Community Research of South Florida, Hialeah, Florida, United States|San Marcus Research Clinic Inc, Miami, Florida, United States|Advanced Phase Facility Research LLC, Miami, Florida, United States|Miami Clinical Research, Miami, Florida, United States|Research Institute of South Florida Inc, Miami, Florida, United States|Florida Institute For Clinical Research LLC, Orlando, Florida, United States|Ormond Beach Clinical Research, Ormond Beach, Florida, United States|Precision Clinical Research, LLC, Tamarac, Florida, United States|Palm Beach Research - ClinEdge - PPDS, West Palm Beach, Florida, United States|North Georgia Clinical Research, Marietta, Georgia, United States|IACT Health, Rincon, Georgia, United States|Clinical Research Atlanta - ERN-PPDS, Stockbridge, Georgia, United States|Investigators Research Group, LLC, Brownsburg, Indiana, United States|MedPharmics, Metairie, Louisiana, United States|George Stanley Walker, MD, LLC, New Orleans, Louisiana, United States|The Clinical Research Center LLC, Saint Louis, Missouri, United States|Montana Medical Research, Missoula, Montana, United States|Pioneer Clinical Research LLC, Bellevue, Nebraska, United States|Meridian Clinical Research, Norfolk, Nebraska, United States|Heartland Clinical Research Inc, Omaha, Nebraska, United States|Meridian Clinical Research-(Omaha Nebraska), Omaha, Nebraska, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|Burke Primary Care, Morganton, North Carolina, United States|Carolina Research Center, Shelby, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Progressive Medicine of the Triad, LLC, Winston-Salem, North Carolina, United States|New Horizons Clinical Research - Velocity, Cincinnati, Ohio, United States|Toledo Institute of Clinical Research, Toledo, Ohio, United States|Oklahoma Institute of Allergy and Asthma Clinical Research LLC, Edmond, Oklahoma, United States|Northwest Research Center, Portland, Oregon, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Frontier Clinical Research, LLC, Smithfield, Pennsylvania, United States|VitaLink Research - Upstate - PPDS, Greenville, South Carolina, United States|VitaLink Research - Spartanburg - PPDS, Spartanburg, South Carolina, United States|Family Medicine Associates of Texas - Hunt - PPDS, Carrollton, Texas, United States|FMC Science, Lampasas, Texas, United States|Centex Studies Inc, McAllen, Texas, United States|ACRC Trials - MRA - PPDS, Plano, Texas, United States|Sherman Clinical Research, Sherman, Texas, United States|J. Lewis Research, Inc., Salt Lake City, Utah, United States|Principle Research Solutions, Spokane, Washington, United States|Paratus Central Coast, Kanwal, New South Wales, Australia|Bluewater Clinical Research Group, Sarnia, Ontario, Canada|Albion Finch Medical Centre, Toronto, Ontario, Canada|Alpha Clinical Research, LLC, Quebec, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04196101</td>    </tr>    <tr>      <th>235</th>      <td>236</td>      <td>A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy</td>      <td>Biological: Pegilodecakin</td>      <td>Eli Lilly and Company|ARMO BioSciences</td>      <td>Phase 1</td>      <td>12.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science</td>      <td>11-Dec-19</td>      <td>PPD Phase 1 Clinic, Austin, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04194892</td>    </tr>    <tr>      <th>236</th>      <td>237</td>      <td>A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Hepatocellular Carcinoma</td>      <td>Drug: Fisogatinib in combination with CS1001</td>      <td>CStone Pharmaceuticals|Blueprint Medicines Corporation</td>      <td>Phase 1|Phase 2</td>      <td>52.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>11-Dec-19</td>      <td>Nanfang Hospital,, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Shanghai East Hospital, Shanghai, Shanghai, China</td>      <td>https://ClinicalTrials.gov/show/NCT04194801</td>    </tr>    <tr>      <th>237</th>      <td>238</td>      <td>A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Parkinsonian Syndrome|Parkinson Disease(PD)|Multiple System Atrophy (MSA)|Progressive Supranuclear Palsy (PSP)</td>      <td>Drug: DaTSCAN™ Ioflupane (123I) Injection</td>      <td>GE Healthcare|PPD</td>      <td>Phase 3</td>      <td>172.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic</td>      <td>10-Dec-19</td>      <td>Beijing Anzhen Hospital, Capital Medical University, Beijing, Chaoyang District, China|Peking Union Medical College Hospital, Beijing, Dongcheng District, China|Nanfang Hospital, Nanfang Medical Univeristy, Guangdong, Guangzhou, China|The Second Affilicated Hospital of Soochow University, Suzhou, Jiangsu, China|Peking University First Hospital, Beijing, China|Beijing Friendship Hospital Afflication to Capital Medical University, Beijing, China|Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China|Tianjin Medical University General Hospital, Tianjin, China</td>      <td>https://ClinicalTrials.gov/show/NCT04193527</td>    </tr>    <tr>      <th>238</th>      <td>239</td>      <td>An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Cancer|Non-small Cell Lung Cancer (NSCLC)</td>      <td>Drug: Cofetuzumab Pelidotin</td>      <td>AbbVie|Pfizer</td>      <td>Phase 1</td>      <td>40.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>6-Dec-19</td>      <td>University of Alabama at Birmingham - Main /ID# 213605, Birmingham, Alabama, United States|Highlands Oncology Group /ID# 215383, Fayetteville, Arkansas, United States|Stanford Univ School Medicine /ID# 213450, Stanford, California, United States|Univ of Colorado Cancer Center /ID# 215295, Aurora, Colorado, United States|Sylvester Comprehensive Cancer /ID# 216433, Miami, Florida, United States|Moffitt Cancer Center /ID# 215101, Tampa, Florida, United States|Washington University-School of Medicine /ID# 213453, Saint Louis, Missouri, United States|The Ohio State University /ID# 211088, Columbus, Ohio, United States|Tennessee Oncology, PLLC /ID# 215326, Nashville, Tennessee, United States|Oncology Consultants /ID# 215932, Houston, Texas, United States|University of Texas MD Anderson Cancer Center /ID# 215876, Houston, Texas, United States|Virginia Cancer Specialists /ID# 216427, Fairfax, Virginia, United States|Rabin Medical Center /ID# 217537, Petakh Tikva, Tel-Aviv, Israel|Rambam Health Care Campus /ID# 217536, Haifa, Israel|Sheba Medical Center /ID# 217538, Ramat Gan, Israel|National Cancer Center Hospital East /ID# 218537, Kashiwa-shi, Chiba, Japan|National Cancer Center Hospital /ID# 218536, Chuo-ku, Tokyo, Japan|Hospital Vall d\'Hebron /ID# 215729, Barcelona, Spain|Hospital Universitario Fundacion Jimenez Diaz /ID# 215110, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 215102, Madrid, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04189614</td>    </tr>    <tr>      <th>239</th>      <td>240</td>      <td>A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Distal Subungual Onychomycosis|Fungal Infection|Fungus, Nail</td>      <td>Drug: BB2603-1|Drug: BB2603-3|Drug: BB2603-10|Drug: Vehicle</td>      <td>Blueberry Therapeutics|IQVIA Biotech</td>      <td>Phase 2</td>      <td>220.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>6-Dec-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04188574</td>    </tr>    <tr>      <th>240</th>      <td>241</td>      <td>A Study to Evaluate the Effect of AZD8154 Administered Via Nebulizer Once Daily in Subjects With Mild Allergic Asthma Challenged With an Inhaled Allergen</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Asthma</td>      <td>Drug: AZD8154 nebulizer suspension, 20 mg/mL|Drug: Placebo</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 2</td>      <td>36.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>5-Dec-19</td>      <td>Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Saskatoon, Saskatchewan, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04187508</td>    </tr>    <tr>      <th>241</th>      <td>242</td>      <td>A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Solid Tumors</td>      <td>Drug: Savolitinib|Drug: Midazolam</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 1</td>      <td>14.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>5-Dec-19</td>      <td>Research Site, Baltimore, Maryland, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04187456</td>    </tr>    <tr>      <th>242</th>      <td>243</td>      <td>MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Diabetic Macular Edema|Macular Edema|Type 2 Diabetes With Diabetic Macular Edema|Type 1 Diabetes With Diabetic Macular Edema|Diabetic Retinopathy</td>      <td>Drug: MS-553</td>      <td>Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.|Fountain Medical Development Co., Ltd.|MingSight Pharmaceuticals Pty Limited</td>      <td>Phase 1</td>      <td>45.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>5-Dec-19</td>      <td>Shanghai General Hospital, Shanghai, China</td>      <td>https://ClinicalTrials.gov/show/NCT04187443</td>    </tr>    <tr>      <th>243</th>      <td>244</td>      <td>Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Prostate Cancer</td>      <td>Drug: rhPSMA-7.3 (18F) Injection</td>      <td>Blue Earth Diagnostics|Parexel</td>      <td>Phase 3</td>      <td>300.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic</td>      <td>5-Dec-19</td>      <td>Tower Urology, Los Angeles, California, United States|John Wayne Cancer Institute, Santa Monica, California, United States|Emory Healthcare, Atlanta, Georgia, United States|MD Anderson Cancer Center, Houston, Texas, United States|Urology San Antonio, San Antonio, Texas, United States|Virginia Oncology Associates PC, Norfolk, Virginia, United States|Turku University Hospital, Turku, Finland</td>      <td>https://ClinicalTrials.gov/show/NCT04186845</td>    </tr>    <tr>      <th>244</th>      <td>245</td>      <td>Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Prostate Cancer</td>      <td>Drug: rhPSMA-7.3 (18F) Injection</td>      <td>Blue Earth Diagnostics|Parexel</td>      <td>Phase 3</td>      <td>375.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic</td>      <td>5-Dec-19</td>      <td>Tower Urology, Los Angeles, California, United States|John Wayne Cancer Institute, Santa Monica, California, United States|Emory Healthcare, Atlanta, Georgia, United States|Urology San Antonio, San Antonio, Texas, United States|Virginia Oncology Associates PC, Norfolk, Virginia, United States|Turku University Hospital, Turku, Finland</td>      <td>https://ClinicalTrials.gov/show/NCT04186819</td>    </tr>    <tr>      <th>245</th>      <td>246</td>      <td>Cryopneumatic Device After Shoulder Surgeries</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Shoulder Injuries|Shoulder Disease</td>      <td>Device: Game Ready ATX shoulder wrap; Game Ready GRPro 2.1|Other: Standard Care</td>      <td>Encore Research Inc.|CoolSystems, Inc.</td>      <td>Not Applicable</td>      <td>250.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>4-Dec-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04185064</td>    </tr>    <tr>      <th>246</th>      <td>247</td>      <td>Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Solid Tumor|Hematological Malignancies</td>      <td>Drug: Belinostat|Drug: Atazanavir</td>      <td>Acrotech Biopharma LLC|Axis Clinicals Limited</td>      <td>Phase 1</td>      <td>8.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>4-Dec-19</td>      <td>John Wayne Cancer Institute @ Providence Saint John\'s Health Center, Santa Monica, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04184869</td>    </tr>    <tr>      <th>247</th>      <td>248</td>      <td>Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Neurodermatitis</td>      <td>Drug: Dupilumab SAR231893|Drug: Placebo|Drug: Moisturizers|Drug: Low to medium potent topical corticosteroids|Drug: Topical calcineurin inhibitors</td>      <td>Sanofi|Regeneron Pharmaceuticals</td>      <td>Phase 3</td>      <td>150.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>3-Dec-19</td>      <td>Investigational Site Number 8400011, Gilbert, Arizona, United States|Investigational Site Number 8400004, Columbus, Georgia, United States|Investigational Site Number 8400003, Newnan, Georgia, United States|Investigational Site Number 8400016, Indianapolis, Indiana, United States|Investigational Site Number 8400009, Athens, Ohio, United States|Investigational Site Number 8400001, Dublin, Ohio, United States|Investigational Site Number 8400007, Tulsa, Oklahoma, United States|Investigational Site Number 8400006, Bellaire, Texas, United States|Investigational Site Number 8400002, Pflugerville, Texas, United States|Investigational Site Number 8400005, Norfolk, Virginia, United States|Investigational Site Number 0320002, Caba, Argentina|Investigational Site Number 0320003, San Miguel De Tucuman, Argentina|Investigational Site Number 3920006, Itabashi-Ku, Japan|Investigational Site Number 3920010, Izumo-Shi, Japan|Investigational Site Number 3920005, Kyoto-Shi, Japan|Investigational Site Number 3920007, Nagasaki-Shi, Japan|Investigational Site Number 3920002, Nagoya-Shi, Japan|Investigational Site Number 3920001, Shinagawa-Ku, Japan|Investigational Site Number 3920003, Tokorozawa-Shi, Japan|Investigational Site Number 3920009, Yokohama-Shi, Japan|Investigational Site Number 4100001, Incheon, Korea, Republic of|Investigational Site Number 4100007, Seongnam-Si, Korea, Republic of|Investigational Site Number 4100002, Seoul, Korea, Republic of|Investigational Site Number 4100003, Seoul, Korea, Republic of|Investigational Site Number 4100006, Seoul, Korea, Republic of|Investigational Site Number 4100004, Seoul, Korea, Republic of</td>      <td>https://ClinicalTrials.gov/show/NCT04183335</td>    </tr>    <tr>      <th>248</th>      <td>249</td>      <td>KW-3357 Study in Patients With Early Onset Severe Preeclampsia</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Preeclampsia</td>      <td>Drug: Antithrombin gamma|Drug: physiological saline</td>      <td>Kyowa Kirin Co., Ltd.|Japan Blood Products Organization</td>      <td>Phase 3</td>      <td>180.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>2-Dec-19</td>      <td>Juntendo University Shizuoka Hospital, Izunokuni, Japan</td>      <td>https://ClinicalTrials.gov/show/NCT04182373</td>    </tr>    <tr>      <th>249</th>      <td>250</td>      <td>Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Chronic Spontaneous Urticaria</td>      <td>Drug: Dupilumab SAR231893|Drug: Placebo|Drug: non sedating H1-antihistamine</td>      <td>Sanofi|Regeneron Pharmaceuticals</td>      <td>Phase 3</td>      <td>234.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>27-Nov-19</td>      <td>Investigational Site Number 8400001, Sweetwater, Florida, United States|Investigational Site Number 8400006, Tampa, Florida, United States|Investigational Site Number 8400009, Saint Louis, Missouri, United States|Investigational Site Number 8400010, Charlotte, North Carolina, United States|Investigational Site Number 8400014, Cincinnati, Ohio, United States|Investigational Site Number 8400011, Charleston, South Carolina, United States|Investigational Site Number 8400003, Dallas, Texas, United States|Investigational Site Number 8400007, San Antonio, Texas, United States|Investigational Site Number 8400013, Sugar Land, Texas, United States|Investigational Site Number 0320004, Caba, Argentina|Investigational Site Number 0320002, Caba, Argentina|Investigational Site Number 0320003, San Miguel De Tucuman, Argentina|Investigational Site Number 1240009, Calgary, Canada|Investigational Site Number 1240004, Quebec, Canada|Investigational Site Number 1240005, Toronto, Canada|Investigational Site Number 1240002, Toronto, Canada|Investigational Site Number 1240006, Trois-Rivieres, Canada|Investigational Site Number 1240007, Windsor, Canada|Investigational Site Number 3920005, Hiroshima-Shi, Japan|Investigational Site Number 3920006, Itabashi-Ku, Japan|Investigational Site Number 3920007, Izumo-Shi, Japan|Investigational Site Number 3920002, Kobe-Shi, Japan|Investigational Site Number 3920004, Nagoya-Shi, Japan|Investigational Site Number 3920001, Shinagawa-Ku, Japan|Investigational Site Number 3920003, Suita-Shi, Japan|Investigational Site Number 3920008, Yokohama-Shi, Japan</td>      <td>https://ClinicalTrials.gov/show/NCT04180488</td>    </tr>    <tr>      <th>250</th>      <td>251</td>      <td>A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Solid Tumours</td>      <td>Drug: Savolitinib|Drug: Famotidine</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 1</td>      <td>32.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>26-Nov-19</td>      <td>Research Site, Baltimore, Maryland, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04179071</td>    </tr>    <tr>      <th>251</th>      <td>252</td>      <td>A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Coronary Artery Disease</td>      <td>Device: The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System</td>      <td>Shanghai Bio-heart Biological Technology Co., Ltd.|CCRF Inc., Beijing, China</td>      <td>Not Applicable</td>      <td>785.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>26-Nov-19</td>      <td>Beijing Anzhen Hospital Capital Medical University, Beijing, Beijing, China|BeijingChao-YangHospital, Beijing, Beijing, China|Fuwai Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China|Nanfnag Hospital, Guangzhou, Guangdong, China|Shanghai Dongfang Hospital, Shanghai, Shanghai, China|Taida International Cardioascular Hospital, Tianjin, Tianjin, China</td>      <td>https://ClinicalTrials.gov/show/NCT04179045</td>    </tr>    <tr>      <th>252</th>      <td>253</td>      <td>MitraClip EXPAND G4 Study</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Mitral Valve Regurgitation|Mitral Regurgitation</td>      <td>Device: MitraClip G4 System</td>      <td>Abbott Medical Devices|Abbott</td>      <td>NaN</td>      <td>100.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>26-Nov-19</td>      <td>University of Alabama at Birmingham, Birmingham, Alabama, United States|Scripps Health, La Jolla, California, United States|University of California - Davis Medical Center, Sacramento, California, United States|Los Robles Regional Medical Center, Thousand Oaks, California, United States|Northshore University Health System, Evanston, Illinois, United States|Via Christi, Wichita, Kansas, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Albany Medical Center, Albany, New York, United States|New York University Hospital, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|St. Thomas Hospital, Nashville, Tennessee, United States|Memorial Hermann Hospital, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04177394</td>    </tr>    <tr>      <th>253</th>      <td>254</td>      <td>The Impact of Myasthenia Gravis in the Real World</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Myasthenia Gravis</td>      <td>NaN</td>      <td>Vitaccess Ltd|argenx BVBA</td>      <td>NaN</td>      <td>2000.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Ecologic or Community|Time Perspective: Prospective</td>      <td>25-Nov-19</td>      <td>Vitaccess Ltd, Oxford, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04176211</td>    </tr>    <tr>      <th>254</th>      <td>255</td>      <td>Clinical Investigation of Safety and Performance of a Medical Device (ClearPlasma) for the Treatment of Patients With Acute Upper Gastrointestinal Hemorrhage.</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Acute Upper Gastrointestinal Hemorrhage|Acute Upper Gastrointestinal Bleeding</td>      <td>Other: Plasma treated with ClearPlasma (Extra-corporeal plasma filtration device)|Other: Regular fresh-frozen plasma (not treated)</td>      <td>PlasFree Ltd.|Sintesi Research Srl</td>      <td>Not Applicable</td>      <td>50.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>22-Nov-19</td>      <td>Department of Surgery, Rabin Medical Center, Petah Tikva, Israel|S.C. di Anestesia e Rianimazione 1, Azienda Ospedaliera Universitaria Policlinico di Modena, Modena, Italy|Area Medicina D\'Urgenza e Pronto Soccorso, Fondazione Policlinico Universitario A. Gemelli, Roma, Italy</td>      <td>https://ClinicalTrials.gov/show/NCT04174989</td>    </tr>    <tr>      <th>255</th>      <td>256</td>      <td>Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Non-valvular Atrial Fibrillation</td>      <td>Drug: Rivaroxaban (Xarelto, BAY59-7939)</td>      <td>Bayer|Janssen Research &amp; Development, LLC</td>      <td>NaN</td>      <td>800.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>22-Nov-19</td>      <td>Many locations, Multiple Locations, Italy</td>      <td>https://ClinicalTrials.gov/show/NCT04174859</td>    </tr>    <tr>      <th>256</th>      <td>257</td>      <td>Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Irritability Associated With Autism Spectrum Disorder (ASD)</td>      <td>Drug: Brexpiprazole|Drug: Placebo</td>      <td>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.|H. Lundbeck A/S</td>      <td>Phase 3</td>      <td>130.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>22-Nov-19</td>      <td>For additional information regarding sites, Princeton, New Jersey, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04174365</td>    </tr>    <tr>      <th>257</th>      <td>258</td>      <td>Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Spinal Muscular Atrophy (SMA)</td>      <td>Other: Prospective observational registry</td>      <td>AveXis, Inc.|United BioSource, LLC</td>      <td>NaN</td>      <td>500.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Ecologic or Community|Time Perspective: Prospective</td>      <td>22-Nov-19</td>      <td>Phoenix Children\'s Hospital, Phoenix, Arizona, United States|Arkansas Children\'s Hospital, Little Rock, Arkansas, United States|University of California Los Angeles Health, Los Angeles, California, United States|Children\'s Hospital of Orange County, Orange, California, United States|University of California Davis Health System, Sacramento, California, United States|Children\'s Hospital Colorado, Aurora, Colorado, United States|Connecticut Children\'s Medical Center, Farmington, Connecticut, United States|Yale-New Haven Health System, New Haven, Connecticut, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|University of Missouri Health System, Columbia, Missouri, United States|Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States|The State University of New York, Stony Brook, New York, United States|Duke Health, Durham, North Carolina, United States|Cincinnati Children\'s Hospital Medical Center, Cincinnati, Ohio, United States|University Hospitals, Cleveland, Ohio, United States|Nationwide Children\'s Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Prisma Health, Greenville, South Carolina, United States|Methodist Le Bonheur Healthcare, Memphis, Tennessee, United States|Children\'s Health, Dallas, Texas, United States|Texas Children\'s Hospital, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Virginia Commonwealth University Health System, Richmond, Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04174157</td>    </tr>    <tr>      <th>258</th>      <td>259</td>      <td>Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Atopic Dermatitis (AD)|Asthma</td>      <td>Drug: dupilumab</td>      <td>Regeneron Pharmaceuticals|Sanofi</td>      <td>NaN</td>      <td>300.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>22-Nov-19</td>      <td>Regeneron Research Site, La Jolla, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04173442</td>    </tr>    <tr>      <th>259</th>      <td>260</td>      <td>Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)</td>      <td>Available</td>      <td>No Results Available</td>      <td>Urinary Tract Infections|Chronic Urinary Tract Infection|Recurrent Urinary Tract Infection|Urinary Tract Infection Bacterial|Bladder Infection</td>      <td>Biological: Uromune</td>      <td>Impatients N.V. trading as myTomorrows|Inmunotek S.L.</td>      <td>NaN</td>      <td>NaN</td>      <td>Industry</td>      <td>Expanded Access</td>      <td>NaN</td>      <td>21-Nov-19</td>      <td>Belgium, Brussels, Belgium|Czech Republic, Praha, Czechia|Denmark, Copenhagen, Denmark|Finland, Helsinki, Finland|France, Paris, France|Germany, Berlin, Germany|Luxembourg, Luxembourg, Luxembourg|The Netherlands, Amsterdam, Netherlands|Norway, Oslo, Norway|Romania, Bukarest, Romania|Serbia, Belgrade, Serbia|Slovakia, Bratislava, Slovakia|Slovenia, Ljubljana, Slovenia|Sweden, Stockholm, Sweden|Turkey, Istanbul, Turkey</td>      <td>https://ClinicalTrials.gov/show/NCT04173013</td>    </tr>    <tr>      <th>260</th>      <td>261</td>      <td>DIStal Versus COnventional RADIAL Access for Coronary Angiography and Intervention</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Coronary Disease</td>      <td>Procedure: Coronary angiography and or Percutaneous coronary Intervention</td>      <td>Terumo Europe N.V.|Cromsource</td>      <td>Not Applicable</td>      <td>1300.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care</td>      <td>21-Nov-19</td>      <td>Cliniques Universitaires Saint-Luc, Brussels, Belgium|Hôpital Civil Marie Curie, Charleroi, Belgium|Klinikum Minden, Minden, Germany|Bács-Kiskun Megyei Kórház, Kalocsa, Hungary|Interventional Cardiologist at Istituto Clinico Humanitas, Milano, Italy|Sant\'Eugenio Hospital, Roma, Italy|Shonan Kamakura General Hospital, Kanagawa, Japan|University Clinic of Cardiology, Skopje, Skopje, North Macedonia|HUG Geneva, Geneva, Switzerland|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom|Sunderland Royal Hospital, Sunderland, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04171570</td>    </tr>    <tr>      <th>261</th>      <td>262</td>      <td>A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Rheumatoid Arthritis</td>      <td>Biological: CT-P17 SC AI (adalimumab)</td>      <td>Celltrion|PPD</td>      <td>Phase 3</td>      <td>50.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>20-Nov-19</td>      <td>Nasz Lekarz Osrodek Badan Klinicznych, Bydgoszcz, Poland</td>      <td>https://ClinicalTrials.gov/show/NCT04171414</td>    </tr>    <tr>      <th>262</th>      <td>263</td>      <td>M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Metastatic or Locally Advanced Unresectable Solid Tumors</td>      <td>Drug: M1774</td>      <td>EMD Serono Research &amp; Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono</td>      <td>Phase 1</td>      <td>24.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>20-Nov-19</td>      <td>University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics - Partner, Houston, Texas, United States|NEXT Oncology, San Antonio, Texas, United States|Research Site, Darmstadt, Germany|Northern Centre for Cancer Care - Sir Bobby Robson Cancer Trials Research Centre, Newcastle upon Tyne, United Kingdom|Royal Marsden Hospital - Dept of Oncology, Sutton, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04170153</td>    </tr>    <tr>      <th>263</th>      <td>264</td>      <td>FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Colorectal Cancer Metastatic</td>      <td>Drug: Oxaliplatin</td>      <td>Criterium, Inc.|Amgen</td>      <td>Phase 2</td>      <td>35.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>19-Nov-19</td>      <td>University of Arizona Cancer Center, Tucson, Arizona, United States|Kansas University Cancer Center, Westwood, Kansas, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04169347</td>    </tr>    <tr>      <th>264</th>      <td>265</td>      <td>Controlled Study Comparing REPaiR® and MIST Therapies for Treatment of Periodontitis</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Periodontal Diseases</td>      <td>Device: MIST (minimally invasive surgical therapy)</td>      <td>McGuire Institute|Biolase Inc</td>      <td>Not Applicable</td>      <td>54.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>19-Nov-19</td>      <td>Medelis Inc, Nashville, Tennessee, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04169139</td>    </tr>    <tr>      <th>265</th>      <td>266</td>      <td>An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Breastcancer</td>      <td>Drug: Oraxol</td>      <td>Athenex, Inc.|PharmaEssentia</td>      <td>Phase 1</td>      <td>24.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>19-Nov-19</td>      <td>Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan|Taipei Veterans Generla Hospital, Taipei, Taiwan, 11217, Taiwan</td>      <td>https://ClinicalTrials.gov/show/NCT04168957</td>    </tr>    <tr>      <th>266</th>      <td>267</td>      <td>Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Metastatic Solid Neoplasm|Lymphoma</td>      <td>Drug: SYNB1891|Drug: Atezolizumab</td>      <td>Synlogic|IQVIA Biotech</td>      <td>Phase 1</td>      <td>70.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>18-Nov-19</td>      <td>University of Colorado Cancer Center, Aurora, Colorado, United States|Hackensack University John Theurer Cancer Center, Hackensack, New Jersey, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Mary Crowley Cancer Research, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04167137</td>    </tr>    <tr>      <th>267</th>      <td>268</td>      <td>Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Diffuse Cutaneous Systemic Sclerosis</td>      <td>Drug: Patients will be randomized to receive EHP-101 or Placebo</td>      <td>Emerald Health Pharmaceuticals Inc.|Iqvia Pty Ltd</td>      <td>Phase 2</td>      <td>36.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>18-Nov-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04166552</td>    </tr>    <tr>      <th>268</th>      <td>269</td>      <td>Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C</td>      <td>Enrolling by invitation</td>      <td>No Results Available</td>      <td>Irritable Bowel Syndrome With Constipation|Functional Constipation</td>      <td>Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)|Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers):</td>      <td>Allergan|Ironwood Pharmaceuticals, Inc.</td>      <td>Phase 3</td>      <td>120.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>18-Nov-19</td>      <td>Central Research Associates, Inc, Birmingham, Alabama, United States|Southeastern Pediatrics Associates, Dothan, Alabama, United States|G &amp; L Research, LLC, Foley, Alabama, United States|The Center for Clinical Trials, Saraland, Alabama, United States|HealthStar Research, Hot Springs, Arkansas, United States|Preferred Clinical Research Partners, Little Rock, Arkansas, United States|Applied Research Center of Arkansas, Little Rock, Arkansas, United States|Advanced Research Center, Anaheim, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Children\'s Hospital of Orange County, Orange, California, United States|Center for Clinical Trials, LLC, Paramount, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Lynn Institute of Denver, Aurora, Colorado, United States|Children\'s National Medical Center, Washington, District of Columbia, United States|Prohealth Research Center, Doral, Florida, United States|Dolphin Medical Research, Doral, Florida, United States|Amedica Research Institute, Inc, Hialeah, Florida, United States|Nemours Children\'s Specialty Care, Jacksonville, Florida, United States|Elite Clinical Research, Miami, Florida, United States|Biotech Pharmaceuticals Group LLC, Miami, Florida, United States|South Miami Medical &amp; Research Group, Inc., Miami, Florida, United States|Valencia Medical &amp; Research Center, Miami, Florida, United States|Advanced Research for Health Improvement,LLC, Naples, Florida, United States|Pediatric &amp; Adult Research Center, Orlando, Florida, United States|Nemours Children\'s Hospital, Orlando, Florida, United States|Oviedo Medical Research, Oviedo, Florida, United States|Treken Primary Care, Atlanta, Georgia, United States|Children\'s Healthcare of Atlanta, Atlanta, Georgia, United States|Childrens Center for Digestive Health Care, Atlanta, Georgia, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|Clinical Trials Specialist, Inc., Doraville, Georgia, United States|Clinical Research Institute, Stockbridge, Georgia, United States|SleepCare Research Institute, Inc., Stockbridge, Georgia, United States|The University of Chicago, Chicago, Illinois, United States|Alliance for Multispecialty Research, LLC, Newton, Kansas, United States|KU Wichita Center for Clinical Research, Wichita, Kansas, United States|Private Practice - Dr. Michael W. Simon, Nicholasville, Kentucky, United States|Meridian Clinical Research, Baton Rouge, Louisiana, United States|Virgo Carter Pediatrics, Silver Spring, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Minnesota Gastroenterology PA, Minneapolis, Minnesota, United States|Gastrointestinal Associates and Endoscopy Center, Flowood, Mississippi, United States|David M. Headley, MD, P.A., Port Gibson, Mississippi, United States|Private Practice - Dr. Craig Spiegel, Bridgeton, Missouri, United States|Foundation Pediatrics Med Clinical Research Partners, LLC, East Orange, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Biomedical Research Alliance of New York/ Montefiore Medical Center, Bronx, New York, United States|Advantage Clinical Trials, Bronx, New York, United States|Columbia University Medical Center and Morgan Stanley Children\'s Hospital of New York, New York, New York, United States|Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States|UNC Physicians Network (Capitol Pediatrics &amp; Adolescent Center), Raleigh, North Carolina, United States|PMG Research, Inc. dba PMG Research of Piedmont Healthcare, Statesville, North Carolina, United States|University of Oklahoma Health Sciences Center/Children\'s Hospital at OU Medical Center, Oklahoma City, Oklahoma, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Children\'s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Frontier Clinical Research, LLC, Scottdale, Pennsylvania, United States|Frontier Clinical Research, LLC, Smithfield, Pennsylvania, United States|Hasbro Children\'s Hospital/Rhode Island Hospital, Providence, Rhode Island, United States|Coastal Pediatric Research, Charleston, South Carolina, United States|Coastal Pediatric Research, Summerville, South Carolina, United States|The Jackson Clinic, P.A., Jackson, Tennessee, United States|GI for Kids, PLLC, Knoxville, Tennessee, United States|Vanderbilt Children\'s Hospital, Nashville, Tennessee, United States|Oak Cliff Research Company, LLC, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Cook Childrens Health Care System, Fort Worth, Texas, United States|Capital Area Primary Care, PLLC dba San Gabriel Clinical Research, Georgetown, Texas, United States|Valley Institute of Research, Harlingen, Texas, United States|Discovery MM Services, Inc., Houston, Texas, United States|Vilo Research Group, Houston, Texas, United States|Cullen Research, Houston, Texas, United States|Pioneer Research Solutions Inc, Houston, Texas, United States|Discovery MM Services, Inc, Missouri City, Texas, United States|AIM Trials, LLC, Plano, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|UT Health San Antonio, San Antonio, Texas, United States|Ace Clinical Research, Sugar Land, Texas, United States|ClinPoint Trials, Waxahachie, Texas, United States|Chrysalis Clinical Research, Saint George, Utah, United States|University of Utah and Primary Children\'s Hospital, Salt Lake City, Utah, United States|Health Research of Hampton Roads, Inc., Newport News, Virginia, United States|Clinical Research Partners, LLC, Richmond, Virginia, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Marshall Health, Huntington, West Virginia, United States|The Medical College of Wisconsin, Milwaukee, Wisconsin, United States|UZ Brussel, Brussels, Belgium|Universitair Ziekenhuis, Ghent, Belgium|KU Leuven, Leuven, Belgium|Medical Center-1-Sevlievo EOOD, Sevlievo, Gabrovo, Bulgaria|MBAL Sv.Ivan Rilski Kozlodui, Kiril I Metodiy, Bulgaria|University Hospital Plovdiv, Plovdiv, Bulgaria|Multi-Profile Hospital for Active Treatment - Ruse JSC MHAT-Ruse, Ruse, Bulgaria|Medical Center-1-Sevlievo EOOD, Sevlievo, Bulgaria|UMHAT Sveta Marina, Varna, Bulgaria|DSMED, Lower Sackville, Nova Scotia, Canada|London Health Sciences Centre, London, Ontario, Canada|SKDS Research Inc, Newmarket, Ontario, Canada|Bluewater Clinical Research Group Inc, Sarnia, Ontario, Canada|Stollery Children\'s Hospital, Edmonton, Canada|Al Mare Perearstikeskus, Harjumaa, Estonia|Merelahe PAK, Tallinn, Estonia|Kiliiniliste Uuringute Keskus, Tartu, Estonia|Kindergastroenterologie, Uni-Kinderklinik Leipzig, Leipzig, Saxony-Anhalt, Germany|Klinikum Kassel GmbH, Kassel, Germany|Svabhegy Pediatric Clinic, Budapest, Hungary|Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak, Budapest, Hungary|Soproni Erzsebet Oktato Korhaz es Rehabilitacious Intezet, Sopron, Hungary|Rambam Health Care Campus, Ruth Rappaport Children\'s Hospital, Haifa, Israel|Wolfson Medical Center, Holon, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah University Hospital, Jerusalem, Israel|The Baruch Padeh Medical Center Poriya, Lower Galilee, Israel|Schneider Children\'s Medical Center of Israel, Petah Tikva, Israel|Sheba medical center, Tel Hashomer, Israel|Azienda Ospedaliera Sant\' Andrea, Naples, Italy|IRCCS Ospedale Pediatrico Bambino Gesu, Roma, Italy|Academisch Medisch Centrum Universiteit Van Amsterdam, Amsterdam, Netherlands|Maasstad Hospital Rotterdam, Rotterdam, Netherlands|Isala Zwolle, Zwolle, Netherlands|Szpital Uniwersytecki "r. A. Jurasza", Bydgoszcz, Poland|Klinika Pediatrii Gastroenterologii Hepatologii Zywienia Dzieci Szpiatl, Gdansk, Poland|Wojew dzki Specjalistyczny Szpital Dzieciecy, Olsztyn, Poland|Korczowski Bartosz, Gabinet Lekarski, Rzeszów, Poland|Centrum Zdrowia MDM, Warsaw, Poland|University Children\'s Hospital, Belgrade, Serbia|University Children\'s Hospital - Tirsova, Belgrad, Serbia|Children\'s Hospital, Clinical Center Nis, Nis, Serbia|Institute for Child and Youth Health Care of Vojvodina, Novi Sad, Serbia|Hospital Regional Universitario de Malaga, Malaga, Spain|Instituto Hispalense Pediatria, Sevilla, Spain|MMI "Regional children\'s clinical hospital", Chernivtsi, Chernivets\'ka Oblast\', Ukraine|Municipal Nonprofit Enterprise "Lviv City Children\'s Clinical Hospital", Lviv, L\'vivs\'ka Oblast\', Ukraine|State Institution "Dnipropetrovsk medical academy", Dnipro, Ukraine|Kharkiv National Medical University, Kharkiv, Ukraine|Vinnytsya National Medical University, Vinnytsya, Ukraine|Birmingham Children\'s Hospital, Birmingham, United Kingdom|Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom|Barts Health NHS Trust - The Royal London Hospital, London, United Kingdom|King\'s College Hospital, London, United Kingdom|Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom|William Harvey Hospital, Willesborough, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04166058</td>    </tr>    <tr>      <th>269</th>      <td>270</td>      <td>A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.</td>      <td>Withdrawn</td>      <td>No Results Available</td>      <td>Hypertension|Renal Insufficiency, Chronic</td>      <td>Drug: Aprocitentan 25 mg|Drug: Placebo</td>      <td>Idorsia Pharmaceuticals Ltd.|Janssen Biotech, Inc.</td>      <td>Phase 3</td>      <td>0.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>14-Nov-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04162366</td>    </tr>    <tr>      <th>270</th>      <td>271</td>      <td>Contingency Management Using Smartphone App in Patients With SUD</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Substance Use Disorders</td>      <td>Device: Smartphone app</td>      <td>BrightView LLC|DynamiCare Health</td>      <td>NaN</td>      <td>108.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>14-Nov-19</td>      <td>BrightView, Cincinnati, Ohio, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04162132</td>    </tr>    <tr>      <th>271</th>      <td>272</td>      <td>Mitopure™ (Proprietary Urolithin A) Bioavailability in Healthy Adults</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy|Healthy Aging</td>      <td>Dietary Supplement: Mitopure™ (Proprietary Urolithin A)|Dietary Supplement: Pomegranate Juice</td>      <td>Amazentis SA|Atlantia Food Clinical Trials</td>      <td>Not Applicable</td>      <td>100.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science</td>      <td>13-Nov-19</td>      <td>Atlantia Food Clinical Trials CRO (Northwestern University campus), Chicago, Illinois, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04160312</td>    </tr>    <tr>      <th>272</th>      <td>273</td>      <td>RHEIA (Randomized researcH in womEn All Comers With Aortic Stenosis)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Aortic Valve Stenosis|Heart Valve Diseases</td>      <td>Procedure: Transcatheter aortic valve replacement</td>      <td>SSS International Clinical Research GmbH|Edwards Lifesciences</td>      <td>Not Applicable</td>      <td>440.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>12-Nov-19</td>      <td>Universitätskliniken Innsbruck, Innsbruck, Austria|Allgemeines Krankenhaus der Stadt Wien, Vienna, Austria|Helsinky University Hospital, Helsinki, Finland|Tampere University Hospital, Tampere, Finland|CHU de Bordeaux - Hôpital cardiologique du Haut-Lévêqu, Bordeaux, France|CHRU de Brest, Brest, France|CHU Lille - Institute Coeur Poumon, Lille, France|CHU Montpellier, Montpellier, France|Hôpital Privé Jacques Cartier, Paris, France|CHU Rennes - Hopital de Pontchaillou, Rennes, France|CHU Rouen - Hopital Charles Nicolle, Rouen, France|Clinique Pasteur, Toulouse, France|Universitätsklinik der Ruhr-Universität Bochum, Bad Oeynhausen, Germany|Deutsches Herzzentrum Berlin, Berlin, Germany|Universitätsklinikum Frankfurt Am Main, Frankfurt, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Mater Misericordiae University Hospital, Dublin, Ireland|St. James´s Hospital, Dublin, Ireland|Ospedale del Cuore G. Pasquinucci, Massa, Italy|Universita di Padova, Padova, Italy|Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy|Catharina Ziekenhuis Eindhoven, Eindhoven, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|St Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Skåne University Hospital, Lund, Sweden|Inselspital Universitätsspital Bern, Bern, Switzerland|Hirslanden Klinik Im Park, Zürich, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Royal Papworth Hospital, Cambridge, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|St Thomas Hospital, London, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04160130</td>    </tr>    <tr>      <th>273</th>      <td>274</td>      <td>Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis</td>      <td>Terminated</td>      <td>No Results Available</td>      <td>Osteoarthritis of the Shoulder|Adhesive Capsulitis</td>      <td>Drug: FX006|Drug: Normal Saline</td>      <td>Flexion Therapeutics, Inc.|Medpace, Inc.</td>      <td>Phase 2</td>      <td>19.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>12-Nov-19</td>      <td>Central Research Associates, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States|Affinity Orthopedic Specialists, Birmingham, Alabama, United States|Coastal Clinical Research, Inc., Mobile, Alabama, United States|Arizona Research Center, Phoenix, Arizona, United States|Tucson Orthopaedic Institute, Tucson, Arizona, United States|TriWest Research Associates, El Cajon, California, United States|CORE Orthopedic Medical Center, Encinitas, California, United States|BioSolutions Clinical Research Center, La Mesa, California, United States|Mountain View Clinical Research Center, Denver, Colorado, United States|Coastal Orthopaedics and Sports Medicine, Bradenton, Florida, United States|South Lake Pain Institute, Clermont, Florida, United States|Universal Axon Clinical Research, Homestead, Florida, United States|Precision Clinical Research, Lauderdale Lakes, Florida, United States|Infinite Clinical Research, Miami, Florida, United States|Jewitt Orthopedic Center, Orlando, Florida, United States|Gulfcoast Research Institute, Sarasota, Florida, United States|Better Health Clinical Research, Inc., Newnan, Georgia, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Arthritis and Rheumatism Associates PC, Wheaton, Maryland, United States|Hassman Research Institute, Berlin, New Jersey, United States|M3 Emerging Medical Research, Durham, North Carolina, United States|University Orthopedics Center, Altoona, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Texas Orthopedic Specialists, Bedford, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Spectrum Medical, Inc., Danville, Virginia, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04160091</td>    </tr>    <tr>      <th>274</th>      <td>275</td>      <td>Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects With Primary Axillary Hyperhidrosis</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Primary Axillary Hyperhidrosis</td>      <td>Drug: WO3970|Drug: Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use</td>      <td>Dr. August Wolff GmbH &amp; Co. KG Arzneimittel|Therapeutics, Inc.</td>      <td>Phase 2</td>      <td>12.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>12-Nov-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04159610</td>    </tr>    <tr>      <th>275</th>      <td>276</td>      <td>A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer</td>      <td>Withdrawn</td>      <td>No Results Available</td>      <td>Advanced Cancer</td>      <td>Drug: LY3200882|Drug: Pembrolizumab</td>      <td>Eli Lilly and Company|Merck Sharp &amp; Dohme Corp.</td>      <td>Phase 1|Phase 2</td>      <td>0.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>12-Nov-19</td>      <td>Dana Farber Cancer Institute, Boston, Massachusetts, United States|CHU de Besancon Hopital Jean Minjoz, Besancon Cedex, France|Gustave Roussy, Villejuif Cedex, France|Institut Catala d\'Oncologia, L\'Hospitalet de Llobregat, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital Madrid Norte Sanchinarro, Madrid, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04158700</td>    </tr>    <tr>      <th>276</th>      <td>277</td>      <td>A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Schizophrenia</td>      <td>Drug: CTP-692|Drug: Placebo</td>      <td>Concert Pharmaceuticals|Cognitive Research Corporation</td>      <td>Phase 2</td>      <td>300.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>12-Nov-19</td>      <td>Woodland International Research Group, LLC, Little Rock, Arkansas, United States|Woodland Research Northwest, LLC, Rogers, Arkansas, United States|Synexus Clinical Research US, Inc., Cerritos, California, United States|ProScience Research Group, Culver City, California, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Synergy San Diego, Lemon Grove, California, United States|Pacific Research Partners, LLC, Oakland, California, United States|Collaborative Neuroscience Network, LLC, Torrance, California, United States|Innovative Clinical Research, Inc., Lauderhill, Florida, United States|Behavioral Clinical Research, Inc., North Miami, Florida, United States|Synexus Clinical Research US, Inc., Atlanta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Uptown Research Institute, LLC, Chicago, Illinois, United States|Pillar Clinical Research, LLC, Lincolnwood, Illinois, United States|CBH Health, LLC, Gaithersburg, Maryland, United States|Hassman Research Institute, Berlin, New Jersey, United States|Hassman Research Institute, Marlton, New Jersey, United States|Neurobehavioral Research, Inc., Cedarhurst, New York, United States|Synexus Clinical Research US, Inc., Jamaica, New York, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|Donald J. Garcia Jr., MD, PA, Austin, Texas, United States|Community Clinical Research, Inc., Austin, Texas, United States|InSite Clinical Research, LLC, DeSoto, Texas, United States|Pillar Clinical Research, LLC, Richardson, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04158687</td>    </tr>    <tr>      <th>277</th>      <td>278</td>      <td>A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Heart Failure</td>      <td>Drug: Empagliflozin|Drug: Placebo to Empagliflozin</td>      <td>Boehringer Ingelheim|Eli Lilly and Company</td>      <td>Phase 3</td>      <td>500.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>8-Nov-19</td>      <td>Cardiology Associates Research Co., Daytona Beach, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Willis Knighton Medical Center, Bossier City, Louisiana, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Aalst - HOSP Onze-Lieve-Vrouw, Aalst, Belgium|Aalborg Universitetsshospital, Aalborg, Denmark|Frederiksberg Hospital, Frederiksberg, Denmark|Herlev and Gentofte Hospital, Herlev, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Viborg Regionhospital, Viborg, Denmark|Elisabeth-Krankenhaus, Essen, Essen, Germany|Universitäts-Herzzentrum Freiburg, Bad Krozingen GmbH, Freiburg, Germany|Klinikum Leverkusen gGmbH, Leverkusen, Leverkusen, Germany|Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jeroen Bosch Ziekenhuis-Hertogenbosch, \'s HERTOGENBOSCH, Netherlands|TREANT Zorggroep, Emmen, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Bravis ziekenhuis, locatie Roosendaal, Roosendaal, Netherlands|Akershus Universitetssykehus HF, Lørenskog, Norway|Hospital Universitario Virgen de la Arrixaca, El Palmar, Spain|Hospital Puerta de Hierro, Majadahonda, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain|Hospital Clínico de Valencia, Valencia, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04157751</td>    </tr>    <tr>      <th>278</th>      <td>279</td>      <td>Bioequivalence Study Assessing Iron Sucrose or Venofer® in Healthy Adult Subjects</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Bioequivalance</td>      <td>Drug: Iron Sucrose Injection|Drug: Venofer Injection</td>      <td>Baxter Healthcare Corporation|Quotient Sciences</td>      <td>Phase 1</td>      <td>196.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>7-Nov-19</td>      <td>Baxter Investigational Site, Miami, Florida, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04155814</td>    </tr>    <tr>      <th>279</th>      <td>280</td>      <td>To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Dyslipidemia</td>      <td>Drug: AZD8233 subcutaneous injection|Drug: Placebo</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 1</td>      <td>33.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment</td>      <td>7-Nov-19</td>      <td>Research Site, Glendale, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Baltimore, Maryland, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04155645</td>    </tr>    <tr>      <th>280</th>      <td>281</td>      <td>A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Anaemia Associated With Chronic Kidney Disease</td>      <td>Drug: efepoetin alfa|Drug: Mircera</td>      <td>PT Kalbe Genexine Biologics|Novotech (Australia) Pty Limited</td>      <td>Phase 3</td>      <td>386.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>7-Nov-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04155125</td>    </tr>    <tr>      <th>281</th>      <td>282</td>      <td>Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Cutaneous Squamous Cell Carcinoma</td>      <td>Drug: Cemiplimab</td>      <td>Regeneron Pharmaceuticals|Sanofi</td>      <td>Phase 2</td>      <td>76.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>7-Nov-19</td>      <td>Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Omaha, Nebraska, United States|Regeneron Study Site, Houston, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04154943</td>    </tr>    <tr>      <th>282</th>      <td>283</td>      <td>Evaluate Efficacy &amp; Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Migraine</td>      <td>Biological: Eptinezumab|Biological: Placebo</td>      <td>H. Lundbeck A/S|Alder Biopharmaceuticals, Inc.</td>      <td>Phase 3</td>      <td>450.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>5-Nov-19</td>      <td>Alabama Clinical Therapeutics, Birmingham, Alabama, United States|Arizona Research Center, Phoenix, Arizona, United States|Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States|Advanced Research Center, Anaheim, California, United States|The Neurology Center of Southern California - Carlsbad, Carlsbad, California, United States|Excell research Inc, Oceanside, California, United States|Anderson Clinical Research, Redlands, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Neurological Clinic - Denver, Denver, Colorado, United States|Coastal Connecticut Research LLC, New London, Connecticut, United States|Ki Health Partners LLC, dba New England Institute for Clinical Research, Stamford, Connecticut, United States|The George Washington Medical Faculty Associates, Washington, District of Columbia, United States|Medicinae Doctor Clinical, Hallandale Beach, Florida, United States|AGA Clinical trials, Hialeah, Florida, United States|Meridien Research - Maitland, Maitland, Florida, United States|Palm Beach Neurology and Premiere Research Institute, West Palm Beach, Florida, United States|Clinical Research of Central Florida, Winter Haven, Florida, United States|Office of Doctor Frank Berenson, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Meridian Clinical Research - Savannah Neurology Specialists, Savannah, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|College Park Family Care Center Physicians, Overland Park, Kansas, United States|Phoenix Medical Research, Prairie Village, Kansas, United States|Central Kentucky Research Associates, Lexington, Kentucky, United States|Boston Clinical Trials, Boston, Massachusetts, United States|MedVadis Research Corporation, LLC, Waltham, Massachusetts, United States|Michigan Head Pain and Neurological institute, Ann Arbor, Michigan, United States|Clinical Research Institute - Minneapolis, Minneapolis, Minnesota, United States|Headache Neurology Research Institute, Ridgeland, Mississippi, United States|StudyMetrix Research, Saint Peters, Missouri, United States|Clinvest Research, Springfield, Missouri, United States|Nevada Headache Institute, Las Vegas, Nevada, United States|Albuqerque Clinical Trials, Albuquerque, New Mexico, United States|Dent Neurologic Institute - Amherst, Amherst, New York, United States|Integrative Clinical Trials, Brooklyn, New York, United States|CTI Clinical Research center, Cincinnati, Ohio, United States|Aventiv Research - Columbus, Columbus, Ohio, United States|Hometown Urgent Care And Research - Huber Heights, Dayton, Ohio, United States|Neuro-Behavioral Clinical Research Inc, North Canton, Ohio, United States|Delricht Research, Tulsa, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Frontier Clinical Rsearch LLC, Smithfield, Pennsylvania, United States|Coastal Carolina Research Center - Mount Pleasant, Mount Pleasant, South Carolina, United States|Chattanooga Medical research LLC, Chattanooga, Tennessee, United States|WR-ClinSearch LLC, Chattanooga, Tennessee, United States|Holston Medical Group - Kingsport, Kingsport, Tennessee, United States|Ventavia Research Group, LLC, Fort Worth, Texas, United States|Texas Center for Drug Development Inc, Houston, Texas, United States|Ventavia Research Group, LLC, Keller, Texas, United States|J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City, Utah, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Neuroscience Group, Neenah, Wisconsin, United States|Ltd "Acad Fridon Todua Medical Center - Ltd Research Institute of Clinical Medicine", Tbilisi, Georgia|Ltd "Aversi Clinic", Tbilisi, Georgia|Ltd "Multiprofile Clinica Consilium Medulla", Tbilisi, Georgia|Ltd Simon Khechinashvili University Clinic, Tbilisi, Georgia|td "Israel-Georgia Medical Research Clinic Helsicore", Tbilisi, Georgia</td>      <td>https://ClinicalTrials.gov/show/NCT04152083</td>    </tr>    <tr>      <th>283</th>      <td>284</td>      <td>Safety &amp; Efficacy of the LSM Procedure (Taiwan)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Presbyopia</td>      <td>Device: Laser Scleral Microporation</td>      <td>ACE Vision Group, Inc.|Vision Renu Taiwan Corporation</td>      <td>Not Applicable</td>      <td>72.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>5-Nov-19</td>      <td>Chang Gung Memorial Hospital, Keelung, Keelung, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan</td>      <td>https://ClinicalTrials.gov/show/NCT04151446</td>    </tr>    <tr>      <th>284</th>      <td>285</td>      <td>Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Leukemia, Myeloid, Acute</td>      <td>Drug: Cusatuzumab|Drug: Azacitidine|Drug: Venetoclax</td>      <td>Janssen Research &amp; Development, LLC|argenx BVBA</td>      <td>Phase 1</td>      <td>60.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>5-Nov-19</td>      <td>City of Hope, Duarte, California, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University Of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Weill Cornell Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Durham VAMC, Durham, North Carolina, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Vermont, Burlington, Vermont, United States|Wisconsin Medical Center, Milwaukee, Wisconsin, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany|Universitätsklinikum Carl-Gustav-Carus Dresden, Dresden, Germany|Goethe Universität Frankfurt, Frankfurt/Main, Germany|Universitätsklinik Freiburg, Freiburg im Breisgau, Germany|Universitaetsklinik Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum Heidelberg Medizinische Klinik V, Heidelberg, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Klinikum der Universität München, München, Germany|Universitätsklinikum Ulm, Ulm, Germany|Szpital Uniwersytecki w Krakowie, Krakow, Poland|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, Poland|Universitatsspital Basel, Basel, Switzerland|Ente Ospedaliero Cantonale, Bellinzona, Switzerland|INSELSPITAL, Universitätsspital Bern, Bern, Switzerland|Centre hospitalier universitaire vaudois, Lausanne, Switzerland|Kantonsspital St.Gallen, St. Gallen, Switzerland</td>      <td>https://ClinicalTrials.gov/show/NCT04150887</td>    </tr>    <tr>      <th>285</th>      <td>286</td>      <td>A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Type 1 Diabetes</td>      <td>Drug: ORMD-0801</td>      <td>Oramed, Ltd.|Integrium</td>      <td>Phase 2</td>      <td>26.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>4-Nov-19</td>      <td>Orange County Research Center, Tustin, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04150107</td>    </tr>    <tr>      <th>286</th>      <td>287</td>      <td>A Study Investigating the Effectiveness of a LifeSeasons NeuroQ Supplement With Lifestyle Changes to Improve Cognitive Function in Healthy Adults Who Have One or More Risk Factors for Cognitive Decline</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Healthy</td>      <td>Dietary Supplement: NeuroQ</td>      <td>LifeSeasons Inc.|KGK Science Inc.</td>      <td>Not Applicable</td>      <td>40.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention</td>      <td>4-Nov-19</td>      <td>Kapoor Medical Center, Studio City, California, United States|LifeSeasons Medical Center, Flower Mound, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04149639</td>    </tr>    <tr>      <th>287</th>      <td>288</td>      <td>A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Advanced Cancer</td>      <td>Drug: LY3475070|Drug: Pembrolizumab</td>      <td>Eli Lilly and Company|Merck Sharp &amp; Dohme Corp.</td>      <td>Phase 1</td>      <td>120.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>4-Nov-19</td>      <td>Cedars Sinai Medical Center, Los Angeles, California, United States|Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States|Florida Cancer Specialists ORLANDO/DDU, Lake Mary, Florida, United States|Washington University Medical School, Saint Louis, Missouri, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Marsden Hospital, Sutton, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04148937</td>    </tr>    <tr>      <th>288</th>      <td>289</td>      <td>A Study Investigating the Effect of Floradapt Mature Immune Defense on Nutrient Uptake and Digestive Health in a Healthy Elderly Population</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Healthy</td>      <td>Dietary Supplement: Floradapt Mature Immune Defense + Multivitamin|Dietary Supplement: Placebo + Multivitamin</td>      <td>Kaneka Americas Holding Inc.|KGK Science Inc.</td>      <td>Phase 2</td>      <td>120.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other</td>      <td>1-Nov-19</td>      <td>KGK Science Inc., London, Ontario, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04147923</td>    </tr>    <tr>      <th>289</th>      <td>290</td>      <td>A Study Investigating the Safety and Efficacy of Bio-Active Silver Hydrosol™ in Providing Immune Support</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy</td>      <td>Other: Silver Hydrosol|Other: Placebo</td>      <td>Natural Immunogenics Corp.|KGK Science Inc.</td>      <td>Not Applicable</td>      <td>60.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other</td>      <td>30-Oct-19</td>      <td>KGK Science Inc., London, Ontario, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04144673</td>    </tr>    <tr>      <th>290</th>      <td>291</td>      <td>Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Lymphoma|Advanced Solid Tumors</td>      <td>Drug: E7766</td>      <td>Eisai Inc.|H3 Biomedicine Inc.</td>      <td>Phase 1</td>      <td>120.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>30-Oct-19</td>      <td>Yale, New Haven, Connecticut, United States|Sylvester Cancer Center, Miami, Florida, United States|MGH, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Center for Immuno-Oncology , DFCI, Boston, Massachusetts, United States|UPMC, Pittsburgh, Pennsylvania, United States|Institut Gustave Roussy, Villejuif, France|Imperial College Healthcare NHS Trust, London, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04144140</td>    </tr>    <tr>      <th>291</th>      <td>292</td>      <td>Study of Safety &amp; PK of Luspatercept (ACE-536) in Pediatric Subjects Who Require Regular RBC Transfusions Due to Beta (β)-Thalassemia.</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Beta-Thalassemia</td>      <td>Drug: ACE-536</td>      <td>Celgene|Acceleron Pharma, Inc.</td>      <td>Phase 2</td>      <td>48.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>29-Oct-19</td>      <td>Children\'s Hospital of Los Angeles, Los Angeles, California, United States|Universitatsklinikum Ulm, Ulm, Germany|General Children\'s Hospital "Agia Sophia", Athens, Greece|Ente Ospedaliero Ospedali Galliera - Centro della Microcitemia e delle Anemie Congenite, Genoa, Italy|Azienda Ospedaliera Universitaria "Federico II", Napoli, Italy|Azienda Ospedaliero Universitaria S. Luigi Gonzaga, Orbassano, Italy|Siriraj Hospital Mahidol University, Bangkok, Thailand|Ege Universitesi Tip Fakultesi Hastanesi, Izmir, Turkey</td>      <td>https://ClinicalTrials.gov/show/NCT04143724</td>    </tr>    <tr>      <th>292</th>      <td>293</td>      <td>A Study to Understand the Safety, Tolerability of a Single Dose of AZD2693 and How the AZD2693 Behaves Inside the Body When Given to Overweight/Mildly Obese Healthy Male Subjects and Healthy Female Subjects of Non-childbearing Potential</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Metabolic Diseases</td>      <td>Drug: AZD2693|Drug: Placebo</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 1</td>      <td>49.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment</td>      <td>29-Oct-19</td>      <td>Research Site, Glendale, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04142424</td>    </tr>    <tr>      <th>293</th>      <td>294</td>      <td>Comparison of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil and Insulin Aspart</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Type 1 Diabetes Mellitus (T1DM)</td>      <td>Drug: Tregopil</td>      <td>Biocon Limited|Profil Institut für Stoffwechselforschung GmbH</td>      <td>Phase 1</td>      <td>60.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>28-Oct-19</td>      <td>Profil Mainz GmbH &amp; Co. KG Malakoff-Passage,Rheinstraße 4C D-55116, Mainz, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04141423</td>    </tr>    <tr>      <th>294</th>      <td>295</td>      <td>A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Bioequivalence</td>      <td>Drug: Olmesartan Medoxomil/Hydrochlorothiazide 40 Mg/25 Mg film-coated tablets for oral use|Drug: Olmetec® Plus 40 Mg/25 Mg film-coated tablets for oral use</td>      <td>Pharmtechnology LLC|Altasciences Company, Inc.</td>      <td>Phase 1</td>      <td>32.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other</td>      <td>25-Oct-19</td>      <td>Altasciences Company Inc., Mont-Royal, Quebec, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04138888</td>    </tr>    <tr>      <th>295</th>      <td>296</td>      <td>Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy Participants</td>      <td>Drug: BBT-877 single dose|Drug: Placebo single dose</td>      <td>Bridge Biotherapeutics, Inc.|KCRN Research, LLC</td>      <td>Phase 1</td>      <td>24.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>25-Oct-19</td>      <td>WCCT, Cypress, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04138849</td>    </tr>    <tr>      <th>296</th>      <td>297</td>      <td>Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy Participants</td>      <td>Drug: BBT-877|Drug: Midazolam|Drug: Itraconazole|Drug: Esomeprazole</td>      <td>Bridge Biotherapeutics, Inc.|KCRN Research, LLC</td>      <td>Phase 1</td>      <td>48.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>25-Oct-19</td>      <td>Celerion, Lincoln, Nebraska, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04138836</td>    </tr>    <tr>      <th>297</th>      <td>298</td>      <td>Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer</td>      <td>Available</td>      <td>No Results Available</td>      <td>Pancreas Cancer|Pancreatic Cancer|Pancreatic Cancer Stage IV|Pancreatic Cancer Stage III</td>      <td>Biological: IMM-101</td>      <td>Impatients N.V. trading as myTomorrows|Immodulon Therapeutics Ltd</td>      <td>NaN</td>      <td>NaN</td>      <td>Industry</td>      <td>Expanded Access</td>      <td>NaN</td>      <td>24-Oct-19</td>      <td>France, Paris, France|UK, London, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04137822</td>    </tr>    <tr>      <th>298</th>      <td>299</td>      <td>Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Retinal Disease</td>      <td>Drug: Aflibercept (BAY86-5321, Eylea)</td>      <td>Bayer|Regeneron Pharmaceuticals</td>      <td>NaN</td>      <td>69.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>23-Oct-19</td>      <td>Many locations, Multiple Locations, Mexico</td>      <td>https://ClinicalTrials.gov/show/NCT04137120</td>    </tr>    <tr>      <th>299</th>      <td>300</td>      <td>The Long-term Effects of Oceanix™ on Resistance Training Adaptations</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Oxidative Stress|Muscle Strength|Resistance Training|Body Composition|Muscle Damage</td>      <td>Dietary Supplement: Oceanix|Other: Resistance Training</td>      <td>Applied Science &amp; Performance Institute|Lonza Ltd.</td>      <td>Not Applicable</td>      <td>25.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>23-Oct-19</td>      <td>Applied Science &amp; Performance Institute, Tampa, Florida, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04136821</td>    </tr>    <tr>      <th>300</th>      <td>301</td>      <td>An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma</td>      <td>Approved for marketing</td>      <td>No Results Available</td>      <td>Locally Advanced or Metastatic Urothelial Carcinoma (UC)</td>      <td>Drug: enfortumab vedotin (EV)</td>      <td>Astellas Pharma Global Development, Inc.|Seattle Genetics, Inc.|Astellas Pharma Inc</td>      <td>NaN</td>      <td>NaN</td>      <td>Industry</td>      <td>Expanded Access:Treatment IND/Protocol</td>      <td>NaN</td>      <td>23-Oct-19</td>      <td>UCLA Hematology Oncology, Los Angeles, California, United States|John Wayne Cancer Institute, Santa Monica, California, United States|St. Joseph Heritage Medical Group, Santa Rosa, California, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|Northwestern University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Community Hospital Anderson, Anderson, Indiana, United States|New England Cancer Specialists, Topsham, Maine, United States|Johns Hopkins University, Baltimore, Maryland, United States|NYU Langone Health, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04136808</td>    </tr>    <tr>      <th>301</th>      <td>302</td>      <td>NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Hereditary Transthyretin-Mediated Amyloid Polyneuropathy</td>      <td>Drug: AKCEA-TTR-LRx|Drug: Inotersen</td>      <td>Ionis Pharmaceuticals, Inc.|Akcea Therapeutics</td>      <td>Phase 3</td>      <td>140.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>23-Oct-19</td>      <td>University of Colorado Hospital - Anschutz Medical Campus, Aurora, Colorado, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Indiana University School of Medicine - Indianapolis, Indianapolis, Indiana, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|The Neurological Institute of New York, New York, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Hospital Son Llàtzer, Palma De Mallorca, Illes Balears, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04136184</td>    </tr>    <tr>      <th>302</th>      <td>303</td>      <td>CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants With Transthyretin‑Mediated Amyloid Cardiomyopathy (ATTR CM)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Transthyretin‑Mediated Amyloid Cardiomyopathy (ATTR CM)</td>      <td>Drug: AKCEA-TTR-LRx|Drug: Placebo</td>      <td>Ionis Pharmaceuticals, Inc.|Akcea Therapeutics</td>      <td>Phase 3</td>      <td>750.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>23-Oct-19</td>      <td>University of Colorado Hospital - Anschutz Medical Campus, Aurora, Colorado, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory Heart and Vascular Center - Emory Clifton Campus, Atlanta, Georgia, United States|Piedmont Heart of Fayetteville, Fayetteville, Georgia, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University Health, Indianapolis, Indiana, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|Boston University School of Medicine, Boston, Massachusetts, United States|New York University Langone Cardiology Associates, New York, New York, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04136171</td>    </tr>    <tr>      <th>303</th>      <td>304</td>      <td>Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Arthritis, Rheumatoid</td>      <td>Biological: GSK3196165|Biological: Sarilumab|Drug: Placebo to GSK3196165/ Sarilumab|Drug: csDMARDs</td>      <td>GlaxoSmithKline|Iqvia Pty Ltd</td>      <td>Phase 3</td>      <td>525.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>22-Oct-19</td>      <td>GSK Investigational Site, Mesa, Arizona, United States|GSK Investigational Site, Mesa, Arizona, United States|GSK Investigational Site, Peoria, Arizona, United States|GSK Investigational Site, Sun City, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Covina, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Palo Alto, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Leandro, California, United States|GSK Investigational Site, Upland, California, United States|GSK Investigational Site, Whittier, California, United States|GSK Investigational Site, Newark, Delaware, United States|GSK Investigational Site, Brandon, Florida, United States|GSK Investigational Site, DeBary, Florida, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Miami Lakes, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Saint Petersburg, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Newnan, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Skokie, Illinois, United States|GSK Investigational Site, Wheaton, Maryland, United States|GSK Investigational Site, Mansfield, Massachusetts, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Lincoln, Nebraska, United States|GSK Investigational Site, Reno, Nevada, United States|GSK Investigational Site, Lebanon, New Hampshire, United States|GSK Investigational Site, Minot, North Dakota, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Baytown, Texas, United States|GSK Investigational Site, College Station, Texas, United States|GSK Investigational Site, Colleyville, Texas, United States|GSK Investigational Site, Cypress, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Lubbock, Texas, United States|GSK Investigational Site, Plano, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Marcos, Texas, United States|GSK Investigational Site, The Woodlands, Texas, United States|GSK Investigational Site, Tomball, Texas, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, Ciudad Autonoma Buenos aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Mar del Plata, Buenos Aires, Argentina|GSK Investigational Site, San Isidro, Buenos Aires, Argentina|GSK Investigational Site, San Nicolas, Buenos Aires, Argentina|GSK Investigational Site, Córdoba, Córdova, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, San Juan, Argentina|GSK Investigational Site, Mons, Belgium|GSK Investigational Site, Barrie, Ontario, Canada|GSK Investigational Site, Brampton, Ontario, Canada|GSK Investigational Site, Burlington, Ontario, Canada|GSK Investigational Site, Trois-Rivieres, Quebec, Canada|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Praha 4, Czechia|GSK Investigational Site, Praha 5, Czechia|GSK Investigational Site, Uherske Hradiste, Czechia|GSK Investigational Site, Zlin, Czechia|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Veszprem, Hungary|GSK Investigational Site, Verona, Veneto, Italy|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Chiba, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Kagoshima, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kochi, Japan|GSK Investigational Site, Kumamoto, Japan|GSK Investigational Site, Nagasaki, Japan|GSK Investigational Site, Nagasaki, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Suwon-si, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Kaunas, Lithuania|GSK Investigational Site, Klaipeda, Lithuania|GSK Investigational Site, Siauliai, Lithuania|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Czestochowa, Poland|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Gdynia, Poland|GSK Investigational Site, Katowice, Poland|GSK Investigational Site, Katowice, Poland|GSK Investigational Site, Kraków, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Lublin, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Sochaczew, Poland|GSK Investigational Site, Torun, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Wrocław, Poland|GSK Investigational Site, Pretoria, Gauteng, South Africa|GSK Investigational Site, Durban, KwaZulu- Natal, South Africa|GSK Investigational Site, Cape Town, South Africa|GSK Investigational Site, Cape Town, South Africa|GSK Investigational Site, Mamelodi East, South Africa|GSK Investigational Site, Pretoria, South Africa|GSK Investigational Site, Stellenbosch, South Africa|GSK Investigational Site, A Coruña, Spain|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barakaldo (Vizcaya), Spain|GSK Investigational Site, Cordoba, Spain|GSK Investigational Site, Elche, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Romford, Essex, United Kingdom|GSK Investigational Site, Northwood, Middlesex, United Kingdom|GSK Investigational Site, Kenilworth, Warwickshire, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04134728</td>    </tr>    <tr>      <th>304</th>      <td>305</td>      <td>Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level (MATINEE)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Pulmonary Disease, Chronic Obstructive</td>      <td>Drug: Placebo|Biological: Mepolizumab</td>      <td>GlaxoSmithKline|PPD</td>      <td>Phase 3</td>      <td>800.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>21-Oct-19</td>      <td>GSK Investigational Site, Dothan, Alabama, United States|GSK Investigational Site, Jasper, Alabama, United States|GSK Investigational Site, Chandler, Arizona, United States|GSK Investigational Site, Chandler, Arizona, United States|GSK Investigational Site, Gilbert, Arizona, United States|GSK Investigational Site, Mesa, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Newport Beach, California, United States|GSK Investigational Site, Palm Springs, California, United States|GSK Investigational Site, Riverside, California, United States|GSK Investigational Site, Vista, California, United States|GSK Investigational Site, Clearwater, Florida, United States|GSK Investigational Site, Daytona Beach, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Port Orange, Florida, United States|GSK Investigational Site, Adairsville, Georgia, United States|GSK Investigational Site, Winder, Georgia, United States|GSK Investigational Site, Woodstock, Georgia, United States|GSK Investigational Site, Valparaiso, Indiana, United States|GSK Investigational Site, Columbia, Maryland, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Henderson, Nevada, United States|GSK Investigational Site, Bronx, New York, United States|GSK Investigational Site, Gastonia, North Carolina, United States|GSK Investigational Site, Gastonia, North Carolina, United States|GSK Investigational Site, Shelby, North Carolina, United States|GSK Investigational Site, Wilmington, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Anderson, South Carolina, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Clinton, South Carolina, United States|GSK Investigational Site, Fort Mill, South Carolina, United States|GSK Investigational Site, Gaffney, South Carolina, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Rock Hill, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Sherman, Texas, United States|GSK Investigational Site, Sugar Land, Texas, United States|GSK Investigational Site, Sydney, New South Wales, Australia|GSK Investigational Site, Westmead, New South Wales, Australia|GSK Investigational Site, Kent Town, South Australia, Australia|GSK Investigational Site, Clayton, Victoria, Australia|GSK Investigational Site, Fitzroy, Melbourne, Victoria, Australia|GSK Investigational Site, Jambes, Belgium|GSK Investigational Site, Ajax, Ontario, Canada|GSK Investigational Site, Newmarket, Ontario, Canada|GSK Investigational Site, St. Charles-Borromee, Quebec, Canada|GSK Investigational Site, Rheine, Nordrhein-Westfalen, Germany|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Gyula, Hungary|GSK Investigational Site, Siófok, Hungary|GSK Investigational Site, Törökbálint, Hungary|GSK Investigational Site, Zalaegerszeg, Hungary|GSK Investigational Site, Haifa, Israel|GSK Investigational Site, Jerusalem, Israel|GSK Investigational Site, Jerusalem, Israel|GSK Investigational Site, Petah Tikva, Israel|GSK Investigational Site, Ramat Gan, Israel|GSK Investigational Site, Rehovot, Israel|GSK Investigational Site, Breda, Netherlands|GSK Investigational Site, Zutphen, Netherlands|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Hamilton, New Zealand|GSK Investigational Site, Havelock North, New Zealand|GSK Investigational Site, Rotorua, New Zealand|GSK Investigational Site, Wellington, New Zealand|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Czestochowa, Poland|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Gdynia, Poland|GSK Investigational Site, Katowice, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Ostrow Wilekopolski, Poland|GSK Investigational Site, Ostrowiec Swietokrzyski, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Rzeszow, Poland|GSK Investigational Site, Rzeszow, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Marbella - Málaga, Andalucia, Spain|GSK Investigational Site, Alzira/Valencia, Spain|GSK Investigational Site, Caceres, Spain|GSK Investigational Site, Lleida, Spain|GSK Investigational Site, Loja/ Granada, Spain|GSK Investigational Site, Pamplona, Spain|GSK Investigational Site, Pozuelo De Alarcón/Madrid, Spain|GSK Investigational Site, Buckshaw Village, Chorley, Lancashire, United Kingdom|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Cardiff, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, Hexham, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Reading, United Kingdom|GSK Investigational Site, Stockton On Tees, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04133909</td>    </tr>    <tr>      <th>305</th>      <td>306</td>      <td>A Study of LY3471851 in Healthy Participants</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy</td>      <td>Drug: LY3471851|Drug: Placebo</td>      <td>Eli Lilly and Company|Nektar Therapeutics</td>      <td>Phase 1</td>      <td>36.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science</td>      <td>21-Oct-19</td>      <td>WCCT Global, Cypress, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04133116</td>    </tr>    <tr>      <th>306</th>      <td>307</td>      <td>A Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Benign Prostatic Hyperplasia</td>      <td>Device: Optilume BPH Catheter System|Device: Optilume Sham Device</td>      <td>Urotronic Inc.|ClinLogix. LLC</td>      <td>Not Applicable</td>      <td>162.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>18-Oct-19</td>      <td>Urological Associates of Southern Arizona, PC, Tucson, Arizona, United States|Arkansas Urology, Little Rock, Arkansas, United States|Advanced Urology Institute, Daytona Beach, Florida, United States|Florida Urology Partners, Tampa, Florida, United States|Comprehensive Urologic Care, Lake Barrington, Illinois, United States|Regional Urology, LLC, Shreveport, Louisiana, United States|Chesapeake Urology Research Associates, Hanover, Maryland, United States|Chesapeake Urology Research Associates, Towson, Maryland, United States|Sheldon Freedman MD, Ltd, Las Vegas, Nevada, United States|Western New York Urology Associates, Cheektowaga, New York, United States|AccuMed Research Associates, Garden City, New York, United States|Manhattan Medical Research Practice, PLLC, New York, New York, United States|Associated Urologists of NC, Raleigh, North Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|North Austin Urology, Austin, Texas, United States|Rio Grande Urology, El Paso, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04131907</td>    </tr>    <tr>      <th>307</th>      <td>308</td>      <td>Post-Market Optimization Study of the EMPOWER® RF Catheter to Ablate Soft Tissue Lesions in the Lung</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Lung Diseases</td>      <td>Device: Radiofrequency (RF) catheter</td>      <td>Broncus Medical Inc|Uptake Medical Technology, Inc.</td>      <td>NaN</td>      <td>15.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>18-Oct-19</td>      <td>Thoraxklinik Heidelberg, Heidelberg, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04131777</td>    </tr>    <tr>      <th>308</th>      <td>309</td>      <td>A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Irritable Bowel Syndrome With Diarrhea</td>      <td>Drug: ORP-101|Drug: Placebo</td>      <td>OrphoMed, Inc.|PPD</td>      <td>Phase 2</td>      <td>320.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment</td>      <td>17-Oct-19</td>      <td>Achieve Clinical Research (Site 155), Birmingham, Alabama, United States|Synexus Clinical Research US, Inc. - Phoenix Southeast (Site 123), Chandler, Arizona, United States|Elite Clinical Studies - Phoenix (Site 116), Phoenix, Arizona, United States|Del Sol Research Management - BTC (Site 165), Tucson, Arizona, United States|Synexus Clinical Research US, Inc. - Orange Grove Family Practice (Site 118), Tucson, Arizona, United States|Del Sol Research Management - BTC (Site 130), Tucson, Arizona, United States|Preferred Research Partners - ClinEdge (Site 103), Little Rock, Arkansas, United States|Applied Research Center (Site 158), Little Rock, Arkansas, United States|Connecticut Clinical Research Foundation (Site 136), Bristol, Connecticut, United States|Imagine Research of Palm Beach County (Site 187), Boynton Beach, Florida, United States|Meridien Research - Lakeland (Site 167), Lakeland, Florida, United States|Precision Clinical Research LLC (Site 139), Lauderdale Lakes, Florida, United States|Meridien Research, Maitland - Inpatient (Site 141), Maitland, Florida, United States|Oviedo Medical Research (Site 140), Oviedo, Florida, United States|Clinical Research Center of Florida (Site 186), Pompano Beach, Florida, United States|Meridien Research - St. Petersburg (Site 132), Saint Petersburg, Florida, United States|Agile Clinical Research Trials, LLC (Site 163), Atlanta, Georgia, United States|Gastrointestinal Diseases, Inc. Research (Site 137), Columbus, Georgia, United States|In Quest Medical Research (Site 131), Peachtree Corners, Georgia, United States|Meridian Clinical Research-(Savannah Georgia) (Site 169), Savannah, Georgia, United States|GNP Research (Site 145), Valdosta, Georgia, United States|Northwest Clinical Trials - ClinEdge (Site 133), Boise, Idaho, United States|Synexus Clinical Research US, Inc. - Chicago (Site 120), Chicago, Illinois, United States|Synexus Clinical Research US, Inc. - Allaw (Site 102), Evansville, Indiana, United States|Alliance for Multispecialty Research, LLC (Site 170), Newton, Kansas, United States|Alliance for Multispecialty Research, LLC (Site 159), Wichita, Kansas, United States|Beth Israel Deaconess Medical Center (Site 115), Boston, Massachusetts, United States|Synexus Clinical Research US, Inc. - Minneapolis (Site 114), Richfield, Minnesota, United States|Sundance Clinical Research (Site 175), Saint Louis, Missouri, United States|Synexus Clinical Research US, Inc. - Omaha (Site 113), Omaha, Nebraska, United States|Synexus Clinical Research US, Inc. - McGill Family Practice, P.C. (Site 126), Papillion, Nebraska, United States|Jubilee Clinical Research - BTC (Site 162), Las Vegas, Nevada, United States|Sierra Clinical Research (Site 179), Las Vegas, Nevada, United States|Lovelace Scientific Resources Inc. (Site 176), Albuquerque, New Mexico, United States|NY Scientific (Site 153), Brooklyn, New York, United States|Long Island Gastrointestinal Research Group LLP (Site 107), Great Neck, New York, United States|Synexus Clinical Research US, Inc. - Queens (Site 119), Jamaica, New York, United States|Mid Hudson Medical Research PLLC (Site 174), Newburgh, New York, United States|Circuit Clinical (Site 161), Orchard Park, New York, United States|Upstate Clinical Research Associates LLC - ClinEdge (Site 164), Williamsville, New York, United States|OnSite Clinical Solutions, LLC - ClinEdge (Site 147), Charlotte, North Carolina, United States|OnSite Clinical Solutions, LLC - ClinEdge (Site 146), Charlotte, North Carolina, United States|Peters Medical Research, LLC - ClinEdge (SIte 111), High Point, North Carolina, United States|PMG Research of Salisbury LLC (Site 110), Salisbury, North Carolina, United States|PMG Research of Wilmington (Site 185), Wilmington, North Carolina, United States|PMG Research of Winston-Salem (Site 124), Winston-Salem, North Carolina, United States|Synexus Clinical Research US, Inc. - Akron (Site 122), Akron, Ohio, United States|Hometown Urgent Care and Research (Site 150), Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc. - Cincinnati (Site 127), Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc. - Columbus (Site 108), Columbus, Ohio, United States|Hometown Urgent Care and Research (Site 149), Columbus, Ohio, United States|Remington Davis Inc (Site 144), Columbus, Ohio, United States|PriMed Clinical Research - ClinEdge (Site 121), Dayton, Ohio, United States|Hometown Urgent Care and Research (Site 151), Dayton, Ohio, United States|Medical Research international (Site 180), Oklahoma City, Oklahoma, United States|Tristar Clinical Investigations, P.C. (Site 168), Philadelphia, Pennsylvania, United States|Frontier Clinical Research, LLC (Site 171), Uniontown, Pennsylvania, United States|Piedmont Research Partners LLC - BTC (Site 157), Fort Mill, South Carolina, United States|Synexus clinical Research US, Inc. - Greer (Site 105), Greer, South Carolina, United States|Meridian Clinical Research-(Dakota Dunes-South Dakota) (Site 160), Dakota Dunes, South Dakota, United States|WR-ClinSearch, LLC (Site 129), Chattanooga, Tennessee, United States|The Jackson Clinic PA - ClinEdge (Site 135), Jackson, Tennessee, United States|New Phase Research &amp; Development (Site 181), Knoxville, Tennessee, United States|Benchmark Research - Austin (Site 178), Austin, Texas, United States|Advanced Medical Trials (SIte 142), Georgetown, Texas, United States|Pioneer Research Solutions (Site 125), Houston, Texas, United States|Synergy Group US, LLC - Missouri City - Hunt (Site 156), Missouri City, Texas, United States|DM Clinical Research - LinQ Research - ERN (Site 109), Pearland, Texas, United States|Synexus Clinical Research US, Inc. - San Antonio (Site 112), San Antonio, Texas, United States|Clinical Trials of Texas Incorporated - ClinEdge (Site 134), San Antonio, Texas, United States|Synexus Clinical Research US, Inc. - Salt Lake City (Site 101), Murray, Utah, United States|Advanced Research Institute (Site 117), Ogden, Utah, United States|Health Research of Hampton Roads Inc. (Site 173), Newport News, Virginia, United States|The Center of Gastrointestinal Health (Site 152), Petersburg, Virginia, United States|Northwest Clinical Research Center - ClinEdge (Site 148), Bellevue, Washington, United States|Exemplar Research, Inc. - Morgantown (Site 172), Morgantown, West Virginia, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04129619</td>    </tr>    <tr>      <th>309</th>      <td>310</td>      <td>Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Neoplasms, Head and Neck</td>      <td>Drug: GSK3359609|Drug: Pembrolizumab|Drug: Placebo</td>      <td>GlaxoSmithKline|Merck Sharp &amp; Dohme Corp.</td>      <td>Phase 3</td>      <td>600.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>16-Oct-19</td>      <td>GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Santa Rosa, California, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Fort Myers, Florida, United States|GSK Investigational Site, Saint Petersburg, Florida, United States|GSK Investigational Site, Bronx, New York, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, West Reading, Pennsylvania, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Viedma, Río Negro, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Argentina|GSK Investigational Site, Blacktown, New South Wales, Australia|GSK Investigational Site, Darlinghurst, New South Wales, Australia|GSK Investigational Site, St Leonards, New South Wales, Australia|GSK Investigational Site, Herston, Queensland, Australia|GSK Investigational Site, Heidelberg, Victoria, Australia|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Hamilton, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Quebec City, Quebec, Canada|GSK Investigational Site, Rimouski, Quebec, Canada|GSK Investigational Site, Bordeaux, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Valenciennes Cedex, France|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Jerusalem, Israel|GSK Investigational Site, Busan, Korea, Republic of|GSK Investigational Site, Hwasun-gun, Jeollanam-do, Korea, Republic of|GSK Investigational Site, Incheon, Korea, Republic of|GSK Investigational Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Maastricht, Netherlands|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Gdynia, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Tomaszow Mazowiecki, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Wieliszew, Poland|GSK Investigational Site, Matosinhos, Portugal|GSK Investigational Site, Brasov, Romania|GSK Investigational Site, Cluj Napoca, Romania|GSK Investigational Site, Constanta, Romania|GSK Investigational Site, Craiova, Romania|GSK Investigational Site, Floresti, Romania|GSK Investigational Site, Oradea, Romania|GSK Investigational Site, Otopeni, Romania|GSK Investigational Site, Satu Mare, Romania|GSK Investigational Site, Suceava, Romania|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Poselok Kuzmolovsky, Russian Federation|GSK Investigational Site, Pushkin, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Málaga, Spain|GSK Investigational Site, Pamplona, Spain|GSK Investigational Site, Pozuelo De Alarcón/Madrid, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Umeå, Sweden|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Manchester, Lancashire, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04128696</td>    </tr>    <tr>      <th>310</th>      <td>311</td>      <td>Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Lupus Erythematosus|Lupus Nephritis</td>      <td>Drug: Itolizumab [Bmab 600]|Drug: EQ001 Placebo</td>      <td>Equillium|Biocon Limited</td>      <td>Phase 1</td>      <td>56.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>16-Oct-19</td>      <td>Clinical Research of West Florida - Clearwater, Clearwater, Florida, United States|SouthCoast Research Center Inc, Miami, Florida, United States|Hope Clinical Trials, Miami, Florida, United States|Clinical Research of West Florida - Tampa, Tampa, Florida, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04128579</td>    </tr>    <tr>      <th>311</th>      <td>312</td>      <td>Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Colorectal Cancer</td>      <td>Drug: Regorafenib (BAY73-4506, Stivarga)|Biological: Nivolumab (Opdivo)</td>      <td>Bayer|Bristol-Myers Squibb</td>      <td>Phase 2</td>      <td>70.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>15-Oct-19</td>      <td>City of Hope National Medical Center, Duarte, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Miami Cancer Institute at Baptist Health South Florida, Miami, Florida, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States|Nebraska Cancer Specialists, Papillion, Nebraska, United States|New York Oncology Hematology. P.C., Albany, New York, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Vanderbilt University Medical School, Nashville, Tennessee, United States|Texas Oncology-Arlington North, Arlington, Texas, United States|Baylor Charles A. Sammons Cancer Center at Dallas, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology-Sherman, Sherman, Texas, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04126733</td>    </tr>    <tr>      <th>312</th>      <td>313</td>      <td>A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Atrial Fibrillation|Atrial Flutter</td>      <td>Other: Zio®XT Monitor</td>      <td>Bristol-Myers Squibb|Pfizer</td>      <td>Phase 4</td>      <td>52000.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention</td>      <td>15-Oct-19</td>      <td>Healthscan Clinical Trials, LLC, Montgomery, Alabama, United States|Hope Clinical Research, Canoga Park, California, United States|Helping Hands Healthcare Group, Fullerton, California, United States|Local Institution, Palm Springs, California, United States|Invesclinic U.S.,LLC, Fort Lauderdale, Florida, United States|Local Institution, Hialeah, Florida, United States|Local Institution, Homestead, Florida, United States|Local Institution, Jupiter, Florida, United States|Nova Clinical Research Center Inc, Miami, Florida, United States|CHR Studies, Miami, Florida, United States|Local Institution, Miami, Florida, United States|Local Institution, Mount Dora, Florida, United States|Block Nation Chase &amp; Smolen, Oviedo, Florida, United States|JSV Clinical Research Study Inc, Tampa, Florida, United States|VICIS Clinical Research, Tampa, Florida, United States|Accel Research Site - Lake Oconee Clinical Research Unit, Eatonton, Georgia, United States|Minesh B. Patel, Michigan City, Indiana, United States|Local Institution, Wichita, Kansas, United States|Local Institution, Wichita, Kansas, United States|Centennial Medical Group, Elkridge, Maryland, United States|Local Institution, Worcester, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Oakland Medical Research, Troy, Michigan, United States|Phillips Medical Services PLLC, Jackson, Mississippi, United States|Robert Lopez, Picayune, Mississippi, United States|Digiovanna Institute For Medical Education, North Massapequa, New York, United States|Local Institution, Durham, North Carolina, United States|Local Institution, Statesville, North Carolina, United States|Local Institution, Statesville, North Carolina, United States|Sterling Research Group, Cincinnati, Ohio, United States|Choice Clinical Research, Cincinnati, Ohio, United States|Local Institution, Springdale, Ohio, United States|Local Institution, Goose Creek, South Carolina, United States|Wellness Clinical Research, Allen, Texas, United States|HRMD Research, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Laguna Clinical Research, Laredo, Texas, United States|DeLeon Research PLLC, Plano, Texas, United States|Local Institution, San Marcos, Texas, United States|Local Institution, The Woodlands, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04126486</td>    </tr>    <tr>      <th>313</th>      <td>314</td>      <td>Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Neovascular (Wet) Age-Related Macular Degeneration</td>      <td>Drug: aflibercept|Drug: High-dose aflibercept</td>      <td>Regeneron Pharmaceuticals|Bayer</td>      <td>Phase 2</td>      <td>100.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment</td>      <td>15-Oct-19</td>      <td>Regeneron Study Site, Fullerton, California, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Largo, Florida, United States|Regeneron Study Site, Asheville, North Carolina, United States|Regeneron Study Site, Ladson, South Carolina, United States|Regeneron Study Site, West Columbia, South Carolina, United States|Regeneron Study Site, Spokane, Washington, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04126317</td>    </tr>    <tr>      <th>314</th>      <td>315</td>      <td>Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Gram-negative Bacterial Infection</td>      <td>Drug: Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3|Drug: Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3</td>      <td>Pfizer|Allergan</td>      <td>Phase 2</td>      <td>48.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science</td>      <td>14-Oct-19</td>      <td>CTSC Clinical Research Center, Sacramento, California, United States|UC Davis Health, Sacramento, California, United States|UC Davis Outpatient Clinic Glassrock Building, Sacramento, California, United States|University of California Davis Health, Investigational Drug Services, Sacramento, California, United States|Rady Children\'s Hospital San Diego, San Diego, California, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Floating Hospital for Children at Tufts Medical Center, Boston, Massachusetts, United States|Tufts Medical Center, IDS Pharmacy, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Bristol Myers Squibb Children\'s Hospital at Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Duke University Investigational Drug Services, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|OU Medical Center, The Children\'s Hospital, Oklahoma City, Oklahoma, United States|University of Oklahoma Investigational Drug Services, Oklahoma City, Oklahoma, United States|University of Utah, Salt Lake City, Utah, United States|Primary Children\'s Hospital, Salt Lake City, Utah, United States|Children\'s Hospital of Richmond at VCU, Richmond, Virginia, United States|VCU Health, Investigational Drug Service, Richmond, Virginia, United States|Virginia Commonwealth University Health Systems, Richmond, Virginia, United States|Tallinn Children\'s Hospital, Tallinn, Estonia|Tartu University Hospital, Pediatric &amp; Neonatal Intensive Care Unit, Tartu, Estonia|Észak-Közép-budai Centrum, Új Szent János Kórház és Szakrendelő, Budapest, Hungary|Debreceni Egyetem Klinikai Központ, Debrecen, Hungary|Kanizsai Dorottya Korhaz, Nagykanizsa, Hungary|Szabolcs-Szatmár-Bereg Megyei Kórházak és Oktatókórház, Jósa András Oktatókórház, Nyíregyháza, Hungary|Nirmal Hospital Pvt Ltd, Surat, Gujarat, India|Kasturba Medical College and Hospital, Manipal, Karnataka, India|Fondazione IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Ambulatori Pediatrici, Milano, Milan, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milano, MI, Italy|Univerzitna nemocnica Martin, Martin, Slovakia|Fakultna nemocnica s poliklinikou Nove Zamky, Nove Zamky, Slovakia|Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Children\'s Hospital, Mackay Memorial Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan</td>      <td>https://ClinicalTrials.gov/show/NCT04126031</td>    </tr>    <tr>      <th>315</th>      <td>316</td>      <td>Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Gout</td>      <td>Procedure: Joint Biopsy</td>      <td>Attune Health Research, Inc.|Horizon Pharma Ireland, Ltd., Dublin Ireland</td>      <td>NaN</td>      <td>8.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Other|Time Perspective: Cross-Sectional</td>      <td>14-Oct-19</td>      <td>Attune Health Research Inc., Beverly Hills, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04125459</td>    </tr>    <tr>      <th>316</th>      <td>317</td>      <td>US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Hairy Cell Leukemia</td>      <td>NaN</td>      <td>Innate Pharma|Iqvia Pty Ltd</td>      <td>NaN</td>      <td>80.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Retrospective</td>      <td>14-Oct-19</td>      <td>Compassionate Care Research Group Inc., Fountain Valley, California, United States|Research Site, Bridgeton, Missouri, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04125290</td>    </tr>    <tr>      <th>317</th>      <td>318</td>      <td>A Pilot Study of BXCL701 in Patients With Pancreatic Cancer</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Cancer of Pancreas|Cancer of the Pancreas|Neoplasms, Pancreatic|Pancreas Cancer|Pancreatic Cancer</td>      <td>Drug: Talabostat Mesylate</td>      <td>BioXcel Therapeutics Inc|IQVIA Biotech</td>      <td>Early Phase 1</td>      <td>15.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>11-Oct-19</td>      <td>BioXcel Clinical Research Site, Boston, Massachusetts, United States|BioXcel Clinical Research Site, New York, New York, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04123574</td>    </tr>    <tr>      <th>318</th>      <td>319</td>      <td>A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Solid Tumour</td>      <td>Drug: Savolitinib|Drug: Itraconazole</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 1</td>      <td>16.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science</td>      <td>10-Oct-19</td>      <td>Research Site, Glendale, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04121910</td>    </tr>    <tr>      <th>319</th>      <td>320</td>      <td>A Study of LY3471851 in Participants With Psoriasis</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Psoriasis</td>      <td>Drug: LY3471851|Drug: Placebo</td>      <td>Eli Lilly and Company|Nektar Therapeutics</td>      <td>Phase 1</td>      <td>40.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science</td>      <td>8-Oct-19</td>      <td>California Dermatology and Clinical Research Institute, Encinitas, California, United States|Therapeutics Clinical Research, San Diego, California, United States|Florida Academic Dermatology Centers, Coral Gables, Florida, United States|ForCare Clinical Research, Tampa, Florida, United States|Medical Dermatology Specialists, Sandy Springs, Georgia, United States|Treasure Valley Dermatology, Boise, Idaho, United States|Dawes Fretzin Clinical Research, Indianapolis, Indiana, United States|Skin Sciences, Louisville, Kentucky, United States|Dermatology Specialist, Louisville, Kentucky, United States|Derm Center, Troy, Michigan, United States|Central Dermatology PC, Saint Louis, Missouri, United States|ActivMed Practices &amp; Research, Inc, Portsmouth, New Hampshire, United States|Remington-Davis, Inc, Columbus, Ohio, United States|Unity Clinical Research, Oklahoma City, Oklahoma, United States|Paddington Testing Company Inc, Philadelphia, Pennsylvania, United States|DermDox Centers for Dermatology, Sugarloaf, Pennsylvania, United States|Rodgers Dermatology, Frisco, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04119557</td>    </tr>    <tr>      <th>320</th>      <td>321</td>      <td>First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Glioblastoma, Adult</td>      <td>Biological: Multiple dose of EO2401</td>      <td>Enterome|Covance</td>      <td>Phase 1|Phase 2</td>      <td>32.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>4-Oct-19</td>      <td>Dana Farber Cancer Institute, Boston, Massachusetts, United States|Centre Georges François Leclerc, Dijon, France|Hôpital Pitié-Salpétrière, Paris, France|Klinik und Poliklinik für Neurologie Universitätsklinikum Bonn, Bonn, Germany|Universitätsklinikum Frankfurt Goethe-Universität Dr. Senckenbergisches Institut für Neuroonkologie, Frankfurt am Main, Germany|Neurologische Klinik &amp; Nationales Zentrum für Tumorenerkrankungen Heidelberg Universitätsklinikum Heidelberg, Heidelberg, Germany|Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany|Zentrum für Neuroonkologie Universitätsklinikum Tübingen, Tübingen, Germany|Hospital Universitari Vall d\'Hebron, Barcelona, Spain|Institit Catala D\'Oncologia - Hospital Duran i Reynals, Hospitalet De Llobregat, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04116658</td>    </tr>    <tr>      <th>321</th>      <td>322</td>      <td>A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>AL Amyloidosis</td>      <td>Drug: Melphalan-Flufenamide (Melflufen)|Drug: Dexamethasone</td>      <td>Oncopeptides AB|PRA Health Sciences</td>      <td>Phase 1|Phase 2</td>      <td>46.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>4-Oct-19</td>      <td>Boston University Medical Center, Boston, Massachusetts, United States|Fakultní Nemocnice Ostrava, Ostrava - Poruba, Czechia|Centre Hospitalier Universitaire de Limoges, Limoges, France|Universitätsklinikum Heidelberg, Heidelberg, Germany|Alexandra General Hospital of Athens, Athen, Greece|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Oslo University Hospital - Rikshospitalet, Oslo, Norway|Instytut Hematologii i Transfuzjologii, Warszawa, Poland|Hospital Clinic de Barcelona, Barcelona, Spain|University College London Hospitals NHS Foundation Trust, London, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04115956</td>    </tr>    <tr>      <th>322</th>      <td>323</td>      <td>Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Psoriatic Arthritis</td>      <td>Drug: Filgotinib|Drug: Placebo to match filgotinib</td>      <td>Gilead Sciences|Galapagos NV</td>      <td>Phase 3</td>      <td>390.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>4-Oct-19</td>      <td>Medvin Clinical Research, Covina, California, United States|Omega Research Debary, LLC, DeBary, Florida, United States|San Marcus Research Clinic, Inc., Miami, Florida, United States|Arthritis Center, Inc., Palm Harbor, Florida, United States|Bluegrass Community Research, Inc., Lexington, Kentucky, United States|Klein &amp; Associates, M.D., P.A., Hagerstown, Maryland, United States|Clinical Research Institute of Michigan, LLC, Saint Clair Shores, Michigan, United States|St. Paul Rheumatology, P.A., Eagan, Minnesota, United States|Arthritis Consultants, Inc., Saint Louis, Missouri, United States|Atlantic Coast Research, Toms River, New Jersey, United States|Joint and Muscle Research Institute, Charlotte, North Carolina, United States|Paramount Medical Research &amp; Consulting, LLC, Middleburg Heights, Ohio, United States|Clinical Research Source Inc, Perrysburg, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Arthritis Group, PC, Philadelphia, Pennsylvania, United States|PA Regional Center for Arthritis and Osteoporosis Research, Wyomissing, Pennsylvania, United States|Articularis Healthcare Inc, dba, Columbia Arthritis Center, PA, Columbia, South Carolina, United States|Southwest Rheumatology Research, LLC, Mesquite, Texas, United States|West Virginia Research Institute PLLC, South Charleston, West Virginia, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04115839</td>    </tr>    <tr>      <th>323</th>      <td>324</td>      <td>Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Psoriatic Arthritis</td>      <td>Drug: Filgotinib|Drug: Adalimumab|Drug: Placebo to match filgotinib|Drug: Placebo to match adalimumab</td>      <td>Gilead Sciences|Galapagos NV</td>      <td>Phase 3</td>      <td>854.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>4-Oct-19</td>      <td>Medvin Clinical Research, Covina, California, United States|Omega Research Debary, LLC, DeBary, Florida, United States|San Marcus Research Clinic, Inc., Miami, Florida, United States|Arthritis Center, Inc., Palm Harbor, Florida, United States|Klein &amp; Associates, M.D., P.A., Hagerstown, Maryland, United States|Clinical Research Institute of Michigan, LLC, Saint Clair Shores, Michigan, United States|St. Paul Rheumatology, P.A., Eagan, Minnesota, United States|Arthritis Consultants, Inc., Saint Louis, Missouri, United States|Physician Research Collaaboration, LLCs, Lincoln, Nebraska, United States|Atlantic Coast Research, Toms River, New Jersey, United States|Joint and Muscle Research Institute, Charlotte, North Carolina, United States|Paramount Medical Research &amp; Consulting, LLC, Middleburg Heights, Ohio, United States|Clinical Research Source Inc, Perrysburg, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Articularis Healthcare Inc, dba, Columbia Arthritis Center, PA, Columbia, South Carolina, United States|Southwest Rheumatology Research, LLC, Mesquite, Texas, United States|West Virginia Research Institute PLLC, South Charleston, West Virginia, United States|Daido Clinic, Nagoya, Japan</td>      <td>https://ClinicalTrials.gov/show/NCT04115748</td>    </tr>    <tr>      <th>324</th>      <td>325</td>      <td>Absolute Oral Bioavailability of Remimazolam</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Bioavailability</td>      <td>Drug: Remimazolam</td>      <td>Paion UK Ltd.|PRA Health Sciences</td>      <td>Phase 1</td>      <td>14.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>2-Oct-19</td>      <td>PRA Health Sciences (PRA) - Early Development Services (EDS), Salt Lake City, Utah, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04113564</td>    </tr>    <tr>      <th>325</th>      <td>326</td>      <td>Oral Remimazolam With and Without Alcohol in Healthy Female Subjects</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Safety Issues</td>      <td>Drug: Remimazolam|Other: Alcohol</td>      <td>Paion UK Ltd.|PRA Health Sciences</td>      <td>Phase 1</td>      <td>21.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>2-Oct-19</td>      <td>PRA Health Sciences (PRA) - Early Development Services, Salt Lake City, Utah, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04113343</td>    </tr>    <tr>      <th>326</th>      <td>327</td>      <td>Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Abuse, Drug</td>      <td>Drug: Remimazolam|Drug: Midazolam|Other: Saline</td>      <td>Paion UK Ltd.|PRA Health Sciences</td>      <td>Phase 1</td>      <td>83.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>1-Oct-19</td>      <td>PRA Health Sciences Early Development Services, Salt Lake City, Utah, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04110535</td>    </tr>    <tr>      <th>327</th>      <td>328</td>      <td>Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Functional Constipation</td>      <td>Drug: Linaclotide|Drug: Placebo</td>      <td>Allergan|Ironwood Pharmaceuticals, Inc.</td>      <td>Phase 2</td>      <td>30.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment</td>      <td>1-Oct-19</td>      <td>Central Research Associates, Inc, Birmingham, Alabama, United States|HealthStar Research, Hot Springs, Arkansas, United States|Preferred Clinical Research Partners, Little Rock, Arkansas, United States|Advanced Research Center, Anaheim, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Center for Clinical Trials, LLC, Paramount, California, United States|Prohealth Research Center, Doral, Florida, United States|South Miami Medical &amp; Research Group, Inc., Miami, Florida, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|SleepCare Research Institute, Inc., Stockbridge, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Minnesota Gastroenterology PA, Minneapolis, Minnesota, United States|David M. Headley, MD, P.A., Port Gibson, Mississippi, United States|Private Practice - Dr. Craig Spiegel, Bridgeton, Missouri, United States|Foundation Pediatrics Med Clinical Research Partners, LLC, East Orange, New Jersey, United States|Biomedical Research Alliance of NY-Montefiore Medical Center, Bronx, New York, United States|Advantage Clinical Trials, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Oklahoma Health Sciences Center/Children\'s Hospital at OU Medical Center, Oklahoma City, Oklahoma, United States|Coastal Pediatric Research, Charleston, South Carolina, United States|Coastal Pediatric Research, Summerville, South Carolina, United States|Cook Childrens Health Care System, Fort Worth, Texas, United States|Clinical Research Partners, LLC, Richmond, Virginia, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Marshall Health, Huntington, West Virginia, United States|Virgo Carter Pediatrics, Morgantown, West Virginia, United States|The Medical College of Wisconsin, Milwaukee, Wisconsin, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04110145</td>    </tr>    <tr>      <th>328</th>      <td>329</td>      <td>A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Urinary Bladder Neoplasms</td>      <td>Drug: E7766</td>      <td>Eisai Inc.|H3 Biomedicine Inc.</td>      <td>Phase 1</td>      <td>120.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>30-Sep-19</td>      <td>Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|University of Southern California, Los Angeles, California, United States|UCLA, Santa Monica, California, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Washington University, Saint Louis, Missouri, United States|The Mount Sinai Hospital, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04109092</td>    </tr>    <tr>      <th>329</th>      <td>330</td>      <td>A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Acute Myeloid Leukemia (AML)</td>      <td>Drug: Venetoclax|Drug: Azacitidine|Other: Best Supportive Care (BSC)</td>      <td>AbbVie|Roche-Genentech</td>      <td>Phase 3</td>      <td>360.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>25-Sep-19</td>      <td>University of Alabama at Birmingham - Main /ID# 214523, Birmingham, Alabama, United States|Mitchell Cancer Institute /ID# 216443, Mobile, Alabama, United States|University of Arkansas for Medical Sciences /ID# 218105, Little Rock, Arkansas, United States|Compassionate Cancer Care Research Group - Fountain Valley /ID# 216156, Fountain Valley, California, United States|UCSD Moores Cancer Center - LaJolla /ID# 216065, La Jolla, California, United States|University of California, Los Angeles /ID# 219149, Los Angeles, California, United States|Colorado Blood Cancer Institute /ID# 214280, Denver, Colorado, United States|St. Alphonsus Regional Medical /ID# 216424, Boise, Idaho, United States|Rush University Medical Center /ID# 218815, Chicago, Illinois, United States|Indiana Univ School Medicine /ID# 216447, Indianapolis, Indiana, United States|University of Kentucky Markey Cancer Center /ID# 215048, Lexington, Kentucky, United States|Norton Cancer Institute /ID# 216401, Louisville, Kentucky, United States|Tulane Medical Center - New Orleans /ID# 218166, New Orleans, Louisiana, United States|Ochsner Clinic Foundation-New Orleans /ID# 214583, New Orleans, Louisiana, United States|Tufts Medical Center /ID# 216110, Boston, Massachusetts, United States|Mass General Hospital /ID# 217307, Boston, Massachusetts, United States|Univ of Mississippi Med Ctr /ID# 216475, Jackson, Mississippi, United States|University of Missouri /ID# 218223, Columbia, Missouri, United States|Saint Louis University Cancer Center /ID# 218164, Saint Louis, Missouri, United States|Oncology Hematology Associates (OHA) - Springfield /ID# 216351, Springfield, Missouri, United States|The John Theurer Cancer /ID# 215191, Hackensack, New Jersey, United States|Univ Rochester Med Ctr /ID# 215881, Rochester, New York, United States|University of North Carolina /ID# 215815, Chapel Hill, North Carolina, United States|Providence Portland Medical Ct /ID# 216231, Portland, Oregon, United States|UPMC Hillman Cancer Ctr /ID# 214051, Pittsburgh, Pennsylvania, United States|Prisma Health /ID# 216066, Greenville, South Carolina, United States|St Francis Cancer Center (Bon Secours) /ID# 216115, Greenville, South Carolina, United States|Gibbs Cancer Center &amp; Research /ID# 216192, Spartanburg, South Carolina, United States|Tennessee Oncology-Nashville Centennial /ID# 218757, Nashville, Tennessee, United States|Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 214584, Dallas, Texas, United States|St George Hospital /ID# 215416, Kogarah, New South Wales, Australia|Liverpool Hospital /ID# 215415, Liverpool, New South Wales, Australia|Wollongong Hospital /ID# 216071, Wollongong, New South Wales, Australia|Gold Coast University Hospital /ID# 214650, Southport, Queensland, Australia|Barwon Health University Hospital Geelong /ID# 217921, Geelong, Victoria, Australia|Box Hill Hospital /ID# 217622, Melbourne, Victoria, Australia|Perth Blood Institute Ltd /ID# 217531, Nedlands, Western Australia, Australia|Toowoomba Hospital /ID# 217922, Toowoomba, Australia|Hospital São Rafael /ID# 215233, Salvador, Bahia, Brazil|Hospital de Clinicas de Porto Alegre /ID# 215044, Porto Alegre, Rio Grande Do Sul, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 215234, Sao Jose Do Rio Preto, Sao Paulo, Brazil|Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA) /ID# 215171, Rio de Janeiro, Brazil|Tom Baker Cancer Centre /ID# 214625, Calgary, Alberta, Canada|University of Alberta Hospital /ID# 215656, Edmonton, Alberta, Canada|Juravinski Hosp &amp; Cancer Cntr /ID# 214623, Hamilton, Ontario, Canada|London Health Sciences Ctr /ID# 216055, London, Ontario, Canada|The Ottawa Hospital /ID# 214627, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Ctr /ID# 215681, Toronto, Ontario, Canada|Princess Margaret Cancer Centre /ID# 214624, Toronto, Ontario, Canada|McGill Univ HC /ID# 215984, Montreal, Quebec, Canada|Jewish General Hospital /ID# 218053, Montreal, Quebec, Canada|Peking University Peoples Hospital /ID# 216331, Beijing, Beijing, China|Fujian Medical Univ Union Hosp /ID# 215561, Fuzhou, Fujian, China|Guangdong Provincial People\'s Hospital /ID# 216284, Guangzhou, Guangdong, China|Nanfang Hospital of Southern Medical University /ID# 215565, Guangzhou, Guangdong, China|The First Hosp of Jilin Univ /ID# 215560, Changchun, Jilin, China|First Hospital of China Medical University /ID# 216285, Shenyang, Liaoning, China|Shanghai Tongji Hospital /ID# 218800, Shanghai, Shanghai, China|West China Hospital /ID# 216606, Chengdu, Sichuan, China|Institute of Hematology &amp; Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 215558, Tianjin, Tianjin, China|The First Affiliated Hospital,College of Medicine, Zhejiang University /ID# 215564, Hangzhou, Zhejiang, China|Beijing Friendship Hospital,Capital Medical University /ID# 216455, Beijing, China|Peking Union Medical College Hospital, Chinese Academy of Medical Sciences /ID# 216454, Beijing, China|Chinese PLA General Hospital /ID# 216286, Beijing, China|Peking University International Hospital /ID# 217439, Beijing, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 218046, Wuhan, China|Tongji Hosp Tongji Med College /ID# 216456, Wuhan, China|Fourth Military Medical University Tangdu Hospital, PLA /ID# 216283, Xi\'an, China|Henan Cancer Hospital /ID# 215566, Zhengzhou Henan, China|Fakultni nemocnice Ostrava /ID# 214809, Ostrava, Praha 5, Czechia|Fakultni Nemocnice Brno /ID# 214807, Brno, Czechia|Ustav hematologie a krevni transfuse /ID# 215137, Praha 2, Czechia|CHRU Lille - Hôpital Claude Huriez /ID# 217474, Lille CEDEX, Hauts-de-France, France|Hopital Bretonneau - CHU Tours /ID# 216186, Tours CEDEX 9, Indre-et-Loire, France|Centre Hospitalier Le Mans /ID# 215148, Le Mans CEDEX 9, Sarthe, France|Institut Gustave Roussy /ID# 215158, Villejuif, Val-de-Marne, France|CHU d\'Angers /ID# 215151, Angers, France|Centre Hospitalier de la Cote /ID# 216185, Bayonne, France|Hopital Avicenne /ID# 215152, Bobigny, France|CHU Henri Mondor /ID# 215159, Creteil, France|Hopital Andre Mignot /ID# 215157, Le Chesnay, France|CHU de Nantes, Hotel Dieu -HME /ID# 217367, Nantes, France|CHU de Nice /ID# 217368, Nice, France|CHU Bordeaux /ID# 215150, Pessac, France|Universitaetsklinikum Leipzig /ID# 214440, Leipzig, Sachsen, Germany|Klinikum Chemnitz gGmbH /ID# 216073, Chemnitz, Germany|Universitatsklinikum Halle (Sa /ID# 221109, Halle, Germany|Universitaetsklinikum Schleswig-Holstein /ID# 215173, Lübeck, Germany|Uniklinikum Giessen-Marburg GmbH /ID# 214734, Marburg, Germany|Krankenhaus Barmherzige Bruede /ID# 215170, Regensburg, Germany|General Hospital of Athens Laiko /ID# 213869, Athens, Attiki, Greece|University General Hospital Attikon /ID# 214298, Athens, Attiki, Greece|Gen Univ Hosp Alexandroupolis /ID# 213870, Alexandroupolis, Greece|Duplicate_General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens P /ID# 213872, Athens, Greece|University General Hospital of Heraklion "PA.G.N.I" /ID# 214075, Heraklion, Greece|Patras University General Hosp /ID# 213871, Rion, Patras, Achaia, Greece|Markusovszky Egyetemi Oktatokorhaz /ID# 215644, Szombathely, Vas, Hungary|Semmelweis Egyetem III /ID# 214423, Budapest VIII, Hungary|Debreceni Egyetem Klinikai Központ /ID# 214422, Debrecen, Hungary|Kaposi Mor Oktato Korhaz /ID# 214426, Kaposvar, Hungary|Szabolcs - Szatmar - Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras /ID# 214425, Nyiregyhaza, Hungary|AOU Federico II /ID# 214278, Naples, Campania, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 213946, Milano, Lombardia, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 214826, Milan, Lombardia, Italy|AOU Ospedali Riuniti di Ancona - G.M. Lancisi, G. Salesi /ID# 213944, Ancona, Marche, Italy|AOU Citta della Salute Scienza /ID# 214505, Turin, Piemonte, Italy|Azienda Ospedaliero-Universitaria di Bologna, Policlinico S.Orsola-Malpighi /ID# 213948, Bologna, Italy|A.O. Spedali Civili Brescia /ID# 214580, Brescia, Italy|Azienda Ospedaliero Universita /ID# 214802, Catania, Italy|AORN A. Cardarelli /ID# 213947, Napoli, Italy|Ospedale S.Eugenio /ID# 214277, Rome, Italy|Aichi Cancer Center Hospital /ID# 215284, Nagoya-shi, Aichi, Japan|University of Fukui Hospital /ID# 215283, Yoshida-gun, Fukui, Japan|National Hospital Organization Kyushu Cancer Center /ID# 214841, Fukuoka-shi, Fukuoka, Japan|Kyushu University Hospital /ID# 215286, Fukuoka-shi, Fukuoka, Japan|Hokkaido University Hospital /ID# 215938, Sapporo-shi, Hokkaido, Japan|National Hospital Organization Mito Medical Center /ID# 214699, Higashi Ibaraki-gun, Ibaraki, Japan|Hitachi General Hospital /ID# 214707, Hitachi-shi, Ibaraki, Japan|Tohoku University Hospital /ID# 214669, Sendai-shi, Miyagi, Japan|Nagasaki University Hospital /ID# 214916, Nagasaki-shi, Nagasaki, Japan|Okayama University Hospital /ID# 214840, Okayama-shi, Okayama, Japan|Kindai University Hospital /ID# 214915, Osaka-sayama-shi, Osaka, Japan|Osaka City University Hospital /ID# 215225, Osaka-shi, Osaka, Japan|Saitama Medical University International Medical Center /ID# 214823, Hidaka-shi, Saitama, Japan|Jichi Medical University Hospital /ID# 216812, Shimotsuke-shi, Tochigi, Japan|NTT Medical Center Tokyo /ID# 214959, Shinagawa-ku, Tokyo, Japan|Yamagata University Hospital /ID# 214698, Yamagata-shi, Yamagata, Japan|JP Red Cross Nagoya Daiichi /ID# 215680, Nagoya, Japan|Saitama Med Ctr Jichi Med Univ /ID# 219148, Saitama, Japan|Pusan National University Hosp /ID# 213941, Busan, Busan Gwang Yeogsi, Korea, Republic of|Seoul National Univ Bundang ho /ID# 215549, Seongnam, Gyeonggido, Korea, Republic of|Samsung Medical Center /ID# 213940, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 213943, Seoul, Korea, Republic of|Pan American Center for Oncology Trials, LLC /ID# 214953, Rio Piedras, Puerto Rico|Moscow State budget healthcare /ID# 214312, Moscow, Moskva, Russian Federation|Nizhniy Novgorod Region clinical hospital named N. A. Semashko /ID# 214309, Nizhniy Novgorod, Nizhegorodskaya Oblast, Russian Federation|City Clinical Hospital №40 /ID# 215223, Moscow, Russian Federation|Clinic of immunopathology under SRIFCI /ID# 217937, Novosibirsk, Russian Federation|St. Petersburg state medical University. Acad. I.P. Pavlova /ID# 215393, Sankt-Peterburg, Russian Federation|Almazov North-West Federal Med /ID# 214306, Sankt-peterburg, Russian Federation|GUZ of Yaroslavl region Yaroslavl Regional Clinical Hospital /ID# 214318, Yaroslavl, Russian Federation|Hospital Santa Creu i Sant Pau /ID# 214714, Barcelona, Spain|ICO l´Hosp- Hosp Duran Reynals /ID# 214715, Barcelona, Spain|Hospital Reina Sofia de Cordob /ID# 214786, Cordoba, Spain|Hospital Universitario Infanta Leonor /ID# 214843, Madrid, Spain|MD Anderson CC Madrid /ID# 214477, Madrid, Spain|Hospital Ramon y Cajal /ID# 214684, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz /ID# 214933, Madrid, Spain|Hospital 12 de Octubre /ID# 214789, Madrid, Spain|Hosp Uni Virgen de la Victoria /ID# 214713, Malaga, Spain|Complejo Hospitalario de Navar /ID# 214788, Pamplona, Spain|China Medical University Hosp /ID# 213952, Taichung City, Taichung, Taiwan|National Taiwan Univ Hosp /ID# 213939, Taipei City, Taipei, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 213953, Kaohsiung, Taiwan|Linkou Chang Gung Memorial Ho /ID# 213951, Taoyuan City, Taiwan|Erciyes University Medical Fac /ID# 214240, Melikgazi, Kayseri, Turkey|Gulhane Askeri Tip Academy /ID# 214242, Ankara, Turkey|Ankara Univ Medical Faculty /ID# 214239, Ankara, Turkey|Istanbul University Cerrahpasa Medical Faculty /ID# 215525, Istanbul, Turkey|Karadeniz University /ID# 214241, Trabzon, Turkey|Leicester Royal Infirmary /ID# 215924, Leicester, England, United Kingdom|Belfast City Hospital /ID# 215923, Belfast, United Kingdom|Heart of England NHS Foundation Trust /ID# 215910, Birmingham, United Kingdom|Bristol Haematology and Onc Ct /ID# 215911, Bristol, United Kingdom|University Hospital of Wales /ID# 215906, Cardiff, United Kingdom|St. James University Hospital /ID# 215922, Leeds, United Kingdom|St Bartholomew\'s Hospital, Bar /ID# 215909, London, United Kingdom|UCLH, University College Hospi /ID# 215921, London, United Kingdom|Guy\'s Hospital /ID# 215908, London, United Kingdom|Christie NHS Foundation Trust /ID# 215905, Manchester, United Kingdom|Nottingham Univ Hospitals NHS /ID# 215904, Nottingham, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04102020</td>    </tr>    <tr>      <th>330</th>      <td>331</td>      <td>Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Type 2 Diabetes Mellitus</td>      <td>Drug: Inhaled Human Insulin|Drug: Insulin Lispro (Humalog U-100)</td>      <td>Dance Biopharm Inc.|Profil Institut für Stoffwechselforschung GmbH</td>      <td>Phase 2</td>      <td>24.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>24-Sep-19</td>      <td>Profil Mainz, Mainz, Malakoff-Passage, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04100473</td>    </tr>    <tr>      <th>331</th>      <td>332</td>      <td>A Double Blind Study on the Gastrointestinal Effects of Arabinoxylan (Leaf Fiber Extract).</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Gastrointestinal Tolerance</td>      <td>Dietary Supplement: 7.25 grams of Arabinoxylan leaf fiber extract|Dietary Supplement: 14.5 grams of Arabinoxylan leaf fiber extract|Dietary Supplement: Control - No Arabinoxylan</td>      <td>Comet Bio Inc.|Biofortis, Merieux NutriSciences</td>      <td>Not Applicable</td>      <td>45.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other</td>      <td>24-Sep-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04100460</td>    </tr>    <tr>      <th>332</th>      <td>333</td>      <td>A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia</td>      <td>Withdrawn</td>      <td>No Results Available</td>      <td>Acute Myeloid Leukemia</td>      <td>Biological: Ficlatuzumab|Drug: Cytarabine</td>      <td>AVEO Pharmaceuticals, Inc.|Biodesix, Inc.</td>      <td>Phase 2</td>      <td>0.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>24-Sep-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04100330</td>    </tr>    <tr>      <th>333</th>      <td>334</td>      <td>An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Gastric Cancer|GastroEsophageal Cancer</td>      <td>Drug: Bavituximab|Drug: Pembrolizumab Injection</td>      <td>Oncologie Inc.|Merck Sharp &amp; Dohme Corp.</td>      <td>Phase 2</td>      <td>80.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>23-Sep-19</td>      <td>Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|Cleveland Clinic Florida - Weston, Weston, Florida, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Siteman Cancer Center - Washington University Medical Campus, Saint Louis, Missouri, United States|White Plains Hospital - Center for Cancer Care, White Plains, New York, United States|Cancer Treatment Centers of America at Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States|Sara Cannon Research Institute, Nashville, Tennessee, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04099641</td>    </tr>    <tr>      <th>334</th>      <td>335</td>      <td>PremiCron Suture for Cardiac Valve Repair</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Aortic Valve Stenosis</td>      <td>NaN</td>      <td>Aesculap AG|B.Braun Surgical SA</td>      <td>NaN</td>      <td>198.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>20-Sep-19</td>      <td>Robert Bosch KH Stuttgart, Stuttgart, Germany|Hospital de la Santa Creu I Sant Pau, Barcelona, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04096859</td>    </tr>    <tr>      <th>335</th>      <td>336</td>      <td>Home Airway Clearance in CF Patients</td>      <td>Suspended</td>      <td>No Results Available</td>      <td>Pulmonary Cystic Fibrosis</td>      <td>Device: SIMEOX</td>      <td>Physio-Assist|Icadom</td>      <td>Not Applicable</td>      <td>224.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>20-Sep-19</td>      <td>Grenoble University Hospital : pneumo-pediatric department, Grenoble, France|Grenoble University-Affiliated Hospital : Pneumology department, Grenoble, France|Montpellier Hospital Center, Montpellier, France|Nice University-Affiliated Hospital : Pneumology department, Nice, France|Nice University-Affiliated Hospital : Pneumo-pediatric department, Nice, France</td>      <td>https://ClinicalTrials.gov/show/NCT04096664</td>    </tr>    <tr>      <th>336</th>      <td>337</td>      <td>Investigating the Efficacy of Brain Octane® Oil on Cognition, Coordination, Reaction Time and Measurements of Physical Performance in Recreationally Active Adults</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Healthy</td>      <td>Dietary Supplement: Brain Octane Oil|Other: Placebo</td>      <td>Bulletproof 360, Inc.|KGK Science Inc.</td>      <td>Phase 2</td>      <td>30.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other</td>      <td>19-Sep-19</td>      <td>KGK Science Inc., London, Ontario, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04095728</td>    </tr>    <tr>      <th>337</th>      <td>338</td>      <td>Ancillary Home Airway Clearance in CF Patients ( HomeCareSIMEOX )</td>      <td>Suspended</td>      <td>No Results Available</td>      <td>Pulmonary Cystic Fibrosis</td>      <td>Device: SIMEOX</td>      <td>Physio-Assist|Icadom</td>      <td>Not Applicable</td>      <td>56.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>19-Sep-19</td>      <td>Grenoble University Hospital : pneumo-pediatric department, Grenoble, France|Grenoble University-Affiliated Hospital : Pneumology department, Grenoble, France|Montpellier Hospital Center, Montpellier, France|Nice University-Affiliated Hospital : Pneumology department, Nice, France|Nice University-Affiliated Hospital : Pneumo-pediatric department, Nice, France</td>      <td>https://ClinicalTrials.gov/show/NCT04095078</td>    </tr>    <tr>      <th>338</th>      <td>339</td>      <td>A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Prostate Cancer</td>      <td>Drug: enzalutamide|Drug: enzalutamide Placebo|Drug: digoxin|Drug: rosuvastatin</td>      <td>Astellas Pharma Global Development, Inc.|Pfizer|Astellas Pharma Inc</td>      <td>Phase 1</td>      <td>24.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>19-Sep-19</td>      <td>Site MD37301, Chisinau, Moldova, Republic of</td>      <td>https://ClinicalTrials.gov/show/NCT04094519</td>    </tr>    <tr>      <th>339</th>      <td>340</td>      <td>CSD190202: Study to Assess Elements of Abuse Liability for Two Electronic Nicotine Delivery Systems</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Smoking|Tobacco Smoking|Tobacco Use</td>      <td>Other: Product A|Other: Product B|Other: Product C|Other: Product D</td>      <td>RAI Services Company|ICON plc</td>      <td>Not Applicable</td>      <td>48.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>18-Sep-19</td>      <td>New Orleans Center for Clinical Research (NOCCR), Knoxville, Tennessee, United States|ICON Clinical Research, San Antonio, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04094363</td>    </tr>    <tr>      <th>340</th>      <td>341</td>      <td>Investigating the Efficacy of Rest-ZZZ Formula in Healthy Participants With Difficulty Falling Asleep or Staying a Sleep</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Sleep|Healthy</td>      <td>Dietary Supplement: Rest-ZZZ|Drug: Active Comparator - Diphenhydramine HCl|Other: Placebo</td>      <td>LifeSeasons Inc.|KGK Science Inc.</td>      <td>Phase 1</td>      <td>27.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other</td>      <td>18-Sep-19</td>      <td>KGK Science Inc., London, Ontario, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04093271</td>    </tr>    <tr>      <th>341</th>      <td>342</td>      <td>Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Pharmacokinetics</td>      <td>Drug: PRA|Drug: SCY-078 plus PRA</td>      <td>Scynexis, Inc.|Clinical Network Services (CNS) Pty Ltd</td>      <td>Phase 1</td>      <td>28.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>17-Sep-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04092751</td>    </tr>    <tr>      <th>342</th>      <td>343</td>      <td>Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Pharmacokinetics</td>      <td>Drug: DAB|Drug: SCY-078 plus DAB</td>      <td>Scynexis, Inc.|Clinical Network Services (CNS) Pty Ltd</td>      <td>Phase 1</td>      <td>28.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>17-Sep-19</td>      <td>CMAX, Adelaide, South Australia, Australia</td>      <td>https://ClinicalTrials.gov/show/NCT04092725</td>    </tr>    <tr>      <th>343</th>      <td>344</td>      <td>Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy Volunteers</td>      <td>Drug: [14C]-CTP-543</td>      <td>Concert Pharmaceuticals|Celerion</td>      <td>Phase 1</td>      <td>6.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science</td>      <td>17-Sep-19</td>      <td>Celerion, Lincoln, Nebraska, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04092712</td>    </tr>    <tr>      <th>344</th>      <td>345</td>      <td>A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>COPD</td>      <td>Drug: Ensifentrine 100mcg|Drug: Ensifentrine 300mcg|Drug: Ensifentrine 1000mcg|Drug: Ensifentrine 3000mcg|Drug: Ensifentrine 6000mcg|Drug: Placebos</td>      <td>Verona Pharma plc|Iqvia Pty Ltd</td>      <td>Phase 2</td>      <td>40.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>16-Sep-19</td>      <td>Respiratory Clinical Trials Ltd, London, United Kingdom|Medicines Evaluation Unit Limited, Wythenshawe, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04091360</td>    </tr>    <tr>      <th>345</th>      <td>346</td>      <td>Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Vasomotor Symptoms|Menopausal Symptoms</td>      <td>Drug: Estetrol oral tablet|Drug: Placebo oral tablet</td>      <td>Estetra|ICON Clinical Research</td>      <td>Phase 3</td>      <td>1000.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>16-Sep-19</td>      <td>Downtown Women\'s Health Care, Denver, Colorado, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04090957</td>    </tr>    <tr>      <th>346</th>      <td>347</td>      <td>A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Coronary Artery Disease</td>      <td>Drug: Treatment A|Drug: Treatment B|Drug: Treatment C</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 1</td>      <td>14.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>12-Sep-19</td>      <td>Research Site, London, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04087187</td>    </tr>    <tr>      <th>347</th>      <td>348</td>      <td>A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Prostate Cancer</td>      <td>Drug: Capivasertib|Drug: Enzalutamide|Drug: Abiraterone</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 1</td>      <td>18.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>12-Sep-19</td>      <td>Research Site, Indianapolis, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Omaha, Nebraska, United States|Research Site, White Plains, New York, United States|Research Site, Gettysburg, Pennsylvania, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Barcelona, Spain|Research Site, Santander, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04087174</td>    </tr>    <tr>      <th>348</th>      <td>349</td>      <td>Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Advanced Solid Tumors</td>      <td>Drug: AB122</td>      <td>Arcus Biosciences, Inc.|Strata Oncology</td>      <td>Phase 1</td>      <td>80.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>12-Sep-19</td>      <td>United States, Alabama, Birmingham, Alabama, United States|United States, California, Bellflower, California, United States|United States, California, Los Angeles, California, United States|United States,San Diego, San Diego, California, United States|United States, California, Vallejo, California, United States|United States, Delaware, Newark, Delaware, United States|United States, Kentucky, Lexington, Kentucky, United States|United States, Louisiana, New Orleans, Louisiana, United States|United States, Maryland, Gaithersburg, Maryland, United States|United States, Minnesota, Saint Louis Park, Minnesota, United States|United States, Ohio, Kettering, Ohio, United States|United States, Pennsylvania, Allentown, Pennsylvania, United States|United States, South Carolina, Greenville, South Carolina, United States|United States, South Carolina, Greenville, South Carolina, United States|United States, Texas, Houston, Texas, United States|United States, Washington, Tacoma, Washington, United States|United States, Wisconsin, La Crosse, Wisconsin, United States|United States, Wisconsin, Marshfield, Wisconsin, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04087018</td>    </tr>    <tr>      <th>349</th>      <td>350</td>      <td>A Study of Baricitinib in Participants With Rheumatoid Arthritis</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Rheumatoid Arthritis</td>      <td>Drug: Baricitinib|Drug: TNF Inhibitor</td>      <td>Eli Lilly and Company|Incyte Corporation</td>      <td>Phase 4</td>      <td>1300.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>12-Sep-19</td>      <td>Arizona Arthritis &amp; Rheumatology Research, Flagstaff, Arizona, United States|Arizona Arthritis &amp; Rheumatology Research, PLLC, Gilbert, Arizona, United States|Arizona Arthritis &amp; Rheumatology Research, Glendale, Arizona, United States|Arizona Arthritis &amp; Rheumatology Associates, P. C., Mesa, Arizona, United States|Hope Research Institute, Peoria, Arizona, United States|Sun Valley Arthritis Center, LTD, Peoria, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Arizona Arthritis &amp; Rheumatology Research, Phoenix, Arizona, United States|Arizona Arthritis &amp; Rheumatology Research, PLLC, Phoenix, Arizona, United States|Prescott Rheumatology, Prescott, Arizona, United States|Arizona Arthritis &amp; Rheumatology Research, PLLC, Sun City, Arizona, United States|Arizona Arthritis &amp; Rheumatology Research, PLLC, Tucson, Arizona, United States|Arthritis and Rheumatism Associates, Jonesboro, Arkansas, United States|Medvin Clinical Research, Covina, California, United States|TriWest Research Associates LLC, El Cajon, California, United States|St. Joseph Heritage Medical Group, Fullerton, California, United States|MD Medical Corporation, Hemet, California, United States|BioSolutions Clinical Research Center, La Mesa, California, United States|Valerius Medical Group and Research Center of Greater Long Beach, Los Alamitos, California, United States|Providence St. Joseph\'s Medical Center, Mission Hills, California, United States|Desert Medical Advances, Palm Desert, California, United States|ACRC Studies, Poway, California, United States|East Bay Rheumatology Medical Group, San Leandro, California, United States|Dan La, MD Inc., Tujunga, California, United States|Iraj Sabahi Research Inc., Turlock, California, United States|Inland Rheumatology Clinical Trials, Upland, California, United States|Medvin Clinical Research, Whittier, California, United States|Danbury Clinical Research, LLC, Danbury, Connecticut, United States|Delaware Arthritis, Lewes, Delaware, United States|Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States|SIMED Health, Gainesville, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|Rheumatology Associates of Central Florida, Orlando, Florida, United States|Arthritis Center, Inc, Palm Harbor, Florida, United States|Lovelace Scientific Resources, Riverview, Florida, United States|West Broward Rheumatology Associates, Inc, Tamarac, Florida, United States|Florida Medical Clinic LLC, Zephyrhills, Florida, United States|Arthritis and Rheumatology of Georgia, Atlanta, Georgia, United States|Arthritis Center of North Georgia, Gainesville, Georgia, United States|Rockford Orthopedic Associates, Rockford, Illinois, United States|Reddy Rheumatology of Northwest Indiana, Merrillville, Indiana, United States|Beacon Medical Group Clinical Research, South Bend, Indiana, United States|Graves-Gilbert Clinic, Bowling Green, Kentucky, United States|Western KY Rheumatology PLLC, Hopkinsville, Kentucky, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Klein &amp; Associates, M.D., P.A, Hagerstown, Maryland, United States|NECCR PrimaCare Research, LLC, Fall River, Massachusetts, United States|University of Michigan, Brighton, Michigan, United States|Pandit Rheumatology PC, Okemos, Michigan, United States|Clinvest Research LLC, Springfield, Missouri, United States|Allied Clinical Research, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|PMG Research of Hickory, LLC, Hickory, North Carolina, United States|Cape Fear Arthritis Care, Leland, North Carolina, United States|PMG Research of Salisbury, Salisbury, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Cincinnati Arthritis Associates, Cincinnati, Ohio, United States|Craig S Thompson MD LLC, Marion, Ohio, United States|Paramount Medical Research, Middleburg Heights, Ohio, United States|Arthritis &amp; Rheumatology Center of Oklahoma PLLC, Oklahoma City, Oklahoma, United States|The Oklahoma Center For Arthritis Therapy, Tulsa, Oklahoma, United States|Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States|Arthritis Group, Philadelphia, Pennsylvania, United States|Pennsylvania Regional Center for Arthritis &amp; Osteoarthritis, Wyomissing, Pennsylvania, United States|Articularis Healthcare d/b/a/ Low Country Rheumatology, PA, Summerville, South Carolina, United States|Nashville Arthritis and Rheumatology, Nashville, Tennessee, United States|Accent Clinical Research Professionals, LLC, Allen, Texas, United States|Accurate Clinical Management LLC - BayTown, Baytown, Texas, United States|Pioneer Research Solutions, Cypress, Texas, United States|El Paso Integrated Physicians Group, P.A., an Elligo Health Research, Inc. Healthcare Enabled Research Organization, El Paso, Texas, United States|Rheumatology Clinic of Houston, PA, Houston, Texas, United States|Accurate Clinical Management LLC - Katy, Houston, Texas, United States|Accurate Clinical Research, Houston, Texas, United States|Southwest Rheumatology, P.A., Mesquite, Texas, United States|Accurate Clinical Research - San Antonio, San Antonio, Texas, United States|Center for Arthritis and Rheumatic Diseases, PC, Chesapeake, Virginia, United States|Spectrum Medical Inc., Danville, Virginia, United States|Arthritis &amp; Osteoporosis Center of Northern Virinia, Manassas, Virginia, United States|TPMG Rheumatology/TPMG Clinical Research, Newport News, Virginia, United States|Arthritis Northwest PLLC, Spokane, Washington, United States|Rheumatology and Pulmonary Clinic, Beckley, West Virginia, United States|Rheumatic Disease Center, Glendale, Wisconsin, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04086745</td>    </tr>    <tr>      <th>350</th>      <td>351</td>      <td>IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Acute Myeloid Leukemia</td>      <td>Drug: Azacitidine|Drug: IMGN632|Drug: Venetoclax</td>      <td>ImmunoGen, Inc.|Jazz Pharmaceuticals</td>      <td>Phase 1|Phase 2</td>      <td>212.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>11-Sep-19</td>      <td>Moffitt Cancer Center, Tampa, Florida, United States|MD Anderson, Houston, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04086264</td>    </tr>    <tr>      <th>351</th>      <td>352</td>      <td>A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects</td>      <td>Completed</td>      <td>No Results Available</td>      <td>TQT Study</td>      <td>Drug: Tetrodotoxin|Drug: Placebos</td>      <td>Wex Pharmaceuticals Inc.|Celerion</td>      <td>Phase 1</td>      <td>25.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science</td>      <td>10-Sep-19</td>      <td>Celerion, Tempe, Arizona, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04083833</td>    </tr>    <tr>      <th>352</th>      <td>353</td>      <td>GEN1042 Safety Trial in Subjects With Malignant Solid Tumors</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Malignant Solid Tumor|Non Small Cell Lung Cancer|Colorectal Cancer|Melanoma</td>      <td>Biological: GEN1042</td>      <td>Genmab|Biontech SE</td>      <td>Phase 1|Phase 2</td>      <td>126.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>10-Sep-19</td>      <td>Sarah Cannon Research Institute, Indianapolis, Indiana, United States|Rigshospitalet (Copenhagen University Hospital), Copenhagen, Denmark|Royal Marsden NHS Foundation Trust, Sutton, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04083599</td>    </tr>    <tr>      <th>353</th>      <td>354</td>      <td>Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Gastric Cancer|Gastroesophageal Junction Cancer|HER2-positive Gastric Cancer</td>      <td>Combination Product: margetuximab plus INCMGA00012|Combination Product: Margetuximab plus INCMGA00012 plus chemo|Combination Product: Margetuximab plus MGD013 plus chemo|Combination Product: Margetuximab plus chemo|Combination Product: Trastuzumab plus chemo</td>      <td>MacroGenics|Zai Lab (Shanghai) Co., Ltd.</td>      <td>Phase 2|Phase 3</td>      <td>860.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>9-Sep-19</td>      <td>Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States|Yale University, New Haven, Connecticut, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala, Ocala, Florida, United States|University of Chicago, Chicago, Illinois, United States|Edward H. Kaplan MD &amp; Associates, Skokie, Illinois, United States|Cancer &amp; Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion, Grand Rapids, Michigan, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States|Stephenson Cancer Center at OUHSC, Oklahoma City, Oklahoma, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04082364</td>    </tr>    <tr>      <th>354</th>      <td>355</td>      <td>A Study of LY3471851 in Participants With Eczema</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Dermatitis, Atopic</td>      <td>Drug: LY3471851|Drug: Placebo</td>      <td>Eli Lilly and Company|Nektar Therapeutics</td>      <td>Phase 1</td>      <td>40.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science</td>      <td>9-Sep-19</td>      <td>California Dermatology and Clinical Research Institute, Encinitas, California, United States|Therapeutics Clinical Research, San Diego, California, United States|Florida Academic Dermatology Centers, Coral Gables, Florida, United States|ForCare Clinical Research, Tampa, Florida, United States|Medical Dermatology Specialists, Sandy Springs, Georgia, United States|Treasure Valley Dermatology, Boise, Idaho, United States|Dawes Fretzin Clinical Research, Indianapolis, Indiana, United States|Skin Sciences, Louisville, Kentucky, United States|Dermatology Specialist, Louisville, Kentucky, United States|Derm Center, Troy, Michigan, United States|Central Dermatology PC, Saint Louis, Missouri, United States|ActivMed Practices &amp; Research, Inc, Portsmouth, New Hampshire, United States|Remington-Davis, Inc, Columbus, Ohio, United States|Unity Clinical Research, Oklahoma City, Oklahoma, United States|Paddington Testing Company Inc, Philadelphia, Pennsylvania, United States|DermDox Centers for Dermatology, Sugarloaf, Pennsylvania, United States|Rodgers Dermatology, Frisco, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04081350</td>    </tr>    <tr>      <th>355</th>      <td>356</td>      <td>Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Rheumatoid Arthritis</td>      <td>Drug: Etanercept|Drug: Enbrel</td>      <td>Joint Stock Company "Farmak"|Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.</td>      <td>Phase 3</td>      <td>160.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>6-Sep-19</td>      <td>PU Kryvyi Rih City Clinical Hospital №2 of the Dnipropetrovsk regional council, Kryvyi Rih, Dnipropetrovsk Region, Ukraine|PU Kryvyi Rih City Clinical Hospital №8 of the Dnipropetrovsk regional council, Kryvyi Rih, Dnipropetrovsk Region, Ukraine|Ivano-Frankivsk Central City Clinical Hospital, Ivano-Frankivsk, Ivano-Frankivsk Region, Ukraine|Communal non-commercial enterprise of Kharkiv Regional Council Regional Hospital of the war veterans, Kharkiv, Kharkiv Region, Ukraine|Municipal nonprofit enterprise City Multidisciplinary Hospital № 18 of Kharkiv City Council, Kharkiv, Kharkiv Region, Ukraine|Khmelnytskyi Regional Hospital, Khmelnytskyi, Khmelnytskyi Region, Ukraine|Communal noncommercial enterprise of Lviv Regional Council Lviv Regional Clinical Hospital, Lviv, Lviv Region, Ukraine|Ternopil University Hospital, Ternopil\', Ternopil\' Region, Ukraine|Vinnitsa Regional Clinical Hospital Named After N.I.Pirogov, Vinnitsa, Vinnitsa Region, Ukraine|Municipal Institution O.Herbachevskiy Regional State Clinical Hospital, Zhytomyr, Zhytomyr Region, Ukraine</td>      <td>https://ClinicalTrials.gov/show/NCT04079374</td>    </tr>    <tr>      <th>356</th>      <td>357</td>      <td>A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Solid Neoplasms</td>      <td>Drug: E7389-LF|Drug: Nivolumab</td>      <td>Eisai Co., Ltd.|Ono Pharmaceutical Co. Ltd|Eisai Inc.</td>      <td>Phase 1|Phase 2</td>      <td>116.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>6-Sep-19</td>      <td>Eisai Trial Site #2, Kashiwa, Chiba, Japan|Eisai Trial Site #1, Chuo Ku, Tokyo, Japan</td>      <td>https://ClinicalTrials.gov/show/NCT04078295</td>    </tr>    <tr>      <th>357</th>      <td>358</td>      <td>The Effects of CGMP in Children and Adults With PKU</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Phenylketonurias</td>      <td>Dietary Supplement: CGMP protein substitute|Dietary Supplement: L-amino acid protein substitute</td>      <td>Vitaflo International, Ltd|Arla Foods</td>      <td>Not Applicable</td>      <td>36.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>3-Sep-19</td>      <td>Hôpital d\'Enfants Brabois, Vandœuvre-lès-Nancy, France|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Centro Hospitalar do Porto, Porto, Portugal|Birmingham Children\'s Hospital, Birmingham, West Midlands, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04076176</td>    </tr>    <tr>      <th>358</th>      <td>359</td>      <td>First in Human Dose Escalation and Expansion Study With M3258 in Combination With Dexamethasone</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Multiple Myeloma</td>      <td>Drug: M3258|Drug: Dexamethasone</td>      <td>EMD Serono Research &amp; Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono</td>      <td>Phase 1</td>      <td>60.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>3-Sep-19</td>      <td>Colorado Blood Cancer Institute, Denver, Colorado, United States|Georgetown University Medical Center- Research Parent, Washington, District of Columbia, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Centre Hospitalier Regional Universitaire de Lille, Lille, France|CHU de Nantes, Nantes, France|CHU de Poitiers, Vauvert, France</td>      <td>https://ClinicalTrials.gov/show/NCT04075721</td>    </tr>    <tr>      <th>359</th>      <td>360</td>      <td>A Study of YH25448 in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)</td>      <td>Suspended</td>      <td>No Results Available</td>      <td>Carcinoma, Non-Small-Cell Lung</td>      <td>Drug: YH25448</td>      <td>Janssen Research &amp; Development, LLC|Yuhan Corporation</td>      <td>Phase 1|Phase 2</td>      <td>30.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>30-Aug-19</td>      <td>City of Hope, Duarte, California, United States|Advent Health Orlando, Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Montefiore Medical Center, Bronx, New York, United States|Tennessee Oncology, Nashville, Tennessee, United States|Hosp. Univ. Vall D\'Hebron, Barcelona, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Virgen de La Victoria, Malaga, Spain|Sarah Cannon Research Institute, London, United Kingdom|The Christie Nhs Foundation Trust, Manchester, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04075396</td>    </tr>    <tr>      <th>360</th>      <td>361</td>      <td>Assessment of Two Insulin Pump Insulin Delivery Systems in Type 1 Diabetes.</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Type1diabetes</td>      <td>Device: AHCL|Device: SAP+PLGM</td>      <td>Christchurch Clinical Studies Trust Ltd|Medtronic</td>      <td>Not Applicable</td>      <td>60.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>29-Aug-19</td>      <td>Christchurch Clinical Studies Trust, Christchurch, Canterbury, New Zealand</td>      <td>https://ClinicalTrials.gov/show/NCT04073576</td>    </tr>    <tr>      <th>361</th>      <td>362</td>      <td>A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Asthma</td>      <td>Drug: AZD7594</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 1</td>      <td>24.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>28-Aug-19</td>      <td>Research Site, Berlin, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04072562</td>    </tr>    <tr>      <th>362</th>      <td>363</td>      <td>Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab in Locally Advanced and Unresectable or Metastatic NSCLC</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Non Small Cell Lung Cancer|Lung Cancer|Lung Cancer Metastatic|Lung Cancer, Non-small Cell|Non Small Cell Lung Cancer Metastatic|NSCLC|Non-small Cell Lung Cancer|Non-small Cell Lung Cancer Metastatic</td>      <td>Biological: MILs™ - NSCLC|Biological: nivolumab</td>      <td>WindMIL Therapeutics|Bristol-Myers Squibb</td>      <td>Phase 2</td>      <td>23.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>28-Aug-19</td>      <td>City of Hope, Duarte, California, United States|University of California - Los Angeles, Los Angeles, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04069936</td>    </tr>    <tr>      <th>363</th>      <td>364</td>      <td>Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Melanoma</td>      <td>Drug: Talimogene laherparepvec|Drug: Pembrolizumab</td>      <td>Amgen|Merck Sharp &amp; Dohme Corp.</td>      <td>Phase 2</td>      <td>100.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>28-Aug-19</td>      <td>Research Site, Santa Barbara, California, United States|Research Site, Newark, Delaware, United States|Research Site, Orlando, Florida, United States|Research Site, Louisville, Kentucky, United States|Research Site, Fridley, Minnesota, United States|Research Site, Cleveland, Ohio, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, The Woodlands, Texas, United States|Research Site, Southport, Queensland, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Paris, France|Research Site, Dresden, Germany|Research Site, Athens, Greece|Research Site, Ioannina, Greece|Research Site, Thessaloniki, Greece|Research Site, Meldola FC, Italy|Research Site, Gdansk, Poland|Research Site, Warszawa, Poland</td>      <td>https://ClinicalTrials.gov/show/NCT04068181</td>    </tr>    <tr>      <th>364</th>      <td>365</td>      <td>A Study to Investigate the Pharmacokinetics of Prolonged-release Melatonin Compared to Standard, Immediate-release Melatonin in Healthy Adults</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy</td>      <td>Dietary Supplement: Prolonged-Release Melatonin|Dietary Supplement: Immediate-Release Melatonin</td>      <td>Pharmavite LLC|KGK Science Inc.</td>      <td>Phase 1</td>      <td>18.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other</td>      <td>26-Aug-19</td>      <td>KGK Science Inc., London, Ontario, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04067791</td>    </tr>    <tr>      <th>365</th>      <td>366</td>      <td>Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Biliary Tract Cancer|Cholangiocarcinoma|Gallbladder Cancer</td>      <td>Drug: Bintrafusp alfa|Drug: Placebo|Drug: Gemcitabine|Drug: Cisplatin</td>      <td>EMD Serono Research &amp; Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono</td>      <td>Phase 2|Phase 3</td>      <td>512.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>26-Aug-19</td>      <td>Ironwood Cancer &amp;amp; Research Centers - Chandler II, Chandler, Arizona, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|Mayo Clinic in Florida - Department of Neurology, Jacksonville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|University of Kansas Medical Center Research Institute, Inc. - University of Kansas Cancer Center/Bloch Pavilion, Pittsburgh, Pennsylvania, United States|Methodist Transplant Physicians, Dallas, Texas, United States|MD Anderson Cancer Center - Unit 429, Houston, Texas, United States|Renovatio Clinical - CENTRAL SITE, The Woodlands, Texas, United States|Hospital de Gastroenterologia Dr. Carlos Bonorino Udaondo, Ciudad Autonoma Buenos Aires, Argentina|Instituto de Investigaciones Metabolicas (IDIM), Ciudad Autonoma Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Ciudad Autonoma Buenos Aires, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Sanatorio El Carmen, Salta, Argentina|Centro Medico San Roque S.R.L., San Miguel de Tucuman, Argentina|Fundacion ARS Medica, San Salvador de Jujuy, Argentina|Blacktown Hospital - PARENT, Blacktown, New South Wales, Australia|Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia|Epworth Freemasons, Melbourne, Victoria, Australia|Monash Health, Victoria, Australia|IC la serena Research, La Serena, Chile|Health &amp; Care - Prosalud Montes y Orlandi Ltda., Providencia, Chile|Centro de Investigación Clínica Bradford Hill, Santiago, Chile|Hospital Clínico Universidad de Chile, Santiago, Chile|Instituto Clinico Oncologico del Sur (ICOS), Temuco, Chile|Aichi Cancer Center Hospital, Nagoya-shi, Aichi-Ken, Japan|Chiba Cancer Center, Chiba-shi, Chiba-Ken, Japan|National Cancer Center Hospital East, Kashiwa-shi, Chiba-Ken, Japan|NHO Kyushu Cancer Center - Dept of Gastroenterology/Hepatology/Pancreatology, Fukuoka-shi, Fukuoka-Ken, Japan|Kanagawa Cancer Center, Yokohama-shi, Kanagawa-Ken, Japan|Kindai University Hospital, Osakasayama-shi, Osaka-Fu, Japan|National Cancer Center Hospital - Dept of Hepatobiliary and Pancreatic Oncology, Chuo-ku, Tokyo-To, Japan|Cancer Institute Hospital of JFCR - Dept of Hepato,Biliary and Pancreatic Medicine, Koto-ku, Tokyo-To, Japan|Kyorin University Hospital, Mitaka-shi, Tokyo-To, Japan|Osaka City University Hospital, Osaka-shi, Japan|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Chungnam National University Hospital - Department of Internal Medicine (Rheumatology), Daejeon, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary\'s Hospital, Seoul, Korea, Republic of|Centrum Onkologii-Instytut im.M.Sklodowskiej Curie, Gliwice, Poland|Pratia, Krakow, Poland|Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Warszawa, Poland|ETG Zamosc, Zamosc, Poland|ICO l´Hospitalet - Hospital Duran i Reynals, L\'Hospitalet de Llobregat, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona - Servicio de Oncologia, Barcelona, Spain|Hospital Universitari Vall d\'Hebron - Dept of Oncology, Barcelona, Spain|Hospital San Pedro de Alcantara - Servicio de Oncologia, Caceres, Spain|Hospital Universitario Reina Sofia - Dept of Oncology, Cordoba, Spain|Hospital General Universitario Gregorio Marañon - Servicio de Oncologia Medica, Madrid, Spain|Hospital Universitario Clinico San Carlos - Servicio de Oncologia, Madrid, Spain|Hospital Universitario HM Madrid Sanchinarro - Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica, Valencia, Spain|Hospital Universitari i Politecnic La Fe - Servicio de Oncologia Medica, Valencia, Spain|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan</td>      <td>https://ClinicalTrials.gov/show/NCT04066491</td>    </tr>    <tr>      <th>366</th>      <td>367</td>      <td>Intratumoral Microdosing of TAK-981 in Head and Neck Cancer</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Head and Neck Cancer</td>      <td>Drug: TAK-981|Biological: Cetuximab|Biological: Avelumab|Combination Product: TAK-981 + Cetuximab|Combination Product: TAK-981 + Avelumab</td>      <td>Presage Biosciences|Takeda</td>      <td>Early Phase 1</td>      <td>12.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science</td>      <td>22-Aug-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04065555</td>    </tr>    <tr>      <th>367</th>      <td>368</td>      <td>A Clinical Study to Evaluate Efficacy and Tolerability of a Cosmetic Product for Arm Firming</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Photodamaged Skin|Skin Care</td>      <td>Other: Topical Body Firming Moisturizer|Other: Body Cleanser|Other: Sunscreen|Other: Placebo Moisturizer</td>      <td>Revision Skincare|Stephens &amp; Associates, Inc.</td>      <td>Not Applicable</td>      <td>46.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>22-Aug-19</td>      <td>Stephens and Associates, Richardson, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04065035</td>    </tr>    <tr>      <th>368</th>      <td>369</td>      <td>Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Urothelial Carcinoma Recurrent|Advanced Urothelial Carcinoma</td>      <td>Drug: Vactosertib(TEW-7197)/ Durvalumab</td>      <td>MedPacto, Inc.|AstraZeneca</td>      <td>Phase 2</td>      <td>48.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>21-Aug-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04064190</td>    </tr>    <tr>      <th>369</th>      <td>370</td>      <td>Expanded Access to NanoDoce</td>      <td>Available</td>      <td>No Results Available</td>      <td>Urogenital Neoplasms</td>      <td>Drug: NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension</td>      <td>NanOlogy, LLC|US Biotest, Inc.</td>      <td>NaN</td>      <td>NaN</td>      <td>Industry</td>      <td>Expanded Access:Individual Patients</td>      <td>NaN</td>      <td>19-Aug-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04060628</td>    </tr>    <tr>      <th>370</th>      <td>371</td>      <td>Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Duchenne Muscular Dystrophy</td>      <td>Drug: Viltolarsen|Drug: Placebo</td>      <td>NS Pharma, Inc.|Nippon Shinyaku Co., Ltd.</td>      <td>Phase 3</td>      <td>74.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>19-Aug-19</td>      <td>Arkansas Children\'s Hospital, Little Rock, Arkansas, United States|University of California Davis Medical Center, Sacramento, California, United States|Children\'s Hospital Colorado, Aurora, Colorado, United States|Ann and Robert H. Lurie Children\'s Hospital of Chicago, Chicago, Illinois, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University College of Physicians &amp; Surgeons, New York, New York, United States|Oregon Health &amp; Science University, Portland, Oregon, United States|Virginia Commonwealth University Health System, Richmond, Virginia, United States|Alberta Children\'s Hospital, Calgary, Canada|Fondazione Policlinico Universitario A. Gemelli - Universita Cattolica del Sacro Cuore, Rome, Italy|Hyogo College of Medicine College Hospital, Hyōgo, Japan|Kumamoto University Hospital, Kumamoto, Japan|National Center of Neurology and Psychiatry, Tokyo, Japan|Pusan National University Yangsan Hospital, Pusan, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Radboud Universitair Medisch Centrum, Nijmegen, Gelderland, Netherlands|Auckland Clinical Studies Ltd, Auckland, New Zealand|Russian National Research Medical University n.a. N.I.Pirogov, structural branch - Research Clinical Institute of Pediatrics n.a. Academician Yu. E. Veltishchev, Moscow, Russian Federation|"Saint Petersburg State Paediatric Medical University" based at Consultative and Diagnostic Centre, Saint Petersburg, Russian Federation|Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation|Hospital Sant Joan de Deu, Barcelona, Spain|Queen Silvia Childrens Hospital, Göteborg, Sweden|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan</td>      <td>https://ClinicalTrials.gov/show/NCT04060199</td>    </tr>    <tr>      <th>371</th>      <td>372</td>      <td>Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus</td>      <td>Terminated</td>      <td>No Results Available</td>      <td>Hepatitis B|HBV|Hepatitis B, Chronic</td>      <td>Drug: Inarigivir soproxil|Drug: Tenofovir alafenamide fumarate (TAF)</td>      <td>Spring Bank Pharmaceuticals, Inc.|PRA Health Sciences</td>      <td>Phase 2</td>      <td>5.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>16-Aug-19</td>      <td>Queen Mary Hospital, Pok Fu Lam, Hong Kong Island, Hong Kong|Prince of Wales Hospital, Sha Tin, New Territories, Hong Kong</td>      <td>https://ClinicalTrials.gov/show/NCT04059198</td>    </tr>    <tr>      <th>372</th>      <td>373</td>      <td>Understanding Patient Experience and Preferences for the QT Scanner Compared to Mammography</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Breast Cancer Screening</td>      <td>Diagnostic Test: QT Scanner</td>      <td>QT Ultrasound LLC|Analysis Group, Inc.</td>      <td>NaN</td>      <td>20.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Case-Only|Time Perspective: Retrospective</td>      <td>15-Aug-19</td>      <td>Analysis Group, Inc., Boston, Massachusetts, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04057391</td>    </tr>    <tr>      <th>373</th>      <td>374</td>      <td>A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Atopic Dermatitis (AD)</td>      <td>Drug: KBL697</td>      <td>KoBioLabs|Novotech (Australia) Pty Limited</td>      <td>Phase 1</td>      <td>36.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>14-Aug-19</td>      <td>Nucleus Network, Melbourne, Victoria, Australia</td>      <td>https://ClinicalTrials.gov/show/NCT04056130</td>    </tr>    <tr>      <th>374</th>      <td>375</td>      <td>A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Dyslipidemia</td>      <td>Drug: AZD6615|Drug: Placebo</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 1</td>      <td>72.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment</td>      <td>13-Aug-19</td>      <td>Research Site, Glendale, California, United States|Research Site, Baltimore, Maryland, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04055168</td>    </tr>    <tr>      <th>375</th>      <td>376</td>      <td>Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)</td>      <td>Enrolling by invitation</td>      <td>No Results Available</td>      <td>Plaque Psoriasis</td>      <td>Drug: DMVT-505 (tapinarof cream, 1%)</td>      <td>Dermavant Sciences GmbH|IQVIA Biotech</td>      <td>Phase 3</td>      <td>477.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>12-Aug-19</td>      <td>Dermavant Investigative Site, Birmingham, Alabama, United States|Dermavant Investigative Site, Phoenix, Arizona, United States|Dermavant Investigative Site, Bryant, Arkansas, United States|Dermavant Investigative Site, Fort Smith, Arkansas, United States|Dermavant Investigative Site, Fountain Valley, California, United States|Dermavant Investigative Site, Fremont, California, United States|Dermavant Investigative Site, Fresno, California, United States|Dermavant Investigative Site, Los Angeles, California, United States|Dermavant Investigative Site, Los Angeles, California, United States|Dermavant Investigative Site, Northridge, California, United States|Dermavant Investigative Site, Oceanside, California, United States|Dermavant Investigative Site, San Diego, California, United States|Dermavant Investigative Site, Santa Ana, California, United States|Dermavant Investigative Site, Santa Monica, California, United States|Dermavant Investigative Site, Denver, Colorado, United States|Dermavant Investigative Site, Cromwell, Connecticut, United States|Dermavant Investigative Site, Boca Raton, Florida, United States|Dermavant Investigative Site, Boynton Beach, Florida, United States|Dermavant Investigative Site, Hialeah, Florida, United States|Dermavant Investigative Site, Margate, Florida, United States|Dermavant Investigative Site, Miami, Florida, United States|Dermavant Investigative Site, Miramar, Florida, United States|Dermavant Investigative Site, Boise, Idaho, United States|Dermavant Investigative Site, Rolling Meadows, Illinois, United States|Dermavant Investigative Site, Evansville, Indiana, United States|Dermavant Investigative Site, Indianapolis, Indiana, United States|Dermavant Investigative Site, New Albany, Indiana, United States|Dermavant Investigative Site, Plainfield, Indiana, United States|Dermavant Investigative Site, Overland Park, Kansas, United States|Dermavant Investigative Site, Louisville, Kentucky, United States|Dermavant Investigative Site, Owensboro, Kentucky, United States|Dermavant Investigative Site, Baton Rouge, Louisiana, United States|Dermavant Investigative Site, New Orleans, Louisiana, United States|Dermavant Investigative Site, Rockville, Maryland, United States|Dermavant Investigative Site, Boston, Massachusetts, United States|Dermavant Investigative Site, Bay City, Michigan, United States|Dermavant Investigative Site, Clarkston, Michigan, United States|Dermavant Investigational Site, Detroit, Michigan, United States|Dermavant Investigative Site, Fort Gratiot, Michigan, United States|Dermavant Investigative Site, Warren, Michigan, United States|Dermavant Investigative Site, Fridley, Minnesota, United States|Dermavant Investigative Site, Saint Joseph, Missouri, United States|Dermavant Investigative Site, Omaha, Nebraska, United States|Dermavant Investigative Site, Las Vegas, Nevada, United States|Dermavant Investigative Site, East Windsor, New Jersey, United States|Dermavant Investigative Site, Hackensack, New Jersey, United States|Dermavant Investigative Site, Verona, New Jersey, United States|Dermavant Investigative Site, Kew Gardens, New York, United States|Dermavant Investigative Site, New York, New York, United States|Dermavant Investigative Site, Rochester, New York, United States|Dermavant Investigative Site, Stony Brook, New York, United States|Dermavant Investigative Site, Cary, North Carolina, United States|Dermavant Investigative Site, High Point, North Carolina, United States|Dermavant Investigative Site, Wilmington, North Carolina, United States|Dermavant Investigative Site, Winston-Salem, North Carolina, United States|Dermavant Investigative Site, Beachwood, Ohio, United States|Dermavant Investigative Site, Bexley, Ohio, United States|Dermavant Investigative Site, Norman, Oklahoma, United States|Dermavant Investigate Site, Norman, Oklahoma, United States|Dermavant Investigative Site, Norman, Oklahoma, United States|Dermavant Investigative Site, Portland, Oregon, United States|Dermavant Investigative Site, Portland, Oregon, United States|Dermavant Investigative Site, Pittsburgh, Pennsylvania, United States|Dermavant Investigative Site, Johnston, Rhode Island, United States|Dermavant Investigative Site, Charleston, South Carolina, United States|Dermavant Investigative Site, Nashville, Tennessee, United States|Dermavant Investigative Site, Arlington, Texas, United States|Dermavant Investigative Site, College Station, Texas, United States|Dermavant Investigative Site, Dripping Springs, Texas, United States|Dermavant Investigative Site, Houston, Texas, United States|Dermavant Investigative Site, Pflugerville, Texas, United States|Dermavant Investigative Site, Plano, Texas, United States|Dermavant Investigative Site, San Antonio, Texas, United States|Dermavant Investigative Site, San Antonio, Texas, United States|Dermavant Investigative Site, Webster, Texas, United States|Dermavant Investigative Site, West Jordan, Utah, United States|Dermavant Investigative Site, Norfolk, Virginia, United States|Dermavant Investigative Site, Spokane, Washington, United States|Dermavant Investigative Site, Edmonton, Alberta, Canada|Dermavant Investigative Site, Surrey, Bristish Columbia, Canada|Dermavant Investigative Site, Surrey, British Columbia, Canada|Dermavant Investigative Site, Ajax, Ontario, Canada|Dermavant Investigative Site, Cobourg, Ontario, Canada|Dermavant Investigative Site, Etobicoke, Ontario, Canada|Dermavant Investigative Site, Hamilton, Ontario, Canada|Dermavant Investigative Site, Markham, Ontario, Canada|Dermavant Investigative Site, North Bay, Ontario, Canada|Dermavant Investigative Site, Oakville, Ontario, Canada|Dermavant Investigative Site, Ottawa, Ontario, Canada|Dermavant Investigative Site, Richmond Hill, Ontario, Canada|Dermavant Investigative Site, Toronto, Ontario, Canada|Dermavant Investigative Site, Waterloo, Ontario, Canada|Dermavant Investigative Site, Windsor, Ontario, Canada|Dermavant Investigative Site, Montréal, Quebec, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04053387</td>    </tr>    <tr>      <th>376</th>      <td>377</td>      <td>To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Advanced Solid Tumors</td>      <td>Drug: ABN401- Escalation Phase|Drug: ABN401- Expansion Phase</td>      <td>Abion Inc|Novotech (Australia) Pty Limited</td>      <td>Phase 1|Phase 2</td>      <td>78.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>12-Aug-19</td>      <td>ST George Private Hospital, Kogarah, New South Wales, Australia|Sydney Southwest Private Hospital, Liverpool, New South Wales, Australia|Scientia Clinical Research, Randwick, New South Wales, Australia|Linear Clinical Research, Perth, Western Australia, Australia|National Cancer Centre, Goyang-si, Gyeonggi-Do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Yonsei University Health System, Severance, Seoul, Korea, Republic of|Asan Medical Centre, Seoul, Korea, Republic of</td>      <td>https://ClinicalTrials.gov/show/NCT04052971</td>    </tr>    <tr>      <th>377</th>      <td>378</td>      <td>Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Cutaneous Squamous Cell Carcinoma|Advanced Cutaneous Squamous Cell Carcinoma|Metastatic Cutaneous Squamous Cell Carcinoma</td>      <td>Drug: Cemiplimab|Biological: RP1</td>      <td>Replimune Inc.|Regeneron Pharmaceuticals</td>      <td>Phase 2</td>      <td>240.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>8-Aug-19</td>      <td>City of Hope, Duarte, California, United States|Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States|University of California San Diego, La Jolla, California, United States|University of California Los Angeles, Los Angeles, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Chris O\'Brien Lifehouse, Camperdown, New South Wales, Australia|Southern Medical Day Care Centre, Wollongong, New South Wales, Australia|Tasman Oncology Research Ltd, Southport, Queensland, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|The Alfred, Melbourne, Victoria, Australia</td>      <td>https://ClinicalTrials.gov/show/NCT04050436</td>    </tr>    <tr>      <th>378</th>      <td>379</td>      <td>Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Severe Asthma</td>      <td>Drug: Biological: Experimental: Tezepelumab</td>      <td>AstraZeneca|Amgen</td>      <td>Phase 3</td>      <td>65.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>7-Aug-19</td>      <td>Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan</td>      <td>https://ClinicalTrials.gov/show/NCT04048343</td>    </tr>    <tr>      <th>379</th>      <td>380</td>      <td>Phase 1b Study to Evaluate ATP128, With or Without BI 754091, in Patients With Stage IV Colorectal Cancer</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Colorectal Cancer|MSS|Stage IV Colon Cancer|Stage IV Rectal Cancer|Metastatic Colorectal Cancer|Liver Metastasis Colon Cancer</td>      <td>Drug: ATP128|Drug: BI 754091</td>      <td>Amal Therapeutics|Boehringer Ingelheim</td>      <td>Phase 1|Phase 2</td>      <td>32.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>6-Aug-19</td>      <td>Honor Health Institute, Scottsdale, Arizona, United States|University of Southern California, Los Angeles, California, United States|University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|University Hospital Antwerpen, Edegem, Belgium|University Hospital Leuven, Leuven, Belgium</td>      <td>https://ClinicalTrials.gov/show/NCT04046445</td>    </tr>    <tr>      <th>380</th>      <td>381</td>      <td>A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson\'s Disease</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Parkinson Disease</td>      <td>Drug: LY03003 ( Rotigotine, extended-release microspheres)|Drug: Placebo, extended-release microspheres</td>      <td>Luye Pharma Group Ltd.|Beijing Bozhiyin T&amp;S Co., Ltd.</td>      <td>Phase 1</td>      <td>30.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>5-Aug-19</td>      <td>Chinese PLA General Hospital, Beijing, China|Xuanwu Hospital Capital Medical University, Beijing, China|Shengjing Hospital of China Medical University, Shenyang, China</td>      <td>https://ClinicalTrials.gov/show/NCT04045678</td>    </tr>    <tr>      <th>381</th>      <td>382</td>      <td>A Study of LY03003 in Patients With Early-stage Parkinson\'s Disease</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Parkinson Disease</td>      <td>Drug: Rotigotine, extended-release microspheres|Drug: Placebo, extended-release microspheres</td>      <td>Luye Pharma Group Ltd.|Beijing Bozhiyin T&amp;S Co., Ltd.</td>      <td>Phase 1</td>      <td>60.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>5-Aug-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04044547</td>    </tr>    <tr>      <th>382</th>      <td>383</td>      <td>A Prospective Observational Study of Renal Cell Cancer Patients Treated With Nivolumab Plus Ipilimumab in the Real World Setting in Japan</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Advanced or Metastatic Renal Cell Carcinoma</td>      <td>NaN</td>      <td>Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd</td>      <td>NaN</td>      <td>250.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>2-Aug-19</td>      <td>Local Institution, Tokyo, Japan</td>      <td>https://ClinicalTrials.gov/show/NCT04043975</td>    </tr>    <tr>      <th>383</th>      <td>384</td>      <td>Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Parkinson\'s Disease</td>      <td>Drug: XC130-A10H|Drug: Placebo</td>      <td>Xoc Pharmaceuticals|Celerion</td>      <td>Phase 1</td>      <td>40.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment</td>      <td>2-Aug-19</td>      <td>Celerion, Tempe, Arizona, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04043338</td>    </tr>    <tr>      <th>384</th>      <td>385</td>      <td>Clearblue Pregnancy Test - Lay User Study</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Pregnancy</td>      <td>Diagnostic Test: Clearblue pregnancy test</td>      <td>SPD Development Company Limited|WCCT Global</td>      <td>NaN</td>      <td>204.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Case-Only|Time Perspective: Prospective</td>      <td>2-Aug-19</td>      <td>WCCT, Cypress, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04043169</td>    </tr>    <tr>      <th>385</th>      <td>386</td>      <td>A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Advanced Solid Tumor|Gynecologic Cancer</td>      <td>Drug: Lucitanib|Drug: Nivolumab</td>      <td>Clovis Oncology, Inc.|Bristol-Myers Squibb</td>      <td>Phase 1|Phase 2</td>      <td>232.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>1-Aug-19</td>      <td>Florida Cancer Specialists, Sarasota, Florida, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Tennessee Oncology, Nashville, Tennessee, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04042116</td>    </tr>    <tr>      <th>386</th>      <td>387</td>      <td>Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Pulmonary Arterial Hypertension</td>      <td>Drug: L606 (Liposomal Treprostinil) Inhalation Solution 51ug|Device: L606 Inhalation System|Other: Placebo Solution</td>      <td>Pharmosa Biopharm Inc.|PPD</td>      <td>Phase 1</td>      <td>64.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other</td>      <td>1-Aug-19</td>      <td>PPD, Austin, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04041648</td>    </tr>    <tr>      <th>387</th>      <td>388</td>      <td>Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia</td>      <td>Drug: Ceftazidime-avibactam</td>      <td>Pfizer|Allergan</td>      <td>Phase 1</td>      <td>32.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science</td>      <td>1-Aug-19</td>      <td>Rady Children\'s Hospital San Diego, San Diego, California, United States|Children\'s Hospital Colorado - Investigational Drug Services, Aurora, Colorado, United States|Children\'s Hospital Colorado, Aurora, Colorado, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Yale New Haven Hospital, Department of Pharmacy Services, New Haven, Connecticut, United States|Yale Center for Clinical Investigation Church Street Research Unit (CSRU), New Haven, Connecticut, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|University of New Mexico Health Sciences Center Hospital Inpatient Pharmacy 4N, Albuquerque, New Mexico, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|UNM Clinical &amp; Translational Sciences Center, Albuquerque, New Mexico, United States|Wuxi Children\'s Hospital, Wuxi, Jiangsu, China|Chengdu Women\'s and Children\'s Central Hospital, Chengdu, Sichuan, China|Beijing Children\'s Hospital, Capital Medical University, Beijing, China|Chengdu Women\'s and Children\'s Central Hospital, Chengdu, China|Tallinn Children\'s Hospital, Tallinn, Estonia|Tartu University Hospital, Pediatric &amp; Neonatal Intensive Care Unit, Tartu, Estonia|Nirmal Hospital Pvt Ltd, Surat, Gujarat, India|ASST degli Spedali Civili di Brescia, Brescia BS, Other, Italy|Detska fakultna nemocnica Kosice, Kosice, Slovakia|Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan|Taipei Municipal Wanfang Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Children\'s Hospital, Mackay Memorial Hospital, Taipei, Taiwan|Taipei Municipal Wanfang Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital-Linkou, Taoyuan, Taiwan</td>      <td>https://ClinicalTrials.gov/show/NCT04040621</td>    </tr>    <tr>      <th>388</th>      <td>389</td>      <td>Precedex Special Investigation (in Pediatric Patients)</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Sedation</td>      <td>Drug: Dexmedetomidine Hydrochloride</td>      <td>Pfizer|Maruishi Pharmaceutical</td>      <td>NaN</td>      <td>110.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Case-Only|Time Perspective: Prospective</td>      <td>31-Jul-19</td>      <td>Pfizer Japan Local Country Office, Tokyo, Japan</td>      <td>https://ClinicalTrials.gov/show/NCT04040439</td>    </tr>    <tr>      <th>389</th>      <td>390</td>      <td>A Volunteer Study to Collect Imaging Data for the Development of the ntelligentUltrasound Anatomy Guide</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Ultrasound Imaging of Anatomical Structures</td>      <td>NaN</td>      <td>Medaphor Limited|IntelligentUltrasound Limited</td>      <td>NaN</td>      <td>30.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>31-Jul-19</td>      <td>Medicentre, Cardiff, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04040179</td>    </tr>    <tr>      <th>390</th>      <td>391</td>      <td>A Study of Sofosbuvir and Ledipasvir From Soviredia 90/400 mg Tablets (Minapharm, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy</td>      <td>Drug: Soviredia|Drug: Harvoni (first dose)|Drug: Harvoni (Second dose)</td>      <td>Genuine Research Center, Egypt|MinaPharm Pharmaceuticals</td>      <td>Phase 1</td>      <td>30.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>31-Jul-19</td>      <td>Genuine Research Center GRC, Cairo, Egypt</td>      <td>https://ClinicalTrials.gov/show/NCT04039958</td>    </tr>    <tr>      <th>391</th>      <td>392</td>      <td>Absorption, Metabolism and Excretion of 14C-olorofim in Man</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Invasive Fungal Infections</td>      <td>Drug: Olorofim</td>      <td>F2G Ltd.|PRA Health Sciences</td>      <td>Phase 1</td>      <td>12.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>31-Jul-19</td>      <td>PRA Health Sciences, Groningen, Netherlands</td>      <td>https://ClinicalTrials.gov/show/NCT04039880</td>    </tr>    <tr>      <th>392</th>      <td>393</td>      <td>Tezepelumab COPD Exacerbation Study</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Chronic Obstructive Pulmonary Disease (COPD)</td>      <td>Biological: Tezepelumab|Other: Placebo</td>      <td>AstraZeneca|Amgen</td>      <td>Phase 2</td>      <td>282.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>31-Jul-19</td>      <td>Research Site, Dothan, Alabama, United States|Research Site, Huntington Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, Riverside, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Westminster, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Brandon, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Panama City, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Evanston, Illinois, United States|Research Site, Buckley, Michigan, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Edmond, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Abingdon, Virginia, United States|Research Site, Everett, Washington, United States|Research Site, Calgary, Alberta, Canada|Research Site, Sherwood Park, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Truro, Nova Scotia, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St Charles Borromee, Quebec, Canada|Research Site, Trois-Rivières, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Aarhus N, Denmark|Research Site, Hvidovre, Denmark|Research Site, København NV, Denmark|Research Site, Odense C, Denmark|Research Site, Roskilde, Denmark|Research Site, Vejle, Denmark|Research Site, Ålborg, Denmark|Research Site, Amiens Cedex 1, France|Research Site, Brest Cedex 2, France|Research Site, Creteil, France|Research Site, Grenoble Cedex, France|Research Site, Lyon Cedex 04, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nantes Cedex 1, France|Research Site, Berlin, Germany|Research Site, Frankfurt, Germany|Research Site, Grosshansdorf, Germany|Research Site, Lübeck, Germany|Research Site, Mainz, Germany|Research Site, Ashkelon, Israel|Research Site, Beer Sheva, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Rehovot, Israel|Research Site, Daegu, Korea, Republic of|Research Site, Gyeonggi-do, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Jeonju-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Eindhoven, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Zutphen, Netherlands|Research Site, Alzira, Spain|Research Site, Barcelona, Spain|Research Site, Málaga, Spain|Research Site, Mérida (Badajoz), Spain|Research Site, Bradford, United Kingdom|Research Site, Chertsey, United Kingdom|Research Site, Cottingham, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle-upon-Tyne, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04039113</td>    </tr>    <tr>      <th>393</th>      <td>394</td>      <td>Single Dose Crossover Comparative Bioavailability Study of Two Formulations of Fluconazole 200 mg in Healthy Adult Subjects Under Fasting Conditions</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Bioequivalence</td>      <td>Drug: Fluconazole|Drug: Diflucan®</td>      <td>Pharmtechnology LLC|Altasciences Company, Inc.</td>      <td>Phase 1</td>      <td>26.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other</td>      <td>30-Jul-19</td>      <td>Altasciences Company Inc., Mont-Royal, Quebec, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04038008</td>    </tr>    <tr>      <th>394</th>      <td>395</td>      <td>Study of NaQuinate in Healthy Volunteers</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Osteoporosis</td>      <td>Drug: NaQuinate|Drug: Placebo</td>      <td>Haoma Medica Limited|Parexel</td>      <td>Phase 1</td>      <td>58.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other</td>      <td>30-Jul-19</td>      <td>Parexel Early Phase Clinical Unit - London, London, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04036617</td>    </tr>    <tr>      <th>395</th>      <td>396</td>      <td>Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Colorectal Cancer|Chemotherapy-induced Peripheral Neuropathy</td>      <td>Drug: Calmangafodipir (5 µmol/kg)|Other: Placebo</td>      <td>PledPharma AB|Solasia Pharma K.K.</td>      <td>Phase 3</td>      <td>301.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention</td>      <td>26-Jul-19</td>      <td>Onze-Lieve-Vrouwziekenuis Aalst, Aalst, Belgium|Imelda GI Clinical Research Center, Bonheiden, Belgium|Cliniques Universitaires St-Luc, Brussels, Belgium|UZ Gent, Gent, Belgium|CHU Liège, Liège, Belgium|AZ Sint Maarten, Mechelen, Belgium|AZ Delta campus Wilgenstraat, Roeselare, Belgium|CHU UCL Namur - Site Godinne, Yvoir, Belgium|Nemocnice Benesov, Benesov, Czechia|Nemocnice Horovice, Horovice, Czechia|Nemocnice Na Pleši, Nová Ves pod Plesi, Czechia|General University Hospital, Prague 2, Czechia|Onkologická Klinika 1. Lf Uk A Tn, Prague, Czechia|Clinique Pasteur-Lanroze, Brest Cedex 2, France|Institut de Cancérologie, Brest, France|Centre Hospitalier Départemental de Vendée - Unité de recherche clinique, La Roche-sur-Yon, France|Centre Oscar Lambret, Lille, France|Hôpital Edouard Herriot - HCL, LYON Cedex 03, France|Hôpital Nord Franche-Comté Site du Mittan, Montbéliard, France|Hopital l\'Archet, CHU de Nice, Nice, France|Clinique Ste Anne, Strasbourg, France|Hopitaux Universitaires de Strasbourg, Strasbourg, France|Hämatolgisch-onkologische Praxis Augsburg, Augsburg, Germany|Onkozentrum Dresden, Dresden, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Onkodok GmbH / Onkologische Schwerpunktpraxis, Gütersloh, Germany|Klinikum Neuperlach, Munchen, Germany|Oncologia Istituti Ospitalieri, Cremona, Italy|Irccs Irst, Meldola - FC, Italy|Hospital San Gerardo, Monza, Italy|Istituto Nazionale Tumori, Napoli, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale degli infermi, Ponderano, Italy|IRCCS azienda Ospedaliera S Maria Nuova, Reggio Emilia, Italy|Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Fukuoka University Hospital, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|St. Marianna University School of Medicine Hospital, Kawasaki, Japan|Aichi Cancer Center Hospital, Nagoya, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Osaka International Cancer Institute, Osaka, Japan|Osaka University Hospital, Osaka, Japan|Sapporo Medical University Hospital, Sapporo, Japan|Shizuoka Cancer Center, Shizuoka, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Fujita Health University Hospital, Toyoake, Japan|Hallym University Sacred Heart Hospital, Anyang-si, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Chonnam National University Hwasun Hospital, Gwangju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Granvia de L´Hospitalet 199-203, Barcelona, Spain|Hospital de La Santa Creu I Sant Pau, Barcelona, Spain|Vall d\'hebron university hospital, Barcelona, Spain|Centro Integral Oncologico, Madrid, Spain|H.G.U.Gregorio Marañón, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Hospital Univ Virgen Macarena, Sevilla, Spain|Hospital Quironsalud Valencia, Valencia, Spain|KMUH: Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Mid Essex Hospital Services NHS Trust - Broomfield Hospital, Chelmsford, United Kingdom|North Tyneside General Hospital, North Shields, United Kingdom|Mount Vernon Cancer Centr, Northwood, United Kingdom|The Royal Marsden Hospital (Surrey), Sutton, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04034355</td>    </tr>    <tr>      <th>396</th>      <td>397</td>      <td>SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Atopic Dermatitis</td>      <td>Drug: DUPILUMAB|Drug: PLACEBO</td>      <td>Sanofi|Regeneron Pharmaceuticals</td>      <td>Phase 4</td>      <td>201.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>26-Jul-19</td>      <td>Investigational Site Number 8400012, North Little Rock, Arkansas, United States|Investigational Site Number 8400002, Redwood City, California, United States|Investigational Site Number 8400001, Rolling Hills Estates, California, United States|Investigational Site Number 8400013, Colorado Springs, Colorado, United States|Investigational Site Number 8400005, Denver, Colorado, United States|Investigational Site Number 8400003, Sarasota, Florida, United States|Investigational Site Number 8400007, Medford, Oregon, United States|Investigational Site Number 8400008, Charleston, South Carolina, United States|Investigational Site Number 8400014, Lynchburg, Virginia, United States|Investigational Site Number 0360003, Carlton, Australia|Investigational Site Number 0360001, Kogarah, Australia|Investigational Site Number 0360006, Phillip, Australia|Investigational Site Number 0360007, Woolloongabba, Australia|Investigational Site Number 2760005, Bad Bentheim, Germany|Investigational Site Number 2760001, Göttingen, Germany|Investigational Site Number 2760004, Münster, Germany|Investigational Site Number 3760005, Afula, Israel|Investigational Site Number 3760003, Jerusalem, Israel|Investigational Site Number 3760001, Rehovot, Israel|Investigational Site Number 7240008, Madrid, Spain|Investigational Site Number 7560001, Bern, Switzerland|Investigational Site Number 7840002, Abu Dhabi, United Arab Emirates</td>      <td>https://ClinicalTrials.gov/show/NCT04033367</td>    </tr>    <tr>      <th>397</th>      <td>398</td>      <td>NOVOsyn® for Trocar Incision After Laparoscopic Appendectomy and Cholecystectomy</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Appendicitis|Cholecystitis</td>      <td>Device: Novosyn® CHD for fascia and skin closure|Device: Novosyn® for fascia and skin closure</td>      <td>Aesculap AG|B.Braun Surgical SA</td>      <td>NaN</td>      <td>282.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>26-Jul-19</td>      <td>Klinikverbund Südwest Krankenhaus Leonberg Alllgemeinchirurgie, Leonberg, Baden-Württemberg, Germany|Diakonie Klinikum gGmbH Schwäbisch Hall, Schwäbisch Hall, Baden-Württemberg, Germany|Hospital Germans Trias i Pujol General and Digestive Surgery, Badalona, Spain|General Surgery Department Hospital Plató, Barcelona, Spain|Quironsalud Sagrado Corazón General Surgery, Sevilla, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04033211</td>    </tr>    <tr>      <th>398</th>      <td>399</td>      <td>PAVES Benchmarking Pilot Study of Daily Disposable Contact Lenses</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Refractive Errors</td>      <td>Device: Phase A - olifilcon B with Tangible Coatings|Device: Phase B - etafilcon A with Tangible Coatings</td>      <td>Vision Service Plan|Foresight Regulatory Strategies, Inc.</td>      <td>Not Applicable</td>      <td>144.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment</td>      <td>25-Jul-19</td>      <td>Ross Eyecare, Atlanta, Georgia, United States|Professional Eye Care Center, Niles, Illinois, United States|RevolutionEyes, Carmel, Indiana, United States|Andover Optometry on Central, Andover, Massachusetts, United States|Professional VisionCare, Westerville, Ohio, United States|Primary Eyecare Group, PC, Brentwood, Tennessee, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04032457</td>    </tr>    <tr>      <th>399</th>      <td>400</td>      <td>Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis</td>      <td>Terminated</td>      <td>No Results Available</td>      <td>Relapsing-remitting Multiple Sclerosis</td>      <td>Drug: Evobrutinib|Drug: Avonex®|Drug: Placebo</td>      <td>EMD Serono Research &amp; Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono</td>      <td>Phase 3</td>      <td>1.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>25-Jul-19</td>      <td>Please Contact U.S. Medical Information, Rockland, Massachusetts, United States|Please Contact the Communication Center, Darmstadt, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04032171</td>    </tr>    <tr>      <th>400</th>      <td>401</td>      <td>Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)</td>      <td>Terminated</td>      <td>No Results Available</td>      <td>Relapsing-remitting Multiple Sclerosis</td>      <td>Drug: Evobrutinib|Drug: Avonex®|Drug: Placebo</td>      <td>EMD Serono Research &amp; Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono</td>      <td>Phase 3</td>      <td>3.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>25-Jul-19</td>      <td>Please Contact U.S. Medical Information, Rockland, Massachusetts, United States|Please Contact the Communication Center, Darmstadt, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04032158</td>    </tr>    <tr>      <th>401</th>      <td>402</td>      <td>A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Schizophrenia|Bipolar I Disorder</td>      <td>Drug: Aripiprazole</td>      <td>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.|PRA Health Sciences</td>      <td>Phase 1</td>      <td>266.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>23-Jul-19</td>      <td>Woodland International Research Group, Little Rock, Arkansas, United States|Woodland International Research Group, Rogers, Arkansas, United States|CITrials - Bellflower, Bellflower, California, United States|Collaborative Neuroscience Network, Garden Grove, California, United States|California Clinical Trials Medical Group, Glendale, California, United States|Synergy Research Centers, Lemon Grove, California, United States|NRC Research Institute, Orange, California, United States|California Neuropsychopharmacology Clinical Research Institute San Diego, San Diego, California, United States|Collaborative Neuroscience Network - South Bay, Torrance, California, United States|Research Centers of America, Hollywood, Florida, United States|Segal Institute For Clinical Research - West Broward Outpatient Clinic, Miami Lakes, Florida, United States|Atlanta Center for Medical Research - Atlanta, Atlanta, Georgia, United States|CBH Health, Gaithersburg, Maryland, United States|St. Louis Clinical Trials, Saint Louis, Missouri, United States|Altea Research Institute - Las Vegas, Las Vegas, Nevada, United States|Hassman Research Institute, Marlton, New Jersey, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Carolina Clinical Trials, Charleston, South Carolina, United States|Community Clinical Research, Austin, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04030143</td>    </tr>    <tr>      <th>402</th>      <td>403</td>      <td>A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Nalbuphine|Idiopathic Pulmonary Fibrosis|Cough</td>      <td>Drug: Nalbuphine ER|Drug: Placebo oral tablet</td>      <td>Trevi Therapeutics|Parexel</td>      <td>Phase 2</td>      <td>56.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>23-Jul-19</td>      <td>11, Belfast, United Kingdom|09, Cambridge, United Kingdom|08, Cottingham, United Kingdom|05, Liverpool, United Kingdom|04, London, United Kingdom|01, London, United Kingdom|02, Manchester, United Kingdom|10, Newcastle Upon Tyne, United Kingdom|07, Norwich, United Kingdom|06, Nottingham, United Kingdom|03, Southampton, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04030026</td>    </tr>    <tr>      <th>403</th>      <td>404</td>      <td>Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Type 2 Diabetes Mellitus</td>      <td>Drug: Ertugliflozin 5 mg|Drug: Ertugliflozin 15 mg|Drug: Placebo|Biological: Insulin|Drug: Metformin</td>      <td>Merck Sharp &amp; Dohme Corp.|Pfizer</td>      <td>Phase 3</td>      <td>150.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>23-Jul-19</td>      <td>The University of Alabama at Birmingham ( Site 2207), Birmingham, Alabama, United States|Children\'s Hospital - Los Angeles ( Site 2201), Los Angeles, California, United States|Center of Excellence in Diabetes and Endocrinology ( Site 2203), Sacramento, California, United States|Joe Dimaggio Children\'s Hospital ( Site 2217), Hollywood, Florida, United States|ICCT Research International, Inc. ( Site 2211), Chicago, Illinois, United States|Barry J. Reiner MD LLC ( Site 2204), Baltimore, Maryland, United States|William Beaumont Hospital ( Site 2219), Royal Oak, Michigan, United States|CHEAR Center LLC ( Site 2200), Bronx, New York, United States|The Children\'s Hospital of Philadelphia ( Site 2205), Philadelphia, Pennsylvania, United States|Southern Endocrinology and Associates PA ( Site 2218), Mesquite, Texas, United States|Cliniques Universitaires Saint-Luc ( Site 2300), Brussels, Bruxelles-Capitale, Region De, Belgium|London Health Sciences Centre ( Site 0002), London, Ontario, Canada|Hopital Maisonneuve-Rosemont CIUSSS de l Est de L Ile de Montreal ( Site 0001), Montreal, Quebec, Canada|Centro De Diabetes Cardiovascular IPS Ltda ( Site 0101), Barranquilla, Atlantico, Colombia|MedPlus Medicina Prepagada S.A. ( Site 0102), Bogota, Distrito Capital De Bogota, Colombia|Clinica Los Yoses ( Site 0200), San Jose, Costa Rica|Hospital Infantil Dr. Robert Reid Cabral ( Site 0300), Santo Domingo, Distrito Nacional (Santo Domingo), Dominican Republic|CHU du BOCAGE ( Site 0407), Dijon, Cote-d\'Or, France|Consultorio Privado Dr. Geraldine Utrilla ( Site 0501), Chiquimula, Guatemala|Endopedia ( Site 0503), Guatemala, Guatemala|Clinicas Las Americas ( Site 0502), Guatemala, Guatemala|Pecsi Tudomanyegyetem Klinikai Kozpont Gyermekgyogyaszati Klinika ( Site 0708), Pecs, Baranya, Hungary|Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 0705), Gyula, Bekes, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi OktatoKorhaz ( Site 0701), Miskolc, Borsod-Abauj-Zemplen, Hungary|Szabolcs Szatmar Bereg Megyei Korhazak es Egyetemi Oktato korhaz ( Site 0704), Nyiregyhaza, Szabolcs-Szatmar-Bereg, Hungary|Heim Pal Orszagos Gyermekgyogyaszati Intezet ( Site 0702), Budapest, Hungary|Semmelweis Egyetem II. sz. Gyermekgyogyaszati Klinika ( Site 0703), Budapest, Hungary|Soroka University Medical Center ( Site 0802), Beer Sheva, HaDarom, Israel|Armon M.C ( Site 0803), Haifa, Heifa, Israel|Rambam Medical Center ( Site 0801), Haifa, Heifa, Israel|The Edmond and Lily Safra Children s Hospital ( Site 0804), Ramat Gan, Tell Abib, Israel|Hadassah Mount Scopus ( Site 0800), Jerusalem, Yerushalayim, Israel|AOU Meyer ( Site 0901), Firenze, Italy|IRCCS G. Gaslini ( Site 0900), Genova, Italy|IRCCS Ospedale Pediatrico Bambino Gesu ( Site 0903), Roma, Italy|Hospital Universiti Sains Malaysia ( Site 1102), Kubang Kerian, Kelantan, Malaysia|Hospital Taiping ( Site 1104), Taiping, Perak, Malaysia|Hospital Pulau Pinang. ( Site 1101), Georgetown, Pulau Pinang, Malaysia|University Malaya Medical Centre ( Site 1100), Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia|Hospital Putrajaya ( Site 1103), Putrajaya, Wilayah Persekutuan Putrajaya, Malaysia|Unidad de Investigacion Clinica Cardiometabolica de Occidente ( Site 1007), Guadalajara, Jalisco, Mexico|Centro de Investigacion Medica de Occidente S.C. ( Site 1001), Zapopan, Jalisco, Mexico|Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 1003), Madero, Tamaulipas, Mexico|Centro de Atencion e Investigacion Clinica SC ( Site 1009), Aguascalientes, Mexico|Centro de Diagnostico Medicont S.A. de C.V ( Site 1006), Mexico City, Mexico|CAIMED Investigación en Salud S.A de C.V ( Site 1008), Mexico, Mexico|Radiologia Total SAPI de CV ( Site 1004), Queretaro, Mexico|Davao Doctors Hospital ( Site 1400), Davao, Davao Del Sur, Philippines|Institute for Studies on Diabetes Foundation Inc. ( Site 1402), Marikina, Rizal, Philippines|West Visayas State University Medical Center ( Site 1401), Iloilo, Philippines|Bashkir State Medical University Hospital ( Site 1603), Ufa, Baskortostan, Respublika, Russian Federation|Federal State Budget Institution Endocrinological Research Center ( Site 1611), Moscow, Moskva, Russian Federation|Children\'s City Clinical Hospital #1 ( Site 1604), Novosibirsk, Novosibirskaya Oblast\', Russian Federation|Rostov Scientific Research Institution of Obstetrics and Pediatry ( Site 1606), Rostov-on-Don, Rostovskaya Oblast\', Russian Federation|Samara City Pediatric Clinical Hospital n.a. N.N. Ivanova ( Site 1610), Samara, Samarskaya Oblast\', Russian Federation|St.Petersburg State Pediatric Medical University ( Site 1600), Saint Petersburg, Sankt-Peterburg, Russian Federation|Kazan State Medical University ( Site 1601), Kazan, Tatarstan, Respublika, Russian Federation|Siberian State Medical University ( Site 1602), Tomsk, Tomskaya Oblast\', Russian Federation|Voronezh State Medical University named after N.N.Burdenko ( Site 1608), Voronezh, Voronezskaja Oblast\', Russian Federation|King Abdulaziz Medical City - Al Ahsa ( Site 1730), Al Ahsa, Ar Riyad, Saudi Arabia|King Abdul Aziz Medical City - AlRiyadh ( Site 1700), Riyadh, Ar Riyad, Saudi Arabia|King Abdul Aziz Medical City - AlRiyadh ( Site 1705), Riyadh, Ar Riyad, Saudi Arabia|King Salman bin Abdulaziz hospital - Al Riyadh ( Site 1720), Riyadh, Ar Riyad, Saudi Arabia|King Salman bin Abdulaziz hospital Al Riyadh ( Site 1710), Riyadh, Ar Riyad, Saudi Arabia|King Abdul Aziz Medical City. National Guard Health Affairs ( Site 1715), Jeddah, Makkah Al Mukarramah, Saudi Arabia|Hera General Hospital ( Site 1725), Mecca, Makkah Al Mukarramah, Saudi Arabia|Cukurova Uni. Tip Fakultesi ( Site 2403), Adana, Turkey|Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 2400), Istanbul, Turkey|Municipal Medical Institution Regional Children Clinical Hospital ( Site 1910), Chernivtsi, Chernivetska Oblast, Ukraine|MHI Regional Childrens Clinical Hospital ( Site 1908), Kharkiv, Kharkivska Oblast, Ukraine|Ukr Center of Endocrine Surgery and Transplatation MOH Ukraine ( Site 1903), Kyiv, Kyivska Oblast, Ukraine|Institute of Endocrinology and Metabolism n.a. Komissarenko ( Site 1905), Kyiv, Kyivska Oblast, Ukraine|Odessa Regional Children Clinical Hospital ( Site 1912), Odesa, Odeska Oblast, Ukraine|Vinnitsa Regional Endocrinology Dispensary, VNMU n.a. M.I.Pyrogov ( Site 1901), Vinnytsia, Vinnytska Oblast, Ukraine|Dubai Diabetes Center ( Site 2002), Dubai, Dubayy, United Arab Emirates|Mediclinic City Hospital ( Site 2005), Dubai, Dubayy, United Arab Emirates|Al Jalila Children s Specialty Hospital ( Site 2004), Dubai, Dubayy, United Arab Emirates|Thumbay Hospital ( Site 2001), Ajman, United Arab Emirates|Rashid Center For Diabetes and Research ( Site 2006), Ajman, United Arab Emirates|Royal London Hospital (Whitechapel) ( Site 2100), London, London, City Of, United Kingdom|West Middlesex University Hospital ( Site 2104), London, London, City Of, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04029480</td>    </tr>    <tr>      <th>404</th>      <td>405</td>      <td>Feasibility Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Mitral Regurgitation</td>      <td>Device: HighLife Transcatheter Mitral Valve Replacement</td>      <td>HighLife SAS|MedPass International</td>      <td>Not Applicable</td>      <td>50.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>23-Jul-19</td>      <td>St. Vincent\'s Hospital - Sydney, Darlinghurst, New South Wales, Australia|The Wesley Hospital, Auchenflower, Queensland, Australia|St. Andrew\'s Hospital, Adelaide, Australia|Warringal Hospital, Heidelberg, Australia|Mount Hospital, Perth, Australia|Medical University of Silesia Hospital, Katowice, Poland|University Hospital of Lord\'s Transfiguration, Poznan, Poland|Institute of Cardiology, Warsaw, Poland|Institute of Cardiology, Warsaw, Poland</td>      <td>https://ClinicalTrials.gov/show/NCT04029363</td>    </tr>    <tr>      <th>405</th>      <td>406</td>      <td>Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Pulmonary Disease, Chronic Obstructive</td>      <td>Drug: Part A: RPL554|Drug: Part B: RPL554|Drug: Placebos</td>      <td>Verona Pharma plc|Iqvia Pty Ltd</td>      <td>Phase 2</td>      <td>37.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>22-Jul-19</td>      <td>VitaLink Research -- Union, Union, South Carolina, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04027439</td>    </tr>    <tr>      <th>406</th>      <td>407</td>      <td>Insulin Tolerance Test Study in Patients With Type 1 Diabetes</td>      <td>Terminated</td>      <td>No Results Available</td>      <td>Type 1 Diabetes|Hypoglycemia</td>      <td>Drug: Pitolisant</td>      <td>High Point Clinical Trials Center|Ferox Therapeutics</td>      <td>Phase 1</td>      <td>5.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science</td>      <td>19-Jul-19</td>      <td>High Point Clinical Trials Center, High Point, North Carolina, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04026750</td>    </tr>    <tr>      <th>407</th>      <td>408</td>      <td>Linaclotide Safety and Efficacy, Functional Constipation, in Pediatric Participants 6 to 17 Years of Age</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Functional Constipation</td>      <td>Drug: Linaclotide 72 μg|Drug: Placebo</td>      <td>Allergan|Ironwood Pharmaceuticals, Inc.</td>      <td>Phase 3</td>      <td>326.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>19-Jul-19</td>      <td>Central Research Associates, Inc, Birmingham, Alabama, United States|Southeastern Pediatrics Associates, Dothan, Alabama, United States|G &amp; L Research, LLC, Foley, Alabama, United States|The Center for Clinical Trials, Saraland, Alabama, United States|HealthStar Research, Hot Springs, Arkansas, United States|Preferred Clinical Research Partners, Little Rock, Arkansas, United States|Applied Research Center of Arkansas, Little Rock, Arkansas, United States|Advanced Research Center, Anaheim, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Center for Clinical Trials, LLC, Paramount, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Lynn Institute of Denver, Aurora, Colorado, United States|Children\'s National Medical Center, Washington, District of Columbia, United States|Prohealth Research Center, Doral, Florida, United States|Dolphin Medical Research, Doral, Florida, United States|Amedica Research Institute, Inc, Hialeah, Florida, United States|Nemours Children\'s Specialty Care, Jacksonville, Florida, United States|Elite Clinical Research, Miami, Florida, United States|Biotech Pharmaceuticals Group LLC, Miami, Florida, United States|South Miami Medical &amp; Research Group, Inc., Miami, Florida, United States|Valencia Medical &amp; Research Center, Miami, Florida, United States|Advanced Research for Health Improvement,LLC, Naples, Florida, United States|Pediatric &amp; Adult Research Center, Orlando, Florida, United States|Nemours Children\'s Hospital, Orlando, Florida, United States|Oviedo Medical Research, Oviedo, Florida, United States|Treken Primary Care, Atlanta, Georgia, United States|Children\'s Healthcare of Atlanta, Atlanta, Georgia, United States|Childrens Center for Digestive Health Care, Atlanta, Georgia, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|Clinical Trials Specialist, Inc., Doraville, Georgia, United States|Clinical Research Institute, Stockbridge, Georgia, United States|SleepCare Research Institute, Inc., Stockbridge, Georgia, United States|The University of Chicago, Chicago, Illinois, United States|Alliance for Multispecialty Research, LLC, Newton, Kansas, United States|KU Wichita Center for Clinical Research, Wichita, Kansas, United States|Private Practice - Dr. Michael W. Simon, Nicholasville, Kentucky, United States|Meridian Clinical Research, Baton Rouge, Louisiana, United States|LSU Health Science Center - Shreveport, Shreveport, Louisiana, United States|Virgo Carter Pediatrics, Silver Spring, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Minnesota Gastroenterology PA, Minneapolis, Minnesota, United States|Gastrointestinal Associates and Endoscopy Center, Flowood, Mississippi, United States|David M. Headley, MD, P.A., Port Gibson, Mississippi, United States|Private Practice - Dr. Craig Spiegel, Bridgeton, Missouri, United States|Foundation Pediatrics Med Clinical Research Partners, LLC, East Orange, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|The Children\'s Hospital at Montefiore, Bronx, New York, United States|Advantage Clinical Trials, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States|PMG Research, Inc. dba PMG Research of Piedmont Healthcare, Statesville, North Carolina, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|University of Oklahoma Health Sciences Center/Children\'s Hospital at OU Medical Center, Oklahoma City, Oklahoma, United States|Children\'s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Frontier Clinical Research, LLC, Scottdale, Pennsylvania, United States|Frontier Clinical Research, LLC, Smithfield, Pennsylvania, United States|Coastal Pediatric Research, Charleston, South Carolina, United States|Coastal Pediatric Research, Summerville, South Carolina, United States|The Jackson Clinic, P.A., Jackson, Tennessee, United States|GI for Kids, PLLC, Knoxville, Tennessee, United States|Vanderbilt Children\'s Hospital, Nashville, Tennessee, United States|Hasbro Children\'s Hospital/Rhode Island Hospital, Providence, Tennessee, United States|Oak Cliff Research Company, LLC, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Cook Childrens Health Care System, Fort Worth, Texas, United States|Capital Area Primary Care, PLLC dba San Gabriel Clinical Research, Georgetown, Texas, United States|Valley Institute of Research, Harlingen, Texas, United States|Vilo Research Group, Houston, Texas, United States|Cullen Research, Houston, Texas, United States|Discovery MM Services, Inc., Houston, Texas, United States|Pioneer Research Solutions Inc, Houston, Texas, United States|Discovery MM Services, Inc, Missouri City, Texas, United States|AIM Trials, LLC, Plano, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|UT Health San Antonio, San Antonio, Texas, United States|ClinPoint Trials, Waxahachie, Texas, United States|Chrysalis Clinical Research, Saint George, Utah, United States|University of Utah and Primary Children\'s Hospital, Salt Lake City, Utah, United States|Health Research of Hampton Roads, Inc., Newport News, Virginia, United States|Clinical Research Partners, LLC, Richmond, Virginia, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Marshall Health, Huntington, West Virginia, United States|The Medical College of Wisconsin, Milwaukee, Wisconsin, United States|UZ Brussel, Brussels, Belgium|Universitair Ziekenhuis, Ghent, Belgium|KU Leuven, Leuven, Belgium|Medical Center-1-Sevlievo EOOD, Sevlievo, Gabrovo, Bulgaria|MBAL Sv.Ivan Rilski Kozlodui, Kiril I Metodii, Bulgaria|Multi-Profile Hospital for Active Treatment - Ruse JSC MHAT-Ruse, Ruse, Bulgaria|Medical Center-1-Sevlievo EOOD, Sevlievo, Bulgaria|University Hospital Plovdiv, Tsentar, Bulgaria|UMHAT Sveta Marina, Varna, Bulgaria|Stollery Children\'s Hospital, Edmonton, Alberta, Canada|DSMED, Lower Sackville, Nova Scotia, Canada|Victoria Hospital - London Health Sciences Centre/Lawson Health Research Institute, London, Ontario, Canada|SKDS Research Inc, Newmarket, Ontario, Canada|Bluewater Clinical Research Group Inc, Sarnia, Ontario, Canada|Al Mare Perearstikeskus, Harjumaa, Estonia|Merelahe PAK, Tallinn, Estonia|Kiliiniliste Uuringute Keskus, Tartu, Estonia|Kindergastroenterologie, Uni-Kinderklinik Leipzig, Leipzig, Saxony-Anhalt, Germany|Klinikum Kassel GmbH, Kassel, Germany|Svabhegy Pediatric Clinic, Budapest, Hungary|Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak, Budapest, Hungary|Soproni Erzsebet Oktato Korhaz es Rehabilitacious Intezet, Sopron, Hungary|Rambam Health Care Campus, Ruth Rappaport Children\'s Hospital, Haifa, Israel|Wolfson Medical Center, Holon, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah University Hospital, Jerusalem, Israel|The Baruch Padeh Medical Center Poriya, Lower Galilee, Israel|Schneider Children\'s Medical Center of Israel, Petah Tikva, Israel|Sheba Medical Center, Tel Hashomer, Israel|Azienda Ospedaliera Sant\' Andrea, Naples, Italy|IRCCS Ospedale Pediatrico Bambino Gesu, Roma, Italy|Academisch Medisch Centrum Universiteit Van Amsterdam, Amsterdam, Netherlands|Maasstad Hospital Rotterdam, Rotterdam, Netherlands|Isala Zwolle, Zwolle, Netherlands|Szpital Uniwersytecki "r. A. Jurasza", Bydgoszcz, Poland|Klinika Pediatrii Gastroenterologii Hepatologii Zywienia Dzieci Szpiatl, Gdansk, Poland|Wojewódzki Specjalistyczny Szpital Dzieciecy, Olsztyn, Poland|Korczowski Bartosz, Gabinet Lekarski, Rzeszow, Poland|Centrum Zdrowia MDM, Warsaw, Poland|University Children\'s Hospital - Tirsova, Belgrade, Serbia|University Children\'s Hospital, Belgrade, Serbia|Children\'s Hospital, Clinical Center Nis, Nis, Serbia|GI for Kids, PLLC, Novi Sad, Serbia|Hospital San Joan de Deu, Barcelona, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Instituto Hispalense Pediatria, Sevilla, Spain|MMI "Regional children\'s clinical hospital", Chernivtsi, Chernivets\'ka Oblast\', Ukraine|Municipal Nonprofit Enterprise "Lviv City Children\'s Clinical Hospital", Lviv, L\'vivs\'ka Oblast\', Ukraine|State Institution "Dnipropetrovsk medical academy", Dnipro, Ukraine|Kharkiv National Medical University, Kharkiv, Ukraine|Vinnytsya National Medical University, Vinnytsya, Ukraine|Birmingham Children\'s Hospital, Birmingham, United Kingdom|Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom|Barts Health NHS Trust - The Royal London Hospital, London, United Kingdom|King\'s College Hospital, London, United Kingdom|Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom|William Harvey Hospital, Willesborough, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04026113</td>    </tr>    <tr>      <th>408</th>      <td>409</td>      <td>Safety and Performance of a Synthetic Tissue Sealant in Reducing Fluid Leakage in Hepatobiliary and Pancreatic Surgery</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Pancreatectomy|Hepatic Resection</td>      <td>Device: Sealing Device</td>      <td>Polyganics BV|Genae</td>      <td>Not Applicable</td>      <td>80.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>18-Jul-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04024956</td>    </tr>    <tr>      <th>409</th>      <td>410</td>      <td>Treatment of Actinic Keratosis With 5% KOH Solution</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Actinic Keratoses</td>      <td>NaN</td>      <td>Infectopharm Arzneimittel GmbH|Gesellschaft für Therapieforschung mbH</td>      <td>NaN</td>      <td>73.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Other|Time Perspective: Prospective</td>      <td>18-Jul-19</td>      <td>Dermatologisches Zentrum, Bonn, Germany|Hautzentrum Dülmen, Dülmen, Germany|Hautärztliche Praxis, Friedrichshafen, Germany|Hautzentrum Nymphenburg, München, Germany|Haut- und Laserzentrum Potsdam, Potsdam, Germany|Hautarzt-Praxis, Stuttgart, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04024579</td>    </tr>    <tr>      <th>410</th>      <td>411</td>      <td>Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Hepatitis B|HBV|Hepatitis B, Chronic</td>      <td>Drug: Inarigivir soproxil|Drug: Nucleoside/nucleotide (NUC) analogue inhibitors</td>      <td>Spring Bank Pharmaceuticals, Inc.|PRA Health Sciences</td>      <td>Phase 2</td>      <td>60.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>17-Jul-19</td>      <td>University of Calgary, Calgary, Alberta, Canada|GI Research Institute, Vancouver, British Columbia, Canada|LAIR Centre, Vancouver, British Columbia, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Liver Center, Toronto, Ontario, Canada|Barts Health NHS Trust, London, England, United Kingdom|King\'s College Hospital NHS Foundation Trust, London, England, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04023721</td>    </tr>    <tr>      <th>411</th>      <td>412</td>      <td>A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Leukemia, Myeloid, Acute</td>      <td>Drug: Azacitidine|Drug: Cusatuzumab</td>      <td>Janssen Research &amp; Development, LLC|argenx BVBA</td>      <td>Phase 2</td>      <td>150.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>17-Jul-19</td>      <td>St Vincents Hospital Sydney, Darlinghurst, Australia|St Vincents Hospital Melbourne, Fitzroy, Australia|The Alfred Hospital, Melbourne, Australia|Royal Perth Hospital, Perth, Australia|Westmead Hospital, Westmead, Australia|Hospital Do Cancer De Barretos - Fundacao Pio Xii, Barretos, Brazil|Hospital Estadual de Campinas - Centro de Hematologia e Hemoterapia, Campinas, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil|Instituto do Cancer do Estado de Sao Paulo \'Octavio Frias de Oliveira\' - ICESP, Sao Paulo, Brazil|Hospital Israelita Albert Einstein, Sao Paulo, Brazil|CHU d\'Angers, Angers, France|CHU Grenoble, Grenoble cedex 9, France|Institut Paoli Calmettes, Marseille Cedex 9, France|Centre Hospitalier Universitaire (CHU) de Bordeaux Hopital HautLeveque Centre Francois Magendie, Pessac, France|CHU Lyon Sud, Pierre - Bénite cedex, France|Institut Universitaire du Cancer Toulouse Oncopole, Toulouse Cedex 9, France|CHRU Tours Hôpital Bretonneau, Tours, France|Rambam Medical Center, Haifa, Israel|Carmel Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Azienda Opedaliero-Universitaria Policlinico Sant\'orsola Malpighi di Bologna, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|Istituto Europeo di Oncologia, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Division of Hematology, Cardarelli Hospital, Napoli, Italy|Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy|Chelyabinck Regional Clinical Hospital, Chelyabinsk, Russian Federation|Ekaterinburg City Clinical Hospital # 7, Ekaterinburg, Russian Federation|S.P. Botkin Moscow City Clinical Hospital, Moscow, Russian Federation|City Clinical Hospital # 40, Moscow, Russian Federation|Nizhny Novgorod Regional Oncology Dispensary, Nizhny Novgorod, Russian Federation|Ryazan Regional Clinical Hospital, Ryazan, Russian Federation|City clinical hospital #15, Saint Petersburg, Russian Federation|Samara Region Clinical Hospital, Samara, Russian Federation|Oncologic Dispensary No.2, Sochi, Russian Federation|St.-Petersburg Clinical Research Institute of Hematology and Transfusiology, St. Petersburg, Russian Federation|Komi Republic Oncology dispensary, Syktyvkar, Russian Federation|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Inst. Cat. Doncologia-H Duran I Reynals, Barcelona, Spain|Hosp. Univ. Vall D\'Hebron, Barcelona, Spain|Hosp. Reina Sofia, Cordoba, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hosp. Univ. Son Espases, Palma, Spain|Hosp. Quiron Madrid Pozuelo, Pozuelo De Alarcon, Madrid, Spain|Hosp. Clinico Univ. de Salamanca, Salamanca, Spain|Hosp. Univ. I Politecni La Fe, Valencia, Spain|Kantonsspital Aarau, Aarau, Switzerland|INSELSPITAL, Universitätsspital Bern, Bern, Switzerland|Hopitaux Universitaires de Geneve, Geneve, Switzerland|UniversitaetsSpital Zuerich, Zürich, Switzerland|Gulhane Egitim ve Arastirma Hastanesi, Ankara, Turkey|Dr.Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey|Ankara University Medical Faculty Hematology Department - Hematology, Ankara, Turkey|Ondokuz Mayis Universitesi Tip Fakultesi, Atakum, Turkey|Istanbul Egitim ve Arastirma Hastanesi, Istanbul, Turkey|Dokuz Eylul Universitesi Tip Fakultesi, İzmir, Turkey|Karadeniz Teknik University Medical Faculty, Trabzon, Turkey</td>      <td>https://ClinicalTrials.gov/show/NCT04023526</td>    </tr>    <tr>      <th>412</th>      <td>413</td>      <td>Comparision of Pharmacokinetics(PK) and Pharmacodynamics(PD) of Biocon Insulin R and Humulin® R</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy Volunteer</td>      <td>Biological: Biocon Insulin R|Biological: Humulin®R</td>      <td>Biocon Limited|Profil Institut für Stoffwechselforschung GmbH</td>      <td>Phase 1</td>      <td>42.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other</td>      <td>17-Jul-19</td>      <td>Profil Mainz GmbH, Mainz, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04022317</td>    </tr>    <tr>      <th>413</th>      <td>414</td>      <td>Comparision of Pharmacokinetic and Pharmacodynamic of Biocon Insulin N and Humulin® N</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy Volunteer</td>      <td>Biological: Biocon Insulin N|Biological: Humulin® N</td>      <td>Biocon Limited|Profil Institut für Stoffwechselforschung GmbH</td>      <td>Phase 1</td>      <td>90.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other</td>      <td>17-Jul-19</td>      <td>Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04022304</td>    </tr>    <tr>      <th>414</th>      <td>415</td>      <td>Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy Volunteer</td>      <td>Biological: Humulin ®70/30|Biological: Biocon Insulin 70/30</td>      <td>Biocon Limited|Profil Institut für Stoffwechselforschung GmbH</td>      <td>Phase 1</td>      <td>78.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other</td>      <td>17-Jul-19</td>      <td>Profil Mainz GmbH &amp; Co. KG Malakoff-Passage,Rheinstraße 4C D-55116, Mainz, Germany|Profil Institut für Stoffwechselforschung GmbH Hellersbergstr. 9 D-41460 Neuss, Neuss, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04022291</td>    </tr>    <tr>      <th>415</th>      <td>416</td>      <td>SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Acute Myeloid Leukemia|High-risk Myelodysplastic Syndrome</td>      <td>Drug: SEL120</td>      <td>Ryvu Therapeutics SA|ICON plc</td>      <td>Phase 1</td>      <td>68.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>16-Jul-19</td>      <td>Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States|Tennessee Oncology, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04021368</td>    </tr>    <tr>      <th>416</th>      <td>417</td>      <td>A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria</td>      <td>Withdrawn</td>      <td>No Results Available</td>      <td>Malaria</td>      <td>Drug: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD|Drug: Sodium ferrous citrate (SFC) 472 mg QD|Drug: Artemisinin-based combination (ACT)|Drug: Placebo|Drug: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 300 mg BID|Drug: Sodium ferrous citrate (SFC) 236 mg BID</td>      <td>Neopharma Japan Co., Ltd.|Parexel</td>      <td>Phase 2</td>      <td>0.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>16-Jul-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04020653</td>    </tr>    <tr>      <th>417</th>      <td>418</td>      <td>The Effect of a Propionate Colon Release Form on ad Libitum Eating and Appetite Perception</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Overweight</td>      <td>Dietary Supplement: Ca-propionate 1 g|Dietary Supplement: Ca-propionate 3 g|Dietary Supplement: Placebo</td>      <td>DSM Nutritional Products, Inc.|Glycemic Index Laboratories, Inc</td>      <td>Not Applicable</td>      <td>21.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other</td>      <td>15-Jul-19</td>      <td>GI Labs, Toronto, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04019951</td>    </tr>    <tr>      <th>418</th>      <td>419</td>      <td>Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Rheumatoid Arthritis|Polyarticular Juvenile Idiopathic Arthritis|Psoriatic Arthritis|Ankylosing Spondylitis|Crohn Disease|Ulcerative Colitis|Plaque Psoriasis|Pediatric Plaque Psoriasis|Pediatric Crohns Disease|Hidradenitis Suppurativa|Non-infectious Uveitis</td>      <td>Drug: 40 mg MSB11022</td>      <td>Fresenius Kabi SwissBioSim GmbH|PRA Health Sciences</td>      <td>Phase 1</td>      <td>216.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science</td>      <td>12-Jul-19</td>      <td>PRA Health Sciences (PRA) - Early Development Services (EDS), Lenexa, Kansas, United States|PRA-EDS, Salt Lake City, Utah, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04018599</td>    </tr>    <tr>      <th>419</th>      <td>420</td>      <td>Impact of Oral Glucose Tolerance Test on Extent of Hemoglobin Glycation</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Blood Glucose, High|Oral Hypoglycaemic Overdose</td>      <td>NaN</td>      <td>Urs E. Nydegger|Labormedizinisches Zentrum Dr. Risch</td>      <td>NaN</td>      <td>100.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Case-Control|Time Perspective: Prospective</td>      <td>12-Jul-19</td>      <td>University of Bern, Bern, Kanton Bern, Switzerland</td>      <td>https://ClinicalTrials.gov/show/NCT04018430</td>    </tr>    <tr>      <th>420</th>      <td>421</td>      <td>A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Insulin Resistance - Type A|Insulin Resistance - Type B|Lipoatrophic Diabetes Mellitus|Insulin Resistance Syndrome</td>      <td>Drug: Empagliflozin Tablets</td>      <td>Kobe University|Boehringer Ingelheim</td>      <td>Phase 3</td>      <td>8.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>12-Jul-19</td>      <td>Kobe University Hospital, Kobe, Hyogo, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan|NIhon University Hospital, Chiyoda-ku, Tokyo, Japan|Okayama University Hospital, Okayama, Japan</td>      <td>https://ClinicalTrials.gov/show/NCT04018365</td>    </tr>    <tr>      <th>421</th>      <td>422</td>      <td>Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.</td>      <td>Completed</td>      <td>Has Results</td>      <td>Immunogenicity|Healthy Volunteers</td>      <td>Combination Product: INTP5|Combination Product: US Neulasta</td>      <td>Intas Pharmaceuticals, Ltd.|Lambda Therapeutic Research Ltd.</td>      <td>Phase 1</td>      <td>200.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other</td>      <td>10-Jul-19</td>      <td>Lambda Therapeutic Research Ltd., Ahmedabad, Gota, India</td>      <td>https://ClinicalTrials.gov/show/NCT04015232</td>    </tr>    <tr>      <th>422</th>      <td>423</td>      <td>DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Adenocarcinoma Gastric Stage IV With Metastases|Adenocarcinoma - GEJ</td>      <td>Drug: Trastuzumab deruxtecan</td>      <td>Daiichi Sankyo, Inc.|AstraZeneca</td>      <td>Phase 2</td>      <td>72.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>10-Jul-19</td>      <td>City of Hope Medical Center, Duarte, California, United States|USC Norris Comprehensive Cancer Center Hospital, Los Angeles, California, United States|Pacific Cancer Care, Monterey, California, United States|UCLA Health, Santa Monica, California, United States|Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|University of Chicago Medical Center UCMC Duchossois Center for Advanced Medicine DCAM, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Alvin J. Siteman Cancer Center Washington University, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|UCL St-Luc, Brussels, Belgium|Hopital de Jolimont, Haine-Saint-Paul, Belgium|UZ Leuven, Leuven, Belgium|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Asst Grande Ospedale Metropolitano Niguarda, Milano, Italy|Oncology Institute Veneto IOVIRCCS, Padua, Italy|Vall d\'Hebron University Hospital and Vall d\'Hebron Institute of Oncology (VHIO), Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Institut Catalan de Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital la Paz, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Biomedical Research Institute Hospital de Valencia, Valencia, Spain|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Christie Hospital, Manchester, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04014075</td>    </tr>    <tr>      <th>423</th>      <td>424</td>      <td>Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.</td>      <td>Completed</td>      <td>Has Results</td>      <td>Pharmacokinetic Bioequivalence Study in Human Healthy Volunteers</td>      <td>Combination Product: INTP5|Combination Product: US Neulasta</td>      <td>Intas Pharmaceuticals, Ltd.|Lambda Therapeutic Research Ltd.</td>      <td>Phase 1</td>      <td>144.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other</td>      <td>10-Jul-19</td>      <td>Lambda Therapeutic Research Ltd., Ahmedabad, Gota, India</td>      <td>https://ClinicalTrials.gov/show/NCT04014062</td>    </tr>    <tr>      <th>424</th>      <td>425</td>      <td>Study to Investigate the Effect of Superba Boost on the Skin.</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Physiology, Skin</td>      <td>Dietary Supplement: Superba Boost (Active)|Dietary Supplement: Vegetable oil (Placebo)</td>      <td>Aker Biomarine Antarctic AS|Atlantia Food Clinical Trials</td>      <td>Not Applicable</td>      <td>70.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science</td>      <td>10-Jul-19</td>      <td>Atlantia Food CRO, Cork, Munster, Ireland</td>      <td>https://ClinicalTrials.gov/show/NCT04013945</td>    </tr>    <tr>      <th>425</th>      <td>426</td>      <td>The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting Conditions</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Bioequivalence</td>      <td>Drug: Candesartan Cilexetil 32mg|Drug: Atacand® PROTECT</td>      <td>Pharmtechnology LLC|Altasciences Company, Inc.</td>      <td>Phase 1</td>      <td>40.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other</td>      <td>9-Jul-19</td>      <td>Altasciences Company Inc., Mont-Royal, Quebec, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04012307</td>    </tr>    <tr>      <th>426</th>      <td>427</td>      <td>Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Agitation|Schizophrenia</td>      <td>Drug: Sublingual film containing BXCL501 (Dexmedetomidine)|Drug: Placebo film</td>      <td>BioXcel Therapeutics Inc|Cognitive Research Corporation</td>      <td>Phase 1</td>      <td>135.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>8-Jul-19</td>      <td>BioXcel Clinical Research Site, Little Rock, Arkansas, United States|BioXcel Clinical Research Site, Cerritos, California, United States|BioXcel Clinical Research Site, Lemon Grove, California, United States|BioXcel Clinical Research Site, Long Beach, California, United States|BioXcel Clinical Research Site, Orange, California, United States|BioXcel Clinical Research Site, Miami Lakes, Florida, United States|BioXcel Clinical Research Site, Atlanta, Georgia, United States|BioXcel Clinical Research Site, Gaithersburg, Maryland, United States|BioXcel Clinical Research Site, Flowood, Mississippi, United States|BioXcel Clinical Research Site, Berlin, New Jersey, United States|BioXcel Clinical Research Site, Austin, Texas, United States|BioXcel Clinical Research Site, Richardson, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04010305</td>    </tr>    <tr>      <th>427</th>      <td>428</td>      <td>Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Chronic Lymphocytic Leukemia</td>      <td>Drug: Acalabrutinib</td>      <td>AstraZeneca|Parexel</td>      <td>Phase 3</td>      <td>549.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>5-Jul-19</td>      <td>Research Site, Chandler, Arizona, United States|Research Site, Long Beach, California, United States|Research Site, Redlands, California, United States|Research Site, Whittier, California, United States|Research Site, Hartford, Connecticut, United States|Research Site, Fort Myers, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Marietta, Georgia, United States|Research Site, Normal, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, New Hyde Park, New York, United States|Research Site, New York, New York, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Fort Belvoir, Virginia, United States|Research Site, Adelaide, Australia|Research Site, Bedford Park, Australia|Research Site, Clayton, Australia|Research Site, Fitzroy, Australia|Research Site, Nedlands, Australia|Research Site, South Brisbane, Australia|Research Site, Belo Horizonte, Brazil|Research Site, Cuiabá, Brazil|Research Site, Curitiba, Brazil|Research Site, Goiania, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Aalborg, Denmark|Research Site, Aarhus, Denmark|Research Site, Herlev, Denmark|Research Site, Holstebro, Denmark|Research Site, København Ø, Denmark|Research Site, Odense, Denmark|Research Site, Roskilde, Denmark|Research Site, Hus, Finland|Research Site, Kuopio, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Bobigny Cedex, France|Research Site, Bordeaux, France|Research Site, Brest, France|Research Site, Clermont Ferrand, France|Research Site, Creteil, France|Research Site, Limoges, France|Research Site, LYON cedex 08, France|Research Site, Reims, France|Research Site, Toulouse Cedex 9, France|Research Site, Tours, France|Research Site, Vandoeuvre-Les-Nancy, France|Research Site, Bonn, Germany|Research Site, Erfurt, Germany|Research Site, Frankfurt, Germany|Research Site, Frechen, Germany|Research Site, Heilbronn, Germany|Research Site, Homburg, Germany|Research Site, Kaiserslautern, Germany|Research Site, Köln, Germany|Research Site, Muenchen, Germany|Research Site, Porta Westfalica, Germany|Research Site, Schwäbisch Hall, Germany|Research Site, Ulm, Germany|Research Site, Catanzaro, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Siena, Italy|Research Site, Torino, Italy|Research Site, Busan, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Ulsan, Korea, Republic of|Research Site, Arnhem, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Dordrecht, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Bergen, Norway|Research Site, Oslo, Norway|Research Site, Trondheim, Norway|Research Site, Barnaul, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Syktyvkar, Russian Federation|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Marbella, Spain|Research Site, Ourense, Spain|Research Site, Oviedo, Spain|Research Site, Valencia, Spain|Research Site, Vitoria, Spain|Research Site, Zaragoza, Spain|Research Site, Luleå, Sweden|Research Site, Lund, Sweden|Research Site, Uppsala, Sweden|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Blackpool, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newmarket, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, West Lothian, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04008706</td>    </tr>    <tr>      <th>428</th>      <td>429</td>      <td>A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Healthy Adult Subjects</td>      <td>Drug: Omaveloxolone|Drug: Midazolam oral solution|Drug: Repaglinide 1 MG|Drug: MetFORMIN 500 Mg Oral Tablet|Drug: Rosuvastatin|Drug: Digoxin tablet|Drug: Gemfibrozil Tablets|Drug: Itraconazole capsule|Drug: Verapamil Pill</td>      <td>Reata Pharmaceuticals, Inc.|Covance</td>      <td>Phase 1</td>      <td>61.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>5-Jul-19</td>      <td>Covance Clinical Research Unit (CRU) Inc., Dallas, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04008186</td>    </tr>    <tr>      <th>429</th>      <td>430</td>      <td>A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator\'s Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Metastatic Colorectal Cancer</td>      <td>Biological: Ipilimumab|Drug: Oxaliplatin|Drug: Leucovorin|Drug: Fluorouracil|Drug: Irinotecan|Drug: Bevacizumab|Drug: Cetuximab|Biological: Nivolumab</td>      <td>Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd</td>      <td>Phase 3</td>      <td>494.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>5-Jul-19</td>      <td>Local Institution, Gilbert, Arizona, United States|Local Institution, Los Angeles, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Local Institution, Miami, Florida, United States|Local Institution, Marietta, Georgia, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Memorial Sloan Kettering Nassau, New York, New York, United States|Northwest Cancer Specialists (Broadway) - USOR, Portland, Oregon, United States|Local Institution, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, United States|Local Institution, Fort Worth, Texas, United States|Oncology &amp; Hematology Associates Of Southwest Virginia, Inc., Roanoke, Virginia, United States|Local Institution, Ciudad Autonoma Beunos Aires, Buenos Aires, Argentina|Fundacion Favaloro, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Caba, Argentina|Instituto Medico Especialazado Alexander Fleming, Caba, Argentina|Centro de Investigaciones Clinicas. Clinica Viedma S. A, Viedma, Argentina|Local Institution, Westmead, New South Wales, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Lkh-Univ.Klinikum Graz, Graz, Austria|Ordensklinikum Standort Barmherzige Schwestern, Linz, Austria|Landeskrankenhaus-Universitaetsklinik fuer Innere Medizin III, Salzburg, Austria|Local Institution, Wiener Neustadt, Austria|Medizinische Universtaet Wien, Wien, Austria|Local Institution, Bonheiden, Belgium|Local Institution, Brussel, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Ipatinga, Minas Gerais, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose De Rio Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Toronto, Ontario, Canada|Centre Hospitalier De L\'Universite De Montreal, Montreal, Quebec, Canada|Centre integre universitaire de sante et de service sociaux de l\'estrie - CHUS, Sherbrooke, Quebec, Canada|Local Institution, Quebec, Canada|Hospital Clinico de la Universidad De Chile, Independencia, Santiago, Chile|Local Institution, Santiago, Chile|Clinica San Carlos de Apoquindo, Santiago, Chile|Local Institution, Hefei, Anhui, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Foshan, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Changzhou, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Qingdao, Shandong, China|Local Institution, Yantai, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Guangzhou, China|Local Institution, Xiamen, China|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Komplexni onkologicke centrum, Novy Jicin, Czechia|Onkologicka klinika, Olomouc, Czechia|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Local Institution, Vejle, Denmark|Chu Jean Minjoz, Besancon Cedex, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon Cedex 08, France|Hopital De La Timone, Marseille, France|Institut du Cancer de Montpellier, Montpellier, France|CHU de Nantes - Hotel Dieu, Nantes, France|Hopital Saint Antoine, Paris, France|Hopital Du Haut-Leveque, Pessac Cedex, France|CHRU de Poitiers La Miletrie, Poitiers, France|Local Institution, Rouen, France|Hopital De Rangueil C H U De Toulouse, Toulouse, France|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|University Hospital Essen, Essen, Germany|Facharztzentrum Eppendorf, Hamburg, Germany|Asklepios Klinik Altona, Hamburg, Germany|Local Institution, Hannover, Germany|Uniklinik Heidelberg, Heidelberg, Germany|Universitaets-Klinikum Marburg, Marburg, Germany|Local Institution, Munich, Germany|Local Institution, Athens, Greece|Local Institution, Heraklion, Greece|Local Institution, Holargos, Greece|Local Institution, Ioannina, Greece|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Catania, Italy|Local Institution, Genova, Italy|ASST Grande Ospedale Niguarda, Milan, Italy|Local Institution, Napoli, Italy|I.O.V. Istituto Oncologico Veneto Ircss, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kanazawa-city, Ishikawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Kitaadachigun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Osaka, Japan|Local Institution, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Bergen, Norway|Local Institution, Lorenskog, Norway|Local Institution, Oslo, Norway|Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico|Local Institution, Brasov, Romania|Local Institution, Bucharest, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Constanta, Romania|Local Institution, Craiova, Romania|Local Institution, Suceava, Romania|Hospital Universitari Germans Trias I Pujol, Badalona-barcelona, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Local Institution, Madrid, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hosp. Univ. Virgen Del Rocio, Sevilla, Spain|Local Institution, Adana, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Leeds, Yorkshire, United Kingdom|Local Institution, Oxford, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04008030</td>    </tr>    <tr>      <th>430</th>      <td>431</td>      <td>A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Asthma</td>      <td>Drug: EQ001|Drug: EQ001 Placebo</td>      <td>Equillium|Biocon Limited</td>      <td>Phase 1</td>      <td>40.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>5-Jul-19</td>      <td>Flinders Medical Centre, Adelaide, Australia|Box Hill Hospital, Box Hill, Australia|Monash Medical Centre, Clayton, Australia|Respiratory Clinical Trials, Kent Town, Australia|TrialsWest, Murdoch, Australia|Melbourne Health, Parkville, Australia|The Queen Elizabeth Hospital, Woodville, Australia|Respiratory Research, Greenland Clinical Centre, Auckland, New Zealand|Dunedin Hospital, Dunedin, New Zealand|The New Zealand Respiratory &amp; Sleep Institute, Greenlane, New Zealand</td>      <td>https://ClinicalTrials.gov/show/NCT04007198</td>    </tr>    <tr>      <th>431</th>      <td>432</td>      <td>Open-label Study of Inhaled RVT-1601 in Preterm Infants</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Respiratory Morbidities of Prematurity (RMP)</td>      <td>Drug: RVT-1601</td>      <td>Respivant Sciences GmbH|Respivant Sciences Inc.</td>      <td>Phase 1</td>      <td>8.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>5-Jul-19</td>      <td>Sharp Mary Birch Hospital for Women &amp; Newborns, San Diego, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04007120</td>    </tr>    <tr>      <th>432</th>      <td>433</td>      <td>Effect of an Arabinogalactan Product</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Postprandial Blood Glucose</td>      <td>Other: arabinogalactan</td>      <td>Biofortis, Merieux NutriSciences|Lonza Inc.</td>      <td>Not Applicable</td>      <td>20.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science</td>      <td>2-Jul-19</td>      <td>Oliver Chen, Addison, Illinois, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04005924</td>    </tr>    <tr>      <th>433</th>      <td>434</td>      <td>Physiologically Guided VT Ablation</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Ventricular Tachycardia</td>      <td>Device: Ablation</td>      <td>Center for Cardiovascular Reseach and Innovation|Boston Scientific Corporation</td>      <td>Not Applicable</td>      <td>80.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>2-Jul-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04004624</td>    </tr>    <tr>      <th>434</th>      <td>435</td>      <td>Evaluate the Effect of Lifenol in Improving Bone Status in Postmenopausal Osteopenic Women</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Osteopenia, Generalized</td>      <td>Dietary Supplement: Lifenol®|Dietary Supplement: Placebo</td>      <td>Naturex SA|Atlantia Food Clinical Trials</td>      <td>Not Applicable</td>      <td>100.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention</td>      <td>1-Jul-19</td>      <td>Atlantia Food Clinical Trials, Cork, Ireland</td>      <td>https://ClinicalTrials.gov/show/NCT04004013</td>    </tr>    <tr>      <th>435</th>      <td>436</td>      <td>Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Metastatic Prostate Cancer|Prostate Adenocarcinoma</td>      <td>Drug: Cabozantinib|Drug: Atezolizumab|Drug: Abiraterone Acetate|Drug: Enzalutamide|Drug: Prednisone</td>      <td>Exelixis|Roche-Genentech|Takeda</td>      <td>Phase 3</td>      <td>580.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>24-Jun-20</td>      <td>Exelixis Clinical Site #1, Nashville, Tennessee, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04446117</td>    </tr>    <tr>      <th>436</th>      <td>437</td>      <td>Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>HIV Infections</td>      <td>Drug: Cabotegravir Tablets|Drug: Rilpivirine Tablets|Drug: Cabotegravir extended release suspension for injection (long-acting)|Drug: Rilpivirine extended release suspension for injection (long-acting)</td>      <td>ViiV Healthcare|Janssen Pharmaceuticals|GlaxoSmithKline</td>      <td>Phase 1</td>      <td>15.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>1-May-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04371380</td>    </tr>    <tr>      <th>437</th>      <td>438</td>      <td>Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Hepatitis B</td>      <td>Drug: NCO-48 Fumarate|Drug: Placebo</td>      <td>Nucorion Pharmaceuticals, Inc.|Ligand Pharmaceuticals|Medpace, Inc.</td>      <td>Phase 1</td>      <td>48.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>16-Mar-20</td>      <td>Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04309526</td>    </tr>    <tr>      <th>438</th>      <td>439</td>      <td>Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Locally Advanced/Metastatic Solid Tumors</td>      <td>Drug: BJ-001|Drug: PD-1 or PD-L1 inhibitor</td>      <td>BJ Bioscience, Inc.|Iqvia Pty Ltd|PPD</td>      <td>Phase 1</td>      <td>92.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>4-Mar-20</td>      <td>Washington University School of Medicine, Saint Louis, Missouri, United States|Mount Sinai, New York, New York, United States|Greenville Hospital System University Medical Center (ITOR), Greenville, South Carolina, United States|NEXT Oncology, San Antonio, Texas, United States|Northwest Medical Specialities, Tacoma, Washington, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04294576</td>    </tr>    <tr>      <th>439</th>      <td>440</td>      <td>Enfortumab Vedotin and Pembrolizumab, With or Without Chemotherapy, vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Urothelial Cancer</td>      <td>Drug: Enfortumab vedotin|Drug: Pembrolizumab|Drug: Cisplatin|Drug: Carboplatin|Drug: Gemcitabine</td>      <td>Astellas Pharma Global Development, Inc.|Merck Sharp &amp; Dohme Corp.|Seattle Genetics, Inc.|Astellas Pharma Inc</td>      <td>Phase 3</td>      <td>1095.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>10-Jan-20</td>      <td>Arizona Oncology Associates PD - HOPE, Tucson, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|University of California Irvine - Newport, Orange, California, United States|Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States|Cancer Centers of Colorado - Denver, Denver, Colorado, United States|Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Georgia Cancer Specialists / Northside Hospital Cancer Institute, Marietta, Georgia, United States|Maine Health Cancer Care, Biddeford, Maine, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New Mexico Cancer Center, Albuquerque, New Mexico, United States|Vidant Medical Center, Greenville, North Carolina, United States|The Cleveland Clinic, Cleveland, Ohio, United States|Toledo Clinic Cancer Center, Toledo, Ohio, United States|Hillman Cancer Center / University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Saint Francis Hospital / Bon Secours - South Carolina, Greenville, South Carolina, United States|UT Health East Texas Hope Cancer Center, Tyler, Texas, United States|University of Virginia, Charlottesville, Virginia, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04223856</td>    </tr>    <tr>      <th>440</th>      <td>441</td>      <td>Non-interventional Study With NOVOCART® 3D for the Treatment of Cartilage Defects of the Knee in Pediatric Patients</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Cartilage Disease</td>      <td>Drug: NOVOCART 3D</td>      <td>Tetec AG|Aesculap AG|Winicker Norimed GmbH</td>      <td>NaN</td>      <td>40.0</td>      <td>Industry</td>      <td>Observational</td>      <td>Observational Model: Case-Only|Time Perspective: Prospective</td>      <td>4-Dec-19</td>      <td>Sportklinik Stuttgart, Stuttgart, Baden Württemberg, Germany|Theresienkrankenhaus und St. Hedwig-Klinik GmbH, Mannheim, Baden-Württemberg, Germany|Klinik und Poliklinik für Orthophädie, Physikalische Medizin und Rehabilitation Knie- und Schulterorthopädie, München, Bayern, Germany|Klinikum rechts der Isar der technischen Universität München, München, Bayern, Germany|Univerisätsklinikum Regensburg, Regensburg, Bayern, Germany|Universitätsmedizin Mainz, Mainz, Rheinland-Pfalz, Germany|Lubinus Clinicum Kiel, Kiel, Schleswig-Holstein, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04186208</td>    </tr>    <tr>      <th>441</th>      <td>442</td>      <td>Mid-Q Response Study</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Heart Failure|Left Bundle-Branch Block|Heart Failure With Reduced Ejection Fraction (HFrEF)|Heart Failure NYHA Class II|Heart Failure NYHA Class III|Heart Failure NYHA Class IV</td>      <td>Device: aCRT ON|Device: aCRT OFF</td>      <td>Medtronic Bakken Research Center|Medtronic|Medtronic Japan Co., Ltd.</td>      <td>Not Applicable</td>      <td>232.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment</td>      <td>27-Nov-19</td>      <td>Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, China|Grantham Hospital, Hong Kong, Hong Kong|Queen Elizabeth Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Hiroshima Prefectural Hospital, Hiroshima, Japan|The Hospital of Hyogo College of Medicine, Hyōgo, Japan|University of Tsukuba Hospital, Ibaraki, Japan|Kitasato University Hospital, Kanagawa, Japan|St. Marianna University Hospital, Kanagawa, Japan|Miyazaki Medical Association Hospital, Miyazaki, Japan|Iwate Medical University Hospital, Morioka, Japan|National Cerebral and Cardiovascular Center, Osaka, Japan|Juntendo University Hospital, Tokyo, Japan|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of</td>      <td>https://ClinicalTrials.gov/show/NCT04180696</td>    </tr>    <tr>      <th>442</th>      <td>443</td>      <td>A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Solid Tumor</td>      <td>Drug: Oraxol</td>      <td>Athenex, Inc.|Zenith Technology Corporation Limited|PharmaEssentia</td>      <td>Phase 2</td>      <td>44.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>27-Nov-19</td>      <td>Monash Medical Centre, Clayton, Australia|Auckland City Hospital, Auckland, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Lotung Poh-Ai Hospital, Yilan, Taiwan|The Christie NHS Foundation Trust, Manchester, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04180384</td>    </tr>    <tr>      <th>443</th>      <td>444</td>      <td>A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Type 2 Diabetes Treated With Insulin</td>      <td>Drug: Afrezza Inhalant Product</td>      <td>Diabetes and Glandular Disease Clinic|Mannkind Corporation|DexCom, Inc.</td>      <td>Phase 4</td>      <td>29.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>14-Oct-19</td>      <td>Diabetes and Glandular Disease Clinic, P.A., San Antonio, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04125082</td>    </tr>    <tr>      <th>444</th>      <td>445</td>      <td>The OPTIMAL Randomized Controlled Trial</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Left Main Coronary Artery Stenosis</td>      <td>Device: IVUS guided Percutaneous Coronary Intervention|Device: QCA guided Percutaneous Coronary Intervention</td>      <td>ECRI bv|Philips Healthcare|Boston Scientific Corporation</td>      <td>Not Applicable</td>      <td>800.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>1-Oct-19</td>      <td>ITA-001, Milan, Italy|UNK-001, Oxford, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04111770</td>    </tr>    <tr>      <th>445</th>      <td>446</td>      <td>Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Chemotherapy Induced Anemia</td>      <td>Drug: Roxadustat (FG-4592)</td>      <td>FibroGen|AstraZeneca|Astellas Pharma Inc</td>      <td>Phase 2</td>      <td>100.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>4-Sep-19</td>      <td>Research Center, Los Angeles, California, United States|Research Center, Covington, Louisiana, United States|Research Center, Bethesda, Maryland, United States|Research Center, Bronx, New York, United States|Research Center, Port Jefferson Station, New York, United States|Research Center, Canton, Ohio, United States|Research Center, Gettysburg, Pennsylvania, United States|Research Center, Philadelphia, Pennsylvania, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04076943</td>    </tr>    <tr>      <th>446</th>      <td>447</td>      <td>A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Solid Tumor</td>      <td>Drug: HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules</td>      <td>Athenex, Inc.|PharmaEssentia|Zenith Technology Corporation Limited</td>      <td>Phase 1</td>      <td>44.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>29-Jul-19</td>      <td>Monash Medical Centre, Melbourne, Australia|Auckland City Hospital, Auckland, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Lotung Poh-Ai Hospital, Ilan, Taiwan|Shuang Ho hospital, New Taipei City, Taiwan|Tri-Service General Hospital, Taipei, Taiwan</td>      <td>https://ClinicalTrials.gov/show/NCT04035473</td>    </tr>    <tr>      <th>447</th>      <td>448</td>      <td>Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>HIV Infections</td>      <td>Drug: DTG/3TC FDC|Drug: CAR</td>      <td>ViiV Healthcare|GlaxoSmithKline|PPD</td>      <td>Phase 3</td>      <td>600.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>16-Jul-19</td>      <td>GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, New Haven, Connecticut, United States|GSK Investigational Site, Pensacola, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Hillsborough, New Jersey, United States|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Beijing, China|GSK Investigational Site, Koebenhavn, Denmark|GSK Investigational Site, Odense C, Denmark|GSK Investigational Site, Bordeaux, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Tourcoing, France|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, München, Germany|GSK Investigational Site, Modena, Emilia-Romagna, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Distrito Federal, Mexico|GSK Investigational Site, Bloemfontein, South Africa|GSK Investigational Site, La Coruña, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Kaohsiung, Taiwan|GSK Investigational Site, Brighton, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04021290</td>    </tr>    <tr>      <th>448</th>      <td>449</td>      <td>Long-term Safety and Efficacy of Prebiotic Enriched Infant Formula</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Infection|Microbial Colonization|Healthy</td>      <td>Other: Supplemented formula|Other: Standard formula</td>      <td>Beneo-Institute|Laboratorios Ordesa|European Union</td>      <td>Not Applicable</td>      <td>160.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science</td>      <td>22-Jun-20</td>      <td>ZNA Koningin Paola Kinderziekenhuis, Antwerp, Belgium|Universitair Ziekenhuis, Brussel, Belgium|CAP Llefià, Barcelona, Spain|Hospital de Nens, Barcelona, Spain|Hospital Sant Joan de Deu, Barcelona, Spain|University Hospital Vall d\'Hebron, Barcelona, Spain|Hospital San Cecilio, Granada, Spain|Equipo Pediátrico San Francisco, Madrid, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04441359</td>    </tr>    <tr>      <th>449</th>      <td>450</td>      <td>Efficacy and Safety of Nitazoxanide 600 mg TID for the Treatment of Hospitalized Patients With COVID-19</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>covid19</td>      <td>Drug: Nitazoxanide|Drug: Placebo</td>      <td>Azidus Brasil|Farmoquimica S.A.|Hospital Casa de Saúde - Vera Cruz - Campinas - SP - Brazil</td>      <td>Phase 2</td>      <td>50.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>9-Jun-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04423861</td>    </tr>    <tr>      <th>450</th>      <td>451</td>      <td>Safety and Tolerability of NTRX-07 in Healthy Volunteers</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Pain, Neuropathic</td>      <td>Drug: NTRX-07-SDD</td>      <td>NeuroTherapia, Inc.|Integrium|Orange County Research Center</td>      <td>Phase 1</td>      <td>48.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science</td>      <td>5-May-20</td>      <td>Orange County Research Center, Tustin, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04375436</td>    </tr>    <tr>      <th>451</th>      <td>452</td>      <td>Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>CoronaVirus Induced Disease-2019 (COVID-19)</td>      <td>Drug: Ibrutinib|Drug: Placebo</td>      <td>AbbVie|Janssen Research &amp; Development, LLC|Pharmacyclics LLC (An AbbVie Company)</td>      <td>Phase 2</td>      <td>46.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>5-May-20</td>      <td>Stanford Univ School Medicine /ID# 221954, Stanford, California, United States|Medstar Washington Hospital Center /ID# 221886, Washington, District of Columbia, United States|GW Medical Faculty Associates /ID# 222023, Washington, District of Columbia, United States|Midway Immunology and Research /ID# 222004, Fort Pierce, Florida, United States|Brigham &amp; Women\'s Hospital /ID# 221847, Boston, Massachusetts, United States|Intermountain Healthcare /ID# 221955, Salt Lake City, Utah, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04375397</td>    </tr>    <tr>      <th>452</th>      <td>453</td>      <td>Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Corona Virus Infection</td>      <td>Drug: NORS (Nitric Oxide Releasing Solution)</td>      <td>Sanotize Research and Development corp.|The Emmes Company, LLC|Keyrus Life Science</td>      <td>Phase 2</td>      <td>200.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention</td>      <td>8-Apr-20</td>      <td>BC Diabetes, Vancouver, British Columbia, Canada|LMC Manna, Pointe-Claire, Quebec, Canada|Diex Recherche Québec, Québec, Quebec, Canada|Diex Recherche Joliette, Saint-Charles-Borromée, Quebec, Canada|Diex Recherche Sherbrooke, Sherbrooke, Quebec, Canada</td>      <td>https://ClinicalTrials.gov/show/NCT04337918</td>    </tr>    <tr>      <th>453</th>      <td>454</td>      <td>Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Infections, Respiratory|Fever|Cough</td>      <td>Diagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals</td>      <td>Dr. Deneen Vojta|Quest Diagnostics|Bill and Melinda Gates Foundation|UnitedHealth Group</td>      <td>NaN</td>      <td>533.0</td>      <td>Industry|Other</td>      <td>Observational</td>      <td>Observational Model: Case-Only|Time Perspective: Retrospective</td>      <td>25-Mar-20</td>      <td>Everett Clinic, Seattle, Washington, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04321369</td>    </tr>    <tr>      <th>454</th>      <td>455</td>      <td>KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Degenerative Disc Disease|Spinal Fusion</td>      <td>Combination Product: TGplPTH1-34 in fibrin|Other: Autologous Bone Graft</td>      <td>Kuros Biosurgery AG|Factory CRO|Kuros BioSciences BV</td>      <td>Phase 2</td>      <td>50.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment</td>      <td>3-Mar-20</td>      <td>University of California San Diego, La Jolla, California, United States|Spine Institute of Louisiana, Shreveport, Louisiana, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04294004</td>    </tr>    <tr>      <th>455</th>      <td>456</td>      <td>SELUTION SLR™ 014 In-stent Restenosis</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Coronary Restenosis</td>      <td>Device: SELUTION SLR™ DEB|Device: Control</td>      <td>M.A. Med Alliance S.A.|Genae|Baim Institute for Clinical Research</td>      <td>Not Applicable</td>      <td>418.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>21-Feb-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04280029</td>    </tr>    <tr>      <th>456</th>      <td>457</td>      <td>The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions in Alopecia Areata</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Alopecia Areata|Depressive Episode|Recurrent Depressive Disorder|Anxiety Disorders|Atopic Dermatitis|Allergic Rhinitis|Asthma|Crohn Disease|Ulcerative Colitis|Pernicious Anemia|Type 1 Diabetes|Hashimoto Thyroiditis|Graves Disease|Rheumatoid Arthritis|Psoriatic Arthritis|Ankylosing Spondylitis|Systemic Lupus Erythematosus|Polymyalgia Rheumatica|Sjogren\'s Syndrome|Psoriasis|Vitiligo|Multiple Sclerosis|Celiac Disease</td>      <td>Other: Exposure of interest (studies 2 &amp; 3).</td>      <td>Momentum Data|Pfizer|University of Surrey</td>      <td>NaN</td>      <td>4000.0</td>      <td>Industry|Other</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Retrospective</td>      <td>27-Jan-20</td>      <td>Momentum Data Ltd, London, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04239521</td>    </tr>    <tr>      <th>457</th>      <td>458</td>      <td>A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Healthy Volunteers</td>      <td>Drug: anle138b|Drug: Placebo</td>      <td>MODAG GmbH|Quotient Sciences|Aptuit (Verona) Srl, an Evotec Company</td>      <td>Phase 1</td>      <td>92.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>23-Dec-19</td>      <td>Quotient Sciences, Nottingham, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04208152</td>    </tr>    <tr>      <th>458</th>      <td>459</td>      <td>MultiPulse Therapy (MPT) for AF</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Atrial Fibrillation, Paroxysmal|Atrial Fibrillation, Persistent|Atrial Fibrillation</td>      <td>Device: Multi Pulse Therapy</td>      <td>Cardialen, Inc.|Genae|Five Corners</td>      <td>Phase 1</td>      <td>50.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility</td>      <td>20-Dec-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04206917</td>    </tr>    <tr>      <th>459</th>      <td>460</td>      <td>A Therapeutic Equivalence Study of Ketoconazole Cream 2%</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Tinea Pedis</td>      <td>Drug: Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.)|Drug: Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)|Drug: Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)</td>      <td>Douglas Pharmaceuticals America Ltd|Novum Pharmaceutical Research Services|ACM Global Laboratories</td>      <td>Phase 3</td>      <td>675.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>18-Dec-19</td>      <td>Moore Clinical Research, Brandon, Florida, United States|Moore Clinical Reseach, Tampa, Florida, United States|FXM Research International, Belize City, Belize</td>      <td>https://ClinicalTrials.gov/show/NCT04203342</td>    </tr>    <tr>      <th>460</th>      <td>461</td>      <td>Clinical Trial Evaluating the Safety and Efficacy of the Use of Chitosan Gel in Patients With Chronic Wounds</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Diabetic Foot Ulcer</td>      <td>Device: ChitoCare gel|Device: Placebo gel</td>      <td>Primex ehf|Vizera d.o.o.|University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia</td>      <td>Not Applicable</td>      <td>60.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>26-Nov-19</td>      <td>University Clinic Vuk Vrhovac, Zagreb, Croatia|General Hospital Brežice, Brežice, Slovenia|General Hospital Celje, Celje, Slovenia|Health Center Koper, Koper, Slovenia|Clinic Golnik - Diabetic Clinic Kranj, Kranj, Slovenia|University Hospital Center Ljubljana, Ljubljana, Slovenia|General Hospital Murska Sobota, Murska Sobota, Slovenia|General Hospital Novo Mesto, Novo Mesto, Slovenia|Hospital Topolšica, Topolšica, Slovenia</td>      <td>https://ClinicalTrials.gov/show/NCT04178525</td>    </tr>    <tr>      <th>461</th>      <td>462</td>      <td>Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Hypertriglyceridemia</td>      <td>Drug: Omega 3 pentaenoic acid|Drug: icosapent ethyl</td>      <td>Matinas BioPharma Nanotechnologies, Inc.|Matinas Biopharma, Inc|MB Clinical Research and Consulting LLC</td>      <td>Phase 2</td>      <td>100.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>26-Nov-19</td>      <td>Matinas Investigational Site, Jacksonville, Florida, United States|Matinas Investigational site, Jupiter, Florida, United States|Matinas Investigational Site, Port Saint Lucie, Florida, United States|Matinas Investigational Site, Addison, Illinois, United States|Matinas Investigational Site, Chicago, Illinois, United States|Matinas Investigational site, Indianapolis, Indiana, United States|Matinas Investigational site, Louisville, Kentucky, United States|Matinas Investigational site, Richmond, Virginia, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04177680</td>    </tr>    <tr>      <th>462</th>      <td>463</td>      <td>Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Renal Insufficiency|Hepatic Insufficiency|Immunosuppression</td>      <td>Drug: Ceftobiprole medocaril</td>      <td>Correvio International Sarl|AMS Advanced Medical Services GmbH|PrimeVigilance LTD</td>      <td>NaN</td>      <td>422.0</td>      <td>Industry|Other</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Retrospective</td>      <td>20-Nov-19</td>      <td>Lungenklinik Neustadt GmbH, Neustadt/Harz, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04170309</td>    </tr>    <tr>      <th>463</th>      <td>464</td>      <td>TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Healthy Volunteers</td>      <td>Drug: MD1003|Drug: Moxifloxacin 400mg|Drug: Placebo for MD1003|Drug: Placebo for moxifloxacin</td>      <td>MedDay Pharmaceuticals SA|Parexel|ERT: Clinical Trial Technology Solutions</td>      <td>Phase 1</td>      <td>64.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other</td>      <td>19-Nov-19</td>      <td>Parexel Early Phase Clinical Unit London, London, Middlesex, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04168723</td>    </tr>    <tr>      <th>464</th>      <td>465</td>      <td>A Study to Evaluate NYX-458 in Subjects With PD-MCI</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Parkinson\'s Disease|Mild Cognitive Impairment</td>      <td>Drug: Placebo Oral Capsule|Drug: NYX-458</td>      <td>Aptinyx|CogState Ltd.|Worldwide Clinical Trials</td>      <td>Phase 2</td>      <td>135.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>1-Nov-19</td>      <td>Aptinyx Clinical Site, Scottsdale, Arizona, United States|Aptinyx Clinical Site, Fresno, California, United States|Aptinyx Clinical Site, Oxnard, California, United States|Aptinyx Clinical Site, Pasadena, California, United States|Aptinyx Clinical Site, Reseda, California, United States|Aptinyx Clinical Site, Simi Valley, California, United States|Aptinyx Clinical Site, New London, Connecticut, United States|Aptinyx Clinical Site, Boca Raton, Florida, United States|Aptinyx Clinical Site, Hallandale Beach, Florida, United States|Aptinyx Clinical Site, Hialeah, Florida, United States|Aptinyx Clinical Site, Miami, Florida, United States|Aptinyx Clinical Site, Miami, Florida, United States|Aptinyx Clinical Site, Miami, Florida, United States|Aptinyx Clinical Site, Sunrise, Florida, United States|Aptinyx Clinical Site, Decatur, Georgia, United States|Aptinyx Clinical Site, Farmington Hills, Michigan, United States|Aptinyx Clinical Site, West Bloomfield, Michigan, United States|Aptinyx Clinical Site, Golden Valley, Minnesota, United States|Aptinyx Clinical Site, Toms River, New Jersey, United States|Aptinyx Clincial Site, Asheville, North Carolina, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States|Aptinyx Clinical Site, Tulsa, Oklahoma, United States|Aptinyx Clinical Site, Sugar Land, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04148391</td>    </tr>    <tr>      <th>465</th>      <td>466</td>      <td>Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>COVID-19</td>      <td>Drug: Olokizumab 64 mg|Drug: Placebo</td>      <td>R-Pharm|Cromos Pharma, LLC|Covance</td>      <td>Phase 2|Phase 3</td>      <td>376.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>30-Jun-20</td>      <td>George Washington University Medical Center, Washington, District of Columbia, United States|Center For Haptitis C/ Atlanta Medical Center, Atlanta, Georgia, United States|PMG Research of DuPage Medical Group, Downers Grove, Illinois, United States|Northwest Indiana Center for Clinical Research, Portage, Indiana, United States|Baystate Infectious Diseases Clinical Research, Springfield, Massachusetts, United States|PMG Research, Inc., Winston-Salem, North Carolina, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04452474</td>    </tr>    <tr>      <th>466</th>      <td>467</td>      <td>Post Marketing Clinical Follow up Study for MagnetOs Putty in Patients With Degenerative Disc Disease</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Degenerative Disc Disease</td>      <td>Device: MagnetOs Putty</td>      <td>Kuros Biosurgery AG|Factory CRO|The London Clinic</td>      <td>Not Applicable</td>      <td>20.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>16-Oct-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04128852</td>    </tr>    <tr>      <th>467</th>      <td>468</td>      <td>A Digital Smoking Cessation Intervention for Adults With Substance Use Disorder</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Tobacco Use Disorder|Substance Use Disorders</td>      <td>Behavioral: Smartphone Contingency Management Intervention</td>      <td>BrightView LLC|Interact for Health|DynamiCare Health</td>      <td>NaN</td>      <td>100.0</td>      <td>Industry|Other</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>9-Jun-20</td>      <td>BrightView Colerain Addiction Treatment Center, Cincinnati, Ohio, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04419922</td>    </tr>    <tr>      <th>468</th>      <td>469</td>      <td>Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Smallpox</td>      <td>Drug: Tpoxx</td>      <td>SIGA Technologies|Biomedical Advanced Research and Development Authority|PPD</td>      <td>Phase 4</td>      <td>34.0</td>      <td>Industry|U.S. Fed</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>19-May-20</td>      <td>PPD Phase I Clinic, Austin, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04392739</td>    </tr>    <tr>      <th>469</th>      <td>470</td>      <td>Assessing Safety and Performance of the ANA Catheter System, Combined With a Stent Retriever in Acute Ischemic Stroke</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Stroke, Ischemic</td>      <td>Device: Neurothrombectomy</td>      <td>Anaconda Biomed S.L.|MedPass International|UCLA Department of Neurology</td>      <td>Not Applicable</td>      <td>125.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>19-Sep-19</td>      <td>Hospital Germans Trias, Badalona, Catalunya, Spain|Hospital Universitario Cruces, Bilbao, Vizcaya, Spain|Hospital Vall d\'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04095767</td>    </tr>    <tr>      <th>470</th>      <td>471</td>      <td>Tolerability and Potential Efficacy of LTh(αΚ) in Subjects With Allergic Rhinitis</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Allergic Rhinitis</td>      <td>Biological: AD17002|Other: Formulation Buffer</td>      <td>Advagene Biopharma Co. Ltd.|Clinipace Worldwide|Taipei Medical University</td>      <td>Phase 1|Phase 2</td>      <td>48.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention</td>      <td>13-Sep-19</td>      <td>Taipei Medical University, Taipei City, Taiwan</td>      <td>https://ClinicalTrials.gov/show/NCT04088721</td>    </tr>    <tr>      <th>471</th>      <td>472</td>      <td>Effect of Probiotic Formula DE111® on Immune System in Preschool Children</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Immune System Support</td>      <td>Dietary Supplement: Probiotic Formula Bacillus subtilis DE111®|Dietary Supplement: Placebo comparator</td>      <td>Deerland Enzymes|Vizera d.o.o.|University of Ljubljana</td>      <td>Not Applicable</td>      <td>102.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care</td>      <td>4-Sep-19</td>      <td>Health center Laško, Laško, Slovenia|Pediatrija Krebs, Maribor, Slovenia|Pediatrinja d.o.o., Maribor, Slovenia|Zasebna otroska in solska ambulanta, Maribor, Slovenia|Health Center Nova Gorica, Šempeter Pri Gorici, Slovenia</td>      <td>https://ClinicalTrials.gov/show/NCT04077034</td>    </tr>    <tr>      <th>472</th>      <td>473</td>      <td>Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNK-001-COVID-19)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Coronavirus|Coronavirus Infection|Severe Acute Respiratory Syndrome Coronavirus 2|Pneumonia|Pneumonia, Viral|Lung Diseases|Respiratory Tract Disease|Respiratory Tract Infections|Coronaviridae Infections|Nidovirales Infections|RNA Virus Infections|Virus Disease|Immunologic Disease|ARDS|Immunologic Factors|Physiological Effects of Drugs|Antiviral Agents|Anti-infective Agents|Analgesics|Antimetabolites, Antineoplastic</td>      <td>Biological: CYNK-001</td>      <td>Celularity Incorporated|IDRI|Lung Biotechnology PBC</td>      <td>Phase 1|Phase 2</td>      <td>86.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>28-Apr-20</td>      <td>Hackensack University Medical Center, Hackensack, New Jersey, United States|Atlantic Health, Morristown, New Jersey, United States|Atlantic Health, Summit, New Jersey, United States|Multicare Health System, Tacoma, Washington, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04365101</td>    </tr>    <tr>      <th>473</th>      <td>474</td>      <td>Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Post-Traumatic Stress Disorder</td>      <td>Drug: Placebo oral capsule|Drug: NYX-783</td>      <td>Aptinyx|Premier Research Group plc|Massachusetts General Hospital</td>      <td>Phase 2</td>      <td>160.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>5-Aug-19</td>      <td>Aptinyx Clinical Site, Tuscaloosa, Alabama, United States|Aptinyx Clinical Site, Phoenix, Arizona, United States|Aptinyx Clinical Site, Little Rock, Arkansas, United States|Aptinyx Clinical Site, Bellflower, California, United States|Aptinyx Clinical Site, Glendale, California, United States|Aptinyx Clinical Site, Imperial, California, United States|Aptinyx Clinical Site, Oakland, California, United States|Aptinyx Clinical Site, Oceanside, California, United States|Aptinyx Clinical Site, Orange, California, United States|Aptinyx Clinical Site, Riverside, California, United States|Aptinyx Clinical Site, San Diego, California, United States|Aptinyx Clinical Site, San Marcos, California, United States|Aptinyx Clinical Site, Santa Ana, California, United States|Aptinyx Clinical Site, Temecula, California, United States|Aptinyx Clinical Site, Torrance, California, United States|Aptinyx Clinical Site, Colorado Springs, Colorado, United States|Aptinyx Clinical Site, Norwich, Connecticut, United States|Aptinyx Clinical Site, Jacksonville, Florida, United States|Aptinyx Clinical Site, Lauderhill, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx, Atlanta, Georgia, United States|Aptinyx Clinical Site, Atlanta, Georgia, United States|Aptinyx Clinical Site, Hoffman Estates, Illinois, United States|Aptinyx Clinical Site, Boston, Massachusetts, United States|Aptinyx Clinical Site, Las Vegas, Nevada, United States|Aptinyx Clinical Site, Berlin, New Jersey, United States|Aptinyx Clinical Site, Cedarhurst, New York, United States|Aptinyx Clinical Site, New York, New York, United States|Aptinyx Clinical Site, Staten Island, New York, United States|Aptinyx Clinical Site, Salisbury, North Carolina, United States|Aptinyx Clinical Site, Canton, Ohio, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States|Aptinyx Clinical Site, Oklahoma City, Oklahoma, United States|Aptinyx Clinical Site, Memphis, Tennessee, United States|Aptinyx Clinical Site, Austin, Texas, United States|Aptinyx Clinical Site, San Antonio, Texas, United States|Aptinyx Clinical Site, Bellevue, Washington, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04044664</td>    </tr>    <tr>      <th>474</th>      <td>475</td>      <td>Implementing Patients´ Competence in Oral Breast Cancer Therapy</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Metastatic Breast Cancer|Advanced Breast Cancer</td>      <td>NaN</td>      <td>Onco Medical Consult GmbH|Eli Lilly and Company|Institut fuer Frauengesundheit</td>      <td>NaN</td>      <td>212.0</td>      <td>Industry|Other</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>24-Jul-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04030728</td>    </tr>    <tr>      <th>475</th>      <td>476</td>      <td>Object Finder for a Retinal Prosthesis</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Retinitis Pigmentosa</td>      <td>Device: Object recognition subsystem</td>      <td>Minnesota HealthSolutions|Johns Hopkins University|Second Sight Medical Products</td>      <td>Not Applicable</td>      <td>10.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility</td>      <td>24-Mar-20</td>      <td>Johns Hopkins Hospital, Baltimore, Maryland, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04319809</td>    </tr>    <tr>      <th>476</th>      <td>477</td>      <td>Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Triple-negative Breast Cancer</td>      <td>Biological: AE37 Peptide vaccine|Biological: Pembrolizumab</td>      <td>Antigen Express, Inc|Merck Sharp &amp; Dohme Corp.|NSABP Foundation Inc</td>      <td>Phase 2</td>      <td>29.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>18-Jul-19</td>      <td>Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Cancer Care Specialists of Central Illinois-Swansea, Swansea, Illinois, United States|West Virginia University, Morgantown, West Virginia, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04024800</td>    </tr>    <tr>      <th>477</th>      <td>478</td>      <td>Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Atopic Keratoconjunctivitis</td>      <td>Drug: Dupilumab</td>      <td>Andover Eye Associates|Statistics &amp; Data Corporation|Regeneron Pharmaceuticals</td>      <td>Phase 2</td>      <td>42.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>5-Mar-20</td>      <td>Vita Eye Clinic, Shelby, North Carolina, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04296864</td>    </tr>    <tr>      <th>478</th>      <td>479</td>      <td>Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Persistent Asthma</td>      <td>Combination Product: fluticasone/formoterol k-haler (medium strength)|Combination Product: Standard of care (ICs/LABA high strength)</td>      <td>Mundipharma Pharmaceuticals S.L.|Alpha Bioresearch S.L.|Dynamic Solutions</td>      <td>Phase 4</td>      <td>208.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>17-Feb-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04271839</td>    </tr>    <tr>      <th>479</th>      <td>480</td>      <td>Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects</td>      <td>Suspended</td>      <td>No Results Available</td>      <td>Alzheimer Disease</td>      <td>Drug: 15mg T3D-959|Drug: 30 mg T3D-959|Drug: 45 mg T3D-959|Drug: Placebos</td>      <td>T3D Therapeutics, Inc.|National Institute on Aging (NIA)|PRA Health Sciences</td>      <td>Phase 2</td>      <td>256.0</td>      <td>Industry|NIH</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>31-Jan-20</td>      <td>Alliance for Wellness d/b/a Alliance for Research, Long Beach, California, United States|National Research Institute, Panorama City, California, United States|Anderson Clinical Research, Redlands, California, United States|Pacific Research Network, San Diego, California, United States|CITrials, Santa Ana, California, United States|IMMUNOe Health and Research Centers, Centennial, Colorado, United States|Research Center for Clinical Studies, Norwalk, Connecticut, United States|Visionary Investigators Network, Aventura, Florida, United States|Indago Research and Health Center, Hialeah, Florida, United States|Infinity Clinical Research, Hollywood, Florida, United States|Charter Research - Lady Lake, Lady Lake, Florida, United States|ClinCloud, LLC, Maitland, Florida, United States|Merritt Island Medical Research, LLC, Merritt Island, Florida, United States|San Marcus Research Clinic, Miami Lakes, Florida, United States|Health Care Family Rehab and Research Center, Miami, Florida, United States|CCM Clinical Research Group, Miami, Florida, United States|Visionary Investigators Network, Miami, Florida, United States|Miami Jewish Health, Miami, Florida, United States|Elite Clinical Research, Miami, Florida, United States|Allied Biomedical Research Institute, Miami, Florida, United States|Global Life Research, Miami, Florida, United States|Miami Dade Medical Research Institute, LLC, Miami, Florida, United States|The Neurology Research Group, Miami, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Combined Research Orlando, Orlando, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Visionary Investigators Network, Pembroke Pines, Florida, United States|Columbus Research and Wellness Institute, Columbus, Georgia, United States|iResearch Atlanta, Decatur, Georgia, United States|Community Clinical Research Center, Anderson, Indiana, United States|PharmaSite Research, Baltimore, Maryland, United States|SShirzadi@mercurycr.us.com, Saint Louis, Missouri, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|Clarity Clinical Research, East Syracuse, New York, United States|Adirondack Medical Research Center, Glens Falls, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|New Hope Clinical Research, Charlotte, North Carolina, United States|Alzheimer\'s Memory Center, Charlotte, North Carolina, United States|Central States Research, LLC, Tulsa, Oklahoma, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Clinical Trial Network, Houston, Texas, United States|Mercury Clinical Research, Sugar Land, Texas, United States|Integrated Neurology Services - Falls Church Office, Falls Church, Virginia, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04251182</td>    </tr>    <tr>      <th>480</th>      <td>481</td>      <td>NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Heart Failure</td>      <td>Drug: Ringer\'s (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) Solution|Drug: Intravenous Bolus Furosemide</td>      <td>Momentum Research, Inc.|Saint-Louis-Lariboisière University Hospitals|Abbott</td>      <td>Not Applicable</td>      <td>230.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science</td>      <td>21-Jan-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04235062</td>    </tr>    <tr>      <th>481</th>      <td>482</td>      <td>Next Generation Probiotics (NGPs) for Metabolic Health</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Microbial Colonization</td>      <td>Other: observational</td>      <td>Danisco|Medfiles Ltd.|4Pharma Ltd.</td>      <td>NaN</td>      <td>100.0</td>      <td>Industry|Other</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Cross-Sectional</td>      <td>14-Jan-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04229082</td>    </tr>    <tr>      <th>482</th>      <td>483</td>      <td>A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Gastrointestinal Cancer</td>      <td>Biological: TMV-018 + 5-FC|Biological: TMV-018 + anti-PD-1|Biological: TMV-018 + 5-FC + anti-PD-1</td>      <td>Themis Bioscience GmbH|Assign Data Management and Biostatistics GmbH|SSS International Clinical Research GmbH</td>      <td>Phase 1</td>      <td>15.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>11-Dec-19</td>      <td>University Hospital Bonn, Bonn, Germany|University Hospital Tübingen, Tübingen, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04195373</td>    </tr>    <tr>      <th>483</th>      <td>484</td>      <td>Epividian / AHF: Positive Pathways - HIV Retention in Care</td>      <td>Enrolling by invitation</td>      <td>No Results Available</td>      <td>HIV/AIDS</td>      <td>Other: Alert to provider</td>      <td>Epividian|AIDS Healthcare Foundation|ViiV Healthcare</td>      <td>NaN</td>      <td>40000.0</td>      <td>Industry|Other</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>1-Nov-19</td>      <td>AHF, Los Angeles, California, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04147832</td>    </tr>    <tr>      <th>484</th>      <td>485</td>      <td>Obstructive Sleep Apnea Syndrome: Evaluation of the Efficacy of Sleepinnov© (Spiri+) Continuous Positive Airway Pressure Device</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Obstructive Sleep Apnea Syndrome</td>      <td>Device: Spiri+</td>      <td>Sleepinnov Technology|University Hospital, Grenoble|ICUREsearch</td>      <td>Not Applicable</td>      <td>20.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>28-Oct-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04141176</td>    </tr>    <tr>      <th>485</th>      <td>486</td>      <td>Safety and Targeting of Anti-hk2 Antibody in mCRPC</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Castration-Resistant Prostatic Cancer|Metastatic Disease</td>      <td>Drug: 111In-DOTA-h11B6</td>      <td>Tomopath Inc.|Invicro|Janssen Research &amp; Development, LLC</td>      <td>Early Phase 1</td>      <td>18.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other</td>      <td>4-Oct-19</td>      <td>Memorial Sloan-Kettering Cancer Center, New York, New York, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04116164</td>    </tr>    <tr>      <th>486</th>      <td>487</td>      <td>The Effect of Farlong® NotoGinseng™ (Farlong® Ginseng Plu®) on Cholesterol and Blood Pressure</td>      <td>Enrolling by invitation</td>      <td>No Results Available</td>      <td>Hyperlipidemias|Hypertension</td>      <td>Dietary Supplement: Farlong NotoGinseng™ (Farlong Ginseng Plus®)|Other: Placebo</td>      <td>LongStar HealthPro, Inc. DBA Farlong Pharmaceutical|Yunnan PanLongYunHai Pharmaceuticals, Ltd.|KGK Science Inc.</td>      <td>Phase 2</td>      <td>100.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care</td>      <td>28-Aug-19</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04069715</td>    </tr>    <tr>      <th>487</th>      <td>488</td>      <td>Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Melanoma Stage IV|Melanoma Stage III</td>      <td>Drug: Encorafenib|Drug: Binimetinib</td>      <td>Pierre Fabre Pharma GmbH|Pierre Fabre Pharma Austria|Pierre Fabre Pharma AG</td>      <td>NaN</td>      <td>750.0</td>      <td>Industry|Other</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>5-Aug-19</td>      <td>11, Graz, Austria|13, Innsbruck, Austria|14, Klagenfurt, Austria|10, Linz, Austria|3, Linz, Austria|12, Salzburg, Austria|23, Wiener Neustadt, Austria|22, Wien, Austria|8, Aschaffenburg, Germany|27, Bremerhaven, Germany|1, Buxtehude, Germany|34, Donauwörth, Germany|20, Essen, Germany|9, Gera, Germany|28, Gießen, Germany|19, Hamburg, Germany|21, Hannover, Germany|2, Heidelberg, Germany|33, Karlsruhe, Germany|29, Landshut, Germany|30, Ludwigshafen, Germany|4, Lübeck, Germany|15, Mainz, Germany|5, Mannheim, Germany|6, Minden, Germany|31, München, Germany|7, München, Germany|16, Münster, Germany|35, Münster, Germany|18, Nürnberg, Germany|17, Schwerin, Germany|32, Zwickau, Germany|24, Chur, Switzerland|26, Winterthur, Switzerland|25, Zürich, Switzerland</td>      <td>https://ClinicalTrials.gov/show/NCT04045691</td>    </tr>    <tr>      <th>488</th>      <td>489</td>      <td>DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Breast Cancer|Non-small Cell Lung Carcinoma</td>      <td>Drug: Trastuzumab deruxtecan (DS-8201a)|Drug: Pembrolizumab</td>      <td>Daiichi Sankyo, Inc.|AstraZeneca UK Limited|Merck Sharp &amp; Dohme Corp.</td>      <td>Phase 1</td>      <td>115.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>2-Aug-19</td>      <td>Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University du Cancer de Toulouse, Toulouse, France</td>      <td>https://ClinicalTrials.gov/show/NCT04042701</td>    </tr>    <tr>      <th>489</th>      <td>490</td>      <td>MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Malignant Pleural Mesothelioma</td>      <td>Drug: MTG201|Drug: Nivolumab Injection [Opdivo]</td>      <td>Momotaro-Gene Inc.|Baylor College of Medicine|Synteract, Inc.</td>      <td>Phase 2</td>      <td>12.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>9-Jul-19</td>      <td>Baylor College of Medicine, Houston, Texas, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04013334</td>    </tr>    <tr>      <th>490</th>      <td>491</td>      <td>Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Bipolar I Disorder</td>      <td>Drug: Endoxifen|Drug: Placebo oral tablet</td>      <td>Jina Pharmaceuticals Inc.|Novum Pharmaceutical Research Services|Lambda Therapeutic Research Ltd.|Intas Pharmaceuticals, Ltd.</td>      <td>Phase 3</td>      <td>124.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment</td>      <td>20-Mar-20</td>      <td>1065 NE 125th St, Miami, Florida, United States</td>      <td>https://ClinicalTrials.gov/show/NCT04315792</td>    </tr>    <tr>      <th>491</th>      <td>492</td>      <td>A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Carcinoma, Non-small Cell Lung Cancer</td>      <td>Biological: nivolumab|Biological: ipilimumab|Drug: cabozantinib|Biological: docetaxel|Biological: ramucirumab|Drug: lucitanib</td>      <td>Bristol-Myers Squibb|Clovis Oncology, Inc.|Exelixis|Eli Lilly and Company</td>      <td>Phase 1|Phase 2</td>      <td>660.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>5-Nov-19</td>      <td>Local Institution, Fayetteville, Arkansas, United States|Local Institution, Tampa, Florida, United States|Local Institution, Marietta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Peoria, Illinois, United States|Local Institution, Lexington, Kentucky, United States|Local Institution, Scarborough, Maine, United States|Local Institution, Detroit, Michigan, United States|Local Institution, Traverse City, Michigan, United States|Local Institution, Durham, North Carolina, United States|Local Institution, Cleveland, Ohio, United States|Local Institution, Nashville, Tennessee, United States|Local Institution, Ciudad Autonoma De Buenos Aires, Buenos Aires, Argentina|Local Institution, Buenos Aires, Distrito Federal, Argentina|Local Institution, Buenos Aires, Distrito Federal, Argentina|Local Institution, Capital, Distrito Federal, Argentina|Local Institution, Darlinghurst, New South Wales, Australia|Local Institution, Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Birtinya, Queensland, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, Innsbruck, Austria|Local Institution, Wien, Austria|Local Institution, Charleroi, Belgium|Local Institution, Gilly, Belgium|Local Institution, Leuven, Belgium|Local Institution, Recoleta, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Copenhagen ?, Denmark|Local Institution, Bordeaux, France|Local Institution, Creteil, France|Local Institution, Grenoble, France|Local Institution, Nantes, France|Local Institution, Paris Cedex 5, France|Local Institution, Pierre Benite, France|Local Institution, Rennes, France|Local Institution, Berlin, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Jena, Germany|Local Institution, Kassel, Germany|Local Institution, Kiel, Germany|Local Institution, Regensburg, Germany|Local Institution, Wurzburg, Germany|Local Institution, Torreon, Coahuila, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Oslo, Norway|Local Institution, Warszawa, Mazowieckie, Poland|Local Institution, Krakow, Poland|Local Institution, San Juan, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Craiova, Romania|Local Institution, Timisoara, Romania|Local Institution, A Coru?a, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Majadahonda - Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04151563</td>    </tr>    <tr>      <th>492</th>      <td>493</td>      <td>Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Metastatic Castration Resistant Prostate Cancer (mCRPC)</td>      <td>Drug: avelumab|Drug: Bempegaldesleukin|Drug: talazoparib|Drug: enzalutamide</td>      <td>Pfizer|EMD Serono|Nektar Therapeutics|Astellas Pharma Inc</td>      <td>Phase 2</td>      <td>127.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>9-Aug-19</td>      <td>Alaska Clinical Research Center, Anchorage, Alaska, United States|21st Century Oncology, Jacksonville, Florida, United States|21st Century Oncology, Jacksonville, Florida, United States|Northwestern Medical Group, Chicago, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Siteman Cancer Center - West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University Infusion Center Pharmacy, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center - South County, Saint Louis, Missouri, United States|Siteman Cancer Center - St. Peters, Saint Peters, Missouri, United States|Montefiore Einstein Center for Cancer Care, Bronx, New York, United States|University of Rochester Cancer Center Pharmacy, Rochester, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|West Chester Hospital, West Chester, Ohio, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Medical Oncology Associates, PS DBA Summit Cancer Centers, Spokane Valley, Washington, United States|Medical Oncology Associates, PS DBA Summit Cancer Centers, Spokane, Washington, United States|GZA Ziekenhuizen campus Sint-Augustinus, Wilrijk, Antwerpen, Belgium|AZ Groeninge, Kortrijk, WVL, Belgium|CHU UCL Namur Site Sainte Elisabeth, Namur, Belgium|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forli-cesena, Italy|Rugani Hospital SRL, Monteriggioni, SI, Italy|Azienda Ospedaliero-Universitaria Senese, Siena, SI, Italy|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika, Lodz, Poland|Med-Polonia Sp. z o.o., Poznan, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warsaw, Poland|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|CETIR Centre Mèdic, Barcelona, Spain|Comite Etico de Investigacion Clinica con Medicamentos del Hospital Universitari Vall d\'Hebron, Barcelona, Spain|Hospital Universitari Vall d\'Hebron, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain</td>      <td>https://ClinicalTrials.gov/show/NCT04052204</td>    </tr>    <tr>      <th>493</th>      <td>494</td>      <td>The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM)</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Subdural Hematoma, Chronic</td>      <td>Device: SQUID|Procedure: Burr-hole|Other: Medical Management</td>      <td>Balt USA|Balt Extrusion|Embo-Flüssigkeiten A.G.|AXIOM Real Time Metrics</td>      <td>Not Applicable</td>      <td>228.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>1-Jun-20</td>      <td>Universitätsklinikum Heidelberg, Heidelberg, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04410146</td>    </tr>    <tr>      <th>494</th>      <td>495</td>      <td>Real-life Pan-HER-blockade With Neratinib</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Breast Neoplasm</td>      <td>Drug: Neratinib</td>      <td>Pierre Fabre Pharma GmbH|iOMEDICO AG|Pierre Fabre Pharma Austria|Pierre Fabre Pharma AG</td>      <td>NaN</td>      <td>200.0</td>      <td>Industry|Other</td>      <td>Observational</td>      <td>Observational Model: Cohort|Time Perspective: Prospective</td>      <td>14-May-20</td>      <td>Medical Practice, Landshut, Bavaria, Germany|Medical Practice, Goslar, Lower Saxony, Germany</td>      <td>https://ClinicalTrials.gov/show/NCT04388384</td>    </tr>    <tr>      <th>495</th>      <td>496</td>      <td>A Study to Assess the Safety and Efficacy of Probiotic to Modulate Psychological Stress</td>      <td>Completed</td>      <td>No Results Available</td>      <td>Stress, Psychological|Healthy</td>      <td>Biological: Probiotic|Other: Placebo</td>      <td>Danisco|ICON plc|Daacro|4Pharma Ltd.</td>      <td>Phase 2</td>      <td>190.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment</td>      <td>14-Oct-19</td>      <td>Atlantia Food Clinical Trials Ltd, Cork, Ireland|MediNova Warwickshire Dedicated Research Centre, Kenilworth, United Kingdom|MediNova North London Dedicated Research Centre, Northwood, United Kingdom|MediNova Research East London Clinical Studies Centre, Romford, United Kingdom|MediNova Yorkshire Dedicated Research Centre, Shipley, United Kingdom|MediNova South London Dedicated Research Centre, Queen Mary\'s Hospital, Sidcup, United Kingdom|MediNova West London Dedicated Research Centre, Wokingham, United Kingdom</td>      <td>https://ClinicalTrials.gov/show/NCT04125810</td>    </tr>    <tr>      <th>496</th>      <td>497</td>      <td>PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma</td>      <td>Active, not recruiting</td>      <td>No Results Available</td>      <td>Severe Uncontrolled Asthma</td>      <td>Drug: Benralizumab</td>      <td>AstraZeneca|Iqvia Pty Ltd|Parexel|Covance|PPD</td>      <td>Phase 3</td>      <td>33.0</td>      <td>Industry</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science</td>      <td>12-Mar-20</td>      <td>Research Site, Birmingham, Alabama, United States|Research Site, Los Angeles, California, United States|Research Site, Orlando, Florida, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Coppell, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Fukuoka-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuyama-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Habikino-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Zentsuji-shi, Japan</td>      <td>https://ClinicalTrials.gov/show/NCT04305405</td>    </tr>    <tr>      <th>497</th>      <td>498</td>      <td>Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance</td>      <td>Not yet recruiting</td>      <td>No Results Available</td>      <td>Essential Thrombocythemia</td>      <td>Biological: Ropeginterferon alfa-2b</td>      <td>PharmaEssentia|Medpace, Inc.|EPS International|Brightech International</td>      <td>Phase 3</td>      <td>160.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>26-Feb-20</td>      <td>NaN</td>      <td>https://ClinicalTrials.gov/show/NCT04285086</td>    </tr>    <tr>      <th>498</th>      <td>499</td>      <td>Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Chronic Hepatitis c Genotype 1</td>      <td>Drug: Narlaprevir|Drug: Ritonavir|Drug: Sofosbuvir</td>      <td>R-Pharm|Almedis|Scientific Center EFiS|ChromSystemsLab</td>      <td>Phase 2</td>      <td>85.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment</td>      <td>29-Jan-20</td>      <td>FBIS CSRI of Epidemiology of Federal Service on Customers, Moscow, Russian Federation|FSIS FRC of food and biotechnology, Moscow, Russian Federation|SBEI HPE MSMDU n.a. A.I. Evdokimov of Ministry of Health of Russia, Moscow, Russian Federation|FSBI HEI HPE Military Medical Academy n.a. S.M. Kirov, Saint Petersburg, Russian Federation|SPb SBIH Center on preventiomn and treatment of AIDS and infectional deseases, Saint Petersburg, Russian Federation</td>      <td>https://ClinicalTrials.gov/show/NCT04246723</td>    </tr>    <tr>      <th>499</th>      <td>500</td>      <td>A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine</td>      <td>Recruiting</td>      <td>No Results Available</td>      <td>Norwalk Gastroenteritis|Norovirus Infections</td>      <td>Biological: Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）|Biological: Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）|Biological: Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）|Biological: Normal saline|Biological: Aluminum adjuvant</td>      <td>National Vaccine and Serum Institute, China|Lanzhou Institute of Biological Products Co., Ltd|Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd.|Zhengzhou University</td>      <td>Phase 1</td>      <td>510.0</td>      <td>Industry|Other</td>      <td>Interventional</td>      <td>Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention</td>      <td>6-Dec-19</td>      <td>qixian Center for Disease Control and Prevention, Hebi, Henan, China</td>      <td>https://ClinicalTrials.gov/show/NCT04188691</td>    </tr>  </tbody></table>
                </table>
              </div>
                </div>
              </aside>
        </div>

        




    <script src="https://code.jquery.com/jquery-3.2.1.slim.min.js" integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.11.0/umd/popper.min.js" integrity="sha384-b/U6ypiBEHpOf/4+1nzFpr53nxSS+GLCkfwBdFNTxtclqqenISfwAzpKaMNFNmj4" crossorigin="anonymous"></script>
    <script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0-beta/js/bootstrap.min.js" integrity="sha384-h0AbiXch4ZDo7tp9hKZ4TsHbi047NrKGLO3SEJAg45jXxnGIfYzk4Si90RDIqNm1" crossorigin="anonymous"></script>

</body>


